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Our greatest weakness is giving up. 
The most certain way to succeed is always to try just one more time 
-Thomas Edison- 
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During my PhD, I was involved in three different projects. The first and the second one concern 
the design and synthesis of potential drugs for the treatment of two diseases involving elderly 
people such as Alzheimer's disease (Chapter 1) and benign prostatic hyperplasia (Chapter 2). 
They have been developed at the Department of Pharmacy and Biotechnology in Bologna under 
the supervision of Prof. C. Melchiorre. 
Chapter 3 treats the development of new isocyanide multicomponent reactions. The research 
project was developed at the University College of London (UCL) under the supervision of Dr. 
T. Sheppard during my second year of PhD. 
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Abbrevations 
5α-DHT: 5α-dihydrotestosterone 
5α-R: 5α-reductase 
5-HT: 5-hydroxytryptamine or serotonin 
α1-AR: α1-adrenoreceptor 
Aβ: amyloid-β peptide 
Aβ40: amyloid-β peptide constituted by 40 aminoacids.  
Aβ42: amyloid-β peptide constituted by 42 aminoacids.  
ACh: acetylcholine 
AChE: acetylcholinesterase 
AD: Alzheimer’s disease 
ADAM: A disintegrin and metalloprotease 
AChEI: AChE inhibitor 
APOE4: apolipoprotein E 4 
APP: amyloid precursor protein  
α-APPs: α-APP soluble fragment 
β-APPs: β-APP soluble fragment 
BACE: β-secretase  
BBB: blood–brain barrier 
BuChE: butyrylcholinesterase 
BPH: benign prostatic hyperplasia 
CCh: carbachol  
ChAT: choline acetyltransferase 
CHO: Chinese hamster ovary 
CNS: central nervous system 
CoQ10: coenzyme Q10 
CQ: clioquinol 
DAG: diacylglycerol 
DCE: dichloroethane 
DCM: dichloromethane 
DHP: dihydropyridine 
DS: Down syndrome 
DR6: death receptor 6 
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ETC: electron transport chain 
FAD: early-onset Alzheimer’s disease 
GABA: γ-aminobutyric acid  
GPCRs: G protein-coupled receptors 
GSK3β: glycogen synthase kinase 3β 
KGDHC: α-ketoglutarate–dehydrogenase complex  
KPI: Kunitz-type protease inhibitor domain 
[3H]NMS= [3H]-N-methyl scopolamine  
IMCR: isocyanide-based multicomponent reactions 
IP3: inositol trisphosphate  
LUTS= lower urinary tract symptoms  
mAChR: muscarinic acetylcholine receptor 
MAPK: mitogen-activated protein kinase 
MAO: monoamine oxidase 
MAOI: monoamine oxidase inhibitor  
MCR: multicomponent reaction 
MTDL: multitarget-directed ligand 
nAChR: nicotinic acetylcholine receptor 
NFTs neurofibrilary tangles  
NMDAR: N-methyl D-aspartate receptor 
NSAID: Non-steroidal anti-inflammatory drug 
NOS: nitric oxide synthase  
NQO1: NAD(P)H:quinone oxidoreductase 1 
OXO-M: oxotremorine 
OXPHOS: oxidative phosphorylation  
P-3CR: Passerini three-component reaction 
PAM: positive allosteric modulator 
PAS: peripheral anionic site 
PDHC: pyruvate–dehydrogenase complex  
PI3K: phosphatidyl inositol 3-kinase 
PKC: protein kinase C 
PLC: phospolipase C  
PS: presenilin 
ROS: reactive oxygen species 
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SAR: structure activity relationship 
TGF-β: transforming growth factor-β 
TOSMIC: tosylmethyl isocyanides 
TURP: transurethral resection of the prostate  
U-4CR: Ugi four-component reaction 
vL-3CR: van Leusen multicomponent reaction 
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1 Introduction 
Alzheimer’s disease (AD) is an irreversible, multi-factorial neurodegenerative disorder that 
occurs gradually, and results in memory loss, unusual behaviour, personality changes, and 
decline in thinking abilities. It constitutes the most common and fatal form of dementia in 
adults.1 Therefore, the incidence of AD is expected to double every 20 years and it is predicted 
that over 100 million individuals will have AD in 2050.2 AD is named from Dr. Alois 
Alzheimer,3 a German doctor who in 1907 noticed changes in the brain tissue of a woman who 
had died of an unusual mental illness. He observed post mortem two characteristic pathological 
features: amyloid plaques and neurofibrillary tangles (NFTs) in the cerebral cortex and limbic 
system.  
So far, the main neuropathological hallmarks of AD are identified as: diffusive loss of neurons, 
dysfunctional cholinergic system, intracellular protein deposits termed NFTs consisting of 
hyperphosphorylated tau protein and extracellular protein deposits termed amyloid or senile 
plaques.4, 5, 6 AD exists in a genetically determined form, known as the familial form (with an 
autosomal dominant character), and a sporadic form. 
Disease-modifying drugs are not available yet because the nature and the exact role of biological 
molecules involved in AD physiopathology are not clearly understood. Thus, the elucidation of 
the molecular mechanisms, which cause AD, would greatly help the design of drugs able to 
interfere with neurotoxic processes. In this section the main molecular mechanisms that cause 
AD are reviewed.  
 
1.1 Amyloidogenesis  
According to this hypothesis, neuronal degeneration in the brain of AD patients is the direct 
consequence of amyloid β-peptide (Aβ) hyperproduction.7 This causes the formation of amyloid 
plaques which consequently induces dendrite and axon retraction and neuronal death.8 The 
peptide Aβ is derived from the amyloid precursor protein (APP).9 The APP gene is localized on 
chromosome 21 which is triplicated in trisomy 21 Down syndrome (DS). In fact, most patients 
who have DS manifest also AD by the age of 50. Post-mortem analysis of their brains showed 
diffusive intraneuronal deposits of Aβ10 in the absence of any tau pathology, suggesting that Aβ 
deposition might be the primary cause of a feed-forward cycle, which results in AD. 
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1.1.1 Proteolytic processing of APP 
APP is a 770 residue transmembrane glycoprotein possessing a large extracellular amino-
terminal domain and a small intracellular cytoplasmatic domain. It is expressed not only in the 
brain but also throughout the body.11 APP is processed post-translationally by glycosylation and 
proteolytic cleavage producing different isoforms in specific tissue types.12, 13 There are several 
APP isoforms arising from the alternative splicing of its pre-mRNA and ranging from 365 to 770 
aminoacids residue. The most important isoforms are those with 695, 751 and 770 aminoacids 
(referred to as APP695, APP751 and APP770). APP695 isoform is predominately expressed in 
the central nervous system (CNS).14 Different subdomains can be identified in the extracellular 
sequence of APP, based on its primary sequences and structural studies (Fig 1).15, 16 These 
include the E1 domain, which consists of the N-terminal growth factor like domain and the metal 
(copper and zinc) binding motif, the Kunitz-type protease inhibitor (KPI) domain present in 
APP751 and APP770 isoforms, the E2 domain which include the sequence that promotes 
fibroblast growth and the extracellular binding sites for heparin, collagen, and laminin. The 
biological properties of APP have been extensively studied since its identification nearly 20 
years ago. It demonstrates a number of interesting putative physiological roles. In fact, it seems 
to participate in synaptic formation and repair,17 in adhesion, intercellular communication and 
membrane-to-nucleus signaling.18 
 
Figure 1: Domain structure of APP695. SP: signal peptide; TM: transmembrane peptide; KPI: 
Kunitz-type protease inhibitor; P: phosporylation sites; CHO: glycosilation sites; RERMS: 
sequence that promotes fibroblast growth.19 
 
The production of Aβ is dependent upon the activities of two proteases: β-secretase (BACE) and 
γ-secretase.20 The cleavage of APP can follow an amyloidogenic or a nonamyloidogenic 
pathway (Fig. 2). The first one starts by α-secretase, the second by β-secretase; two different 
proteases which cleave at different position within APP molecule leading to the release of the 
large soluble N-terminal fragments α-APPs and β-APPs, respectively. Cleavage by α-secretase 
occurs within the region containing Aβ (between Lys16 and Leu17), precluding Aβ formation. α-
APPs has been suggested to exhibit neuroprotective and synapse-promoting activities,21 but the 
exact mechanism or the receptor mediating these effects have not been identified yet. On the 
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other hand, β-APPs is further processed by an unknown protease, producing a ̴35-kDa amino-
terminal domain fragment that binds to the death receptor DR6. This interaction to DR6 triggers 
activation of caspase-6 and mediates axonal pruning during embryogenesis.22  
Two C-terminal fragments C83 and C99 are also produced by α-secretase and BACE 
respectively. Both C83 and C99 can be further cleaved by γ-secretase, within the APP 
transmembrane domain which leads to the formation of Aβ from C99 and of p3, a shorter, 
presumably non pathogenic Aβ from C83. The release of the free N-terminus of Aβ is therefore 
considered the first critical step in amyloid formation.23 The majority of secreted Aβ peptides are 
constituted by 40 aminoacids in lenght (Aβ40), although the longer species, 42 aminoacids in 
length (Aβ42), have received greater attention due to its propensity to nucleate and produce 
insoluble β sheets that are neurotoxic.24 
 
Figure 2: Schematic description of the amyloidogenic and nonamyloidogenic pathways of APP 
cleavage.25 
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Amyloids from AD and in other degenerative disorders, may share a common pathway for fibrils 
formation and accumulation in plaques. The initiating event is protein misfolding or 
denaturation, which results in the acquisition of the ability to aggregate in an infinitely 
propagating way.26 In AD, Aβ monomers can aggregate into oligomeric assembles or soluble 
spherical aggregates of approximately 3-10 nm (Fig. 3). Small nuclei of such aggregates can 
induce protofibril and amyloid fibril formation. Amyloid fibrils have a “cross β” structure. It is a 
double β-sheet, with each sheet formed from parallel segments, stacked in-register.27, 28 This 
structural motif of amyloid fibrils is not commonly present in native protein structure and the 
formation of protein aggregates is related to the onset and/or progression of the disease. Aβ-
induced neurodegeneration appears to result, at least in part, from the activation of apoptotic 
pathways,29, 30 including caspases31, 32, 33and Jun N-terminal kinase34 which consequently induce 
neuronal death.  
 
Figure 3: Pathway of amyloid fibril formation.35 
 
However, a body of evidence suggests that soluble amyloid oligomers may primary be involved 
in the mechanism of pathogenesis. Indeed, it is shown that amyloid oligomers can form pores or 
channels in cell membranes increasing permeability and intracellular calcium concentration.36, 37 
The increase of Ca+2 may be the initiator of many pathogenic pathways; reactive oxygen species 
(ROS) production,38 altered signalling pathway,39, 40 mitochondrial dysfunction41 and cell death42 
(Fig. 4). The accumulation of autophagosomes and autolysosomes has been recognized as a 
common component of AD and other neurodegenerative disorders.43 The up-regulations of these 
defensive mechanisms may be a protective response to the enhanced Aβ deposition. The fact that 
amyloid aggregates and autophagics vesicles continue to accumulate suggests that this response 
is not entirely successful. The failure to clear amyloid plaques may also contribute to 
pathogenesis and neuronal loss.44  
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Figure 4: Common and disease-specific pathways in degenerative diseases..45 
 
Although the neurotoxic properties of Aβ have been described for over a decade,46 it is still not 
known how Aβ participates in a pathologic cascade that causes progressive cognitive decline. It 
is also not well-known if Aβ, which is detected in both cerebrospinal fluid and plasma in healthy 
individuals,47 is fundamental in normal physiology. Initially, it was believed that the cleavage of 
APP by BACE was pathological, while the cleavage by α-secretase was physiological. In reality, 
β- and γ-secretase processing of APP also occurs under physiological conditions. This suggests 
that all fragments of APP, including the Aβ peptide, are essential for normal physiology.48, 49 
Interestingly, deficiencies for presenilin 1 and especially presenilins 1 and 2 (catalytic subunits 
of γ-secretase, see 1.1.4) abolished γ-secretase activity causing disastrous effects in many tissues, 
leading to prenatal death of the embryos in all animals investigated so far.50, 51, Similar data were 
shown for the α-secretase isoforms ADAM 10 and ADAM 17/TACE (see 1.1.2). Indeed, 
ADAM17/TACE null mice or mice carrying mutation inactivating the active site of the enzyme 
die during late fetal period with hypoplastic lungs and defective development of eyes and skin.52 
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These data clearly suggest that α- and γ-secretase have other functions apart from APP 
processing. 
The abnormal processing of APP by e α-, β-, and γ-secretase is a key step in AD pathogenesis.53, 
54
 More than 30 mutations in APP gene have been identified which affect the production and/or 
aggregation of the Aβ peptide. These missense mutations were found in patients with early-onset 
AD (FAD), i.e. familial cases with Mendelian inheritance. They account for about 0.5% of all 
AD cases. In particular, the cleavage of APP770 is facilitated by the mutations 
K670M671→N670L671 near the BACE cleavage site.55 These mutations are referred to as the 
“Swedish mutations” and they leads to an increase of BACE cleavage and a 6-7 fold Aβ peptide 
production, and a decrease of the α-secretase product p3.56 Other FAD mutations have been 
identified near the γ-secretase site, and these increase the generation of the more toxic Aβ42.57 
Moreover, FAD mutations near the α-secretase site appear to reduce the efficiency of α-secretase 
activity, thus providing more APP substrate for BACE cleavage, increasing the production of 
Aβ. 
 
1.1.2  α-secretase 
α-secretase is a membrane-bound metalloprotease involved in the non-amyloidogenic pathway of 
APP processing. It cleaves APP between Lys16 and Leu17 in the Aβ sequence and the subsequent 
membrane-bound carboxy-terminal fragment (C83) is further processed by γ-secretase leading to 
the p3 fragment. Very little is known about the toxicity or functions of these p3 fragments. 
However, evidence suggests that α-secretase-mediated cleavage of APP is the nonamyloidohenic 
pathway and it is thought that increasing α-secretase activity could be beneficial in AD. 
Stimulation of α-secretase ca be accomplished by the activation of protein kinase C (PKC), 
which can be stimulated by M1 and M3 muscarinic receptors agonist, and such agents are 
considered reasonable candidates for AD therapy.58  
Many members of the “A disintegrin and metalloprotease” or ADAM family have been 
implicated as α-secretase. The most important are ADAM10 and ADAM17/TACE. ADAM10 is 
the major constitutive α-secretase in many cell types. Overexpression of ADAM10 in the brain 
lowers the number of Aβ plaques and leads to an improvement of cognitive performance in 
mouse AD model.59 ADAM 17 is another α-secretase expressed in neuronal cells. It has also a 
crucial role in the release of a series of membrane-bound proteins, such as transforming growth 
factor-α and tumor necrosis factor-α.60  
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1.1.3  β-secretase 
Human β-secretase or BACE (for beta-site APP-cleaving enzymes) is a type I integral membrane 
aspartic protease. It is also known as Asp2 (for novel aspartic protease 2) and memapsin2 (for 
membrane aspartic protease/pepsin 2). BACE catalyzes the internal cleavage of APP at Asp1 
residue of the Aβ sequence, producing a secreted ectodomain of APP, called β-APPs and the 
C99 fragment, the membrane bound C-terminal 99 amino acids that is the substrate of γ-
secretase. Two β-secretases were identified: BACE-1 and BACE-2. BACE-1 is the major β-
secretase. It has a rather broad tissue distribution, but it is enriched in brain and in neuronal cells, 
consistent with the finding that Aβ is normally produced and released in patients with AD and in 
normal individuals.61, 62 BACE hydrolyzes APP specifically at the Met-Asp site and an acidic pH 
is optimum for its activity. The gene that encodes for BACE is located on chromosome 11, but 
no AD-causing mutation in this gene has been identified yet.   
This protease was identified in 199963, 64, 65 and in 2000 his crystal structure was obtained in a 
peptide mimetic inhibitor complex (Fig. 5).66  
 
 
Figure 5: The crystal structure of memapsin 2 complexed to inhibitor OM99-2. The N-lobe and 
C-lobe are blue and yellow, respectively. The inhibitor bound between the lobes is shown in 
red.66 
 
Hussain et al. showed that transfection of BACE-1 in cells expressing APP, causes an increase in 
secretion of β-secretase-derived fragments. Mutation of either of the putative catalytic aspartyl 
residues (Asp93 and Asp289) abrogates its activity. On the other hand, genetic inactivation of 
BACE-1 causes a decrease in Aβ deposition in different APP-overexpressing mouse AD 
models.67, 68, 69, 70 
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Several publications have documented increased BACE-1 protein and activity in the brain of AD 
patients. In fact, BACE-1 expression is under a complex regulation. It is affected by many stress 
factors associated with neurodegenerative disease such as oxidative stress,71 ischemia,72 
hypoxia73 and traumatic brain injury.74 The human BACE-1 promoter contains binding sites for 
several putative transcription factors like for example the nuclear factor κB (NF-κB).75 The 
activation of this transcription factor is associated with chronic stress and inflammation in 
macrophages, astrocytes, and microglia in the CNS, where it has been found to mediate different 
responses to trauma in neurons and glia. Bourne et al.76 suggested that NF-κB acts as an activator 
of BACE1 transcription in activated astrocytes, a feature present in the AD brain. In the aged and 
AD brain, NF-κB transcription factor-mediated responses to stress are attenuated,77, 78 and there 
is an increase of NF-κB activity79 which may be a significant contributor to increase Aβ levels.  
Soon after the discovery of BACE-1, an homologous novel aspartic protease was discovered, 
BACE-2.80, 81 BACE-1 and BACE-2 share ~64% amino acid similarity, and both have two 
aspartic protease residues, six conserved luminal cysteine residues, a C-terminal transmembrane 
domain and other similar structural characteristics. The high degree of similarity between 
BACE-1 and BACE-2 suggests that BACE-2 might also function as β-secretase. BACE-2 gene is 
localized on chromosome 21 in the DS region. Consequently, a third copy of the BACE-2 gene 
(and the APP gene) is present in DS and this suggests a potential role of BACE-2 in the FAD 
syndrome found in DS patients. In fact, cell transfection studies demonstrate that BACE-2 cuts 
APP at the BACE site82 and the Flemish FAD mutation of APP (Ala→Gly at position 21 of Aβ) 
causes an increase in Aβ production that is mediated by BACE-2 but not BACE-1.83 Thus, 
BACE-2 may play an important role in the pathogenesis of Flemish FAD. However, BACE-2 
cleaves at two other positions (Phe19 and Phe20) within the Aβ domain near the α-secretase 
cleavage site.84 Interestingly, BACE-2 may also function like an alternative α-secretase, so that 
the processing of APP by BACE-2 leads to a reduction of Aβ production in cells.  
BACE is a particularly attractive drug target because it initiates Aβ formation and is the rate-
limiting enzyme for Aβ production in cells. For example knockout of BACE1 in mice drastically 
reduces Aβ production and reduces amyloid plaque and AD symptoms in AD mouse model.69, 70 
The advantage of inhibiting BACE-1 instead of γ-secretase is that this does not result in blocking 
Notch signaling which is fundamental for cell life (see 1.1.4). Several factors must be taken into 
consideration for the development of new BACE-1 inhibitors. Since its catalytic site is 
exceptionally long, it is very difficult to develop small compounds targeting BACE-1. The 
compound should have low molecular weight and high lipophilicity to cross the blood-brain 
barrier (BBB) and achieve high concentrations in the brain. In addition, since it is not known yet 
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whether BACE-2 is dispensable in vivo, it may be necessary to design BACE-1-selective drug 
that do not exhibit inhibition of BACE-2 or other aspartic proteases. Because of the high degree 
of homology between BACE-1 and BACE-2, the design of new BACE-1 selective-drugs could 
be very difficult.  
 
1.1.4  γ-secretase 
γ-secretase is a type I membrane-spanning protein composed by 19 transmembrane domains. It 
was identified in 1993 as the protease responsible of the cleavage of APP releasing the Aβ 
peptide.85 
Presenilin 1 (PS1) was later identified as the major constituent of its proteolytic activity. The 
remainder of the γ-secretase activity is mediated by presenilin 2 (PS2), a close homolog of PS1.86 
PS is an aspartyl protease with eight transmembrane segments.87 Two transmembrane aspartates, 
Asp257 and Asp385 in TM6 and TM7 respectively, are essential for γ-secretase activity. In fact, 
mutations of these aminoacids abolished completely its activity. Moreover, γ-secretase activity is 
diminished in cells derived from PS knockout mice.88 This result confirms that PS is the catalytic 
subunit of γ-secretase.89  
PS requires the association of three additional subunits: nicastrin, aph-1 and pen-2 to become 
proteolytically active. The reason(s) why PS requires these proteins for its activity remains 
unclear. It has been suggested that the single transmembrane domain nicastrin is a “gate-keeper” 
restricting access of substrates to the catalytic site.90 However, up to now less is known about 
aph-1 and pen-2 functions.  
In the human genome, two PS genes (PS1 and PS2) and two aph-1 genes (aph-1a and aph-1b), 
have been identified. It was shown that either PS1 or PS2 and either aph-1a or aph-1b are 
incorporated into the mature γ-secretase tetrameric complex. Thus, a minimum of four different 
γ-secretase complexes may exist with potentially different biological functions.91  
A structure at 12-Å resolution of the complex PS1/Aph1a/Pen2/Nicastrin with cryoelectron 
microscopy revealed a globular and porous structure with a smooth cytosolic side and a larger 
irregular extracellular surface (Fig. 6).92 At the cytosolic side there is a sizable pore that reaches 
halfway into the membrane region and, at the extracellular space, other two large cavities are 
present. Cysteine scanning studies demonstrated that the aspartate-containing active site, 
presumably located within the transmembrane domain, is water accessible.93 Thus it appears that 
γ-secretase, similar to other intramembrane cleaving proteases, sequesters its substrate from the 
hydrophobic lipid bilayer of the membrane in a structure that allows entrance of water molecules 
that are necessary for its hydrolysis activity. 
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The majority of FAD cases are caused by mutations within the PS genes. More than 150 
mutations were identified in the gene for PS1, and only 10 for PS2.94 PS2 containing γ-secretase 
complexes do not have the major role in Aβ production and, therefore, this is the reason why 
there are fewer PS2 mutations that lead to FAD.95 The effect of PS mutations is represented by a 
gain of toxic functions of γ-secretase; they shift the preferred site of γ-cleavage from position 40 
to 42 of APP, leading to an increase of the more amyloidogenic form of Aβ in cultured cells and 
in the brain of transgenic mice.96 Given that PS1 and PS2 inactivation completely prevents Aβ 
formations, it means that these mutations cause an “incomplete digestion” of APP substrate, 
generating fewer but longer Aβ peptides.97, 98 
 
 
Figure 6: Structure of the complex PS1/Aph1a/Pen2/Nicastrin with cryoelectron microscopy.92 
 
Other proteins that have been shown to be substrates for γ-secretase cleavage include Notch99 
and the Notch ligands Delta1 and Jagged2,100 ErbB4,101 CD44,102 and E-cadherin.103 Current data 
also indicate that two members of the α-secretase family ADAM, i.e. ADAM17/TACE and 
ADAM 10, may be involved in the cleavage of Notch.104, 105, 106  
Notch is a cell-surface receptor that mediates signal transduction between the cell surface and the 
nucleus. Four Notch genes (Notch 1–4) and five ligands (Jagged 1 and 2; Delta 1, 2 and 3) have 
been identified in vertebrates.107 Notch-1 (commonly referred to as Notch) has been widely 
investigated, while other Notch genes have been studied minimally. Notch proteins contain on 
the extracellular sequence an epidermal growth factor domain. Activation of Notch by ligand 
binding causes a proteolytic cleavage at site2 near to the membrane surface108, creating the 
‘Notch Extracellular Truncated’ derivative (NEXT). NEXT is then cleaved by a second protease 
at site3 within the transmembrane domain near to the inner membrane surface, releasing the 
intracellular domain, which enters the cell nucleus to modify gene expression (Fig. 7).  
The site2 cleavage appears to be the key step in the Notch activation and it is regulated by ligand 
binding. Current data indicate that ADAM17/TACE and ADAM 10 may be involved in this 
extracellular 
cytosolic 
40 Å 
19 
 
ligand-regulated cleavage. However, it seems that ADAM17/TACE is the major site2 
protease.108 On the other hand, cleavage of Notch at site3 depends on PS activity. The 
involvement of the PS in the site3 of Notch receptors has been established from several lines of 
evidence. In fact, small animals with loss of function in PS genes show a Notch signaling 
deficient phenotype. For example, mice with PS 1 deficiency display a complex pathological 
morphology affecting mesoderm segmentation, cardiovascular, and nervous system.109, 110 
Because of the essential role of γ-secretase in the generation of Aβ peptides, γ -secretase 
inhibitors may be useful in the treatment of AD. Many γ-secretase inhibitors have been identified 
that lower Aβ production in AD models.111 Nevertheless, recent studies showed that inhibition of 
γ-secretase has the expected benefit of reducing Aβ, but has undesirable biological effects as 
well, because of the inhibition of Notch processing.112 For example, blocking Notch signaling in 
the crypts of the intestinal epithelium induces differentiation into goblet cells and interferes with 
the normal replacement of the epithelium, explaining the gastrointestinal toxicity of γ-secretase 
inhibitors.113, 114 In addition, immune suppression or autoimmune disorders might be caused by 
Notch deficiency.115, 116 
 
 
 
 
 
 
Figure 7: Notch cleavage pathway.117 
 
Several approaches to increase the therapeutic window, i.e., to find compounds that efficiently 
block Aβ generation without affecting Notch signaling, have been explored. For example γ-
secretase modulators have attracted much attention in the last years because they would shift the 
production of amyloid peptides in favour of shorter forms of Aβ. Recent study suggested that 
Aβ40, compared to Aβ42, seems to be benign and may even be protective presumably because 
Aβ40 suppresses the deposition of Aβ42.118 A subset of non-steroidal anti-inflammatory drugs 
(NSAIDs), such as ibuprofen, sulindac sulfide and indomethacin, are able to reduce the ratio 
Aβ42/Aβ40 without affecting the amount of Aβ40 and, most importantly, Notch cleavage.119 The 
decrease of Aβ42 was accompanied by an increase in the production of shorter Aβ38 peptides. 
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The mechanism of action is independent from their anti-inflammatory action but it is not fully 
understood. It seems that NSAIDs could reduce secretion of Aβ42 by shifting γ-secretase activity 
towards production of Aβ38. However, future studies need to be conducted to understand this 
complex mechanism. Furthermore, Netzer et al.120 observed that in vitro generation of Aβ by γ-
secretase ATP dependent. In addition, they showed that the tyrosine-kinase inhibitor imatinib 
mesylate (Gleevec) is able to reduce Aβ production in vitro and in vivo without influencing 
Notch cleavage. Gleevec is a useful drug for chronic myelogenous leukemia. Its activity depends 
on the interaction with the ATP-binding site of Abl tyrosine-kinase. It does not appear that Abl 
kinase is required for Aβ production or for Aβ inhibition by Gleevec. Because Gleevec targets 
several other tyrosine-kinases (e.g. ARG, platelet-derived growth factor receptor (PDGFR), Src, 
c-kit), it is possible that its activity on Aβ production depends upon inactivation of one of these 
other enzymes. Indeed, in support to this hypothesis, it has been reported that the activation of 
PDGFR-Src-Rac1 cascade induces cleavage of APP through activation of β and γ-secretase.121 
Nowadays, masitinib, a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in 
dogs, is in Phase II clinical trials as potential drug for AD.122  
In 2009, G protein-coupled receptors (GPCRs) have been proposed as a target for drugs that 
selectively block APP processing and do not affect Notch signaling.123 G protein–coupled 
receptor 3 (GPR3), an active orphan receptor, is constitutively expressed in areas of the normal 
brain implicated in AD and it is increased in patients with sporadic AD. It seems a regulator of 
Aβ production. In fact in AD mice models, overexpression of GPR3 caused an increase of Aβ40 
and Aβ42 without affecting γ-secretase expression, whereas genetic ablation caused a decrease 
of accumulation of Aβ peptide. Thus, the expression of GPR3 is involved in assembly of γ-
secretase complex affecting APP processing, in the absence of any effect of Notch processing. 
This finding suggests that GPR3 represents a potential therapeutic target for the treatment of AD. 
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1.2 Neurofibrillar tangles and tau 
Tau is a member of the microtubule associated protein family widely expressed in the brain. Its 
primary function is to maintain microtubule stability.124 This protein contains several 
phosphorylation sites and in its hyperphosphorylated form is the major component of 
neurofibrillar tangles (NFTs) found in AD brains. The tau hypothesis argues that in AD, 
phosphorylation of tau reduces its ability to bind microtubules and indeed, in diseased neurons, 
tau aggregates into polymers that constitute the intracellular neurofibrillary lesions of AD.125, 126, 
127
 Similar inclusions are found in a number of other neurodegenerative diseases, where they are 
found in the absence of Aβ deposits. These diseases include, for example, Pick’s disease and 
Parkinson disease.  
The longest version of tau proteins contains 441 aminoacids. Alternative splicing generates six 
major isoforms in the adult brain. Tau is post-translationally modified by phosphorylation, 
glycosylation, glycation, ubiquitination and proteolytic processing.128 Some researchers support 
the hypothesis that the dementia symptoms in AD correlate to a greater extent with the gradual 
appearance and spread of tangles throughout the brain, than with the deposition of Aβ in senile 
plaques.129, 130  
Tau aggregation is a multistep process which starts with a nucleation step, followed by the 
progressive addition of tau proteins in an elongation process which induces pretangles, paired 
helical filaments and finally, neurofibrillar tangles (Fig. 8). Tau bound to microtubule (TauMT) 
can be displaced into cytoplasm (Taucyt) by various factors. Mutations,131 proteolysis or the 
presence of polyanionic structures132, 133, 134 probably play a crucial role in the aggregation of the 
nuclei and may be, therefore, therapeutic targets.  
 
Figure 8: Nucleation-elongation pathway in tangles formation.35 
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Tau mutations are all clustered in the microtubule-binding region and in the carboxy-terminal 
part of the protein. The pathway leading from a mutation in tau to neurodegeneration is still 
unknown. It is supposed that the primary effect of most missense mutations is a change in the 
conformation of tau that results in a minor ability to interact with microtubules, as reflected by a 
reduction of mutant tau to promote microtubule assembly.135, 136. Thus, microtubules will be 
destabilized with resultant deleterious effects on cellular processes and rapid axonal transport 
(Fig. 9). 
 
Figure 9: NFTs formation and microtubules disintegration.  
 
The hypothesis that tau proteolysis contributes to tangle formation in vivo has been known for a 
long time.137 An important fraction of tau found in the brain of AD patients is truncated at 
position Glu391 and Asp421 (numbering referred for the longest form of tau). Removal of the 
carboxy-terminal part of tau enhances neurofibrillary nucleation in vitro.138 This indicates that in 
sporadic AD, truncated tau species might play an important role. Both amino- and carboxy-
terminal parts of tau appear to have an inhibitory effect on the aggregation of tau. They fold back 
in a “hairpin” conformation on the central domain which contains the microtubule-binding 
portions (R) (Fig. 10).139 In repeats R2 and R3 there are two peptide motifs with a high 
propensity to form β-sheet structures.140 In fact, a synthetic 4R tau construct, truncated at both 
the amino and carboxy terminus, showed to have a high tendency to form intracellular tau 
aggregates.141  
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Figure 10: “Hairpin” conformation of tau.35 
 
Tau is phosphorylated by several protein kinases; cyclic AMP-dependent protein kinase 
(PKA),142 calmodulin-dependent protein kinase II (CaMKII),143 glycogen synthase kinase-3β 
(GSK-3β)144, 145, 146 and cyclin-dependent protein kinase 5 (cdk5). Glycogen synthase kinase-3 
was discovered over 20 years ago as a regulator of glycogen metabolism.147 It is a serine–
threonine kinase and a well-established component of the Wnt signalling pathway, which is 
essential during embryonic development. It also plays important roles in protein synthesis, cell 
proliferation, cell differentiation, microtubule dynamics, cell motility and neuronal development 
by phosphorylating initiation factors, transcription factors and proteins involved in microtubule 
functions and cell adhesion.148, 149 There are two isoforms of the protein, GSK-3α and GSK-3β. 
They share 98% of homology, but they are not functionally identical, although both have been 
suggested to be involved in AD pathogenesys.149 GSK-3α has been implicated in the 
amyloidogenic processing of APP to yield Aβ peptides,150 while GSK-3β has been implicated in 
the tau-related pathogenesis of AD by phosphorylating tau.151 GSK itself is also regulated by 
phosphorylation. Phosphorylation at Ser9 of GSK-3β and the equivalent Ser21 of GSK-3α by 
PKC inhibits its activity. On the other hand, phosphorylation at Tyr216/Tyr279 of GSK-3β and 
GSK-3α, respectively, increases its activity.152 
In the last few years, the interest for GSK-3 increased because it may offer an attractive target 
for drugs aimed at ameliorating AD. This is supported by the hypothesis that there is a 
correlation between Aβ accumulation and hyperphosphorylation of tau protein. Indeed, Aβ 
increases the phosphorylation of tau by activation of GSK-3. Wang et al.153 suggested that Aβ 
causes a reduction in PKC activity and, the subsequent inhibitory phosphorylation at Ser9, may 
be a crucial mechanism for the activation of GSK-3. More recently, it was shown that GSK-3 
regulates Aβ42 toxicity in vivo in a Drosophila model of AD overexpressing Aβ42. Inhibition of 
GSK-3 by lithium chloride, a direct inhibitor of GSK-3α and GSK-3β,154 rescued Aβ42 toxicity, 
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suppressing the locomotor dysfunction caused by expression of the peptide in flies’ neurons. 
GSK-3 effects on Aβ42 toxicity appear to be mediated by a tau-independent mechanism; it is 
suggested that inhibition of GSK-3 may increase Aβ degradation or clearance by enhancing the 
expression of Aβ-degrading enzymes.155 On the contrary, increased GSK-3 activity reduces Aβ-
degrading enzymes activity with subsequent amyloidosis.156 
Finally, Phiel et al.150 proposed that GSK-3α itself regulates production of Aβ. They showed that 
lithium chloride is able to block the production of Aβ40 and Aβ42 in cultured cells and in the 
brain of mice that overproduce amyloid peptides by interfering with APP cleavage at γ-secretase 
cleavage site. Furthermore, overexpression of GSK-3α increases Aβ production. Interestingly, 
lithium chloride does not inhibit Notch processing indicating that lithium is not a direct inhibitor 
of γ-secretase. It means that GSK-3α might regulate γ-secretase activity by regulating the access 
of substrate to γ-secretase complex. 
In conclusion, GSK-3 offers an attractive target for drugs aimed at reducing the formation of 
amyloid plaques and neurofibrillary tangles, the pathological hallmarks of AD. Thus, Abbott has 
identified potential inhibitors of GSK-3β, one of these (ABT-3174919) is now in preclinical 
trials for AD.122 Moreover, AL-108/davunetide is in Phase II for the treatment of mild cognitive 
impairment and AD. Davunetide seems to protect microtubules against hyperphosphorylated tau-
induced damage and it seems to have protective and cognition-enhancing properties.122 
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1.3 The cholinergic hypothesis  
The cholinergic hypothesis is the first theory proposed to explain AD. It states that a loss of 
cholinergic function in the CNS contributes to the cognitive decline associated with AD.157 The 
neuronal damage and death encompass regions critical for learning and memory, including the 
neocortex, hippocampus, amygdala, anterior thalamus and basal forebrain.158, 159 The key role of 
the acetylcholine system (choline acetyltransferase [ChAT], acetylcholine [ACh], 
acetylcholinesterase [AChE], muscarinic and nicotinic ACh receptors) in normal brain functions 
and in the memory impairment in AD, have been known for a long time.157, 160, 161, 162 
The cholinergic system uses ACh as neurotransmitter which is synthesized in neurons by action 
of ChAT, then concentrated in vesicles, and released from the pre-synaptic cell following 
depolarization. ACh, after interaction with receptors in the synaptic cleft, is hydrolyzed by action 
of AChE (Fig. 11). 
 
Figure 11: Schematic representation of the alterations that occur in cholinergic system in early 
AD brain compared with healthy young neurons.163 
 
The cholinergic hypothesis was developed a little earlier than the amyloid hypothesis of AD. In 
fact, the first finding in this field emerged in 1976 when it was found a significant loss of ChAT 
activity in different parts of the AD brain.164 ,165, 166 This discovery was soon confirmed with the 
finding that neurons in the basal part of the brain were selectively degenerated in AD,167 which 
explained the reduction in ChAT activity in the cortex and hippocampus. 
The cholinergic neurons release ACh, which can bind two different receptor subtypes: the 
nicotinic receptors (nAChRs) and the muscarinic receptors (mAChRs). nAChRs are ligand-
gated-ion-channels composed of different subunits assembled in pentameric structures. 
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Differently, mAChRs are metabotropic receptors that use G proteins as signal transducing 
molecules. M1, M3 and M5 receptor subtypes couple to Gq family G proteins, which activate 
phospolipase C (PLC), releasing inositol trisphosphate (IP3) and intracellular calcium. M2 and 
M4 mAChRs couple to Gi proteins which inhibit adenylate cyclase, decreasing the production of 
cAMP from ATP and inhibiting voltage-gated Ca2+ channels. Importantly, in 2012, X-ray 
structure of the M2 and M3 subtypes has been determined.168, 169 Several groups have reported a 
selective loss of different nAChRs subtype (α7 or α4β2) in AD brains.170, 171, 172 Moreover, also a 
reduction of mAChRs is thought to be involved in the development of AD. The major subtypes 
of mAChRs involved in cognition are the post-synaptic M1 receptors, which mediate the effects 
of ACh, and the pre-synaptic M2 receptors, which regulate ACh release. A decreased in density 
of M2 in post-mortem AD brain tissue have been reported.173 On the other hand, normal levels of 
M1 receptor contrasted with its diminished activity,174 suggesting that the coupling of these 
receptors to their G-proteins is impaired.175 This finding demonstrated that the extent of 
reduction in M1/G-protein coupling is correlated to the severity of cognitive symptoms in AD.175 
Both the amyloid and the cholinergic hypothesis of AD have been widely investigated and 
debated. There are various indications that a relationship exists between the two hypotheses. 
However, the link between them has not been established yet. The main pathways linking them 
are summarized below. 
A Toxicity of Aβ on the cholinergic system 
In animal models of AD, fragments of β-amyloid protein and tau protein are thought to interfere 
with central cholinergic transmission, specifically with synthesis and release of ACh.176 In 
cultured rat cortical neurons, Aβ40 and Aβ42 decreased the cholinergic neuron number and 
shortened neurite outgrowth length.177, 178 It was further shown that neuronal nAChRs interact 
with Aβ42 and Aβ40.179, 180, 181 Binding studies have revealed that the affinity of Aβ42 binding to 
α7nAChRs is exceptionally higher than the affinity of Aβ40. This interaction can be inhibited by 
α7nAChR antagonists.179 It has been suggested that the high-affinity binding of Aβ42 to 
α7nAChRs may be an important early step that promotes the internalization and accumulation of 
Aβ42 in neurons of AD brains. In fact, in vitro and in vivo studies revealed a substantial 
intraneuronal Aβ42 accumulation only in cells that express high levels of α7nAChRs.180, 181 
Moreover, Aβ peptides can block the interaction of ACh with their receptors on hippocampal 
neurons. The potential blockade of basal forebrain and hippocampal nAChRs by endogenous Aβ 
peptides promotes the cognitive decline associated with AD.  
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Moreover, subtoxic concentration of Aβ impaired the mAChR activation of G-proteins. A 
reduction of mAChR-stimulated phosphatidylinositol hydrolysis was found in rat primary 
cortical neurons exposed to Aβ fragments.182 Machova´et al.183 suggested that the results point to 
a complex malfunction of muscarinic/G-protein coupling, rather than a depletion of a specific 
mAChR subtype. 
B Cholinergic regulation of APP processing 
The relation between the effects of mAChRs184, 185, 186 and nAChRs187, 188, 189 stimulation and the 
modulation in APP processing has been studied for a long time. Biochemical studies revealed 
that stimulation of α7nAChRs can increase αAPPs which might be due to an enhanced cleavage 
of APP by α-secretase. Galantamine has an interesting pharmacological profile as it is both a 
reversible acetylcholinesterase inhibitor (AChEI) and an allosteric potentiator of nAChRs.190 
Furthermore, it increases the release of sAPPα, promoting the non-amyloidogenic processing of 
APP. The action of galantamine was prevented by α-bungarotoxin, a specific antagonist for 
α7nAChRs, but not atropine, a selective mAChR antagonist, suggesting the specific involvement 
of α7nAChRs. Agonist induced activation of M1 and M3 mAChRs, which are coupled to PLC 
and PKC activation, stimulates sAPPα release in vitro.185 This implicates increased α-secretase 
activity through mAChR activation. In fact, it is well-known that α-secretase-mediated cleavage 
of APP is regulated by several kinases like, for example, PKC.191, 192 M2 and M4 mAChRs are 
not effective in increasing sAPPα. Recent results showed that M2 stimulation decreased the 
BACE-1 expression.193 Since BACE-1 is a key enzyme in the accumulation of Aβ, its inhibition 
by a selective M2 mAChR agonist would be an important therapeutic target. 
 
1.3.1 Acetylcholinesterase 
AChE is a serine protease that hydrolyzes ACh in cholinergic brain synapses. The principal 
biological role of AChE is termination of impulse transmission at cholinergic synapses by rapid 
hydrolysis of the neurotransmitter ACh.194 The first X-ray crystallographic determination of 
AChE structure of was obtained from Torpedo californica.195 Later, it was also obtained the 
crystallographic structure of the human AChE.196 From crystallography, it was possible to 
observe at atomic resolution the protein binding pocket for ACh. It was found that the active site 
consists of a catalytic triad (Ser203, His447, Glu334) which lies in the bottom of a deep and narrow 
gorge, which is delimited by the ring of 14 aromatic amino acid residues (Fig. 12). Despite the 
complexity of this array of aromatic rings, it was suggested on the basis of modeling, which 
involved docking of the ACh molecule, that the quaternary group of the choline moiety makes 
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cation-pi interaction with the indole ring of Trp86. At the top of the gorge, a peripheral binding 
site (PAS) was also identified. It is delimited by Tyr72, Tyr124, Tyr341, Glu285, Asp74 and Trp286. 
Inestrosa and co-workers197, 198 proved for the first time the ‘‘non cholinergic action” of AChE, 
suggesting that PAS is able to induce Aβ aggregation. Thus, the interaction of Aβ at the PAS of 
AChE catalyzes some conformational changes in Aβ fibrils to form the β-sheet with increased 
aggregating potential.199, 200 The high concentration of AChE observed inside Aβ plaques support 
this hypothesis.201  
 
Figure 12: Active center gorge of human AChE. 
 
In vitro and in vivo studies have consistently demonstrated a link between Aβ production and 
cholinergic dysfunction. Scientific efforts to target AD are based on the identification of disease-
modifying compounds that are capable of affecting both cholinergic system and APP processing.  
However, to date, the only drugs approved by FDA for clinical use in AD are AChEI (tacrine, 
donepezil, rivastigmine, and galantamine, Fig. 13) and memantine, a NMDA antagonist (see 
1.7). Donepezil, rivastigmine and galantamine are generally preferred due to their modest risk of 
hepatotoxicity compared to tacrine. Tacrine, rivastigmine and galantamine interact at the 
catalytic site of the enzyme, while donepezil spans the whole length of the catalytic site 
simultaneously interacting with the tryptophan residues characteristic of the active and PAS of 
AChE.202  
AChEIs can provide symptomatic improvements but they do not offer long term cure for this 
disorder. Moreover, not all AD patients are responsive to the efficacy of AChEIs and to date the 
differences between ‘responders’ and ‘non-responders’ remain unclear. 
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Figure 13: Molecular structure of AChEIs used in clinical practice for AD 
 
1.4 Role of ApoE 
Apolipoprotein (Apo) E is a 34kDa lipid transport protein encoded on the long arm of 
chromosome 19. Its aminoacid sequence is essentially identical in many species, thus, it is likely 
to be a protein fundamental for life functions. In fact, apoE plays important roles in 
neurobiology;203, 204, 205 it is the major apolipoprotein in the CNS capable of redistributing lipids, 
including cholesterol, to sites of injury to repair cells. It is synthesized and secreted mainly in 
astrocytes but it is expressed also in some neurons in response to brain injury.206  
In the mid-1970s, Utermann et al.207 found that apoE was polymorphic; the gene encodes three 
alleles: apoE2 (frequency in population 5-10%), apoE3 (60-70%), and apoE4 (15-20%). ApoE4 
involvement in neuropathology is well documented and it is one of the genetic risk factor for 
sporadic and familial AD.208, 209, 210, 211, 212 Indeed, 40-80% of patients with AD possess at least 
one apoE4 allele.213 Similarly, apoE4 is associated with earlier onset and severity of head 
trauma,214, 215, 216 stroke,217 Parkinson’s disease,218, 219, 220 amyotrophic lateral sclerosis,221, 222 
multiple sclerosis223 and other severe CNS diseases. On the other hand, apoE2 seems protective 
relative to the prevalent apoE3.224 
ApoE has two structural domains: a 22-kDa N-terminal domain, which contains the LDL 
receptor binding region, and a 10-kDa C-terminal domain, which contains the major lipid 
binding element. Interaction between the C- and N-terminal domains is a unique property of 
apoE4.225, 226 X-ray crystallography has demonstrated the structural basis of domain interaction. 
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In apoE4, Arg-112 allows Arg-61 to form a salt bridge with Glu-255 at the C-terminus (Fig. 14). 
Differently, apoE2 and apoE3 have a cysteine in position 112. Thus, Arg-61 has a different 
conformation, and domain interaction does not occur. Interestingly, only human apoE has Arg-
61; the 17 other species in which the apoE gene is present all have Thr-61.227 Mutation of Arg-61 
to Thr or Glu-255 to Ala in apoE4 prevents C-terminal/N-terminal interaction and makes apoE4 
structurally and functionally similar to apoE3. Domain interaction between Arg-61 and Glu-255 
makes apoE4 unstable and it is thought to be responsible for the detrimental effects of apoE4. 
Protein instability is an important component of several neurodegenerative disorders. ApoE4 is 
the less stable isoform. In fact, it denaturates at lower concentration of guanidine-HCl and urea, 
and at lower temperature. This makes apoE4 more susceptible to form molten globules and to 
increase its propensity to proteolysis.  
Small molecules that are predicted to interact with apoE4 in the region of Arg-61 would disrupt 
domain interaction and may convert apoE4 to an “apoE3-like” molecule (Fig. 14). Thus, apoE4 
could be a new target for drugs development for AD. 
 
Figure 14: ApoE4 domain interaction mediated by salt bridge formation between Arg-61 and 
Glu-255.228 
 
Throughout life, neurons must be remodeled and regenerated to maintain synapto-dendritic 
connections. Through its lipid transport function, apoE is an important factor in this process. 
ApoE3 and apoE2 are effective in repairing neuronal cells, but apoE4 is less so. The detrimental 
insults could be oxidative stress, inflammation, excess Aβ production and aging process itself. 
Although apoE4 is strongly linked to AD pathology, its exact mode of action is still unknown. 
Many mechanisms have been suggested and are summarized below. 
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A Effects of ApoE4 on Aβ deposition and clearance 
Through interactions with Aβ, apoE4 may increase amyloid deposition, plaque formation and 
reduce its clearance in a mouse model of AD.229, 230, 231, 232 In vitro lipid-free apoE3 and apoE4 
can form stable complex with Aβ peptides. However, apoE4 forms complexes more rapidly and 
effectively.233, 234 Prolonged incubation of apoE with Aβ peptide gives rise to insoluble, high 
molecular weight complexes that precipitate in fibers. Moreover, apoE4 forms a denser, more 
extensive matrix of amyloid monofibrils and does so more rapidly and effectively than apoE3.235, 
236
 In addition, apoE4 enhances zinc- and copper-induced Aβ aggregation.237 Thus, increased 
amyloid fibril formation caused by apoE4 might trigger or exacerbate neurodegeneration and the 
development of AD. However, poorly lipidated apoE3 and apoE4 yielded different results when 
incubated with Aβ peptides. It seems that apoE3 bound with a 20-fold greater affinity than 
apoE4 to Aβ. This suggests that the lipidation status of apoE modifies its ability to interact with 
Aβ peptides.238, 239 It is thought that the binding of apoE3 to Aβ, might enhance clearance of the 
peptide, preventing the conversion of Aβ into neurotoxic specie.239 
B Effects of ApoE4 on Aβ production. 
Many studies have been focused on the role of apoE4 in stimulating Aβ accumulation. However, 
apoE4 also enhances Aβ production. In rat neuroblastoma cells transfected with human wild-type 
APP695, lipid-poor apoE4 increased Aβ production more than apoE3 (60% vs. 30%).240 It seems 
that LRP, a member of the LDL receptor family,241 may mediate the isoform-specific effects of 
apoE on Aβ release. Ye et al.240 suggested that the binding of apoE4 to LRP accelerates APP 
endocytosis and recycling and thus enhances Aβ production.242, 243, 244 
C Effects of ApoE4 on Tau Phosphorylation 
In AD brains, tau is abnormally hyperphosphorylated and self-assembles into pathological paired 
helical filaments, which result in NFTs. Evidence from in vitro and in vivo studies suggests that 
apoE3 and apoE4 have different effects on the interaction with hyperphosphorylated tau. In vitro, 
apoE3 forms stable complex with tau, on the other hand apoE4 does not interact significantly.245, 
246
 Phosphorylation of tau inhibited the interaction of apoE3 with tau suggesting that apoE3 
binds to tau and may protect it from hyperphosphorylation inducing NFTs formation.247 In 
addition, it was found that, single-nucleotide polymorphisms (SNPs) in the GRB-associated 
binding protein 2 (GAB2) gene in apoE4 carriers, highly increase LOAD (late-onset AD) risk. 
GAB2 is the main activator of phosphatidylinositol 3-kinase (PI3K). PI3K promotes cell survival 
by activating its downstream effector Akt kinase.248 Akt inactivates GSK-3α and GSK-3β by 
phosphorylating the former at Ser21 and the latter at Ser9. Thus, GAB2 might protect neurons 
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from tangle formation and cell death and a loss of function of GAB2 would diminish such 
protection. Six SNPs which reduce GAB2 function were identified and, in association of apoE4 
allele increase AD genetic risk.249 Discovery of these LOAD susceptibility genes provides new 
opportunities in the scientific understanding, treatment and prevention of AD. 
D ApoE4 Fragmentation and AD 
The neuronal expression of apoE is induced to protect neurons from injury and to promote 
intraneuronal repair. However, when synthesized in neurons, apoE can be cleaved by proteases, 
and the fragments are toxic for cells leading to cell death and to the formation of cytoplasmic 
NFT-like inclusions in the cytoplasm and in mitochondria.250 ApoE4 is more susceptible to 
proteolytic cleavage than apoE3, when expressed in transfected neuronal cells.251 In addition, 
apoE fragments are produced at higher levels in brains of AD patients than in brains of non-
demented controls. 
E ApoE4 potentiation of Aβ-induced lysosomal leakage and apoptosis 
Internalized Aβ42 is degradation resistant, and it accumulates as insoluble aggregates in 
endosomes and lysosomes leading to their leakage through free radicals generation. In cultured 
cells, apoE4 enhances Aβ-induced lysosomal leakage and apoptosis to a greater extent than 
apoE3. It is suggested that, because of its unique conformation and reactivity, apoE4 forms toxic 
intermediates (molten globules) and assumes detrimental activities when it reaches acidic pH in 
lysosomes destabilizing their membrane. 
 
1.5 The role of metallobiology in AD 
Mounting evidences support the idea that endogenous ‘biometals’, such as Cu, Fe, Zn and 
exogenous Al, can be involved as factors or cofactors in the etiopathogenesis of AD. In AD, the 
process of Aβ misfolding and plaque aggregation seems to be greatly influenced by alterations in 
the homeostasis of these metal ions. Indeed, they are found with high concentration in both the 
core and rim of AD senile plaques.252 
In eukaryotes, Cu, Fe and Zn are the most abundant biochemically functional metals. These 
elements are often referred to as ‘‘trace metals’’. Although they exist in a smaller amount 
compared to carbon, hydrogen, nitrogen, oxygen and phosphorous, they are just as essential. In 
fact, metals are important for enzymatic function, playing important roles in catalysis, structural 
stability, transport of oxygen and cellular signaling. Genetic dysfunction, environmental 
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exposure, ageing, inadequate dietary intake and drug interaction can all induce an alteration in 
their homeostasis leading to deleterious effects and neurotoxicity (Fig. 15). 
 
Figure 15: Schematic representation of the factors affecting the delicate balance between metal 
ions accumulation and deficiency.253 
 
The “amyloid cascade theory” has dominated AD research for the past 15 years but the exact 
factors that drive Aβ accumulation remain a mystery. However, the interest for the role of metal 
dyshomeostasis as a pathogenic factor for AD has been strongly revived after the finding that 
therapeutic strategies restoring metal ion homeostasis in the brain of both AD patients and AD 
transgenic mice are able to reverse amyloid aggregation, dissolve amyloid plaques and delay the 
cognitive impairment associated to AD.254, 255, 256 
 
1.5.1 Metals in AD 
Most of the glutamatergic synapses in the cerebral cortex co-release Zn with glutamate.257, 258, 259 
This cation has been found to have a primary role in AD because of its efficacy to induce fast 
precipitation of Aβ together with its ability to build up protease resistant ‘non-structured’ 
aggregates.260 Studies on AD animal models have also revealed that genetic ablation of synaptic 
Zn greatly reduces the amount of amyloid plaques.261 Moreover, several studies showed that 
compounds affecting Zn homeostasis can decrease Aβ deposition in the brain.262, 263 Finally, 
expression levels of Zn transporters (ZnT1, ZnT3,264 ZnT4 and ZnT6265), essential for loading 
Zn into synaptic vesicles, were discovered to be altered in the brain of individuals affected by 
mild cognitive impairment and AD. Zn may again be important as it has been shown to enhance 
the synthesis of the PS subunit of γ-secretase, altering the processing of APP to favor the 
amyloidogenic pathway.266  
Like Zn, Cu is synaptically released after stimulation of the N-methyl-D-aspartate (NMDA) 
receptor by glutamate267 and it acts as a potent mediator of Aβ aggregation under conditions of 
mild acidosis.268 Nevertheless, Cu has the additional property of producing strong mitochondrial 
oxidative stress.269  
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The third transition metal found localized in human amyloid plaques is Fe. Despite having a high 
concentration in AD plaque,270 Fe ions are not likely to interact directly with Aβ in vivo. In fact, 
studies of various metal-ion chelators in solubilizing Aβ from postmortem AD-affected brain 
tissue have correlated the dissolution of precipitated Aβ with the release of Cu and Zn, but not 
Fe.271 Several studies suggest that Fe homeostasis is altered in AD, however it seems a secondary 
effect via another process such as increased heme oxygenase activity in response to oxidative 
stress.272 
In the context of AD-related metal dyshomeostasis, the role of Al is the subject of a controversial 
debate because of the paucity of reliable studies and data. Several researchers indicated that Al 
can contribute to both tau and Aβ pathology. Al, a highly reactive element, can promote tau and 
Aβ pathology as the ion can easily cross-link hyperphosphorylated proteins.273 Moreover, Drago 
et al,274 indicated that Al seems to be very effective in promoting in vitro ‘structured’ 
aggregation of Aβ associated with particularly high neurotoxicity. 
 
1.5.2 Aβ binding to metals 
Multivalent metal ions are fundamental to redox chemistry. The ability of these metal ions to 
occupy multiple valence states and undertake facile redox cycling, has been utilized by a variety 
of enzymes including ceruloplasmin,275 cytochrome c oxidase275 and amine oxidases.276 Aβ is a 
metalloprotein that displays high affinity binding of Cu2+, Zn2+ and Fe3+ ions.277 The metal 
binding site for Zn and Cu implicate three histidine residues (His6, His13, His14) which coordinate 
the metal ions through the imidazole nitrogens. Aβ possesses a strong positive formal reduction 
potential and rapidly reduces Cu2+ and Fe3+ to Cu+ and Fe2+, respectively. Molecular oxygen is 
then trapped generating free radical and peroxides species via Fenton chemistry or Haber- Weiss 
reaction with the Aβ42 species exhibiting the greatest activity (Fig. 16).278 
 
 
Figure 16: Redox chemistry involving Aβ and metals.279 
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Excessive levels of Aβ and metal ions may generate ROS concentration exceeding the capacity 
of the normal oxidation defence system. A broad range of lipid peroxidation products can evolve 
from the cascade of events described above. High levels of reactive electrophilic aldehydes and 
4-hydroxy-2-nonenal (HNE) have been found in AD brain tissue. These aldehydes readily react 
with nucleophile such as DNA, protein and other lipids initiating a cascade of oxidation events 
leading to cellular dysfunction and ultimately death (Fig. 17). 
 
Figure 17: Redox cycle and ROS generation.279 
 
Moreover, it is suggested that Aβ, in the presence of Cu2+ and H2O2, forms dityrosine cross-
linked structures which facilitate further peptide aggregation, leading to the formation of higher 
ordered oligomers that accumulate in the senile plaques (Fig. 18).280 
 
Figure 18: Generation of Aβ dityrosine oligomers.279 
 
1.5.3 Metal homeostatic therapy 
Although metal ion dyshomeostasis is certainly not the only cause of the disease, therapeutic 
interventions aimed at restoring metal homeostasis remain strong candidates as disease-
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modifying strategies for AD treatment. 5-Chloro-7-iodo-8-hydroxyquinoline (clioquinol, CQ) 
has generated a great interest because of promising results in vitro and in vivo. CQ (Fig. 19) was 
produced as a topical antiseptic and sold as an oral intestinal amebicide in 1934. In the early 
1970s, it was withdrawn from the market as an oral agent because of its severe side effects. CQ 
is currently available in some countries as a topical formulation for the treatment of skin 
infections. Its ability to act as a zinc and copper chelator281 has renewed the interest of many 
researchers for its possible use in the treatment of AD. Prana Biotechnology has developed a 
new hydroxyquinoline derivative (PBT-2) with a better toxicological profile than that of CQ. 
PBT-2 is currently in Phase II for the treatment of AD.122 
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Figure 19: CQ structure. 
 
1.6 Role of oxidative stress in AD 
Oxidative stress is defined as a breaching of the antioxidant defense system. The brain is the 
most aerobically active organ in the body due its high metabolic requirements. The brain 
accounts for 2% of total body mass and it consumes 20% of total oxygen. Neurons are subject to 
a number of unique conditions that make them particularly vulnerable to oxidative stress. This 
vulnerability is a consequence of the high energy and oxygen consumption rate and the high 
amount of unsaturated lipid content in neuronal membrane.282 Therefore, it is essential to 
maintain oxidative balance and control in the brain, and this is tightly regulated by antioxidants 
that are present in higher amounts than in any other organs. In the case of age-related 
neurodegeneration, like that observed in AD, this balance between oxidative radicals and 
antioxidant defenses is altered, resulting in various forms of cellular and molecular damage than 
can culminate in cell death. Although it is debatable whether oxidative stress is the cause or 
consequence of the disease, recent evidence suggesting that oxidative stress occurs earlier than 
all other known changes indicates a causative role in the pathogenesis of AD.283 
 
37 
 
1.6.1  Contribution of ROS 
ROS that are generated intracellularly and extracellularly by various mechanisms are among the 
major intermediary risk factors that initiate and promote neurodegeneration in idiopathic AD.284, 
285
 Individuals affected by AD showed increased oxidative damage to every class of biological 
macromolecules, like sugars, lipids, proteins, and nucleic acids. 
A schematic pathway of pathological lesions induced by oxidative stress is shown in Figure 20.  
 
Figure 20: Schematic pathway of pathological lesions induced by oxidative stress.286 
 
The vast majority of oxidative-stress-dependent protein modifications involve the adduction of 
products following the oxidation of carbohydrate or lipid moieties (glycoxidation and 
lipoxidation, respectively) and results in the formation of stable adducts called advanced 
glycation end products (AGEs) or advanced lipoxidation end products (ALEs).287 AGE 
modification and the resulting cross-linking of protein deposits have been shown to occur in both 
senile plaques and NFTs in AD. ROS cause damage to lipid by forming lipid peroxidation and 
products such as maloaldehyde and 4-hydroxynonenal (4-HNE). 4-HNE adducts bind directly to 
tau, inhibiting its dephosphorylation. Aβ generated ROS also disrupt ion homeostasis, changing 
the function of ion motive ATPase and promoting the activation of N-methyl-D-aspartate 
(NMDA) receptors which determine an increase of intercellular Ca2+ levels. Moreover, DNA 
damage induced by free radicals, in particular by hydroxyl radical (·OH), triggers DNA damage, 
which may be an important factor in the progression of cell death in AD.288 
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1.6.2  Mitochondrial dysfunction 
Mitochondria are dynamic organelles required for several biosynthetic processes and provide 
most of the cellular energy demand. Moreover, they maintain Ca2+ homeostasis and take part in 
apoptosis. They are composed by outer and inner membranes containing phospholipid bilayers 
and proteins (Fig. 21). The two membranes, however, have different properties. Because of this 
double-membraned organization, there are five distinct compartments within the mitochondrion. 
They are: 
 
• the outer membrane 
• the intermembrane space (the space between the outer and inner membranes) 
• the inner membrane 
• the cristae space (formed by infoldings of the inner membrane)  
• the matrix (space within the inner membrane) 
 
 
 
 
Figure 21: Mitochondrion structure. 
 
The outer membrane, like the plasma membrane, is composed by lipid and protein in ratio of 1:1 
and it does not offer a barrier to small molecules that can simply diffuse through pores in the 
membrane formed by a membrane spanning protein called porin. ATP synthesis occurs in the 
matrix space via the electronic transport chain (ETC), localized in the inner membrane, that 
performs the redox reactions of oxidative phosphorylation (OXPHOS). The inner membrane 
contains also the ATP/ADP carrier that allows ADP to cross the inner membrane while 
simultaneously transferring out ATP from the matrix space. The composition of the inner 
membrane differs from the outer in that it is more proteinacious and contains an unusual 
phospholipid, cardiolipin. Unlike the outer membrane, the inner membrane does not contain 
porins and is highly impermeable to all molecules. In fact, almost all ions and molecules require 
special membrane transporters to enter or exit the matrix. Perhaps, the most important function 
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of mitochondria is the synthesis of ATP, the most important source of energy. In fact, 
mitochondria are defined as “the power house” of the cell.289 In neurons, mitochondria are 
significantly localized at synapses and are essential for their normal function, supplying them 
with ATP for neurotransmission.290 The energy released by the flow of ETC is used to pump 
protons out of the mitochondria inner membrane through complexes I, II, III, and IV (Fig. 22). 
This generates an electrochemical gradient across the mitochondria inner membrane. The 
potential stored is coupled to ATP synthesis by complex V (ATP synthase). 
 
Figure 22: The two faces of mitochondria.291 
 
Oxygen normally serves as the ultimate electron acceptor and is reduced to water.292 However, 
OXPHOS in a major source of toxic endogenous free radicals. In fact, when ETC is inhibited, 
electrons accumulate in complex I and III, where they can be donated directly to molecular 
oxygen to yield O2·- that can be further detoxified by the mitochondrial manganese superoxide 
dismutase producing H2O2 by the glutathione peroxidase. However, O2·- in the presence of NO·, 
formed by the nitric oxide synthase, can lead to the formation of ONOO-. Furthermore, H2O2 in 
the presence of reduced transition metals can be converted via Fenton reaction to the hydroxyl 
radical OH·. Other mitochondrial enzymes can generate ROS, like α-ketoglutarate–
dehydrogenase complex (KGDHC) and pyruvate–dehydrogenase complex (PDHC). KGDHC 
and PDHC are two enzymes of the tricarboxylic acids cycle. The reduced activity of these key 
enzymes favors the aberrant production of ROS, especially in the form of H2O2.293  
Abnormalities in the oxidative balance and the reduced rate of glucose metabolism are one of the 
best documented dysfunctions in AD, which precedes, rather than follows, the clinical 
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manifestation of the disease.294 If ROS levels overwhelm the defense mechanism of the cells, 
oxidative damage of proteins, lipid and DNA takes place, leading to cell degeneration and death 
(Fig. 20). The reduction of cerebral metabolism in AD places mitochondria at the center of the 
attention and indeed, several studies corroborate the idea that mitochondrial dysfunction is a 
hallmark of Aβ-induced neuronal toxicity in AD. 
Many researchers showed that both APP and Aβ are present in mitochondria in the brains of AD 
patients.295, 296, 297 APP is imported to mitochondria and spans the mitochondrial intermembrane 
space with the NH2-terminus inside the matrix and COOH-terminal fragment facing the cytosol, 
staying in close association with outer membrane channels. Docking APP in mitochondrial 
import channels has been proposed to inhibit the import of nuclear-encoded proteins, essential 
for mitochondrial function.295, 296 It appears that Aβ is also present in mitochondria of non-
demented human brains, albeit at a lower level.297 Likewise, Sheng et al.298 demonstrated that 
constitutive low levels of APP are involved in maintaining mitochondrial functions. In brain 
specimens from AD patients, mitochondrial APP and Aβ induce ROS generation,299 decrease 
COX activity and ATP production.296 Interestingly, it was demonstrated that Aβ binds to alcohol 
dehydrogenase (ABAD). ABAD is localized in mitochondrial matrix and plays an essential role 
in mitochondria. The interaction of Aβ and ABAD inhibits ABAD activity and leads to elevated 
ROS production, cell death, and subsequent memory impairment in transgenic mice AD 
models.300 Furthermore, evidence indicates that γ-secretase, which is essential for Aβ production, 
is present in mitochondria.301 Moreover, it seems that ATP synthase inhibition and COX 
inhibition drives APP processing towards the amyloidogenic pathway302 and tau 
phosphorylation.303  
Besides mitochondria are highly affected by oxidative damage, another key event, resulting from 
mitochondrial dysfunction, is the opening of the mitochondrial permeability transition pore, 
leading to loss of mitochondrial permeability and consequent release of cytochrome C into the 
cytosol.304 This event results in the activation of a family of cysteine protease called caspase, the 
intracellular executors of apoptosis, ultimately leading to the activation of caspase-dependent 
nucleases, which result in DNA fragmentation and cell death.  Thus, considering the extreme 
importance of oxidative stress and mitochondria in AD, therapeutic antioxidant strategies 
preventing oxidative damage and targeting mitochondria are currently pursued.  
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1.7  Inflammation and AD 
According to the inflammatory hypothesis of AD, chronic cerebral inflammation causes injury to 
neurons, contributing over time to cognitive decline.305 It is hypothesized that neuronal injury 
results from the direct effects of inflammatory effectors, such as cytokines or activated 
complement, or indirect effects, such an increased production of neurotoxic Aβ in response to 
cytokines or other inflammatory stimuli.306 Microglia and astrocytes, the primary immune 
effector cells of the brain, are thought to be the key elements in this process. In AD, the number 
of reactive astrocytes and activated microglia is increased, and they are found in and around 
neuritic plaques.  
Aβ is thought to be neurotoxic and to play a key role in the pathophysiology of AD. 
Significantly, Aβ induces microglia to produce many agents with the potential to injure neurons, 
including inflammatory and chemotactic cytokines,307 chemokines,308 NO309 and ROS310, 311 
(Fig. 23) 
 
Figure 23: Schematic inflammation process in AD brains.286 
 
The proinflammatory cytokine IL-1 is thought to play a critical role in neuronal injury in AD.308 
IL-1 is increased in AD brains and e found mainly around diffusive amyloid plaques.312 It 
accounts for increasing the translation of mRNA encoding APP313 and its over-expression could 
lead to an early onset of AD. IL-1 increases Aβ, then Aβ could induce additional IL-1 
expression314 resulting in a positive feedback loop. IL-1 also induces astrocytes and microglia 
proliferation.315 Although astrocytes have neuroprotective functions, excessive astrocytic 
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proliferation can inhibit neurite growth, whereas microglial proliferation is associated with 
cytotoxic activity. Finally, IL-1 induces microglial inducible macrophage nitric oxide synthase 
(NOS)316 and the release of ROS that enhance the degenerative process.317 Although under some 
conditions IL-1 may be neuroprotective, existing evidence strongly suggests a negative role for 
IL-1 in AD. 
Tumor necrosis factor (TNF)-α is thought to be involved in AD pathogenesis too. Thus, He et 
al.318 showed that TNF receptor 1 knockout protects against AD-like disease in mice. 
Cyclooxygenase (COX) is an enzyme that converts arachidonic acid to prostaglandin H2 (PGH2), 
the precursor of prostanoids (prostaglandins, prostacyclin and thromboxane), important biological 
mediators of inflammation. Although COX-1 is constitutively expressed in many cell types and 
tissues, COX-2 is increased during inflammation, resulting in proinflammatory prostanoids 
synthesis.319 Cyclooxygenases are the key targets of non-steroidal anti-inflammatory drugs 
(NSAIDs). COX is strongly implicated in AD by epidemiologic studies of long term NSAIDs 
use. It was shown that such long term use reduced AD risk by half.320 These findings have been 
confirmed in a number of other studies, but did not lead to successful treatment trials yet. One 
possible reason for this failure may be that, like many other inflammatory mediators, 
prostaglandins are janus-faced, exerting beneficial or toxic functions depending on the setting. 
For example, COX-2, which is localized postsynaptically, is involved in modulating 
physiological synaptic transmission, but excessive activation in pathological conditions in 
transgenic mice induces neuronal apoptosis and cognitive deficits.321 Thus, it was shown that 
transgenic over-expression of COX-2 in neurons led to a two-fold increase in Aβ plaque and 
cognitive deficits in an APP mouse model322 323 supporting a detrimental role for COX-2 in 
neurodegeneration and AD. 
NSAIDs have been shown to directly affect the production of Aβ. For example, ibuprofen, 
flurbiprofen, indomethacin and sulindac sulphide were shown to decrease Aβ42 peptide by up to 
80% in cultured cells but this effect was not observed with naproxen, celecoxib, or aspirin.324 
Since not all NSAIDs had this effect, it would seem that this effect occurs through a process that 
is independent of their anti-inflammatory COX inhibition.325 
 
1.8 The glutamatergic hypothesis 
Glutamatergic neurons form the major excitatory system in the brain and play a critical role in 
several physiological functions. The neurotransmitter glutamate activates many metabotropic 
receptors and three major types of ionotropic receptors; α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA). There is 
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increasing evidence for the involvement of glutamate-mediated neurotoxicity in the pathogenesis 
of AD. In particular, the overactivation of NMDA seems to be one of the major causes that 
mediate neurotoxicity in AD.  
NMDA is a voltage-gated ion (or ionotropic) channel permeant to Ca2+, Na+ and K+ (Fig. 24). It 
is a tetrameric hetero-oligomeric protein. Two major subunit families designated NR1, NR2 as 
well as a minor subunit designated NR3 have been cloned. A functional NMDA receptor is 
formed by one or more NR1 subunits, plus one or more NR2 subunits. NR1 contains the glycine-
binding site, while NR2 expresses the glutamate recognition site.326, 327 Glycine is a co-agonist, 
necessary for NMDA activation. There are four known subtypes of NR2 (A, B, C and D) and 
eight splice variants of NR1. NR3 (NRL or Chi-1) seems to be expressed predominantly in the 
developing CNS.  
The subunits are differentially expressed in the brain. For example, the NR2B subunit 
predominates in extrasynaptic rather than in synaptic NMDARs and it is thought that excessive 
stimulation of extrasynaptic receptors containing NR2B might contribute to neurotoxicity, 
whereas NR2A might be neuroprotective maintaining physiological synaptic activity.328  
NMDA receptors can be blocked by competitive glutamate antagonists such as D-AP5 ((2R)-
amino-5-phosphonovaleric acid)329 and glycine antagonists such as 5,7-DCKA (5,7-
dichlorokynurenic acid).330 Polyamines such as spermine and spermidine are positive modulators 
binding to NR2B subunits but they also block the channel at higher concentrations. Ifenprodil331 
is the prototypic ‘‘selective‘‘ antagonist for NR2B containing receptors, while Zn2+ is a potent, 
voltage-independent antagonist at NR2A containing receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Scheme of the NMDA receptor.332  
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The gating of NMDA receptor involves a voltage-dependent Mg2+ blockade of the channel pore. 
When the signal arrives at the glutamatergic synapse, glutamate is released and it binds to both 
NMDA and AMPA receptors (Fig. 25). However, only the latter is activated, since Mg2+ blocks 
the NMDA channel (this ion is trapped in a narrow region of NMDA and it is attracted into the 
cell which has a negative membrane potential). Activation of AMPA receptors leads to a 
continued influx of Na+ ions into the cell which leads to a decrease in membrane potential 
(partial depolarization). This depolarization removes Mg2+, since the charge of the neuronal 
membrane is now much less negative. At this stage, Ca2+ ions can freely enter the cell via the 
NMDA receptor channel and initiate a number of enzymatic processes that are involved in the 
fixation of increased synaptic strength (neuronal memory formation).333  
 
Figure 25: Activation of NMDA receptor.332 
 
On the other hand, excessive activation of NMDA can also evoke neuronal dysfunction and even 
damage and death. This cell death caused by an excessive activation of glutamate receptors has 
been termed “excitotoxicity”334, 335 and is thought to contribute to a wide range of neurological 
disorders such as stroke and trauma, but also neurodegenerative diseases like AD.336 
Overactivation of NMDARs results in a excessive opening of ion channels that causes an 
exaggerated Ca2+ influx, which can result in the production of damaging free radicals and 
activation of proteolytic processes that contribute to cell injury or death.337, 338, 339, 340, 341 The 
signaling cascade that leads to apoptosis  
and cell death is summarized in Figure 26. The excessive Ca2+ influx (a) causes oxygen free-
radical formation and activation of neuronal NOS that leads to nitric oxide (NO•) and 
peroxynitrite (ONOO–) production (c).342, 343, 344 Cytochrome-c is then released from 
mitochondria with the subsequent activation of pro-apoptotic enzyme such as caspases (d).345, 346 
Moreover, NMDAR hyperactivation leads to the stimulation of the p38 mitogen-activated kinase 
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(MAPK)–MEF2C pathway (b) which activates transcription factors that can go into the nucleus 
to influence neuronal injury and apoptosis.347  
 
Figure 26: Scheme of the apoptotic cell injury and death pathways triggered by excessive 
NMDAR activity.348 
 
There are several potential links between glutamate-mediated excitotoxicity and the main 
hallmarks of AD such as Aβ and hyperphosphorylated tau proteins. For example, Aβ destabilizes 
calcium homeostasis, increasing NMDA responses and therefore excitotoxicity.349  
APP and Aβ have different effects on glutamatergic activity (Fig. 27). In fact, APP blocks 
NMDAR activity (1), and it enhances glutamate transport removing glutamate from the synaptic 
cleft (2). On the other hand, Aβ stimulates NMDA receptors (3) and it blocks glutamate uptake 
(4) thereby increasing glutamate concentrations in the synaptic cleft (5).350, 351, 352, 353, 354 
 
Figure 27: Effects of APP and Aβ on glutamatergic activity. 355 
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Moreover, it was reported that glutamate transporters are down-regulated in AD and Aβ can 
either directly or indirectly inhibit glutamate reuptake or even enhance its release.356 Excessive 
NMDAR activity has also been reported to increase the hyperphosphorylation of tau, which 
contributes to NFTs.357 
 
1.8.1 Memantine: a NMDA receptor uncompetitive fast off-rate inhibitor 
Excitotoxicity represents an attractive target for neuroprotective efforts because it is involved in 
the pathophysiology of a wide variety of acute and chronic neurodegenerative disorders. 
However, the same processes that in excess lead to exitotoxic cell death, are at lower levels 
absolutely crucial for normal neuronal function. In fact, the blockade of NMDARs in the 
brainstem, an area responsible for wakefulness and attention, would cause drowsiness and even 
coma. It is therefore essential to preserve physiological NMDAR activity in order to maintain 
these normal functions and avoid intolerable clinical side effects. Consequently, to be clinically 
acceptable, an anti-excitotoxic therapy must block excessive activation of NMDARs while 
maintaining normal function intact. Drugs that simply compete with glutamate or glycine at the 
agonist-binding sites block normal function and therefore do not meet this requirement. Thus, 
they have failed in clinical trials to date, because of their severe and unacceptable side effects 
such as drowsiness, hallucinations and coma.358, 359 
Memantine (Fig. 28) is a drug approved by the European Union and the US FDA for the 
treatment of moderate-to-severe AD and since this time, it is on the market in Europe, USA and 
many other countries in the world.360  
NH2
 
Figure 28: Memantine structure. 
 
Memantine mechanism of action differs from that of the major therapies in AD which are all 
AChEIs (see 1.3.1). In fact, AChEIs offered only symptomatic relief, whereas memantine is 
thought to be the first neuroprotective drug that achieved clinical approval. It is a low-affinity, 
open-channel blocker, which is a drug that only enters the channel when it is excessively opened 
by agonist. Indeed, memantine blocks the excessive NMDAR activity while sparing normal 
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excitatory synaptic function.348 A low micromolar concentration of memantine blocks the effects 
of higher amounts of NMDAR agonist to a greater extent than the effects of lower concentration 
of agonist. This phenomenon can be explained by the fact that, as memantine blocks only open 
channels, more channels are blocked when more agonist is present. Thus, memantine is an 
example of a drug that has an “uncompetitive” mechanism of action. An uncompetitive 
antagonist can be distinguished from a noncompetitive antagonist. The latter is a compound that 
binds in a site that is different from the agonist-binding site. On the other hand, an uncompetitive 
drug is a receptor antagonist whose inhibitory action depends on prior activation of the receptor 
by an agonist. Memantine has also fast off-rate properties. It means that, although memantine is 
highly selective for the NMDAR, it has a low affinity for the receptor. It assures fast association 
and dissociation kinetics with the receptor  during prolonged depolarization, restoring normal 
NMDA activity (Fig. 29). Lipton348 suggested that NMDAR activity can be compared to a 
television. The agonist sites act as the ‘on/off ’ switch button of the television. Drugs that 
interact with agonist sites cut off all normal NMDAR functions and result in clinically 
unacceptable side effects. Instead, during excessive Ca2+ flux through the NMDAR, it would be 
necessary to regulate the volume control (or ‘volume’ of ion flow) of the NMDAR. Several 
experiments suggested that memantine possesses this mechanism of action.  
 
 
Figure 29: Fast blocking/unblocking channel properties of memantine.355 
 
The Fast Off-rate and the Uncompetitive mechanism of memantine make this drug very tolerant 
compared to other NMDA-type receptor antagonists. Molecules that possess these both 
properties have been coined UFO drugs. 
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1.9 The role of G protein-coupled receptors in AD 
G protein-coupled receptors (GPCRs) are the largest class of cell-surface receptors and play 
essential and crucial roles in every organ system.361 GPCRs are involved in several key 
neurotransmitter systems in the brain that are disrupted in AD. GPCRs are membrane-bound 
proteins that are activated by extracellular ligands such as light, peptides, neurotransmitters and 
transducer intracellular signals via interactions with G proteins. The resulting change in 
conformation of the GPCR induced by ligand binding activates the G protein, which is composed 
by a heterotrimeric complex of α, β, and γ subunits. In their inactive state, G proteins are bound 
to guanosine 5-diphosphate (GDP). Activation of the G protein causes the exchange of 
guanosine 5-triphosphate (GTP) for GDP within the α subunit. Activated G protein subunits then 
modulate the function of various effector molecules such as enzymes, ion channels, and 
transcription factors. Inactivation of the G protein occurs when the bound GTP is hydrolyzed to 
GDP, resulting in reassembly of the heterotrimer. The most of GPCRs are often termed 
rhodopsin-like GPCRs and are structurally similar in that they consist of an extracellular N-
terminal domain, seven transmembrane-spanning domains, and an intracellular C-terminus 
domain.  
Current AD drugs target AChE which stimulates cholinergic system. However, 
neurodegeneration does not involve a specific neurotransmitter system. Glutamatergic, 
serotonergic, adrenergic and peptidergic neurotransmitter systems are also involved in the 
pathology of AD. The cleavage of APP by α-, β-, and γ-secretases, Aβ deposition and amyloid 
plaque formation are regulated by GPCRs. In this section it is discussed the involvement of 
GPCRs in the amyloid cascade and the pharmacological approaches to target the putative 
therapeutic properties of AD-associated GPCRs.  
 
1.9.1  Metabotropic glutamate receptors 
Glutamate is the transmitter of the vast majority of the fast excitatory synapses in the mammalian 
CNS and plays an important role in a wide variety of CNS functions.362 In the past, the actions of 
glutamate in mammalian brain were thought to be mediated exclusively by activation of 
glutamate-gated cation channels termed ionotropic glutamate receptors (iGluRs). However, in 
the mid 1980s, it was discovered that glutamate interacts also with metabotropic glutamate 
receptors (mGluRs), which are coupled to effector systems through GTP-binding proteins. 
mGluRs are divided into three groups: group I (mGluR1 and mGluR5), group II (mGluR2 and 
mGluR3) and group III (mGluR4, mGluR6, mGluR7 and mGluR8).363 In general, group I 
mGluRs couple to Gq and activate PLC, resulting in the hydrolysis of phosphotinositides and 
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generation of IP3 and DAG. This classical pathway leads to calcium mobilization and activation 
of PKC. They are thought to participate in the regulation of synaptic plasticity and postsynaptic 
glutamatergic excitability.364, 365 In contrast to group I mGluRs, group II and group III mGluRs 
are coupled to Gi proteins that inhibit adenylyl cyclase and cAMP production. It is becoming 
increasingly appreciated that group II and group III mGluRs also couple to other signaling 
pathways, including activation of MAPK and PI3K pathways.366 Group I mGluRs-linked PLC 
activity is downregulated in the cerebral cortex of AD patients.367 By contrast mGluR2 is 
overexpressed in the hippocampus of patients with AD and its activation leads to tau 
phosphorylation.368, 369 Kim et al.370 showed that group I mGluR stimulation leads to activation 
of α- and β-secretases, accumulation of C83 and C99, respectively, and increased release of 
Aβ40 (Figure 30). The 40 amino acid isoform of Aβ seems to be antiamyloidogenic in vivo.118 
Similar to group I mGluRs, group II mGluR stimulation activates the α- and β-secretases. 
However, group II mGluR stimulation causes the release of Aβ42. On the other hand the 42 
amino acid isoform of Aβ seems to aggregate into amyloid much more rapidly than Aβ40 in 
vitro. In fact, Aβ42 is the predominant isoform of Aβ that accumulates in the brains of patients 
with AD and it is essential for seeding Aβ deposition in vivo.371, 372  
 
Figure 30: mGluRs signaling pathway.373 
 
Thus, Aβ42 production could be blocked with a specific group II mGluR antagonist, whereas 
upregulation of group I mGluR signaling may increase synaptic Aβ40 generation. Moreover, 
group II mGluR inhibitors seem to enhance hippocampus-dependent cognitive functions in 
50 
 
rodents.374 Only two drugs are currently in development as mGluR antagonists for the treatment 
of AD. ADX71149 is in Phase II as an mGluR2 antagonist and BCI-838 is in preclinical phase as 
a mGluR2/R3 antagonist.122  
 
1.9.2 5-Hydroxytryptamine receptors 
Several lines of evidence suggest that 5-hydroxytryptamine (5-HT also known as serotonin) 
signaling pathway is impaired in AD. Therefore, the serotonergic system appears to be a 
particularly attractive target, because it has been involved not only in cognitive processes but 
also in depression, psychosis, and aggression.375 
5-HT4 receptors are highly expressed in the hippocampus, basal ganglia and amygdala.376 Brains 
of AD patients display a reduction in the number of 5-HT4, therefore they might be involved in 
the memory and cognition deficits in AD.377
 
 It was shown that in vitro378 and in vivo379 
stimulation of 5-HT4 leads to an increase in the soluble fragment sAPPα and ACh release (Fig. 
31). Stimulation of ACh in rat frontal cortex improves cholinergic function which is important 
for memory acquisition and retention. To date, it is still unclear whether the effects of 5-HT4 
receptors on APP metabolism are directly linked to an increase in the activity of the α-secretase 
or an effect on the trafficking of APP. Moreover, the 5-HT6 receptor class of serotonin receptors 
has received the most attention in recent years because the blockade of 5-HT6 seems to attenuate 
both the cognitive and the behavioral abnormalities of AD via modulation of multiple 
neurotransmitters and synaptic plasticity (Fig. 31). In particular, in vivo it was shown that the 
administration of a 5-HT6 antagonist is able to increase ACh release.380 Moreover, it is 
reported381, 382 that 5-HT6 antagonists reversed the amnesic effects of anticholinergic drugs and 
have been shown to be effective in diverse learning paradigms, all of which may depend on ACh 
transmission. Many of the findings on 5-HT6 receptor interactions demonstrate a complex 
relationship with excitatory amino acids. Thus, it was shown that the blockade of 5-HT6 
increases the release of glutamate in the cortex and in the hippocampus.383 5-HT6 receptor 
antagonists are in clinical development for cognitive disorders. For example, 
SGS518/LuAE58054 reached with success Phase III trials and AVN-211 and Syn-120 are in 
Phase I.122 
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Figure 31: 5-Hydroxytryptamine signaling pathway.373 
 
1.9.3  β2-adrenergic receptors 
β2-adrenergic receptors (β2-ARs) are typical GPCRs, expressed in hippocampus and cortex,384 
the main brain regions involved in AD. Activation of β2-ARs enhances γ-secretase activity and 
results in increased Aβ40 and Aβ42 production. Thus, in vivo and in vitro, treatment with β2-AR 
agonists increased amyloid plaque formation. On the other hand, treatment with β2-AR 
antagonists reduced Aβ production. The γ-secretase activity regulation by β2-ARs is independent 
of cAMP signaling pathway but correlates with receptor endocytosis. It has been suggested that 
β2-AR constitutively associates with γ-secretase by directly binding to PS1 at the plasma 
membrane. Once agonist treatment induces endocytosis of β2-ARs, endocytosis of PS1 occurs, 
leading to the traffic of PS1 to the late endosomes and lysosomes systems which provide an 
optimal environment for γ-secretase activity.385  
It is known that environmental influences activate β2-ARs. Stress has been recently determined 
to be a risk factor for AD386 because can elevate the concentration of endogenous β2-AR ligands 
epinephrine and norepinephrine.387 The abnormal activation of β2-ARs, which could result from 
the response to stress, might contribute to Aβ accumulation. As β2-AR antagonists are widely 
used in the treatment of cardiovascular disease, these results suggest the use of β2-AR 
antagonists to decrease the incidence of AD pathogenesis.  
 
1.9.4 Adenosine A2A receptors 
Adenosine receptors are GPCRs whose endogenous ligand is adenosine. In humans, there are 
four types of adenosine receptors classified as A1, A2A, A2B and A3. A2ARs are by far the most 
abundant in the mammalian brain. The interest for the A2A subtype is growing because of its 
potential involvement in several diseases like, schizophrenia, anxiety, depression and 
neurodegenerative diseases. In fact, A2ARs in striatal neurons seem to control the dopaminergic 
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signaling.388 However, there is currently a major interest in the ability of A2A receptors to 
regulate glutamate release. This makes A2ARs a good target for the modulation of synaptic 
plasticity at glutamatergic synapses. Thus, A2AR-deficient mice display improved spatial 
recognition memory,389 whereas in vivo overexpression of the A2AR leads to memory deficits.390 
Caffeine is the most widely consumed psychoactive drug. Some of the most evident effects of 
caffeine, such as its psychomotor effects or its memory enhancing effects, are now recognized to 
be due to its ability to antagonize adenosine A2A receptors. Interestingly, caffeine consumption 
has been found to reduce the incidence of AD.391 Thus, caffeine reduces the expression of both 
PS1 and BACE in caffeine-treated transgenic mice accompanied by a modest reduction of Aβ40 
and Aβ42 generation.392 Furthermore, it is protective against Aβ-induced neurotoxicity in 
cultured neurons of rats393 and against Aβ-induced cognitive impairments in mice (Figure 32).394 
Collectively, these findings suggest that the adenosinergic system is a promising therapeutic 
avenue to target AD. 
 
Figure 32: Adenosine A2A receptor and Aβ-mediated toxicity.373 
 
1.9.5 M1 muscarinic receptors 
Muscarinic receptors, a family of five GPCR subtypes (M1-M5), have been implicated in the 
pathophysiology of major diseases of the CNS, including AD. They are composed by seven 
transmembrane regions. M1, M3 and M5 mAChRs activate G proteins of class Gq that activate 
PLC, which in turn hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to DAG and IP3. 
DAG acts as a second messenger that activates PKC, while IP3 increases the cytosolic 
concentration of Ca2+ (Figure 33). On the other hand, M2 and M4 activate Gi that inhibits 
adenylate cyclase activity, decreasing the production of cAMP from ATP, which, in turn, results 
in decreased activity of cAMP-dependent protein kinases (Figure 33). 
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Figure 33: Intracellular signaling pathway of mAChRs.395  
 
The M1 mAChR is predominant in cerebral cortex and hippocampus, two major brain regions 
that develop amyloid plaques and NFTs in AD. Postsynaptic M1 mAChRs have a major role in 
hippocampal-based memory and learning, regulation of cognition and psychosis and in particular 
in short-term memory, which is impaired in AD.396, 397 M1 is a promising target because 
activation of this receptor seems to have beneficial effects on the three major hallmarks of AD 
(cholinergic hypofunction, Aβ and tau neuropathology). Therefore, M1 stimulation might possess 
not only beneficial effects on memory and cognitive deficits, but also disease-modifying 
properties.398, 399 In the past, many efforts have been focused on the synthesis of highly selective 
mAChRs orthosteric agonists to improve cognitive impairment in AD patients. Representative 
chemical structures are shown in Figure 34. Unfortunately, all the mAChR agonists presented 
below exhibit nonselective profiles of binding affinities across the different mAChR subtypes, 
because they target the highly conserved ACh binding site. Despite they revealed good effects on 
cognition and memory in Phase II and III, their clinical developments have failed due to serious 
side effects.400, 401  
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Figure 34: Representative structures of orthosteric mAChRs. 
 
However, to date, targeting the M1 subtype is considering an attractive tool for the treatment of 
AD. In this section, evidences of the linkage between M1, cholinergic hypofunction, amyloid 
aggregation and tau hyperphosphorylation are reviewed: 
A Modulation of Aβ levels via M1 mAChRs 
Stimulation of M1 can increase formation of the neuroprotective and neurotrophic α-APPs, 
preventing the formation of Aβ.185, 402, 403 The decrease of Aβ was reported in many in vitro 
systems following treatment with muscarinic agonists.404, 405 Stimulation of M1 activates PKC- 
and MAPK- pathways that lead to activation of α-secretase,406, 407 the enzyme responsible of the 
non-amyloidogenic pathway of APP processing (Figure 35). The α-secretase involved in M1-
mediated effect is ADAM17408 (or TACE) activated by PKC isoforms α and ε.409 Recently, also 
BACE-1 has been found to be regulated by M1 mAChR. Its level was found to be elevated in 
sporadic AD brains. It was shown, in vitro410 and in vivo,411 a reduction in BACE-1 activity after 
M1 activation. Jiang et al.410 suggested that M1 mAChRs directly interacts with BACE-1 and 
thereby regulate its level through promoting the ubiquitin-proteasome degradation of BACE-1. 
Moreover, overexpression and downregulation of M1 mAChRs decreases and increases the level 
of BACE-1 and the generation of Aβ, respectively.  
Activation of M3 mAChRs also elevates α-APPs secretion but M1 stimulation is preferable to 
prevent peripheral side effects mediated by the M3 subtype.185 M2 and M4 mAChRs are not 
effective in elevating α-APPs and M2 may even have an inhibitory effect on α-APPs release. This 
may be one of the major disadvantages of AChEIs vs direct acting M1 agonists, since AChEIs, 
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due to the inhibition of AChE, elevate synaptic ACh that can activate all receptor subtypes, 
including the inhibitory M2 and M4.185 Thus, any possible elevation of α-APPs via activation of 
M1, may be inhibited by M2 activation.  
 
Figure 35: Various effects that can be modulated by activation of M1 mAChRs. 412 
 
Many efforts have been made in developing selective M1 orthosteric agonists. However, some 
agonists showed disappointing clinical results in AD. This may be attributable to one or more of 
the followings reasons: lack of selectivity for the M1 subtype, low bioavailability, extensive 
metabolism, and low safety margin.413, 414 In fact, selectivity for an mAChR subtype in vitro is 
not always reflected into good selectivity in vivo and a good bioavailability/pharmacokinetic 
profile. Indeed, xanomeline was highly selective in vitro, but it exhibited bad pharmacokinetics 
and poor selectivity in vivo with high incidence of side effects in AD patients.415  
Over the years selective partial M1 orthosteric agonists were developed. These include AF102B 
(Cevimeline, EVOXAC™) prescribed in USA and Japan for the treatment of Sjogren’s 
syndrome, AF150(S) and AF267B (Figure 36).415, 416  
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Figure 36: Structure of AF102B, AF150(S) and AF267B.  
 
These agonists, in particular AF267B, do not cause down regulation of M1 mAChRs following 
chronic administration. They penetrate the BBB restoring learning and memory impairments in 
several animal models. Studies in vivo confirm the linkage between the M1 stimulation and Aβ 
metabolism. In rabbits, where the sequence of Aβ42 is similar to humans, treatments with 
AF102B decreased Aβ40, while AF267B and AF150(S) reduced levels of both Aβ42 and Aβ40 
in the cerebrospinal fluid (CSF) and all three M1 agonists decreased cortical Aβ42.416 Moreover, 
chronic treatment with AF102B significantly decreased CSF Aβ in AD patients.417 
Physostigmine (an AChEI) and hydroxychloroquine (an anti-inflammatory drug) did not reduce 
CSF Aβ levels when tested in AD patients in the same study as AF102B.  Nitsch et al.417 
suggested that the reduction in Aβ production can be explained by an indirect inhibitory effect on 
γ-secretase via M1 mAChR-mediated phosphorylation of PS-1. However, more studies will be 
required to better investigate the correlation between M1 activation and γ-secretase. 
In rat cortical and hippocampal primary cell cultures, AF150(S) and AF267B were more potent 
in elevating α-APPs than carbachol (CCh), oxotremorine (OXO-M) and physostigmine.416 After 
exposure of neurons from spinal cord to muscarinic agonists, any increase in α-APPs was 
detected, as these neurons do not contain M1 mAChRs. Thus, from these results we can envisage 
that the M1 mAChR activation has a major role in α-APPs elevation.416  
In transgenic (3xTg-AD) mice, dicyclomine, a relative selective M1 muscarinic antagonist, 
caused a significant increase in Aβ deposition, BACE-1 and GSK-3β activity and a decrease in 
ADAM-17 activity. On the other hand, treatment with AF267B reduced the major hallmarks of 
AD. Thus, it improved the memory impairment, decreased Aβ42, BACE-1 activity and tau 
hyperphosphorylation and increased steady-state level of ADAM17 and PKC.411  
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Taken together, these data suggest a tight correlation between the cholinergic and amyloid 
hypothesis. M1 selective activation, due to its beneficial effects on the hallmarks of AD, can be 
considered the first disease-modifying treatment.  
Great efforts have been devoted to developing β- and/or γ-secretase inhibitors as a rationale 
therapy in AD. However, inhibition of β- and/or γ-secretase alone, could lead to accumulation of 
APP or C99 if the α-secretase remained unmodified. M1 selective agonists can prevent this 
drawback because of their dual properties; activation of α-secretase and inhibition of γ-secretase 
and BACE-1.  
B Modulation of hyperphosphorylated tau protein via M1 mAChRs 
Activation of M1 decreases tau phosphorylation as shown in vitro418, 419 and in vivo.420, 411 This 
effect is mediated via activation of PKC-pathway, leading downstream to a decrease in GSK-3β 
activity. In 3xTg-AD mice with PS, APP and tau mutants, chronic administration of AF267B 
reduced the level of hyperphosphorylated tau. Moreover, it was found a decrease in the activity 
of GSK-3β compared to the control. In contrast, dicyclomine (an M1 antagonist) led to an 
increase of GSK-3β activity and hyperphosphorylated tau.411  
C Modulation of cognitive impairment via M1 mAChRs 
AF150(S) and AF267B restored memory and learning deficits in several animal models that 
mimic AD pathology. 3xTg-AD mice were tested in the Morris water maze after AF267B 
treatment. It was found that the time to reach the hidden platform was substantially reduced 
compared to not-treated 3xTg-AD.411 Moreover, ablation of M1 mAChRs in the 3xTgAD and 
triple mutant APP (Tg-SwDI) mice exacerbated the cognitive impairment.421 Medeiros et al.421 
found that deletion of M1 mAChRs resulted in impairment of c-Fos and p-CREB signaling in 
AD-like mouse brain. c-Fos and p-CREB are transcriptional factors considered key mediators of 
stimulus-induced nuclear responses that underlie the development, function, and plasticity of the 
nervous system.422, 423  
These date confirm that M1 mAChRs are key receptors involved in memory and learning 
processes. 
 
1.9.5.1     Allosteric ligands 
In the past, several attempts have been made to generate compounds which are selective for the 
M1 subtype. However, many of these efforts have failed because these first generations of 
muscarinic agents bind to the highly conserved orthosteric ACh binding site. For example, 
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AF267B was suggested to have selective agonist activity at M1 during its initial screening.411 
However, when evaluated across multiple systems, AF267B was found to have activity at M3 
and M5 receptor subtypes.424 Selective targeting of M1 mAChRs for the development of novel 
drugs has proven challenging because the high degree of homology of the orthosteric agonist 
binding site among the five mAChR subtypes. Allosteric modulation of GPCRs represents a 
valid alternative for identifying subtype selective ligands because it is thought that allosteric 
binding sites are less conserved than the orthosteric binding sites (Fig. 37).  
 
Figure 37: Schematic representation of a mAChRs showing orthosteric and putative allosteric 
binding sites and effector mechanisms.425  
 
Recently, several allosteric compounds, both positive allosteric modulators (PAMs) and 
allosteric agonists, have been identified. PAMs are unable to activate receptors directly, but their 
binding potentiates the effect of ACh through enhancement of the affinity of ACh for its site 
and/or through increased coupling efficiency to the G-proteins. In contrast, allosteric mAChR 
agonists bind to an allosteric site on the receptor and can directly activate the receptor in the 
absence of ACh. They have the potential to stabilize unique receptor conformations, which may 
in turn cause differential activation of signal transduction pathways. 
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Figure 38: Structures of allosteric M1 muscarinic agonists.  
 
AC-42 (Fig. 38) was the first allosteric agonist described for the M1 mAChRs.426, 427, 428 Using a 
series of chimeric receptors, AC-42 was shown to activate M1 receptors at a region that is clearly 
distinct from the orthosteric ACh binding site and involves N terminus-TM1 and extracellular 
loop 3-TM7 regions.426 The residues in these regions are not conserved among the muscarinic 
subtypes, which probably accounts for the selectivity of AC-42. On the other hand, ACh 
interacts with the orthosteric site that is embedded in the transmembrane domains of the receptor 
and involves TM3, TM5 and TM6.429 TM3 plays a crucial role in this orthosteric site and is 
believed to be essential in activation mechanism of mAChRs and many other GPCRs.430 
Moreover, ACh is thought to bind to TM3 through a binding salt bridge believed to exist 
between the choline head group of ACh and aspartate-105 (Asp105). Receptor binding of classic 
agonists such as CCh (a nonselective muscarinic orthosteric agonist), is mediated largely through 
interactions with two highly conserved residues, tyrosine-381 and asparagine-382 in TM6.431, 432 
Spalding et al.426 demonstrated that the potency of AC-42 was not significantly attenuated by 
either of the point mutations Y381A or N382A in TM6. Differently, these mutations abolished 
the agonist activity of CCh. This result prompted the authors to categorize AC-42 as an “ectopic” 
agonist, in the knowledge that its binding site is partially or totally distinct from that for CCh. 
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The investigation of the mode of interaction of AC-42 with various orthosteric ligands confirmed 
that AC-42 exhibited characteristics associated with allosteric ligands.427 For example, in 
functional assays, atropine inhibited M1 receptor-mediated calcium mobilization in a manner 
completely consistent with orthosteric antagonism, when tested against the classic orthosteric 
agonist CCh (Fig. 39 A). Moreover, Schild slope was not significantly different from unity over 
concentrations of antagonist spanning six orders of magnitude. On the other hand, the 
translocation of the AC-42 concentration-response curve by atropine (Fig. 39 B) led to Schild 
slopes significantly less than unity (0.69 ± 0.01) indicating that the antagonism does not reflect a 
simple orthosteric interaction. Schild slopes that deviate significantly from unity reflects the 
saturability of negative allosteric interaction, i. e. increasing of the concentration of one ligand 
results in a progressive inability to further antagonize the other ligand.433  
To validate this mechanism of interaction, [3H] N-methyl scopolamine ([3H]NMS) inhibition 
binding studies, were performed. The radioligand [3H]NMS was used as an orthosteric-site 
“probe”. NMS is a well-known muscarinic orthosteric antagonist. Both atropine and pirenzepine 
fully inhibited specific [3H]NMS binding at radioligand concentrations of either 0.2 nM or 2 nM 
(Fig. 40 A), as expected for simple orthosteric antagonism. On the other hand, AC-42 was 
unable to expel [3H]NMS from the orthosteric binding site. This was more marked when the 
concentration of radioligand was increased 10-fold (Fig. 40 B). This effect confirms that AC-42 
interacts in a site that is different from ACh binding site. For comparison, the same experiment 
was also performed with the well characterized and prototypical negative mAChR allosteric 
modulator gallamine. As expected, gallamine also inhibited the specific binding of the 
radioligand [3H]NMS (Fig. 40 B). It is evident that the inhibition of AC-42 is more notable when 
the concentration of [3H]NMS was 10-fold higher. This can be explained by the fact that 
allosteric ligands can have effects on the binding of the orthosteric ligands. The saturability in 
the allosteric site becomes more evident when the concentration of orthosteric radioligand is 
increased.434 
Allosteric modulators of GPCRs cause a conformational change in the receptor and they may 
alter the equilibrium of radioligand binding by reducing its rate of association and affecting its 
dissociation. 435 An altered dissociation rate is unequivocally indicative of an allosteric action: 
the dissociation of a radioligand–receptor complex can only be modified by the binding of a 
compound to a site distinct from the radioligand binding site. Therefore, [3H]NMS dissociation 
binding studies were also performed to validate the allosteric character of AC-42. As shown in 
Figure 41 the presence of gallamine (1 mM) produced a marked retardation of [3H]NMS 
dissociation. It is noteworthy that AC-42 (100 µM) also significantly slowed the rate of 
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[3H]NMS dissociation, although this effect was much less marked than that for gallamine. The 
reason of this behavior depends from the concentration used for AC-42 that is close to its 
solubility limits. Thus it was not possible to determine the maximum extent of its ability to retard 
[3H]NMS dissociation. Nonetheless, the ability of AC-42 to significantly alter the dissociation 
rate of [3H]NMS confirmed that it binds to a site that is topographically distinct from the 
orthosteric binding site. Despite these promising results, the in vivo use of AC-42 has remained 
in question.436 
 
          A 
 
 
 
 
 
 
 
 
                                                            B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Concentration-dependent antagonism of CCh-stimulated (A) or AC-42-stimulated 
(B) calcium mobilization in CHO-hM1 cells by atropine (3 nM–300 µM) with inset Schild 
regressions.427 
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Figure 40: Inhibition of 0.2 and 2 nM [3H]NMS binding in CHO-hM1 cell membranes by 
atropine or pirenzepine (A) or AC-42 or gallamine (B).427  
 
 
Figure 41: Effect of AC-42 (100 µM) or gallamine (1 mM) on atropine (1 µM)-induced 
dissociation of [3H]NMS from CHO-hM1 cell membranes.427 
 
An additional structure analog of AC-42, AC-260584 (Fig. 38) was also recently reported as an 
orally bioavailable M1 allosteric agonist with antipsychotic and cognitive enhancing effect. 
Acute systemic administration of AC-260584 significantly reversed amphetamine and MK-801-
induced hyperlocomotion and apomorphine-induced climbing, two animal models predictive of 
antipsychotic efficacy.437 Interestingly, AC-260584 also improved the performance of mice in 
the Morris water maze, a measure of hippocampal-dependent spatial memory.438 
Another active M1 allosteric agonist, 77-LH-28-1, was discovered as a structural analog of AC-
42.439 77-LH-28-1 is selective for M1 but it has also weak agonist activity at M3 at higher 
concentrations. Site-directed mutagenesis studies revealed that 77-LH-28-1 acts as a bi-topic 
ligand i.e. it binds to an allosteric site that partially overlaps the orthosteric site.440 Moreover, 
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pharmacokinetic and in vivo electrophysiological studies demonstrated that 77-LH-28-1 is able 
to penetrate into the CNS after subcutaneous administration and it activates M1 mAChRs to 
stimulate CA1 cell firing in vivo.439 Recent studies have also shown that 77-LH-28-1 can 
enhance NMDA-mediated neuronal excitation in the rat hippocampus.441  
Recently, TBPB (Fig. 38) was found to be a selective M1 allosteric agonist.442 It has high affinity 
on the M1 subtype and no detectable agonist activity at other mAChR subtypes (Fig. 42).443 
Jones et al.444 evaluated the effects of TBPB in a cell line expressing the M1 receptor containing 
a mutation (tyrosine 381 to alanine: Y381A) in the orthosteric binding site. CCh lost completely 
its effect at M1 Y381A at concentrations that fully activated the wild type (wt) M1 receptor. In 
contrast, increasing concentrations of TBPB activated the mutant M1 with an EC50 similar to the 
wt M1 mAChR, indicating that TBPB is not acting at a site identical to the orthosteric binding 
site. Using chimeric receptors, it was also established that TBPB and AC-42 share the same 
binding pocket adjacent to the orthosteric binding site.445 
 
 
Figure 42: Concentration response curves for TBPB at M1–M5. M1 EC50= 289 nM, 82% CCh 
Max. 
 
To further evaluate the effects of TBPB at the allosteric binding site of M1, the effects of TBPB 
on M1 activation in the presence of increasing concentrations of the nonselective orthosteric 
mAChR antagonist atropine were determined. As shown in Fig. 43 A, increasing concentrations 
of atropine (1-10 nM) competitively antagonized the action of CCh at the M1 receptor. On the 
other hand, increasing concentrations of atropine (0.3-3.0 nM) produced a robust decrease in the 
maximum effect of TBPB at M1, consistent with a noncompetitive interaction (Fig. 43 B).  
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Figure 43: Effects of atropine in antagonizing CCh and TBPB at M1.444 
 
Moreover, Jacobson et al.445 investigated the allosteric interactions of TBPB at the M1 subtype 
through kinetic experiments of [3H]NMS dissociation. As reported in Figure 44 , the orthosteric 
ligand atropine (1 µM) is able to displace [3H]NMS with a t1/2 of 12 min. In contrast, the classic 
muscarinic allosteric compound gallamine drastically slowed the atropine-induced dissociation 
of [3H]NMS (t1/2 = 97 min). Similarly, TBPB (100 µM) showed a significant retardation of 
[3H]NMS dissociation with a t1/2 of 20 min. 
 
 
Figure 44: Effect of TBPB (100 µM; ■), gallamine (1 mM; ○) and clozapine (10 µM; ▲) on the 
atropine-induced dissociation of [3H]NMS binding to human M1 receptor expressed on CHO-K1 
membranes. Atropine alone (1µM; □).445  
 
Taken together, these findings provide support for hypothesis that TBPB is an allosteric agonist. 
Furthermore, recent studies revealed that TBPB increases non-amyloidogenic APP processing, 
reducing Aβ production in vitro.444 Interestingly, TBPB potentiates also NMDA receptor 
currents in CA1 hippocampal pyramidal cells.444, 446 An important effect of activation of the M1 
subtype in the hippocampus and other brain regions is the potentiation of currents through the 
NMDA subtype of the glutamate receptor.447 Potentiation of NMDAR currents is thought to be 
important for both cognition and psychosis and has been postulated to play a role in the 
antipsychotic effects of mAChR agonists. 
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Finally, VU0184670 and VU0357017 (Fig. 45) have been recently discovered. They represent 
highly potent, selective and systemically M1 allosteric agonists.425 These compounds are 
optimized analogs of M1 allosteric agonists identified through high-throughput-screenings. They 
did not display any agonist or antagonist activity at M2-M5 and possessed an exceptionally clean 
pharmacology profile when tested in a screen of sixty-eight GPCRs, ion channels and transporter 
targets. Mutagenesis studies revealed that the allosteric site is located in the third extracellular 
loop and the first turn of the seventh transmembrane span. Similar to TBPB, they potentiated 
NMDA current and reversed cognitive deficit in vivo. 
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Figure 45: Chemical structures of VU0184670 and VU0357017. 
 
In addition to the discovery of novel M1-selective allosteric agonists, much progress has been 
made in the discovery of novel M1 PAMs that act as allosteric potentiators of this receptor. In a 
recent publication, researchers reported the discovery of benzyl quinolone carboxylic acid 
(BQCA, Fig. 46) as highly selective and efficacious allosteric modulator.448 
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Figure 46: Chemical structure of BQCA  
 
BQCA had no agonist activity alone, but it induced a robust leftward shift in ACh concentration-
response curve. Interestingly, at 100 µM, BQCA was able to increase ACh potency 128.8 ±20.1-
fold (Fig. 47). Moreover, BQCA had no effect at the M2-M5 subtypes.  
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Figure 47: ACh concentration-response curve obtained with different concentrations of 
BQCA.448  
 
To determine if BQCA interacts with the ACh binding site, [3H]NMS competition assays were 
performed. 100 µM BQCA had no effect on the binding of [3H]NMS (Fig. 48). Moreover, 
BQCA reduced the concentration of ACh required to displace [3H]-NMS 45-fold at 10 µM. 
 
 
 
 
 
 
 
 
 
Figure 48: [3H]NMS competition assays.448 
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1.10 Multitarget-Directed-Ligand approach for the treatment of Alzheimer’s disease. 
AD constitutes an overwhelming health, social and economic problem to nations. So far, the 
therapeutic paradigm “one-compound-one-target” has failed. This could be due to the multiple 
pathogenic mechanisms involved in AD as discussed previously. However, in the last decade, 
new strategies have emerged to find an efficient therapy to combat multifactorial diseases like 
neurodegenerative diseases, cancer, depression ecc… One of these approaches is represented by 
the development of ligands capable to interact with multiple targets simultaneously, or the so-
called “multitarget-directed ligands” (MTDLs).449, 450, 451, 452 However, the design of such a drug 
may not be easy because it could also bind targets that are not directly involved with the disease 
and could be responsible for side effects (Fig. 49). 
 
Figure 49: a) Schematic representation of the discovery approach, based on “one-molecule one-
target” paradigm. b) MTDLs approach to drug discovery.449 
 
The concept of the multitarget approach is particularly applicable to AD since the molecular 
basis of this disease can be considered as a complex network of pathological events (Fig. 50). 
However, nowadays, the drugs used in the clinical practice are based only on the cholinergic 
hypothesis. Cholinergic hypothesis states that the loss of cholinergic function is closely related to 
cognitive dysfunction of AD patients. So the primary therapeutic approach address cognitive loss 
associated with AD, has been the cholinergic replacement strategy. Current treatments for AD 
are mainly based on the inhibition of AChE. The only AChE inhibitors approved by FDA are 
tacrine, donepezil, galantamine and rivastigmine (see 1.3). Later on, memantine was approved 
for the treatment of AD. It possesses a different mechanism of action; it is an NMDAR 
antagonist (see 1.8). However, their clinical usefulness is limited because of the severe 
peripheral side effects associated to long-term therapies such as confusion, hallucinations, 
extreme or sudden changes in behavior, nausea, ecc.. Moreover, another limitation depends on 
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the fact that they have only a palliative effect and seem unable to address the molecular 
mechanisms that underlie the pathogenic processes. Therefore, the development of multitarget 
modifying molecules is an attractive approach to slow down the progression of AD. Many efforts 
have been made to find effective and selective MTDLs. This paragraph will focus on the recent 
approaches devoted to the design of multitarget ligands. 
 
Figure 50: Representation of the interconnected pathways in AD.449 
 
1.10.1     Dual binding site AChE inhibitors 
The development of the so-called “dual binding site” AChEIs was suggested by the peculiar 
architecture of the enzyme, with the two target sites at the top and the bottom of a gorge.453, 454 
The inhibition of AChE at its catalytic site increases the concentration of ACh in the synaptic 
cleft, restoring central cholinergic activity. More importantly, they are able to reduce Aβ 
aggregation interacting with the PAS of AChE. The rational development of these drugs was 
suggested by the finding that PAS accelerates the aggregation of this toxic peptide.200, 201, 198, 199 
Thus, inhibitors targeting the PAS of the enzyme will decrease the aggregation rate of Aβ, 
therefore facilitating its clearance. This strategy could represent a new area of research for the 
AD treatment based on both the cholinergic and the amyloid hypothesis. 
The observation that AChE gorge and PAS are enriched of aromatic amino acids capable of 
forming cation-pi interactions with basic counterparts or pi-pi stacking, dual binding site AChEIs 
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were designed by linking the molecular features of well-known AChEIs through a polyamine 
chain. The nature and the length of the polyamine chain are critical since they play an active role 
in the target recognition process as postulated by the universal template design strategy.455  
Bis(7)-tacrine (Fig. 51) was one of the first homodimers reported in the literature showing good 
selectivity and increased potency for AChE (AChE IC50=0.4 nM vs BuChE IC50= 390 nM).456 
Bis(7)-tacrine seemed to increase the spontaneous quantal ACh release from peripheral 
cholinergic terminals in the electric organ of Torpedo marmorata at lower concentrations than 
tacrine (IC50 bis(7)-tacrine=100 nM vs IC50 tacrine= 100 µM).457 It showed also to improve 
memory in rats458 and revealed an NMDAR antagonist character, with an IC50 of 0.76 mM 
preventing glutamate-induced neuronal apoptosis.459 Moreover, bis(7)-tacrine also showed 
neuroprotection against hydrogen peroxide-induced oxidative stress.460 Interestingly, this 
compound inhibited the AChE-induced Aβ aggregation with an IC50 of 41.7 mM.461 Its ability to 
block Aβ assembly was demonstrated by computational and crystallographic studies462, 463 by its 
interaction with the PAS of the enzyme. Finally, Fu et al.464 reported a decrease by bis(7)-tacrine 
in the generation of both secreted and intracellular Aβ42 (48.5% reduction at 3 mM), Aβ40 
(37.7% reduction at 3 mM) and the aberrant insoluble β-fragment (APPβ), and an increase in the 
amount of soluble amyloid protein precursor α fragment (s-APPα). They demonstrated that 
bis(7)-tacrine is able to activate α-secretase and to inhibit BACE-1 with an IC50 of 7.5 mM.  
In 2003, Piazzi et al.465 reported the synthesis and biological activity of AP2238 (Fig. 51), a dual 
inhibitor designed by combining in the same molecule two moieties optimal for the binding at 
each enzyme site and linked by an appropriate spacer. The phenyl ring in the spacer was chosen 
by the fact that it could favorably interact with some of the numerous aromatic residues of the 
AChE gorge. AP2238 is a good inhibitor of AChE (IC50= 44.5 nM) and a good antiaggregating 
molecule (35% inhibition at 100 µM, 1.6-fold more potent than donepezil). 
Camps et al.466 developed a dual binding site inhibitor by combining the 5,6-dimethoxy-2[(4-
piperidinyl)-methyl-1-indanone] moiety of donepezil with tacrine, which would thus replace the 
benzyl moiety of donepezil. Compound A (Fig. 51) was a subnanomolar inhibitor with an IC50 of 
0.09 nM, more potent than all parent compounds (tacrine, 6-chlorotacrine and donepezil). 
Furthermore, compound A inhibited the AChE-induced Aβ aggregation up to 46.1% (at 100 µM) 
presumably by interaction at the PAS of the enzyme. Thus, by molecular binding studies, it was 
shown that the tacrine moiety may be stacked between the aromatic rings of Trp86 and Tyr337 in 
the catalytic site of hAChE. The aromatic nitrogen of tacrine, protonated at physiological pH, is 
hydrogen-bonded to the main chain carbonyl oxygen of His447. Finally, the indanone ring makes 
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pi-pi interactions with Trp286 in the peripheral site of enzyme and is responsible for the inhibition 
of the AChE-induced Aβ aggregation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51: Chemical structures of some dual binding site AChE inhibitors. 
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Caproctamine (Fig. 51) represents one of the first examples of a successfully designed AChEI 
endowed with additional pharmacological effects beneficial in AD.467 Caproctamine is a 
polyamine-based dual inhibitor of AChE designed from benextramine using the universal 
template approach.468 
Caproctamine was able to inhibit AChE (IC50= 0.17 mM) and to block the mAChRs (M2 Kb= 
0.41 µM). From docking studies it was shown that caproctamine was able to simultaneously 
contact both the active and the peripheral sites of AChE. Thus, the inhibition of AChE activity 
would potentiate the remaining cholinergic transmission in affected brain regions while 
antagonism of muscarinic M2 autoreceptors would facilitate the release of ACh in the synapse. 
An improved AChE-induced Aβ aggregation inhibitory profile was shown by a series of 
heterodimers in which a 1,2,3,4-tetrahydroacridine moiety was linked through a suitable spacer 
to an indole ring. The indole ring was shown to interact with the Trp86 of the catalytic gorge by 
forming a pi-pi stacking. In particular, compounds B and C were the most potent AChEIs of the 
series; they displayed IC50 values of 20 and 60 pM, respectively. Moreover, they were able to 
inhibit the AChE-induced Aβ aggregation with IC50 values 1 order of magnitude lower than that 
of propidium.469 
 
1.10.2     AChEIs Targeting Other Neurotransmitter Systems 
It is well-known that AD is caused by a decline of cholinergic and glutamatergic neurons in the 
brain. However, other neurotransmitter systems are involved in the neuropsychiatric 
abnormalities observed in AD patients. Thus, it is argued that the noradrenergic deficits of AD 
stem from locus ceruleus atrophy and are linked to depression,470 while the serotoninergic 
deficits in raphe atrophy are linked to depression and psychosis.471 
A recent and renewed interest has regarded monoamine oxidases (MAOs) as a “druggable” 
target for the treatment of neurodegenerative diseases like AD, Parkinson’s disease and 
amyotrophic lateral sclerosis. MAOs are a family of enzymes that catalyze the oxidation of 
xenobiotics and endogenous amines, including monoamine neurotransmitters such as serotonin 
(5-HT), noradrenalin (NA), and dopamine (DA).472 Two distinct enzymatic isoforms, namely 
MAO-A and MAO-B, have been isolated and studied. Both are found in neurons and astroglia, 
while outside the CNS, MAO-A is also present in the liver, gastrointestinal tract and placenta, 
and MAO-B is mostly found in blood platelets.473 Both enzymes oxidatively deaminate DA, 
whereas MAO-A preferentially deaminates 5-HT, NA and adrenaline. MAO-B metabolizes also 
benzylamine and phenethylamine. Moreover, another MAO activity seems to be involved in the 
pathogenic process of neurodegenerative diseases. In fact, MAO, during its catalytic activity of 
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deamination of neurotransmitters, produces H2O2 which is a possible source of radical ROS that 
can promote harmful cellular alterations in pathological conditions (Fig. 52) 
 
Figure 52: ROS endogenous production and monoamines metabolism.474  
 
Within this complex scenario, MAO inhibitors (MAOIs) might play a beneficial action in AD by 
reducing oxidative stress conditions in the brain and increasing the activity of other 
neurotransmitter systems (e.g., serotonin, noradrenalin) whose levels are influenced by the 
catabolic action of MAOs. The initial design strategy for combined MAO/AChE agents resulted 
in a series of inhibitors (e.g., compound A, Fig. 53) that were designed linking the tricyclic 
1,2,3,4-tetrahydrocyclopent[b]indole carbamate scaffold, inspired by the known natural AChEI 
physostigmine, with a propargylamino group, belonging to selegiline, a potent, selective and 
irreversible “suicide-type” MAO-B inhibitor. These compounds were good AChEIs, but they 
were still irreversible MAO inhibitors associated to severe side effects.475 More interestingly, the 
synthetic iminic compounds represented by the general formula B (Fig. 53), were also tested and 
showed from moderate to good dual inhibitory activities. Regarding MAO inhibition, most of 
them exhibited a reversible mechanism of action and a marked selectivity for MAO-A.475 
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Figure 53: MAO/AChE inhibitors. 
 
Youdim and co-workers.476 studied a large series of N-propargylaminoindans and N-propargyl-
phenethylamines (Fig. 54), as dual MAO-AChE inhibitors. The molecular design was based on 
the combination in the same molecule of a propargylaminic fragment, characterizing well known 
MAOIs such as rasagiline and selegiline, with a carbamate moiety, which could add the AChE 
inhibitory property. In addition to AChE and MAO-B inhibition, these molecules might display a 
potential antidepressant action through MAO-A inhibition. The most promising compound was 
ladostigil (Fig. 54).476 Ladostigil showed to be a potent and selective AChEI. It also displayed 
high MAO inhibition in the CNS and low MAO inhibition in the liver and small intestine with 
fewer side effects. Moreover, ladostigil decreased apoptosis via prevention of caspase-3 
activation through a mechanism related to regulation of the Bcl-2 family proteins. This resulted 
in reduced levels of Bad and Bax and increased levels of Bcl-2. It also stimulated the release of 
the nonamyloidogenic soluble APP via a C-MAP kinase dependent pathway. Due to its 
promising profile, ladostigil is currently in Phase II as a potential MTDL drug for the treatment 
of AD.122 
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Figure 54: Other MAO/AChEI inhibitors.476 
 
In 2012, Simoni et al.477 reported the synthesis of MTDLs obtained combining galantamine and 
memantine in new entities. Galantamine and memantine are two of the few approved drugs used 
for the treatment of AD. Galantamine is an AChEI while memantine is a NMDA antagonist.  
These compounds were designed using the dual target design strategy.478 Among all the 
compounds, memagal (Fig. 55) seemed to be the most promising MTDL. Thus, it was able to 
inhibit AChE with an IC50 of 1.16 nM and to interact with both the catalytic site and the PAS of 
the enzyme. Moreover it was found to interact with NMDAR with a Ki of 4.6 µM.  
 
 
 
 
 
Figure 55: Molecular structure of memagal. 
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1.10.3     AChEIs with Antioxidant Properties 
As already discussed (see 1.6), oxidative stress is recognized as a central feature of AD 
pathogenesis. Oxidative stress refers to the production of high concentrations of ROS in AD 
patients. ROS oxidize lipids and damage membranes in the brain destabilizing several systems or 
equilibriums inside neurons. Free radicals can also oxidize DNA and RNA and their oxidation 
products were found to be elevated in vulnerable neurons in the brains of AD patients. Therefore, 
treatments that specifically target sources of ROS have attracted particular attention. In the 
search 
for MTDLs, lipocrine (Fig. 56)479 was design combining the 1,2,3,4-tetrahydroacridine moiety of 
tacrine with the structure of lipoic acid (LA), an antioxidant exerting different protective effects 
in neurodegeneration underlying AD.480 Lipocrine is one of the most potent AChEIs (IC50= 0.25 
nM).  
Kinetic studies verified that lipocrine also interacts with the AChE PAS. Furthermore, it 
inhibited AChE-induced Aβ aggregation was tested. It emerged as significantly more potent than 
all the other AChEIs investigated at the time. Considering its antioxidant effect, lipocrine 
decreased by 51% the production of ROS species at 10 µM demonstrating a good profile as a 
neuroprotectant against oxidative stress.  
Fang et al.481 synthesized a series of tacrine–ferulic acid hybrids as MTDLs for AD. Among all 
the compounds, compound A (Fig. 56) was the most promising drug candidate. It inhibited 
AChE with high potency (IC50= 4.4 nM) and, in experiments performed by the oxygen radical 
absorbance capacity method,482 A showed a value of 1.5 trolox equiv. in decreasing ROS 
species. 
 
 
 
 
 
 
 
 
 
 
Figure 56: Molecular structures of AChEIs with antioxidant properties. 
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1.10.4     Development of Memoquin 
Recently, a new drug candidate, memoquin (Fig. 57) has been identified.483 It possessed some of 
the above-mentioned activities relevant to AD, such as the ability to inhibit AChE, Aβ 
processing and aggregation, and the ability to counteract oxidative stress. It was rationally 
designed by replacing the linear alkyl chain of caproctamine with a radical scavenger function 
(Fig. 57). Caproctamine was chosen as the lead compound because of its well balanced affinity 
profile as an AChEI and a competitive M2 mAChRs antagonist.467 Concerning the radical 
scavenger moiety, attention was focused on the benzoquinone moiety, the key fragment of 
coenzyme Q10 (CoQ10). CoQ10 is a natural antioxidant that may have potential activity against 
AD.484 The benzoquinone ring of memoquin is a lipophylic and planar pi-system which has been 
recognized as an important design feature for obtaining high-binding specificity with Aβ and for 
perturbing protein-protein interactions in the fibrillogenesis process.485 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57: Design strategy leading to memoquin. 
 
The biological profile of memoquin was then widely studied by both in vitro (Fig. 58) and in 
vivo assays. It was shown that memoquin was able to decrease the formation of free radicals with 
an percent inhibition 44.1±3.7, which is slightly lower than that of trolox ((57.6±0.9)%). 
Moreover, memoquin was a good substrate for the enzyme NAD(P)H:-quinone oxidoreductase 
1(NQO1). NQO1 activity is increased in the hippocampal pyramidal neurons of AD patients. It 
was demonstrated that the quinone moiety of memoquin is transformed by NQO1 into the 
hydroquinone form. Therefore, it was suggested that the reduced form of memoquin is the real 
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antioxidant specie. This molecular mechanism was also confirmed in cellular assays, using SH-
SY5Y cells.483 Moreover, memoquin was a potent inhibitor of the activity of human AChE, with 
IC50 (1.55 nM) and Ki (2.60 nM) values 15 and 8 times lower, respectively, than those of 
donepezil. Kinetic measurements also revealed that the inhibition was of mixed type and this 
reflected the interaction of memoquin with both the catalytic site and the PAS of the enzyme. 
Docking simulations confirmed that memoquin was able to bind simultaneously Trp86 and Trp286 
of the catalytic site and the PAS, respectively.483 As we have already discussed, AChE can 
induce Aβ aggregation through the PAS. So, AChEIs that bind to the PAS could block this 
proaggregating process. Thus, memoquin was able to inhibit the AChE-induced Aβ40 
aggregation with an IC50 of 28.3 µM. Interestingly, among the classical AChEIs (tacrine, 
donepezil, galantamine, rivastigmine, propidium), only propidium, which is a specific inhibitor 
of PAS, displayed a comparable anti-aggregating potency.486 Memoquin also inhibited in vitro 
the self-assembly of Aβ42, which is the most amyloidogenic Aβ form. At the concentration of 50 
µM, memoquin was able to inhibit fibril formation by (95.5±0.4)%. Finally, memoquin also 
inhibited BACE-1, the enzyme involved in Aβ production from APP, with an IC50 of 108 nM. 
 
Figure 58: Memoquin activities in vitro. 
 
Memoquin was then tested in vivo487 using the anti-NGF transgenic mouse (AD11 mouse), 
which is an animal model for AD.488 Memoquin was able to prevent the AD-like hallmarks at 
three stages (at 2, 6, and 15 months of age). At all ages, memoquin rescued the cholinergic and 
behavioral deficits linked to attention and memory. Moreover, it was able to prevent or rescue τ 
hyperphosphorylation in the cortex, and it reduced Aβ expression and accumulation. 
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2 Aim of the project 
AD is an irreversible, multi-factorial neurodegenerative disorder characterized by a progressive 
decline in cognitive faculties.489 Several lines of evidence implicate impaired cholinergic 
neurotransmission in the brain as contributing to cognitive loss and neuropsychiatric symptoms 
of AD. The “cholinergic hypothesis” postulates that augmentation of cholinergic tonus can be 
achieved by enhancing activity of the neurotransmitter ACh. Two families of receptors mediate 
the action of ACh: nAChRs, which function as ligand-gated ion channels, and mAChRs, which 
are members of the GPCRs. mAChRs family is composed by five receptor subtypes. The M1 
subtype is the most abundant in the cortex and hippocampus, two regions involved in learning 
and memory. This suggests that M1-selective agonists can be of therapeutic value in AD. 
Stimulation of M1 mAChRs might possess not only beneficial effects on memory and cognitive 
deficits, but also disease-modifying properties.398 Thus, it is thought that activation of the M1 
subtype could reduce Aβ levels and hyperphosphorylated tau protein, the two major hallmarks of 
AD.490 Although activation of M1 mAChRs is beneficial, many efforts have failed to produce 
highly selective compounds because of the highly conserved orthosteric binding site across all 
mAChRs. However, in recent years, the research has focused the attention on the development of 
allosteric ligands. They are compounds that bind the receptor in a site that is different from the 
orthosteric site. Allosteric ligands offer many advantages. Since allosteric binding sites are less 
conserved than the orthosteric sites, high subtype selectivity can be achieved. Moreover, they 
might be less toxic because in many cases, direct acting agonists lead to receptor desensitization, 
internalization or down-regulation.491  
The aim of this project was to synthesize multi-potent ligands, which would exploit the allosteric 
site on the M1 receptors, restoring the central cholinergic deficit of AD patients. The rationale 
that led to the design of these new compounds was based on the structural similarity between 
TBPB and memoquin. TBPB is a high selective M1 allosteric agonist.425 Memoquin is a MTDL 
bearing a benzoquinone moiety which possesses antioxidant properties.483 Indeed, NQO1 
enzyme whose activity is increased in neurons of patients with AD, may convert the 
benzoquinone ring into a hydroquinone form, which can neutralize ROS. This effect could be of 
therapeutic value because it is well known that oxidative stress plays a significant role in the 
neurodegeneration of cholinergic system.283 Interestingly, idebenone, a synthetic derivative of 
CoQ10, had been shown in a clinical trial to improve cognitive function and behavioral deficits 
in patients with mild to moderate AD.492 Moreover, the quinone ring is a privileged motif for 
inhibiting Aβ fibrils formation.493, 494, 495 
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The first library of compounds (1-10) contain a benzoquinone linked to 1-(2-methoxy-benzyl)-
[4,4']bipiperidinyl moiety which might mimic the bipiperidinyl group of TBPB (Fig. 59). The 
[4,4']bipiperidinyl moiety was chosen because, among several memoquin congeners with 
different chain lengths, the best MTDL profile was observed with an hexamethylene spacer 
between inner and outer nitrogen atoms.496, 497Moreover, it has been shown that the 2-methoxy 
substituent on the aryl group was optimal for the interaction with AChE.496 On the other hand, 
the substituents on the benzoquinone group exploit different electronic and lipophilic properties 
to obtain Structure-Activity-Relationship (SAR) for M1 receptors whose crystal structure is 
unknown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59: Design strategy for compounds 1-10. 
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Figure 60: Design strategy for compounds 1-10. 
O
O
R1
R2 N N OCH3
O
O
N N OCH3
1
O
O
N N OCH3
2: X=CH, Y=CH
3: X=N, Y=CH
4: X= N, Y=N
Y
X
O
O
N N OCH3
5
O
O
N N OCH3
6
O
O
N N OCH3
7: R1= CH3
8: R1= OCH3
9: R1= Cl
10: R1= H
R1
81 
 
The selected quinones are shown in Figure 60. The 2,3-dimethylbenzoquinone of compound 1 
was replaced by a naphthoquinone affording compound 2. The naphthoquinone is more 
lipophilic and bulkier than 2,3-dimethylbenzoquinone. Moreover, the planar and aromatic 
structure of the benzene ring allows the molecule to establish a cation-pi interaction or a pi-pi 
stacking with the biological counterpart. To extend the interactions with the target, the 
naphthoquinone was replaced by a quinolinoquinone and a quinoxaline-5,8-dione affording 
compounds 3 and 4, respectively. Thus, a nitrogen atom is able to create an H-bond interaction 
with the counterpart, modifying the affinity for the receptor. To increase the steric hydrance and 
the lipophilicity of the compound, the anthraquinone was introduced, leading to 5. Compound 6 
was designed replacing the planar and aromatic naphthoquinone of 2 with the 5,6,7,8-tetrahydro-
[1,4]naphthoquinone. The latter possesses an aliphatic and less planar cycle compared to an 
aromatic ring. This substituent is not able to establish a cation-pi interaction or a pi-pi stacking 
with the target. This allows us to obtain important information about the chemical environment 
of the binding site on M1 receptors. Compounds 7-10 were designed introducing only one 
substituent on the quinone ring. The substituents exploit different electronic and lipophilic 
effects according to the Craig’s diagram.498 Finally, to verify whether the benzoquinone plays a 
role, compounds 11 (Fig. 61) in which the quinone is replaced by a carbamic group was also 
synthesized. 
 
 
 
 
 
 
 
 
 
 
 
Figure 61: Design strategy for compound 11. 
 
To extend the SAR for the allosteric site on the M1 subtype, other molecules were developed 
through chemical optimization of the lead compound VU0184670 (Fig. 62).425 In 2010, Lebois et 
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allosteric agonists. Among all the compounds, VU0184670 showed the highest potency at M1 
mAChRs (EC50= 152 nM). Moreover, it was completely inactive at M2-M5 up to the highest 
concentrations tested (30 µM). From the SAR on VU0184670 analogs, it was established that N-
methylation of the secondary nitrogen atom was detrimental for the activity. Furthermore, 
alternate chain lengths abolished M1 activity. We decided to introduce a cyclic constrained 
structure on the lead compound, through substitution of the ethylendiamine chain with a 
piperazine ring, to study the effect of conformationally restricted structures on biological 
activity. Compounds 12 and 13 (Fig. 62) were designed by replacing the carbamic group with a 
2,3-dimethylbenzoquinone and a naphthoquinone, respectively. These two quinones were 
selected from the observation that, among the previous products 1-10 (Fig. 60), compounds 1 
and 2 were the most promising. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 62: Design strategy for compounds 12 and 13. 
 
To increase the diversity of the compounds, a second library of products was designed (14-17, 
Fig. 63). The new molecules contain an amide group and an amine chain as in TBPB, but they 
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[4,4']bipiperidinyl moiety of compounds 1-10. The linker between the amide and the amine chain 
contains an aromatic substituent to mimic the 1,3-dihydro-benzoimidazol-2-one of TBPB. The 
presence of a phenyl ring offers the opportunity to verify whether electronic (σ) and/or lipophilic 
(pi) properties of substituents in the ortho position could extent any favorable effects on the 
biological profile. The substituents were selected in such a way as to have σ and pi values in 
positive or negative direction, in all combinations.498 All the compounds were synthesized 
through multicomponent reaction (MCR) between an amine chain, an aromatic aldehyde, an 
isocyanide and trimethoxyborane. The synthesis of 14-17 allows us to apply also in medicinal 
chemistry, the use of isocyanide multicomponent reactions (see Chapter 3).  
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Figure 63: Design strategy for compounds 14-17. 
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3 Chemistry 
The key intermediate for the synthesis of the amino-quinones 1-10 and the derivate of carbamic 
acid 11 was 1-(2-methoxybenzyl)-[4-4’]bipiperidine (18). It was synthesized through reductive 
amination between the commercially available 4,4'-bipiperidine and 2-methoxy-benzaldehyde 
(Scheme 1). In accordance with the widely reported reactivity of the quinone system in the 1,4-
Michael addition and in substitution reactions, the amino-quinones were synthesized from the 
reaction between 18 and the appropriate quinone. The quinone 19, used in the synthesis of 1 
(Scheme 3), was obtained from oxidation of the commercially available 2,3-dimethyl-benzene-
1,4-diol with MnO2 (Scheme 2). The synthesis of 1 was performed at RT in a biphasic system 
formed by CHCl3 and H2O. As shown in Scheme 4, also compound 2 was obtained at RT, 
through 1,4-Michael addition between 18 and the corresponding 1,4-naphthoquinone. Quinoline-
5,8-dione 20, synthesized treating 8-hydroxyquinoline with bis(trifluoroacetoxy)iodobenzene 
(PIFA) (Scheme 5),499 was then reacted with 18 leading to the desired amino-quinone 3 (Scheme 
6). The reaction was performed in the presence of 0.1 eq. of CeCl3. Metal ions catalyze the 
amination of quinoline-5,8-dione and the amino group would be preferentially introduced onto 
the 6-position of the quinone.500, 501 The formation of a metal chelate complex, in which the 
nitrogen and the oxygen of the neighboring carbonyl group coordinate to the metal ion, was 
proposed to increase the electrophilicity of the carbon in 6-position, facilitating the amination. 
The regiochemistry of 6 was confirmed through HMBC and HMQC experiments. The synthesis 
of quinoxaline-5,8-dione 23 was performed from the commercially available 2-amino-3-
nitrophenol (Scheme 7). Hydrogenation of the nitro group afforded the diamine derivative 21502 
which was then condensed with sodium glyoxal bisulfate to give quinoxaline 22503 in 90% 
yields. Oxidation of the arene with PIFA generated the quinone 23.504 This step was followed by 
1,4-Michael addition of 18 to the quinone scaffold to afford 4 (Scheme 8). A catalytic amount of 
CeCl3 was used to improve the yield of the reaction. The synthesis of the anthraquinone 
derivative 5 is shown in Scheme 9. It was obtained in very low yield treating 18 with the 
corresponding 1,4-anthraquinone. The final compound 6 (Scheme 11) was synthesized from 18 
and the quinone 25 obtained from the commercially available 5,6,7,8-tetrahydro-naphthalen-1-ol 
as shown in Scheme 10. The synthesis of the quinone 27 is described in Scheme 12. Addition of 
HCl to p-toluquinone afforded the hydroquinone 26 that was oxidized to the corresponding 
quinone 27 with potassium dichromate.505 Substitution reaction between 27 and the amine chain 
18 in EtOH at reflux led to the desired product 7 in 54% yield (Scheme 13). Similarly, 
substitution reaction between 18 and 2,5-dimethoxy-1,4-benzoquinone and 2,5-dichloro-1,4-
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benzoquinone afforded 8 (Scheme 14) and 9 (Scheme 15), respectively. In both cases, an excess 
of quinone (5 eq.) was used, to ensure the mono-substitution. The last amine-quinone of this 
series (10) was obtained through 1,4-Michael addition between 18 and 1,4-benzoquinone at RT. 
Also in this case an excess of quinone was used (Scheme 16). The synthesis of 11 is shown in 
Scheme 17. It contains a carbamic group instead of a quinone ring as in the previous 
compounds. It was synthesized in good yield, coupling 18 with ethyl chloroformate. 
The key intermediate for the synthesis of the amino-quinones 12 and 13 was the amine 31 
(Scheme 18). Its synthesis started from protection of the amine group of piperidone 
hydrochloride with (Boc)2O. The reaction was performed in MeOH in the presence of 
triethylamine. 28 was then reacted with an excess of piperazine, sodium cyanoborohydride and 
acetic acid affording the intermediate 29, which was reacted with benzoyl chloride to give 30. 
Removal of the protecting Boc group gave 31 in good yield. Finally, addition of amine 31 to 2,3-
dimethyl-1,4-benzoquinone (19) and 1,4-naphthoquinone led to 12 (Scheme 19) and 13 (Scheme 
20.), respectively.  
The syntheses of the compounds 14-17 through borane-mediated Ugi-type reaction are reported 
in Scheme 21-24. Amine 18, tert-butyl isocyanide and aldehydes with different substituents in 
ortho position were coupled in the presence of trimethoxyborane under microwave irradiation, to 
give the corresponding α-amino amides. Presently, there is a great interest in using borane 
derivatives to generate iminium ions, which are critical intermediate in Ugi and Mannich 
multicomponent reactions (see Chapter 3). 
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4 Results and Discussion 
4.1 Compounds 1-11 
Allosteric interactions are quite complex and there are several pharmacological approaches that 
can be used to detect and quantify the interactions at GPCRs. These biological assays are: 
radioligand binding assays, functional cellular assays, dissociation binding studies and site-
directed mutagenesis studies. All these approaches have been used to study the effects of 
compounds 1-11 on mAChRs. Moreover, 1-11 were also tested to assess their inhibition of 
AChE. All the results are reported and discussed below. 
 
A Radioligand Binding Assays 
Radioligand binding assays often provide the most direct way for visualizing an allosteric ligand. 
As we already discussed, an allosteric ligand binds to a site on the receptor that is spatially 
distinct from the orthosteric site to which the endogenous ligand (or another primary ligand) 
binds, allowing the primary and allosteric ligands to bind simultaneously and form a ternary 
complex with the receptor. The interaction of the orthosteric radioligand and the receptor may be 
modified by the presence of the allosteric ligand. Therefore, if the binding of the second ligand 
does not fully inhibit the radioligand binding, this effect could suggest that the second ligand 
might possess an allosteric behavior. Radioligand binding assays were performed by Prof. 
Spampinato’s group using the muscarinic orthosteric antagonist [3H]NMS. The experiments 
were conducted in HEK293 cells transfected with M1 and M2 mAChRs. As expected, atropine, 
another muscarinic orthosteric antagonist, was able to fully displace [3H]NMS from its site as 
shown in the binding isotherm in Figure 64 (bottom: 8.35% [3H]NMS bound). This behavior 
reflects their competitive interaction.  
 
 
 
 
 
 
 
 
 
Figure 64: Atropine binding isotherm. 
Atropine 
Bottom: % [3H]NMS 
bound 
 
IC50 Atropine (log M) 
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Compounds 1-11 were tested to firstly indentify which compounds do not fully inhibit [3H]NMS 
binding. The results are summarized in Table 1. The pKi value, the pIC50, and the percent 
inhibition of specific [3H]NMS binding are reported for both the M1 and the M2 subtype. The 
ligand potency is expressed as IC50, which represents the concentration of ligand required to 
decrease [3H]NMS bound by 50%. Ki is the dissociation constant of the ligand for its receptor 
and represents the affinity of the ligand. Among all the compounds, 1, 2 and 11 appeared to be 
the most interesting because they were not able to fully displace [3H]NMS from the orthosteric 
binding site on M1 mAChRs, suggesting that they might interact at a site that is distinct from 
ACh binding site. From these preliminary results we can also observe that the quinone ring did 
not seem to be essential for the interaction with the allosteric site on the M1 subtype. In fact, 11 
whose bottom value was 36.49% possesses a carbamic group instead of a quinone moiety as in 1 
and 2. Compound 1, compared to 2 and 11, displayed the highest affinity and the highest potency 
for M1 mAChRs. Moreover, its affinity for M1 was 1400-fold higher than that for the M2 subtype 
(pKi 9.53 vs 6.38). This selectivity for the M1 subtype is very important because activation of 
muscarinic M2 autoreceptors would inhibit the release of ACh in the synapse, contrasting the 
activation of M1. An analysis of the results reported in Table 1 reveals that the substituents on 
the quinone moiety markedly affected the interaction of the compounds with the allosteric site on 
M1 mAChRs. It turned out that the replacement of the 2,3-dimethylbenzoquinone of 1 with a 
bulkier substituent as naphthoquinone in compound 2 caused a reduction in affinity, potency and 
percentage of [3H]NMS bound. Moreover, the introduction of an even bulkier substituent as 
anthraquinone (compound 5) was detrimental for the interaction with the allosteric site on the M1 
subtype. In fact, 5 completely inhibited [3H]NMS binding (bottom: 1.84% [3H]NMS bound). The 
introduction of quinoline-5,8-dione and quinoxaline-5,8-dione as in 3 and 4, respectively, 
generated more polar compounds. In fact, the nitrogen atom might form H-bond interactions 
with the biological counterpart. From the competition binding of [3H]NMS, we can observe that 
4 completely displaced [3H]NMS from ACh binding site and 3 showed a bottom value of 
17.85%. This might suggest that the introduction of more polar quinones may have a detrimental 
effect on the interaction on the allosteric site on the M1 subtype. This effect was more marked for 
4 that contains two nitrogen atoms in the quinone ring. From these results, we can envisage that 
the substituents on the quinone group might interact with a lipophilic pocket that is present in the 
allosteric site on M1 but not on M2 mAChRs. Thus, the introduction of polar groups like a 
nitrogen as in 3 and 4 might not favour the interaction with M1 receptors. Moreover, these 
findings suggest that the allosteric binding site on the M1 subtype might possess a definite 
binding area. Indeed, the best activity is obtained with small substituents like a methyl group as 
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in 1. On the other hand, bulkier substituents may not be optimal to be embedded in the lipophilic 
pocket. In addition, compound 11, which possesses a carbamic group, retained its activity on M1 
mAChRs. Its affinity and potency were even higher than those of 2. This could suggest that a 
planar and less bulky structure and two oxygen groups able to form hydrogen bonds are 
sufficient for the interaction with the allosteric site on M1 mAChRs. 
The influence of a single substituent on the quinone ring was also exploited according to Craig 
diagram.498 An analysis of the results reveals that compounds 7-10 fully inhibited [3H]NMS 
binding and their affinities for M1 mAChRs were lower than that of atropine. It turned out that 
the second substituent on the quinone ring is essential for the interaction with the allosteric 
binding site. Thus, compound 7 bearing only one methyl group on the quinone ring, fully 
inhibited [3H]NMS binding, while compound 1 caused a 47.46% inhibition of [3H]NMS binding. 
From the results shown in Table 1, we can also observe that the chemical and physical properties 
of the quinone moiety markedly affected the interaction with M1 mAChRs but not with the M2 
subtype. This finding suggests that the allosteric site on M1 mAChRs might possess a defined 
binding area that is marked affected by the nature of the substituents on the quinone ring.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Table 1: Binding constants of atropine and 1-11 at 
M1 and M2 mAChRs. a Assays were performed in 
HEK293 cells transfected with M1 and M2 
mAChRs using [3H]NMS 1 nM. The values are the 
mean of two independent experiments. b pKi= -
log(Ki), Ki represents the dissociation constant of 
the ligand. c pIC50=-log(IC50), IC50 represents the 
concentration of ligand required to decrease 
[3H]NMS bound by 50%. d Bottom represents the 
lowest asymptote (basal response) of the curve. e 
nt: not tested. 
Compound M1a M2a 
 
R1 R2 pKib  pIC50c Bottomd 
(% [3H]NMS 
bound) 
 
pKib  pIC50c Bottomd  
(% [3H]NMS 
bound) 
 
Atropine   8.36 7.84 8.35    
1 Me Me 9.53 9.00 47.46 6.38 6.11 0 
2 
 
6.25 5.72 32.82 6.62 6.35 0 
3 
N
 
7.42 6.90 17.85 6.74 6.47 0 
4 
N
N
 
6.60 6.07 4.73 6.55 6.28 0.27 
5 
 
6.61 6.09 1.84 6.38 6.11 0 
6 
 
nte nte nte nte nte nte 
7 CH3 H 6.98 6.45 0 nte nte nte 
8 OCH3 H 6.48 5.95 0 nte nte nte 
9 Cl H 6.29 5.77 0 nte nte nte 
10 H H 5.59 5.07 0 nte nte nte 
R3 
11 
EtO
O
 
7.82 7.30 36.49 6.09 5.82 5.63 
O
O
N N OCH3
R1
R2
R3 
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B  Functional Assays  
Functional assays were also performed by Prof. Spampinato’s group using a protocol described by 
Thomas et al.506 It is well known that ligands binding to M1 mAChRs activate Gq proteins, which, 
in turn, activate PLC with the subsequent generation of IP3 and DAG. However, the ability of this 
receptor subtype to influence additional downstream effector pathways (via distinct G protein 
subtypes) has also been reported. Thus, the M1 subtype has been shown to activate also adenylyl 
cyclase activity via a Gs protein-dependent mechanism.507 Among a range of orthosteric muscarinic 
agonists, OXO-M exhibited the greatest intrinsic activity in adenylyl cyclase activation and cAMP 
accumulation.506 In the light of these considerations, functional assays were performed studying the 
effects of these new compounds on the production of cAMP induced by OXO-M. Compounds 1-11 
were analyzed firstly at a concentration of 100 nM on HEK293 cells transfected with M1 mAChRs. 
The results are summarized in Table 2. The EC50 represents the concentration of a ligand required 
to induce a response of 50% of its maximal effect. Rmax % is the percent of the maximal response of 
each compound referred to OXO-M. An analysis of the results reported in Table 2 reveals that at 
100 nM 1 and 2 caused a marked increase in cAMP production. This effect was much more marked 
for compound 1. In fact, it was able to triplicate cAMP accumulation induced by OXO-M. On the 
other hand, compound 2 increased the production of cAMP by 189.1%. Moreover, it was shown 
that 11 caused a decrease in cAMP production by 62.5%. This indicates that 11, unlike 1 and 2, may 
destabilize the receptor conformation induced by OXO-M, negatively affecting the downstream 
signaling cascade. Functional assays performed without the orthosteric agonist OXO-M showed that 
1, 2 and 11, alone, did not have any noteworthy effect on cAMP production (Fig. 65). The present 
finding suggests that these compounds do not possess intrinsic activity. Thus, they are not able to 
induce (1 and 2) or inhibit (11) Gs protein-dependent pathways.  
 
 
 
 
 
 
 
 
 
Figure 65: cAMP assays performed with 1, 2, and 11 without OXO-M. 
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Interestingly, compounds 7 and 10 were able to increase cAMP accumulation by 181.4% and 
166.5%, respectively, while completely displacing [3H]NMS (Table 1, 0% [3H]NMS bound). 
Derivative 8 is probably even more interesting: it did not increase the maximal response of OXO-M 
but it caused a leftward shift in OXO-M concentration response curve with a significant increase of 
the pEC50 value compared to that of OXO-M alone (7.59 vs 5.23). This suggests that a lower OXO-
M concentration is required to obtain the same maximal response. This effect would be particularly 
useful in AD where the levels of the neurotransmitter ACh are reduced. The same behaviour was 
displayed by compounds 4, 5, and 9. However, their effects were not so marked as for 8. 
To study the effect of different concentrations of 1 and 2 on the activation of M1 mAChRs, 
functional studies were performed also at 0.01 µM and 1 µM. An analysis of the results shown in 
Figure 66A and in Table 3 reveals that increasing concentration of 1 caused a marked increase in 
cAMP production induced by OXO-M. Moreover, increasing concentrations of 1 were associated 
with an increase in pEC50 and therefore in OXO-M potency. Interestingly, the stimulation of cAMP 
production was more marked when the concentration was increased from 0.01 µM to 0.1 µM. Thus, 
the percentage of the maximal response at 0.01 µM was 63.9% and reached 327.4% when the 
concentration was 0.1 µM. However, when the concentration was 1 µM the maximal response was 
found to be 444.4%. This effect reflects the saturability of the allosteric interaction; once the 
allosteric sites are completely occupied, no further allosteric effect is observed.508 An analysis of the 
results shown in Figure 66B and in Table 3 reveals that, in the presence of OXO-M, increasing 
concentration of 2 caused a decrease in cAMP production. This effect could be due to the fact that, 
at lower concentrations, 2 interacts with the allosteric site affecting positively cAMP production, 
whereas, at higher concentrations, after saturating the allosteric site, it might bind also to a different 
binding site, contrastating OXO-M effect.  
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Table 2: Functional studies (cAMP assay) of compounds 1-10 were 
performed in HEK293 transfected with M1 mAChRs. The values are the 
mean of two independent experiments. a pEC50= -log(EC50), EC50 
represents the concentration of ligand required to decrease the [3H]NMS 
bound by 50%. b Rmax % is the percentage of the maximal response using 
OXO-M as reference compound. c The effect of the compounds on the 
production of cAMP is summarized as: 
    = increase in cAMP production;   = reduction in cAMP production;    
       = any effect on cAMP production. d nt: not tested. 
 
Compound pEC50a Rmax%b Effectc 
 
R1 R2    
Oxotremorine    5.23 100  
1 Me Me 6.09 327.4  
2 
 
4.42 189.1  
3 
N
 
5.20 85.1  
4 
N
N
 
6.51 97.0  
5 
 
6.27 71.5  
6 
 
ntd ntd ntd 
7 CH3 H 4.45 181.4  
8 OCH3 H 7.59 93.0  
9 Cl H 6.67 92.3  
10 H H 3.92 166.5  
R3 
11 
EtO
O
 
4.43 62.5  
R3 
O
O
N N OCH3
R1
R2
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66: Effect of three different concentrations of 1 (A) and 2 (B) on the production of cAMP induced by OXO-M. 
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Table 3: Effect of three different concentrations of 1 (A) and 2 (B) on cAMP production induced 
by OXO-M. The values are the mean of two independent experiments. a pEC50= -log(EC50), EC50 
represents the concentration of a ligand required to induce a response of 50% of its maximal effect. 
b
 Rmax is the maximal response of cAMP production in pmol/mg. c Rmax% is the percentage of the 
maximal response referred to OXO-M.  
 
C [3H]NMS Dissociation Binding Studies 
Allosteric modulators cause a conformational change in the receptor that is often manifested as an 
alteration of the dissociation rate of a preformed orthosteric ligand-receptor complex.435 Hence, a 
change in receptor conformation induced by an allosteric agent would be expected to slow down the 
orthosteric ligand dissociation rate. A kinetic assay determines the ligand dissociation rate (Koff) as 
a function of time. Since kinetic studies represent the most sensitive direct measurement of 
allosteric interactions at GPCRs, [3H]NMS dissociation binding assays were also performed to 
validate the allosteric character of 1 (Figure 67). It was shown that 1 significantly slowed the rate 
of [3H]NMS dissociation induced by the orthosteric antagonist atropine (Table 4). In fact, atropine 
alone was able to displace completely [3H]NMS with an half-life of 7.9 min, whereas, in the 
presence of 1, the half-life was 13.1. Thus, the ability of 1 to significantly alter the dissociation rate 
of [3H]NMS reinforces the hypothesis that it binds to a site topographically distinct from ACh 
binding site.  
 
Compound Concentration pEC50a                   Rmaxb  Rmax %c 
OXO-M 0,1 µM 5,23 39,04 100 
OXO-M + 1 
0,01 µM 5,35 24,9 63,9 
0,1 µM 6,09 127,8 327,4 
1 µM 6,58 173,5 444,4 
OXO-M + 2 
0,01 µM 6,01 70,06 179,5 
0,1 µM 5,42 73,83 189,1 
1 µM 5,47 47,98 122,9 
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Figure 67: [3H]NMS kinetic studies in the presence of atropine alone and atropine plus 1. 
 
 
 
 
 
 
 
 
 
Table 4: [3H]NMS kinetic studies in the presence of atropine and atropine plus 1. The values are 
the mean of two independent experiments. a The concentration of atropine and 1 was 10 µM. b Koff 
denotes the rate constant for dissociation of the radioligand from its site. c Half-life is the time 
required to decrease the [3H]NMS bound by 50%.  
 
 
 
 
 
 
 
 
Compounda Koff  (min-1)b Half-life (min)c 
Atropine 0.088 7.9 
Atropine + 1 0.053 13.1 
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D Mutagenesis studies 
To confirm that 1 and 2 bind at an allosteric site, mutagenesis studies were also performed. In 
literature, it is reported that Y381A mutation in TM6 profoundly affected the binding of the 
orthosteric agonist CCh. However, the allosteric agonists AC-42 and TBPB still produced a robust 
agonist response similar to that obtained in wt M1 mAChRs.426, 444 Moreover, chimeric receptors 
revealed that Phe77 in TM2 plays an important role for the interaction of AC-42 and TBPB with the 
allosteric site on the M1 subtype.445 In the light of these considerations, functional experiments were 
performed on M1 mAChRs containing Y381A and F77I mutations. The concentration of OXO-M, 1 
and 2 was 100 nM. The results are shown in Figure 68. From the analysis of the graphs, we can 
observe that, as expected, OXO-M and derivatives 1 and 2 activated wild type M1 mAChRs with 
the subsequent production of cAMP. Y381A mutation on the orthosteric site abrogated the effect of 
OXO-M and also that of 1 and 2. In functional assays, it was observed that 1 and 2 were not able to 
activate the M1 subtype in the absence of the orthosteric agonist OXO-M (Fig. 65). The finding on 
M1 mAChRs bearing Y381A mutation confirms that, when OXO-M cannot interact with the 
orthosteric site, derivates 1 and 2 loose completely their activity. Therefore, no cAMP accumulation 
was detected. On the other hand, F77I mutation on the allosteric site did not completely abrogate 
OXO-M activity, while derivative 1 was completely inactive. The present finding suggests that 
compound 1 might share the same binding pocket of the allosteric ligands AC-42 and TBPB. 
Interestingly, derivative 2 retained its activity, suggesting a possible interaction with a site different 
from that of 1, explaining why F77I mutation did not affect its activity.  
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Figure 68: Effects of OXO-M and compounds 1 and 2 (100 nM) on wild type or M1 mAChRs containing F77I and Y381A mutations.
-8 -7 -6 -5 -4 -30
25
50
75
VM2
VM6
100
110
120
130
140
150 OXO-M
log [OXO-M]
p
m
o
l
/
m
g
-9 -8 -7 -6 -5 -4 -3
0
5
10
15
20
25
30
35
OXO+VM2
OXO+VM6
OXO
log [OXO-M]
p
m
o
l
/
m
g
-9 -8 -7 -6 -5 -4 -3
0
5
10
15
20
25
30
35
OXO+VM2
OXO+VM6
OXO
log[Ossitremorina]
p
m
o
l
/
m
g
WT M1 mAChRS 
F77I  mutation 
Y381A  mutation 
OXO-M + 1 
OXO-M + 2 
-M + 2 
O-M + 1 
-M + 2 
OXO-M + 1 
105 
 
E AChE Inhibition  
The inhibitory effects of compounds 1-11 on human recombinant AChE and BuChE from human 
serum were assessed in comparison to memoquin, a dual binding AChEI, which accounts for its 
remarkable nanomolar activity.483 The experiments were performed by Dr. Bartolini’s group and the 
results are summarized in Table 5. The inhibition activity is expressed as IC50 value that represents 
the concentration of inhibitor required to decrease enzyme activity by 50%. The inhibitory potency 
of 1-11 was evaluated on both AChE and BuChE because selectivity for AChE over BuChE may be 
beneficial for AD. Thus, BuChE may have a role inverse to that of AChE in AD.509 Moreover, 
BuChE does not possess the PAS that is responsible for the Aβ assembly into amyloid fibrils.198 
From an analysis of the results shown in Table 5 it turned out that 1-11 were modest AChEI. They 
inhibited AChE with IC50 values ranging from 2.56 to 290 µM while memoquin displayed an IC50 
of 1.55 nM. It is plausible that the constrained structure of 1-11 does not allow an optimal 
interaction with AChE gorge as already observed for other memoquin monomeric derivates.510  
In previous assays, it was envisaged that the substituents on the quinone ring may give critical 
interactions with a lipophylic pocket in the allosteric site on the M1 subtype. Thus, the physical and 
chemical properties of such substituents play an important role in driving the ligand in the allosteric 
site. An analysis of the results reported in Table 5 reveals that changing the electronic and 
lipophilic properties of the quinone ring did not markedly affect the inhibitory potency against 
AChE and BuChE. Among all the compounds, the most potent AChEIs were compounds 3 and 5. 
They were 6-fold and 5-fold, respectively, more selective for AChE than for BuChE. However, 
from studies on mAChRs, it was found that a quinoline-5,8-dione (3) or a bulky quinone as 
anthraquinone (5) did not display any positive effect on M1 activation. Binding and functional 
assays on mAChRs revealed that compounds 1 and 2 were the most promising. In AChE inhibition 
assays, 1 and 2 displayed an IC50 values of 12.2 and 17.0 µM, respectively. Moreover, 2 was 
slightly more potent for BuChE than for AChE. Compound 11, bearing a carbamic group, was 
expected to be a pseudo-irreversible AChE inhibitor. It is well known that carbamates might form a 
carbamoylated complex with the serine residue of the catalytic triad of AChE enzyme, which is 
hydrolyzed in hours. Unfortunately, the inhibitory activity of 11 resulted time-independent, 
suggesting that it was not an irreversible inhibitor.  
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Table 5: Inhibitory activities on human AChE 
and BuChE of 1−11 and the reference compound 
memoquin. a Human recombinant AChE and 
BuChE from human serum were used. IC50 
represents the concentration of inhibitor required 
to decrease enzyme activity by 50% and is the 
mean of two independent measurements, each 
performed in duplicate. b Data from ref.510 
Compound IC50 AChE 
(µM)a 
IC50 BuChE 
(µM)a 
Selectivity  
AChE/BuChE 
 
R1 R2    
Memoquinb   0.00155±0.00011 0.144±0.100 0.011 
1 Me Me 12.2 ± 0.6 14.9 ± 0.7 0.82 
2 
 
17.0 ± 0.9 13.9 ± 0.6 1.22 
3 
N
 
2.56 ± 0.18 15.2 ± 0.8 0.17 
4 
N
N
 
10.8 ± 0.8 12.1 ± 1.2 0.89 
5 
 
2.64 ± 0.23 13.8 ± 0.7 0.19 
6 
 
9.53 ± 0.26 3.04 ± 0.13 3.13 
7 CH3 H 10.1 ± 0.7 16.1 ± 1.2 0.63 
8 OCH3 H 24.4 ± 1.4 3.58 ± 0.15 6.81 
9 Cl H 9.45 ± 0.41 21.8 ± 0.2 0.43 
10 H H 8.20 ± 0.43 30.9 ± 1.5 0.27 
11 
EtO
O
 
290 ± 11 102 ± 5 2.84 
O
O
N N OCH3
R1
R2
R3 
N
O
N
H
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O
H
N N
O
Memoquin
4
4
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F Antioxidant Activity 
Several studies on the antioxidant properties of 1,4-benzoquinone derivatives, such as idebenone 
and CoQ, have conclusively demonstrated that the antioxidant activity is due exclusively to their 
hydroquinone form, since the quinone, in principle, cannot scavenge radicals.511 Furthermore, 
NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) was shown to catalyze the two-
electron reduction of quinones to hydroquinones, bypassing the production of semiquinones and, 
consequently, preventing their participation in redox-cycling and the subsequent generation of ROS. 
Moreover, NQO1 was found to be increased in AD in response to the perturbation of the balance 
between generation and scavenging of ROS.512 In the light of these considerations, compounds 1, 2, 
and 8 were tested with respect to their ability to accept electrons from NAD(P)H via rat NQO1, in 
comparison with menadione as a reference compound, following the absorbance change of 
NAD(P)H. The results are shown in Figure 69 and in Table 6 and expressed in terms of variation 
of absorbance (∆abs) at 340 nm per minute. High values in ∆abs/min mean that high amounts of 
NAD(P)H have been oxidized to reduce the quinone ring to the corresponding hydroquinone form. 
To study the effect of the concentration on the ability to accept electrons, the experiments were 
performed using three different concentrations of tested compounds (20, 40, and 80 µM) to. Only 
two concentrations were used for the reference compound menadione, because the best activity was 
obtained at concentrations higher than 20 µM. However, at 80 µM, a decrease in menadione activity 
was observed (∆abs/min 1.045 vs 0.630) because at higher concentrations, menadione solubility 
decreases slowing down the enzymatic rate. An analysis of the graph shown in Figure 69 reveals 
that at 20 µM the best substrate of NQO1 was compound 1. Its ∆abs/min value was higher than that 
of menadione at 40 µM (1.124 vs 1.045). Moreover, almost no difference was observed between 
∆abs/min values obtained with the three concentrations of 1. Compound 8 at 20 µM was found to 
be a good substrate for NQO1, being not very different from menadione in terms of reduction by the 
enzyme (1.042 vs 1.045). We can also observe that increasing concentrations of 8 caused a decrease 
in ∆abs/min. This was caused by the fact that, at high concentrations, the solubility of 8 was 
reduced and therefore, the results obtained are not accurate.  
Finally, compound 2 was completely inactive up to 80 µM. We can envisage that the methyl groups 
of 1 and the methoxy group of 8, through their electron donating effects, can stabilize the 
hydroquinone form and the subsequent phenoxy radicals. On the other hand, the naphthoquinone is 
less stable in its reduced form.  
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Figure 69: Ability of 1, 2, and 8 to accept electrons from the rat enzyme NQO1. The results are 
expressed in terms of variation of absorbance (∆abs) at 340 nm per minute. 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Ability of 1, 2, and 8 to accept electrons from the rat enzyme NQO1. The results are 
expressed in terms of variation of absorbance (∆abs) at 340 nm per minute. 
 
 
 
 
 
 
Concentration 
(µM) 
Menadione 
(∆abs/min) 
1 
(∆abs/min) 
2 
(∆abs/min) 
8 
(∆abs/min) 
20  1.124 0.085 1.042 
40 1.045 0.860 0.188 0.840 
80 0.630 1.020 0.116 0.630 
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4.2 Compounds 12 and 13 
Functional and binding studies of 12 and 13 on mAChRs are in progress to verify whether they 
might be selective M1 allosteric ligands. AChE inhibition assays were also performed and the 
results are shown below.  
 
A AChE Inhibition  
An analysis of the results shown in Table 7 reveals that the change of position of the basic nitrogen 
in the amine chain is detrimental for the interaction with AChE gorge. Thus, compound 12 was 
14.5-fold less potent than its homologous 1. Furthermore, 13 was 13.4-fold less potent than 2. 
These results might indicate that the structures of 13 and 14 are too constrained to create optimal 
interactions with AChE gorge. Moreover, since the protonable nitrogen belongs to the piperazin 
ring, the rotation around N-C bond is not allowed, making, perhaps, more difficult the formation of 
hydrogen bonds with the biological counterpart.  
 
 
 
 
 
 
 
Table 7: Inhibitory activities on human AChE and BuChE of 12, 13 and the reference compound 
memoquin. a Human recombinant AChE and BuChE from human serum were used. IC50 represents 
the concentration of inhibitor required to decrease enzyme activity by 50% and is the mean of two 
independent measurements, each performed in duplicate. b Data from ref.510 
Compound IC50 AChE 
(µM)a 
IC50 BuChE 
(µM)a 
Selectivity  
AChE/BuChE 
 
R1 R2    
Memoquinb  0.00155±0.00011 0.144±0.100 0.011 
12 CH3 CH3 177 ± 9 562 ± 22 0.31 
13 
 
228 ± 7 159 ± 13 1.43 
O
O
N N N
R1
R2
O
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4.3 Compounds 14-17 
Functional and binding studies of 14-17 on mAChRs are in progress to verify whether they might 
be promising drugs to target the neurodegeneration in AD. AChE inhibition assays were also 
performed and the results are shown below.  
 
A AChE Inhibition  
In the design of these compounds, we hypothesized that the two aromatic rings of 14-17 might 
create pi-pi stacking interactions with aromatic aminoacids in the gorge of AChE and with Trp286 in 
the PAS of the enzyme. Surprisingly, an analysis of the results reported in Table 8 reveals that 
these compounds were not good AChEIs. In fact, all the compounds showed an IC50 values ranging 
from 71.3 to 124 µM. Moreover, they were more selective for BuChE than for AChE. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8: Inhibitory activities on human AChE and BuChE of 14−17 and the reference compound 
memoquin. a Human recombinant AChE and BuChE from human serum were used. IC50 represents 
the concentration of inhibitor required to decrease enzyme activity by 50% and is the mean of two 
independent measurements, each performed in duplicate. b Data from ref.510 
 
Compound IC50 AChE 
(µM)a 
IC50 BuChE 
(µM)a 
Selectivity  
AChE/BuChE 
 
R1    
Memoquinb  0.00155±0.00011 0.144±0.100 0.011 
14 H 124 ± 7 6.86 ± 0.29 18.1 
15 OCH3 122 ± 2 6.94 ± 0.30 17.8 
16 CH3 77.7 ± 5.3 8.72 ± 0.46 8.91 
17 Cl 71.3 ± 5.5 7.47 ± 0.39 9.54 
OCH3
N
N
N
H
O
R
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5 Conclusions and Future Works 
A Compounds 1-11 
Despite the therapeutic potential of M1 mAChRs for the treatment of AD, high selective orthosteric 
ligands for the M1 subtype have not been identified yet. However, allosteric modulation of GPCRs 
represents a valid alternative for identifying subtype selective ligands because it is expected that 
allosteric binding sites, unlike the orthosteric pockets, are less conserved among receptor subtypes. 
In the present thesis, we studied the effect of some quinone derivatives on M1 mAChRs activation.  
The pharmacological approaches used to detect and quantify the interaction at mAChRs are 
radioligand binding assays, functional cellular assays, dissociation binding studies and site-direct 
mutagenesis studies. Among all the compounds, 1 and 2 were the most promising. In fact, from 
radioligand binding assays (Table 1) it was shown that 1 and 2 did not displace completely the 
orthosteric antagonist [3H]NMS, suggesting that they might interact at an allosteric site. Moreover, 
compound 1 was 1400-fold more selective for M1 than for the M2 subtype. In functional assays 
(Table 2, Fig. 66), 1 and 2 (100 nM) were able to increase the production of cAMP induced by the 
orthosteric agonist OXO-M by 327.4% and 189.1%, respectively. However, they were not able to 
activate M1 mAChRs in the absence of OXO-M. Mutagenesis studies revealed that 1 looses 
completely its functional activity with F77I mutation in the allosteric site of the M1 subtype, 
suggesting that 1 might share the same binding pocket of the allosteric agonists AC-42 and TBPB. 
On the other hand, compound 2 retained its activity, indicating that its binding site might be 
different from that of 1. The mode of action of 1 was evaluated also in kinetic experiments. Similar 
to AC-42 and TBPB, 1 was able to reduce [3H]NMS dissociation rate from M1 mAChRs (Fig. 67, 
Table 4). Taking together, these results suggest that 1 and 2 are positive allosteric modulators i. e., 
they do not have intrinsic activity but their binding potentiates the effect of orthosteric agonists such 
as OXO-M and ACh. From our results, also compounds 7, 8 and 10 appear to be interesting. In fact, 
in functional assays, 7 and 10 (100 nM) were able to increase cAMP accumulation induced by 
OXO-M by 181.4% and 166.5%, respectively (Table 2). Mutagenesis studies are in progress to 
better clarify their mode of action. Regarding compound 8, it caused a leftward shift in OXO-M 
response curve, without affecting cAMP production. This finding suggests that in presence of 8, a 
lower OXO-M concentration is required to obtain the maximal response. This effect might be useful 
in AD. It is well known that in the brain of AD patients the levels of the neurotransmitter ACh are 
reduced. Therefore, the use of ligands that are able to induce M1 activation also with low levels of 
ACh could restore the impaired signalling pathway and memory deficit. Functional experiments 
with different concentration of 8 and mutagenesis studies are in progress to better study the mode of 
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action of this interesting compound. Despite the promising results on M1 activation, compounds 1-
11 were modest AChEIs (Table 5). Again, the constrained structure of these derivatives might not 
allow an optimal binding into AChE gorge. However, their inhibitory effects were in the µM range, 
which might contribute to further increase ACh concentration in the synapses.  
Compounds 1, 2 and 8 were also tested to determine their ability to accept electrons from NAD(P)H 
via NQO1, in comparison with the reference compound, menadione (Fig. 69, Table 6). It turned out 
that 1 and 8 were good substrate of NQO1 with 1, at 20 µM, even more active than menadione.  
In conclusion, we demonstrated that these quinone derivatives could be promising candidates to 
target M1 mAChRs. As discussed, the activation of the M1 subtype has the potential for positive 
disease-modifying treatments in a variety of psychiatric and neurological diseases such as AD. 
Moreover, the ability of these compounds to interact with an allosteric site could result in selective 
targeting of the M1 subtype, reducing the side effects associated with activation of the other receptor 
subtypes. The addition of antioxidant properties could be very interesting, since it is well known 
that in the brain of AD patients the balance between generation and scavenging of ROS is altered.  
 
B Compounds 12 and 13 
Assays on mAChRs are in progress to study the mechanism of action of 12 and 13 on the M1 
subtype. Compounds 12 and 13 inhibited AChE with an IC50 of 177 and 228 µM, respectively 
(Table 7). Perhaps, as for 1-11, their structures are too constrained to penetrate into AChE gorge. 
 
C Compounds 14-17 
Regarding derivatives 14-17, only AChE inhibition assays were performed. From the results shown 
in Table 8, we can observe that they were not good AChEIs. Perhaps, as for 1-13, their structures 
are too constrained to fit well into AChE gorge. Assays on mAChRs are in progress to verify their 
activity as allosteric ligands.  
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6 Experimental section 
6.1 Chemistry  
All reactions were carried out at atmospheric pressure with stirring unless otherwise indicated. All 
solvents and chemicals were purchased from suppliers and used without further purification. For 
microwave-assisted organic synthesis a CEM Discover BenchMate reactor was used. Reaction 
progress was monitored by TLC plates pre-coated with silica gel 60 F254 (Sigma Aldrich) visualized 
by UV (254 nm) or chemical stain (KMnO4, bromocresol green and Ce-Mo). Flash and gravity 
column chromatography were performed on silica gel (particle size 40-63 µM, Merck). Melting 
points were determined using Büchi SMP-20 apparatus. Compounds were named relying on the 
naming algorithm developed by CambridgeSoft Corporation and used in Chem-BioDraw Ultra 
11.0. Optical activity was determined using a Perkin Elmer instrument. 1H-NMR and 13C-NMR 
spectra were recorded at 200-400 and 50-100 MHz, respectively, on Varian instruments. Chemical 
shifts were measured in ppm and are quoted as δ, relative to TMS. Multiplicities are quoted as s 
(singolet), d (doublet), t (triplet), q (quartet), quintet and m (multiplet), br (broad) with coupling 
constants defined as J given in Hz. Mass spectra were recorded on a V.G. 7070 E spectrometer or 
on a Waters ZQ 4000 apparatus operating in electrospray (ES) mode. 
 
5-[1'-(2-Methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-2,3-dimethyl-[1,4]benzoquinone (1) 
 
 
 
 
 
A solution of 18 (200 mg, 0.70 mmol) and KH2PO4 (95 mg, 0.70 mmol) in H2O (8 ml) was added 
dropwise to a solution of 19 (95 mg, 0.70 mmol) in CHCl3 (2 ml). The mixture was stirred 
vigorously at RT for 2 h. The aqueous phase was then washed with CHCl3 (3 x 10 ml). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. The crude 
was purified by gravity chromatography (DCM-MeOH-aqueous 33% ammonia, 9:1:0.05) affording 
1 as a purple slurry (148 mg, 0.35 mmol, 50%); ES [M+H+]: 
 
423; δH (400 MHz, CD3OD) 0.81-0.86 
(1H, m, CH), 1.02-1.07 (5H, m, CH, 2CH2), 1.44 (2H, d, J 13.0, CH2), 1.51 (2H, d, J 9.4, CH2), 
1.67 (3H, s, CH3), 1.68 (3H, s, CH3), 1.77-1.82 (2H, m, CH2-N), 2.55 (2H, t, J 11.8, CH2-N), 2.72 
(2H, d, J 12.2, CH2-N), 3.31 (2H, s, CH2-Ph), 3.54 (3H, s, OCH3), 3.66 (2H, d, J 13.0, CH2-N), 5.39 
O
O
N N OCH3
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(1H, s, CH-C=O), 6.63 (1H, t, J 8.0, Ar), 6.68 (1H, d, J 8.0, Ar), 6.97-7.0 (2H, m, Ar); δC (100 
MHz, CDCl3) 10.83, 11.09, 28.35, 29.00, 40.21, 40.50, 49.19, 53.35, 54.33, 55.83, 105.67, 110.22, 
119.77, 124.13, 128.65, 131.34, 139.15, 140.55, 153.10, 158.17, 184.89, 186.18.  
 
2-[1'-(2-Methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-[1,4]naphthoquinone (2) 
 
 
 
 
A solution of 18 (100 mg, 0.35 mmol) and KH2PO4 (48 mg, 0.35 mmol) in H2O (4 ml) was added 
dropwise to a solution of 1,4-naphthoquinone (55 mg, 0.35 mmol) in CHCl3 (1 ml). The mixture 
was stirred vigorously at RT for 2 h. The aqueous phase was then washed with CHCl3 (3 x 10 ml). 
The combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. The 
crude was purified by gravity chromatography (DCM-MeOH-aqueous 33% ammonia, 9:1:0.05) 
affording 2 as a red solid (30 mg, 0.07 mmol, 20%); mp= 53 °C; ES [M+H+]:
 
445; δH (400 MHz, 
CDCl3) 1.09-1.15 (1H, m, CH), 1.39-1.45 (5H, m, 2CH2, CH), 1.66 (2H, d, J 12.1, CH2), 1.77 (2H, 
d, J 8.6, CH2), 2.03 (2H, t, J 11.1, CH2-N), 2.84 (2H, t, J 11.5, CH2-N), 3.01 (2H, d, J 10.2, CH2-N), 
3.61 (2H, s, CH2-Ph), 3.77 (3H, s, OCH3), 4.02 (2H, d, J 12.1, CH2-N), 5.96 (1H, s, CH-C=O), 6.82 
(1H, d, J 7.7, Ar), 6.89 (1H, t, J 7.7, Ar), 7.20 (1H, t, J 7.7, Ar), 7.33 (1H, d, J 7.7, Ar), 7.56 (1H, t, J 
7.4, Ar), 7.63 (1H, t, J 7.4, Ar), 7.93 (1H, d, J 7.4, Ar), 7.98 (1H, d, J 7.4, Ar); δC (100 MHz, 
CDCl3) 28.92, 29.26, 40.37, 40.70, 49.76, 53.60, 55.38, 55.87, 110.42, 110.60, 120.36, 125.40, 
126.55, 128.41, 131.02, 132.19, 132.50, 132.87, 132.71, 153.87, 157.82, 183.29, 183.45.  
 
6-[1'-(2-Methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-quinoline-5,8-dione (3) 
 
 
 
 
A solution of 18 (120 mg, 0.42 mmol), KH2PO4 (57 mg, 0.42 mmol) and CeCl3 (10 mg, 0.04 mmol) 
in H2O (4 ml) was added dropwise to a solution of 20 (67 mg, 0.42 mmol) in CHCl3 (1 ml). The 
mixture was stirred vigorously at RT for 2 h. The aqueous phase was then washed with CHCl3 (3 x 
10 ml). The combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. 
The crude was purified twice by gravity chromatography (DCM-MeOH-aqueous 33% ammonia, 
O
O
N N OCH3
N
O
O
N N OCH3
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9:1:0.05) affording 3 as a purple slurry (30 mg, 0.07 mmol, 16%); ES [M+H+]:
 
 446; δH (400 MHz, 
CD3OD) 1.21-1.23 (1H, m, CH), 1.28-1.44 (5H, m, CH, 2CH2), 1.79 (2H, d, J 12.6, CH2), 1.88 (2H, 
d, J 12.2, CH2), 2.25 (2H, t, J 11.8, CH2-N), 3.01-3.11 (4H, m, CH2-N), 3.72 (2H, s, CH2-Ph), 3.84 
(3H, s, OCH3), 4.22 (2H, d, J 13.0, CH2-N), 6.14 (1H, s, CH-C=O), 6.93 (1H, t, J 7.7, Ar), 6.99 (1H, 
d, J 7.7, Ar), 7.29-7.32 (2H, m, Ar), 7.71 (1H, dd, J 7.7, 4.7, Ar), 8.37 (1H, d, J 7.7, Ar), 8.86 (1H, 
d, J 4.7, Ar); δC (100 MHz, CD3OD) 27.92, 29.14, 39.74, 40.26, 49.44, 53.15, 54.39, 55.66, 107.74, 
110.35, 119.91, 122.87, 126.75, 129.23, 129.71, 131.58, 134.81, 147.67, 153.40, 153.61, 158.22, 
181.51, 182.16.  
 
-[1'-(2-Methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-quinoxaline-5,8-dione (4) 
 
 
 
 
A solution of 18 (107 mg, 0.37 mmol), KH2PO4 (50 mg, 0.37 mmol) and CeCl3 (9 mg, 0.04 mmol) 
in H2O (4 ml) was added dropwise to a solution of 23 (67 mg, 0.42 mmol) in CHCl3 (2 ml). The 
mixture was stirred vigorously at RT overnight. The aqueous phase was then washed with CHCl3  
(3 x 10 ml). The combined organic extracts were dried over Na2SO4, filtered and concentrated in 
vacuo. The crude was purified by gravity chromatography (DCM-MeOH-aqueous 33% ammonia 
9.5:0.5:0.05) affording 4 as a red solid (50 mg, 0.11 mmol, 30%); mp= 90°C; δH (400 MHz, 
CD3OD) 1.45-1.55 (6H, m 2CH, 2CH2), 1.90 (2H, d, J 10.6, CH2), 2.03 (2H, d, J 11.4, CH2), 3.01 
(2H, t, J 12.0, CH2-N), 3.12 (2H, t, J 12.4, CH2-N), 3.54 (2H, d, J 13.0, CH2-N), 3.92 (3H, s, 
OCH3), 4.26 (2H, d, J 13.8, CH2-N), 4.30 (2H, s, CH2-Ph), 6.24 (1H, s, CH-C=O), 7.04 (1H, t, J 7.5, 
Ar), 7.12 (1H, d, J 7.5, Ar), 7.41 (1H, dd, J, 7.5, 1.6, Ar), 7.49 (1H, td, J 7.5, 1.6, Ar), 8.91 (1H, s, 
Ar), 8.94 (1H, s, Ar); δC (100 MHz, CD3OD) 26.38, 28.87, 37.94, 39.68, 49.34, 52.67, 54.75, 55.46, 
107.37, 110.97, 117.07, 120.59, 131.89, 132.63, 147. 43, 148.35, 158.44, 162.48, 180.45.  
 
2-[1'-(2-Methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-anthracene-1,4-dione (5) 
 
 
 
 
 
N
N O
O
N N OCH3
O
O
N N OCH3
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A solution of 18 (97 mg, 0.37 mmol) and KH2PO4 (50 mg, 0.37 mmol) in H2O (4 ml) was added 
dropwise to a solution of 1,4-anthraquinone (77 mg, 0.35 mmol) in CHCl3 (3 ml). The mixture was 
stirred vigorously at RT for 1 h. The aqueous phase was then washed with CHCl3 (3 x 10 ml). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. The crude 
was purified twice by gravity chromatography (DCM-MeOH-aqueous 33% ammonia, 9:1:0.1) 
affording 5 as a red solid (14 mg, 0.03 mmol, 8%); mp= 52°C; δH (400 MHz, CD3OD) 1.42-1.57 
(6H, m, 2CH, 2CH2), 1.86 (2H, d, J 11.0, CH2), 2.02 (2H, d, J 11.8, CH2), 3.00 (4H, t, J 12.2, CH2-
N), 3.52 (2H, d, J 12.6, CH2-N), 3.92 (3H, s, OCH3), 4.21 (2H, d, J 13.4, CH2-N), 4.29 (2H, s, CH2-
Ph), 6.06 (1H, s, CH-C=O), 7.04 (1H, t, J 7.5, Ar), 7.12 (1H, d, J 7.5, Ar), 7.41 (1H, d, J 7.5, Ar), 
7.49 (1H, td, J 7.5, 1.2, Ar), 7.63-7.69 (2H, m, Ar), 8.04 (2H, d, J 7.1, Ar), 8.40 (1H, s, Ar), 8.45 
(1H, s, Ar); δC (100 MHz, CD3OD) 26.39, 20.80, 39.80, 46.92, 49.14, 52.68, 54.75, 55.45, 109.82, 
110.98, 117.06, 120.59, 126.23, 128.64, 128.73, 128.79, 129.17, 129.38, 129.61, 129.72, 131.88, 
132.63, 134.32, 135.00, 155.14, 158.44, 182.22, 183.38.  
 
2-[1'-(2-Methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-4a,5,6,7,8,8a-hexahydro-
[1,4]naphthoquinone (6) 
 
 
 
 
 
A solution of 18 (162 mg, 0.56 mmol) KH2PO4 (76 mg, 0.56 mmol) in H2O (8 ml), was added 
dropwise to a solution of 25 (91 mg, 0.56 mmol) in CHCl3 (2 ml). The mixture was stirred 
vigorously at RT for 2 h. The aqueous phase was then washed with CHCl3 (3 x 10 ml). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. The crude 
was purified by flash chromatography (EtOAc-MeOH, 9:1) affording 6 as a purple slurry (80 mg, 
0.71 mmol, 30%); δH (400 MHz, CDCl3) 1.07-1.11 (1H, m, CH [amine chain]), 1.31-1.43 (5H, m, 
2CH2, CH [amine chain]), 1.64-1.69 (6H, m, 2CH2 [tetrahydro-naphthalene ring], CH2 [amine 
chain]), 1.76 (2H, d, J 9.8, CH2 [amine chain]), 2.07-2.1 (2H, m CH2-N), 2.35-2.41 (4H, m, 2CH2 
[tetrahydro-naphthalene ring]), 2.76 (2H, t, J 11.7, CH2-N), 3.01 (2H, d, J 11.7, CH2-N), 3.61 (2H, 
s, CH2-Ph), 3.81 (3H, s, OCH3), 3.89 (2H, d, J 12.5, CH2-N), 5.68 (1H, s, CH-C=O), 6.86 (1H, d, J 
7.8, Ar), 6.93 (1H, td, J 7.8, 1.6, Ar), 7.23 (1H, td 7.8, 1.6, Ar), 7.35 (1H, dd, J 7.8, 1.6, Ar); δC (100 
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MHz, CDCl3) 21.08, 21.37, 22.64, 29.05, 29.16, 40.48, 40.73, 49.67, 53.70, 55.38, 55.98, 108,18, 
110.42, 120.31, 128.27, 130.92, 140.48, 142.79, 152.57, 157.83, 185.27, 186.25. 
 
2-[1'-(2-Methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-5-methyl-[1,4]benzoquinone (7) 
 
 
 
 
A solution of 18 (200 mg, 0.69 mmol) in EtOH (5 ml) was added dropwise to a solution of 27 (216 
mg, 1.38 mmol) in EtOH (10 ml) at 78 °C. The mixture was stirred at reflux for 3 h. The solvent 
was then evaporated under reduced pressure and the crude was purified by flash chromatography 
(Et2O-MeOH, 7:3) affording 7 as a purple solid (150 mg, 0.37 mmol, 54%); mp= 98°C; ES 
[M+H+]:
 
409; δH (400 MHz, CDCl3) 1.05-1.12 (1H, m, CH), 1.34-1.41 (5H, m, CH, 2CH2), 1.68 
(2H, d, J 12.6, CH2), 1.78 (2H, d, J 9.0, CH2), 1.99-2.04 (2H, m, CH2-N), 2.01 (3H, d, J 1.2, CH3), 
2.81 (2H, t, J 11.8, CH2-N), 3.01 (2H, d, J 11.4, CH2-N), 3.59 (2H, s, CH2-Ph), 3.82 (3H, s, OCH3), 
3.98 (2H, d, J 12.6, CH2-N), 5.74 (1H, s, CH-C=O), 6.38 (1H, d, J 1.2, CH-C=O), 6.87 (1H, t, J 7.5, 
Ar) 6.94 (1H, t, 7.5, Ar), 7.24 (1H, td, J 7.5, 1.4, Ar), 7.36 (1H, dd, J 7.5, 1.4, Ar); δC (100 MHz, 
CDCl3) 15.64, 29.16, 29.21, 40.52, 40.74, 49.57, 53.80, 55.39, 56.11, 108.00, 110.41, 120.28, 
128.16, 130.82, 131.85, 146.65, 152.16, 157.82, 185.23, 186. 24.  
 
2-Methoxy-5-[1'-(2-methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-[1,4]benzoquinone (8) 
 
 
  
 
A solution of 18 (218 mg, 0.75 mmol) in EtOH (5 ml) was added dropwise to a solution of 2,5-
dimethoxy-1,4-benzoquinone (480 mg, 3.75 mmol) in EtOH (20 ml) at 78 °C. The mixture was 
stirred at reflux for 3 h and then at RT overnight. The solvent was then evaporated under reduced 
pressure and the crude was purified by flash chromatography (DCM-MeOH-aqueous 33% 
ammonia, 9.5:0.5:0.03, then 9.5:0.5:0.05) affording 8 as a pink solid (160 mg, 0.38 mmol, 50%); 
mp=153°C; ES [M+H+]:
 
425; δH (400 MHz, CDCl3) 1.10-1.14 (1H, m, CH), 1.28-1.39 (3H, m, CH, 
CH2), 1.46-1.55 (2H, m, CH2), 1.70 (2H, d, J 12.6, CH2), 1.79 (2H, d, J 10.6, CH2), 2.14, (2H, t, J 
11.4, CH2-N), 2.88 (2H, t, J 12.2, CH2-N) 3.1 (2H, d, J 11.4, CH2-N), 3.72 (2H, s, CH2-Ph), 3.79 
O
O
N N OCH3
O
O
N N
H3CO
H3CO
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(3H, s, OCH3), 3.82 (3H, s, OCH3), 4.08 (2H, d, J 13.0, CH2-N), 5.66 (1H, s, CH-C=O), 5.69 (1H, s, 
CH-C=O), 6.87 (1H, d, J 7.4, Ar), 6.94 (1H, t, J 7.4, Ar), 7.24-7.28 (1H, m, Ar), 7.41 6.87 (1H, d, J 
7.4, Ar); δC (100 MHz, CDCl3) 28.54, 29.34, 40.08, 40.49, 49.86, 53.32, 55.44, 55.58, 56.25, 
104.95, 105.79, 110.52, 120.51, 128.94, 131.46, 152.58, 157.90, 159.94, 179.77, 184.74. 
 
2-Chloro-5-[1'-(2-methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-[1,4]benzoquinone (9) 
 
 
 
 
A solution of 18 (162 mg, 0.56 mmol) in EtOH (5 ml) was added dropwise to a solution of 2,5-
dichloro-1,4-benzoquinone (496 mg, 2.80 mmol) in EtOH (20 ml) and THF (2 ml) at 78 °C. The 
mixture was stirred at reflux for 15 min. The solvent was then evaporated under reduced pressure 
and the crude was purified by flash chromatography (DCM-MeOH-aqueous 33% ammonia, 
9.5:0.5:0.03, then 9.5:0.5:0.1) affording 9 as a purple solid (140 mg, 0.30 mmol, 50%); mp=166°C; 
ES [M+H+]: 429; δH (400 MHz, CDCl3) 1.12-1.17 (1H, m, CH), 1.26-1.42 (3H, m, CH, CH2), 1.51-
1.59 (2H, m, CH2), 1.71, (2H, d, J 12.6, CH2), 1.81 (2H, d, J 11.4, CH2), 2.19 (2H, t, J 11.4, CH2-
N), 2.89 (2H, t, J 12.2, CH2-N), 3.13 (2H, d, J 11.0, CH2-N), 3.76 (2H, s, CH2-Ph), 3.83 (3H, s, 
OCH3), 4.02 (2H, d, J 13.0, CH2-N), 5.83 (1H, s, CH-C=O), 6.76 (1H, s, CH-C=O), 6.89 (1H, d, J 
7.4, Ar), 6.96 (1H, t, J 7.4, Ar), 7.26-7.30 (1H, m, Ar), 7.44 (1H, d, J 7.4, Ar); δC (100 MHz, 
CDCl3) 28.37, 29.25, 39.94, 40.38, 49.70, 53.19, 55.44, 106.16, 110.54, 120.56, 129.12, 131.60, 
131.75, 145.60, 151.77, 157.92, 177.43, 182.60.  
 
2-[1'-(2-Methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-[1,4]benzoquinone (10) 
 
 
 
 
 
A solution of 18 (140 mg, 0.49 mmol) and KH2PO4 (67 mg, 0.49 mmol) in H2O (5 ml) was added 
dropwise over a period of 2 h to a solution of 1,4-benzoquinone (265 mg, 2.45 mmol) in CHCl3 (5 
ml) and THF (1 ml) at 30-40 °C. The excess of 1,4-benzoquinone was then filtered and the residue 
was portioned between CHCl3 and water. The aqueous phase was separated and the organic phase 
O
O
N N
H3CO
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was washed with H2O (3 x 20 ml). The combined organic extracts were dried over Na2SO4, filtered 
and concentrated in vacuo. The crude was purified by flash chromatography (DCM-MeOH-aqueous 
33% ammonia, 9.5:0.5:0.05) affording 10 as a dark purple solid (45 mg, 0.11 mmol, 24%); mp= 
123°C; δH (400 MHz, CDCl3) 1.08-1.11 (1H, m, CH), 1.25-1.37 (5H, m, CH, CH2, CH2), 1.66 (2H, 
d, J 12.6, CH2), 1.80 (2H, d, J 9.4, CH2), 1.97 (2H, td, J 11.8, 2.0, CH2-N), 2.83 (2H, t, J 12.2, CH2-
N), 2.97 (2H, d, J 11.8, CH2-N), 3.48 (2H, s, CH2-Ph), 3.55 (3H, s, OCH3), 3.96 (2H, d, J 12.6, 
CH2-N), 5.75 (1H, d, J 2.4, CH-C=O), 6.53 (1H, d, J 10.0, CH-C=O), 6.58 (1H, dd J 10.0 2.4, CH-
C=O), 6.86 (1H, d, J 7.5, Ar), 6.93 (1H, td, J 7.5, 1.4, Ar), 7.22 (1H, td, J 7.5, 2.0, Ar), 7.34 (1H, dd, 
J 7.5, 1.4, Ar); δC (100 MHz, CDCl3) 29.23, 29.31, 40.61, 40.76, 49.57, 53.91, 55.37, 56.26, 
108.037, 110.39, 116.33, 120.22, 127.97, 130.66, 134.99, 137.30, 151.90, 157.80, 185.00, 186.06.  
 
1'-(2-Methoxy-benzyl)-[4,4']bipiperidinyl-1-carboxylic acid ethyl ester (11) 
 
 
 
 
Ethyl chloroformate (14 mg, 0.13 mmol) and 18 (38 mg, 0.13 mmol) were dissolved in DCM (10 
ml). The mixture was stirred at RT for 18 h. The solvent was evaporated under reduced pressure 
and the crude was purified by flash chromatography (DCM-MeOH, 9:1) affording 11 as a pale 
yellow oil (31 mg, 0.08 mmol, 65%); ES [M+H+]+:
 
361; δH (400 MHz, CDCl3) 1.04-1.14 (3H, m, 
CH, CH2), 1.23 (3H, t 7.1, OCH2CH3), 1.24-1.31 (1H, m, CH), 1.60-1.74 (6H, m, 3CH2), 2.27 (2H, 
t, J 11.2, CH2-N), 2.66 (2H, t, J 12.3, CH2-N), 3.18 (2H, d, J 11.8, CH2-N), 3.82 (3H, s, OCH3), 3.84 
(2H, s, CH2-Ph), 4.10 (2H, q, J 7.1, OCH2CH3), 4.14-4.16 (2H, br m, CH2-N), 6.88 (1H, d, J 7.5, 
Ar), 6.96 (1H, td, J 7.5, 1.2, Ar), 7.29 (1H td, J 7.5, 1.6, Ar), 7.49 (1H, dd, J,7.5, 1.2, Ar); δC (100 
MHz, CDCl3) 12.65, 27.90, 29.15, 39.84, 40.54, 44.07, 52.94, 55.05, 55.49, 61.10, 110.59, 120.72, 
129.64, 132.18, 155.47, 158.00. 
 
5-[4-(4-Benzoyl-piperazin-1-yl)-piperidin-1-yl]-2,3-dimethyl-[1,4]benzoquinone (12) 
 
 
 
 
 
O
N N
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A solution of 31 (154 mg, 0.57 mmol) and KH2PO4 (78 mg, 0.57 mmol) in H2O (8 ml) was added 
dropwise to a solution of 19 (77 mg, 0.57 mmol) in CHCl3 (2 ml). The mixture was stirred 
vigorously at RT for 4 h. The aqueous phase was then washed with CHCl3 (3 x 10 ml). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. The crude 
was purified by flash chromatography (Et2O-MeOH, 8.5:1.5) affording 12 as a purple slurry (100 
mg, 0.24 mmol, 43%); δH (400 MHz, CDCl3) 1.64 (2H, ddd, J 23.9, 12.4, 3.7, CH2), 1.87 (2H, d, J 
11.7, CH2), 1.97 (6H, s, 2CH3), 1.49-1.64 (5H, m, 2CH2-N, CH), 2.83 (2H, td, J 12.4, 2.0, CH2-N), 
3.42-3.44 (2H, m, CH2-N), 3.77-3.80 (2H, m, CH2-N), 3.89 (2H, d, J 12.9, CH2-N), 7.52 (1H, s, 
CH-C=O), 7.72-7.73 (5H, m, Ar); δC (100 MHz, CDCl3) 12.28, 12.45, 27.86, 42.37, 48.47, 49.18, 
61.37, 108.87, 127.04, 128.44, 129.67, 135.69, 139.10, 141.16, 152.24, 170.16, 185.13, 186.10. 
 
2-[4-(4-Benzoyl-piperazin-1-yl)-piperidin-1-yl]-[1,4]naphthoquinone (13) 
 
 
 
 
 
A solution of 31 (179 mg, 0.65 mmol) in THF (2 ml) was added dropwise to a solution of 
naphthoquinone (104 mg, 0.65 mmol) in THF (1 ml). The mixture was stirred vigorously at RT for 
1 h. The solvent was evaporated under reduced pressure and the crude was purified by flash 
chromatography (EtOAc-MeOH, 9:1) affording 13 as a red slurry (250 mg, 0.58 mmol, 90%); δH 
(400 MHz, CDCl3) 1.62 (2H, ddd, J 23.10, 11.7, 3.4, CH2), 1.85 (2H, ddd, J 11.9, CH2), 2.46-2.57 
(5H, m, 2CH2-N, CH), 2.88 (2H, t, J 11.9, CH2-N), 3.34-3.36 (2H, m, CH2-N), 3.70-3.72 (2H, m, 
CH2-N), 4.01 (2H, d, J 12.9, CH2-N), 5.93 (1H, s, CH-C=O), 3.72-3.73 (5H, m, Ar), 7.53 (1H, td, J 
7.4, 1.2, Ar), 7.59 (1H, td, J 7.4, 1.2, Ar), 7.89(1H, d, J 7.4, Ar), 7.93 (1H, d, J 7.4, Ar); δC (100 
MHz, CDCl3) 27.99, 42.35, 48.51, 49.31, 61.20, 111.08, 125.39, 126.57, 127.00, 128.41, 129.66, 
132.34, 132.73, 133.79, 135.64, 153.53, 170.14, 183.04, 183.45.  
 
N-tert-Butyl-2-[1'-(2-methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-2-phenyl-acetamide (14) 
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18 (100 mg, 0.35 mmol), benzaldehyde (55 mg, 0.52 mmol), tert-butyl isocyanide (43 mg, 0.52 
mmol) and trimethoxyborane (109 mg, 1.05 mmol) were dissolved in DCE (1 ml). The mixture was 
stirred under microwave irradiation at 80 °C for 20 min. After evaporating the solvent under 
reduced pressure, the crude was purified by flash chromatography (CHCl3-MeOH-aqueous 33% 
ammonia,9.5:0.5:0.03) affording 14 as a yellow oil (65 mg, 0.14 mmol, 40%); ES [M+H+]: 478; δH 
(400 MHz, CDCl3) 1.03-1.05 (2H, m, 2CH), 1.15-1.20 (1H, m, CHH), 1.24-1.32 (3H, m, CHH, 
CH2), 1.35 (9H, s, tBu), 1.60-1.67 (4H, m, 2CH2), 1.72-1.75 (1H, m, CHH-N), 1.97 (2H. t, J 11.6, 
CH2-N), 2.02-2.07 (1H, m, CHH-N), 2.6 (1H, dd, J 11.2, 2, CHH-N), 2.95-3.02 (3H, m,CH2-N, 
CHH-N), 3.55 (2H, s, CH2-Ph), 3.69 (1H, s, CH-C=O), 3.80 (3H, s OCH3), 6.84 (1H, d, J 7.6, Ar), 
6.92 (1H, t, J 7.6, Ar), 7.18-7.32 (6H, m, Ar), 7.34 (1H, dd, J 7.5, 1.6, Ar); δC (100 MHz, CDCl3) 
28.70, 29.40, 29.82, 30.00, 40.62, 40.75, 50.44, 54.04, 54.15, 55.38, 56.22, 110.37, 120.24, 126.23, 
127.72, 127.91, 128.27, 128.90, 130.56, 136.44, 157.76, 170.89. 
 
N-tert-Butyl-2-[1'-(2-methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-2-(2-methoxy-phenyl)-
acetamide (15) 
 
 
 
 
 
18 (150 mg, 0.52 mmol), 2-methoxybenzaldehyde (106 mg, 0.78 mmol), tert-butyl isocyanide (65 
mg, 0.78 mmol) and trimethoxyborane (162 mg, 1.56 mmol) were dissolved in DCE (1.3 ml). The 
mixture was stirred under microwave irradiation at 80 °C for 20 min. After evaporating the solvent 
under reduced pressure, the crude was purified by flash chromatography (CHCl3-MeOH then 
CHCl3-MeOH-aqueous 33% ammonia, 9.5:0.5 then 9.5:0.5:0.05) affording 15 as a yellow oil (98 
mg, 0.19 mmol, 36%); δH (400 MHz, CDCl3) 0.98-1.05 (2H, m, 2CH), 1.07-1.16 (1H, m, CHH), 
1.23 (1H, ddd, J 23.2, 11.8, 3.5, CHH), 1.33-1.43 (2H, m, CH2), 1.37 (9H, s, tBu), 1.59-1.69 (4H, 
m, 2CH2), 1.72-1.78 (1H, m, CHH-N), 2.07 (2H, t, J 11.4, CH2-N), 2.15 (1H, td, J 11.8, 2, CHH-N), 
2.62 (1H, dd, J 11.4, 1.2, CHH-N), 2.98-3.03 (3H, m, CH2-N, CHH-N), 3.64 (2H, s, CH2-Ph), 3.79 
(3H, s, OCH3), 3.81 (3H, s, OCH3), 4.39 (1H, s, CH-C=O), 6.87-6.88 (2H, m, Ar), 6.90-6.95 (2H, 
m, Ar), 7.16 (1H, dd, J 7.5, 1.2, Ar), 7.20-7.24 (2H, m, Ar), 7.39 (1H, d, J 7.1, Ar); δC (100 MHz, 
CDCl3) 28.75, 28. 93, 30.10, 30.28, 40.44, 40.49, 49.18, 50.32, 53.71, 54.08, 55.41, 55.44, 55.86, 
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67.67, 110.42, 110.98, 120.29, 120.38, 124.39, 128.43, 128.67, 130.10, 131.07, 157.83, 158.18, 
171.19.  
 
N-tert-Butyl-2-[1'-(2-methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-2-o-tolyl-acetamide (16) 
 
 
 
 
 
18 (150 mg, 0.52 mmol), 2-methylbenzaldehyde (94 mg, 0.78 mmol), tert-butyl isocyanide (65 mg, 
0.78 mmol) and trimethoxyborane (162 mg, 1.56 mmol) were dissolved in DCE (1.3 ml). The 
mixture was stirred under microwave irradiation at 80 °C for 20 min. After evaporating the solvent 
under reduced pressure, the crude was purified by flash chromatography (CHCl3-MeOH then 
CHCl3-MeOH-aqueous 33% ammonia, 9.5:0.5 then 9.5:0.5:0.03) affording 16 as a yellow oil (68 
mg, 0.14 mmol, 27%); δH (400 MHz, CDCl3) 1.05-1.11 (2H, m, 2CH), 1.14-1.26 (2H, m, CH2), 
1.33-1.38 (2H, m, CH2), 1.33 (9H, s, tBu), 1.57-1.70 (3H, m, CH2, CHH), 1.73-1.78 (2H, m, CHH, 
CHH-N), 2.02 (2H, t, J, 11.8, CH2-N), 2.10 (1H, td, J 11.8, 2, CHH-N), 2.43 (3H, s, CH3), 2.64 (1H, 
dd, J 11.4, 2.4, CHH-N), 2.99 (2H, d, J 9.0, CH2-N), 3.06-3.09 (1H, m, CHH-N), 3.58 (2H, s, CH2-
Ph), 3.80 (3H, s, OCH3), 4.00 (1H, s, CH-C=O), 6.86 (1H, d, J 7.6, Ar), 6.93 (1H, t, J 7.6, Ar), 7.12-
7.17 (3H, m, Ar), 7.23 (1H, td, J 7.6, 2, Ar), 7.24-7.28 (1H, m, Ar), 7.37 (1H, dd, J 7.6, 1.2, Ar); δC 
(100 MHz, CDCl3) 19.51, 27.66, 28.22, 28.90, 29.03, 39.64, 39.74, 49.22, 49.44, 52.89, 53.46, 
54.39, 55.07, 70.47, 109.40, 119.31, 124.93, 126.27, 127.13, 129.79, 134.62, 136.49, 156,79, 
170.49 
 
N-tert-Butyl-2-(2-chloro-phenyl)-2-[1'-(2-methoxy-benzyl)-[4,4']bipiperidinyl-1-yl]-acetamide 
(17) 
 
 
 
 
 
18 (150 mg, 0.52 mmol), 2-chlorobenzaldehyde (110 mg, 0.78 mmol), tert-butyl isocyanide (65 mg, 
0.78 mmol) and trimethoxyborane (162 mg, 1.56 mmol) were dissolved in DCE (1.3 ml). The 
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mixture was stirred under microwave irradiation at 80 °C for 20 min. After evaporating the solvent 
under reduced pressure, the crude was purified by flash chromatography (CHCl3-MeOH then 
CHCl3-MeOH-aqueous 33% ammonia, 9.5:0.5 then 9.5:0.5:0.03) affording 17 as a yellow oil (70 
mg, 0.14 mmol, 27%); δH (400 MHz, CDCl3) 1.04-1.09 (2H, m, 2CH), 1.11-1.18 (1H, m, CHH), 
1.20-1.29 (1H, m, CHH), 1.32-1.42 (2H, m, CH2), 1.37 (9H, s, tBu), 1.62-1.65 (3H, m, CH2, CHH), 
1.72-1.76 (1H, m, CHH), 1.86 (1H, td, J 11.4, 2.4, CHH-N), 2.05 (2H, t, J 11.4, CH2-N), 2.22 (1H, 
td, J 11.8, 2.0, CHH-N), 2.58 (1H dd, J 11.4, 2.0, CHH-N), 3.01 (2H, d, J 11.0, CH2-N), 3.08 (1H, 
dd J 11.3, 1.7, CHH-N), 3.62 (2H, s, CH2-Ph), 3.81 (3H, s, OCH3), 4.52 (1H, s, CH-C=O), 6.86 
(1H, d, J 7.6, Ar), 6.93 (1H, t, J 7.6, Ar), 7.16-7.26 (3H, m, Ar), 7.30 (1H, dd, J 7.6, 1.8, Ar), 7.35-
7.39 (2H, m, Ar); δC (100 MHz, CDCl3) 28.69, 29.00, 29.98, 30.15, 30.89, 40.38, 40.47, 49.46, 
50.63, 53.74, 54.00, 55.39, 55.92, 70.40, 110.42, 120.35, 126.53, 128.34, 128.78, 129.76, 130.29, 
130.97, 133.89, 135.57, 157.80, 170.14.  
 
1-(2-Methoxy-benzyl)-[4,4']bipiperidinyl (18) 
 
 
 
 
4,4'-Bipiperidyl dihydrochloride (2.3 g, 9.40 mmol) and KOH (140 mg, 2.55 mmol) were dissolved 
in MeOH (50 ml). 2-Methoxybenzaldehyde (980 mg, 7.20 mmol) was added and the mixture was 
stirred at reflux for 3 h. After cooling at 0 °C, NaBH3CN (180 mg, 2.90 mmol) was added slowly 
and the mixture was stirred at RT overnight. After evaporating the solvent, the reaction was 
quenched at 0 °C by dropwise addition of water (40 ml). The aqueous phase was acidified with 6N 
HCl and extracted with Et2O (3 x 20 ml). The aqueous phase was then basified with 40% NaOH  
and extracted with CHCl3 (3 x 40 ml). The combined organic extracts were dried over Na2SO4, 
filtered and concentrated in vacuo. The crude was purified by flash chromatography (DCM-MeOH-
aqueous 33% ammonia, 6.5:3.5:0.35) affording 18 as a white solid (600 mg, 2.10 mmol, 30%); δH 
(400 MHz, CDCl3) 1.03-1.15 (4H, m, 2CH, CH2), 1.25-1.35 (2H, m, CH2), 1.64-1.68 (4H, m, 
2CH2), 1.88 (1H, br s, NH), 1.96 (2H, td, J 11.9, 2.1,  CH2-N), 2.55 (2H, t, J 11.8, CH2-N), 2.96 
(2H, d, J 11.6, CH2-N), 3.07 (2H, d, J 12.1, CH2-N), 3.54 (2H, s, CH2-Ph), 3.81 (3H, s, OCH3), 6.82 
(1H, d, J 7.5, Ar), 6.92 (1H, t, J 7.5, Ar), 7.22 (1H, t, J 7.5, Ar), 7.35 (1H, d, J 7.5, Ar); δC (100 
MHz, CDCl3) 29.30, 29.65, 40.83, 41.01, 46.38, 54.06, 55.35, 55.37, 56.39, 110.34, 120.19, 126.45, 
127.81, 130.53, 157.76.  
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2,3-Dimethyl-[1,4]benzoquinone (19) 
 
 
 
 
MnO2 (2.5 g, 29 mmol) was added to a solution of 2,3-dimethyl-benzene-1,4-diol (500 mg, 3.62 
mmol) in anhydrous Et2O (50 ml). The mixture was stirred at RT for 4 h and then filtered through 
Celite. The solvent was evaporated under reduced pressure affording 19 as a yellow solid (500 mg, 
3.62 mmol, 100%); δH (400 MHz, CDCl3) 2.04 (3H, s, CH3), 2.05 (3H, s, CH3), 6.72 (1H, s, Ar), 
6.73 (1H, s, Ar).  
 
Quinoline-5,8-dione (20)499 
 
 
 
 
Water (1 ml) was added to a solution of bis(trifluoroacetoxy)iodobenzene (1.4 g, 3.22 mmol) in 
acetonitrile (2.5 ml). After cooling at 0 °C, 8-hydroxyquinoline (400 mg, 2.80 mmol) was added 
portionwise and the cooling bath was removed. The resulting mixture was stirred for 3 h at RT. The 
solvent was evaporated under reduced pressure and the crude was purified by flash chromatography 
(DCM-EtOAc, 6:4) affording 20 as an orange solid (100 mg, 0.64 mmol, 23%); δH (200 MHz, 
CDCl3) 7.16 (1H, d, J 11.0, CH-C=O), 7.17 (1H, d, J 11.0, CH-C=O), 7.86 (1H, dd, J 7.8, 4.5, Ar), 
8.37 (1H, dd, J 7.8, 1.6, Ar), 9.03 (1H, dd, J 4.5, 1.6, Ar).  
 
2,3-Diamino-phenol (21)502 
OH
NH2
NH2
 
2-Amino-3-nitrophenol (500 mg, 3.20 mmol) was dissolved in MeOH (30 ml) and 10% Pd/C was 
added. The reaction mixture was allowed to stir under H2 (1 atm) for 4 h, monitoring the 
consumption of starting material by TLC. The reaction mixture was filtered through Celite and 
concentrated in vacuo to yield a brown solid (397 mg, 3.20 mmol, 100%), which was used in the 
O
O
N
O
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next step without further purification; δH (200 MHz, CDCl3) 6.37 (2H, m, Ar), 6.67 (1H, t, J 8.0, 
Ar). 
 
Quinoxalin-5-ol (22)503 
 
 
 
2,3-Diamino-phenol 21 (150 mg, 1.21 mmol) was dissolved in a mixture of 4 M NaOAc (1.5 ml) 
and 2 M AcOH (2.3 ml) and heated to 60 °C. In a separate flask, sodium glyoxal bisulfite (338 mg, 
1.27 mmol) was dissolved in H2O (9 ml) and heated to 60 °C. When both solutions reached ~60 °C, 
the solution of 21 was transferred by pipette to the sodium glyoxal bisulfite solution. The reaction 
mixture was allowed to stir at 60 °C for 1 h. After cooling the mixture to RT, the pH was adjusted 
to ~8 using 1N NaOH. The resulting aqueous solution was extracted with EtOAc (8 x 100 ml), 
dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography (petrol-EtOAc, 5:5) to yield 22 as a yellow solid (160 mg, 1.09 mmol, 90%); δH 
(400 MHz, CDCl3) 7.26 (1H, dd, J 7.5, 1.2, Ar), 7.67 (1H, dd, J 8.5, 1.2, Ar), 7.72 (1H, dd, J 8.5, 
7.5, Ar), 7.84 (1H, br s, OH), 8.73 (1H, d, J 2.0, Ar), 8.92 (1H, d, J 2.0, Ar).  
 
Quinoxaline-5,8-dione (23)504 
N
N
O
O
 
Quinoxalin-5-ol 22 (150 mg, 1.03 mmol) was dissolved in CH3CN (3 ml) and H2O (1.5 ml) and 
cooled in an ice bath. In a separate flask, bis(trifluoroacetoxy)iodobenzene (976 mg, 2.27 mmol) 
was dissolved in CH3CN (3 ml) and H2O (1.5 ml) and added dropwise to the solution containing 22 
at 0 °C. The reaction mixture was allowed to stir at RT for 4 h, then diluted with H2O (10 ml). The 
aqueous solution was extracted with EtOAc (3 x 20 ml), dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude was purified by flash chromatography (DCM-EtOAc, 3:7) to 
afford 23 as a yellow solid (60 mg, 0.37 mmol, 36%); δH (400 MHz, CDCl3) 7.26 (2H, s, Ar), 9.07 
(2H, s, Ar).  
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5,6,7,8-Tetrahydro-naphthalene-1,4-diol (24) 
 
 
 
 
A solution of potassium persulphate (1.8 g, 6.74 mmol) in H2O (13 ml) was added dropwise over a 
period of 3-4 h, to a solution of 5,6,7,8-tetrahydro-naphthalen-1-ol (500 mg, 3.37 mmol) and NaOH 
(3 g, 74.11 mmol). Stirring was continued overnight at RT. The reaction mixture was then acidified 
to pH 3-4, filtered and extracted with ethyl acetate (3 x 100 ml). The aqueous solution was acidified 
with an excess of 37% HCl and heated for 30 min. After cooling, the solution was extracted with 
Et2O (3 x 100 ml). The dried ether extracts were evaporated under reduced pressure affording 24 as 
a brown solid (310 mg, 1.89 mmol, 56%); δH (400 MHz, (CD3)2CO) 1.79-1.82 (4H, m, 2CH2), 
2.68-2.71 (4H, m, 2CH2), 6.55 (2H, s, Ar), 7.41 (1H, br s, OH); δC (100 MHz, (CD3)2CO) 22.36, 
23.42, 111.21, 124.68, 147.73.  
 
5,6,7,8-Tetrahydro-[1,4]naphthoquinone (25) 
 
 
 
 
Ag2O (741 mg, 3.20 mmol) and Na2SO4 (200 mg) were added to a solution of 24 (105 mg, 0.64 
mmol) in dry toluene (7 ml). The mixture was stirred at RT overnight and then filtered through 
Celite. The solvent was evaporated under reduced pressure affording 25 as a brown solid (103 mg, 
0.60 mmol, 100%); δH (400 MHz, (CD3)2CO) 2.48-2.52 (4H, m, 2CH2), 3.21-3.24 (4H, m, 2CH2), 
7.49 (2H, s, Ar);  
 
2-Chloro-5-methyl-benzene-1,4-diol (26)505 
 
 
 
 
p-Toluquinone (2 g, 16.30 mmol) was dissolved in CH3COOH (10 ml). Concentrated HCl (6 ml) 
was added dropwise at 0 °C. The mixture was stirred at RT for 4 h. The solvent was then 
OH
OH
Cl
OH
OH
O
O
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evaporated under reduced pressure and the crude was purified by flash chromatography (petrol-
EtOAc, 8:2) affording 26 as a purple solid (1.2 g, 7.44 mmol, 46%); δH (400 MHz, CD3OD) 2.10 
(3H, s, CH3), 6.65 (1H, s, Ar), 6.68 (1H, s, Ar); δC (100 MHz, CD3OD) 14.50, 115.04, 116.80, 
118.12, 124.29, 145.22, 148.39. 
 
2-Chloro-5-methyl-[1,4]benzoquinone (27)505 
 
 
 
 
A solution of 26 (1.2 g, 7.44 mmol) in MeOH was added dropwise at 0 °C to a solution of K2Cr2O7 
(4.4 g, 14.88 mmol) and H2SO4 (3 ml) in H2O (60 ml). The mixture was stirred at 0 °C for 4 h and 
then filtered. The filtrate was concentrated and the residue portioned between DMC and water. The 
organic layer was separated and the aqueous phase extracted with DCM (3 x 500 ml). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo affording 27 
as a yellow solid (750 mg, 4.80 mmol, 64%); δH (400 MHz, CDCl3) 2.10 (3H, s, CH3) 6.77 (1H, s, 
Ar), 7.01 (1H, s, Ar).   
 
4-Oxo-piperidine-1-carboxylic acid tert-butyl ester (28) 
 
 
 
 
Di-tert-butyl dicarbonate (4 g, 19 mmol) was added dropwise at 0 °C to a solution of 4-piperidone 
monohydrate hydrochloride (2 g, 13 mmol) in 10% NEt3 (4 equiv.)/MeOH. The mixture was stirred 
at RT overnight. The solvent was then evaporated under reduced pressure and the crude was 
purified by flash chromatography (petrol-EtOAc, 7:3) affording 28 as a white solid (2.5 g, 12.60 
mmol, 97%); δH (400 MHz, CDCl3) 1.42 (9H, s, OtBu), 2.36 (4H, t, J 6.2, 2CH2-C=O), 3.64 (4H, t, 
J 6.2, 2CH2-N); δC (100 MHz, CDCl3) 28.26, 41.04, 42.89, 80.26, 154.35, 207.56. 
 
4-Piperazin-1-yl-piperidine-1-carboxylic acid tert-butyl ester (29) 
 
 
O
O
Cl
N
O
Boc
N NBoc NH
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28 (2 g, 10.60 mmol) and piperazine (4.6 g, 53 mmol) were dissolved in MeOH (42 mmol). Acetic 
acid was added until pH 6-7, followed by the addition of sodium cyanoborohydride (1.7 g, 26.50 
mmol) at 0 °C.  The mixture was stirred at RT for 24 h. The solvent was evaporated under reduced 
pressure and excess sodium cyanoborohydride was quenched by careful addition of a solution of 
Na2CO3 (20 ml). The aqueous phase was extracted with EtOAc (3 x 20 ml) and the combined 
organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. The crude was purified 
by flash chromatography (DCM-MeOH-aqueous 33% ammonia, 9:1:0.1) affording 29 as a 
transparent oil (910 mg, 3.40 mmol, 32%); δH (400 MHz, CDCl3) 1.28-1.32 (2H, m, CH2), 1.35 
(9H, s, OtBu), 1.74 (2H, d, J 11.3, CH2), 2.48-2.53 (1H, m, CH), 2.66 (2H, t, J 11.5, CH2-N), 2.79-
2.81 (4H, m, 2CH2-N), 3.14-3.16 (4H, m, 2CH2-N), 4.00 (2H, d, J 12.9, CH2-N); δC (100 MHz, 
CDCl3) 27.74, 28.34, 43.00, 44.27, 45.86, 61.53, 80.00, 154.81. 
 
4-(4-Benzoyl-piperazin-1-yl)-piperidine-1-carboxylic acid tert-butyl ester (30) 
 
 
 
 
Benzoyl chloride (950 mg, 6.76 mmol) was added dropwise at 0 °C to a solution of 29 (910 mg, 
3.38 mmol) and NEt3 (684 mg, 6.76 mmol) in DCM (12 ml). The mixture was stirred at RT for 4h. 
The solvent was evaporated under reduced pressure and the crude was purified by flash 
chromatography (DCM-MeOH, 9.5:0.5) affording 30 as a yellow oil (800 mg, 3.40 mmol, 63%); δH 
(400 MHz, CDCl3) 1.28 (2H, ddd, J 24.0, 11.9, 4.0, CH2), 1.33 (9H, s, OtBu), 1.64-1.67 (2H, m, 
CH2), 1.28-1.61 (7H, m, 3CH2-N, CH), 3.29-3.31 (2H, m, CH2-N), 3.65-3.67 (2H, m, CH2), 3.96-
4.01 (2H, m, CH2), 7.27-7.28 (5H, m, Ar). 
 
Phenyl-(4-piperidin-4-yl-piperazin-1-yl)-methanone (31) 
 
 
 
 
A solution of HCl in dioxane (18 ml) was added dropwise at 0 °C to a solution of 30 (800 mg, 2.14 
mmol) in MeOH (3 ml). The mixture was stirred at RT overnight. The solvent was then evaporated 
under reduce pressure and the residue was basified with 4N NaOH. The aqueous layer was 
N NBoc N
O
HN N N
O
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extracted with DCM (2 x 20 ml). The combined organic extracts were dried over Na2SO4, filtered 
and concentrated in vacuo affording 31 and a yellow oil (582 mg, 2.14 mmol, 100%); δH (400 MHz, 
CDCl3) 1.23 (2H, ddd, J 23.9, 12.1, 3.7, CH2), 1.61 (2H, m, CH2), 2.20 ( 1H, tt, J 11.5, 3.7, CH), 
2.30-2.32 (2H, m, CH2-N), 2.39 (2H, t, 12.1, CH2-NH), 2.44-2.45 (2H, m, CH2-N), 2.93-2.96 (2H, t, 
12.1, CH2-NH), 3.23-3.25 (2H, m, CH2-N), 3.59-3.61 (2H, m, CH2-N), 7.21-7.22 (5H, m, Ar). 
 
6.2 Biology 
A Methods for assays at mAChRs 
• cDNA constructs 
cDNA encoding the human M1 and M2 mAchRs were obtained from Missouri University of 
Science and Technology cDNA resource Center (Rolla, MO). Single point mutations of M1 receptor 
(F77I and Y381A) were introduced with the Stratagene Quick-Change Kit (La Jolla, CA) and 
confirmed by sequencing. Wild type plasmids were transfected with Lipofectamine 2000 (Life 
Technologies) into HEK293 cells and stable clones were selected in 1mg/ml G418. Mutated 
plasmids were transiently transfected in HEK293 cells with polyethilenimine and analyzed 48 h 
after transfection. 
• Cell Membrane preparation.  
Cell membrane preparation was performed using a method described by Thomas et al.506 Confluent 
monolayers of HEK293-M1 cells were rapidly washed with 10 mM HEPES, 0.9% NaCl, and 0.2% 
EDTA, pH 7.4 (HBS-EDTA) before incubation with HBS-EDTA for 15 min to lift cells. Cells were 
centrifuged (400g, 4 min), and the pellet was resuspended in 10 mM HEPES and 10 mM EDTA, 
pH 7.4, homogenized using a tissue grinder and centrifuged (40,000g, 15 min, 4°C). The cell pellet 
was resuspended in 10 mM HEPES and 0.1 mM EDTA, pH 7.4, and rehomogenized and 
centrifuged as described above. The final pellet was resuspended in the 10mM HEPES and 10 mM 
EDTA, pH 7.4, buffer either used immediately or snap-frozen and stored at -80°C. Protein 
concentration was determined by BCA Protein Assay (Pierce). 
• Radioligand binding assays 
Radioligand binding studies were performed by incubating HEK293-M1 or M2 cell membranes (70 
µg of protein/tube) with [3H]NMS (1 nM) and a range of concentrations of the tested compounds at 
RT for 2 h in buffer containing 25 mM sodium phosphate, 5 mM MgCl2, 0.1% bovine serum 
albumin (BSA), pH 7.4 (binding buffer). The final assay volume was 1 ml. Compounds were 
serially diluted in binding buffer to generate eight different test concentrations over a 4 log unit 
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range. Nonspecific binding was defined as that remaining in the presence of 30 µM atropine. The 
reaction was terminated by rapid filtration through GF/C filter mates presoaked in 0.3% 
polyethylenimine, followed by four washes with ice-cold wash buffer (25 mM sodium phosphate, 
pH 7.4); filters were allowed to dry before bound radioactivity was measured using liquid 
scintillation counting. Binding data represent the mean of two determinations and were analyzed by 
nonlinear regression analysis with the use of Prism software (GraphPad Software, Inc., San Diego, 
CA). Receptor expression levels for M1 and M2 cell lines were 213 ± 25 and 5940 ± 50 fmol/mg, 
respectively. 
• Functional assays 
Functional assays were performed using a method described by Thomas et al.506 HEK293 cells 
seeded at 40,000 cells/well in 24-well plates were transfected with M1 receptor 2 days before assay, 
then the cells were washed twice with 450 µl of Ca2+-free KHB containing 100 µM EGTA. Cells 
were incubated at 37°C with tested compounds for 5 min, then with OXO-M for 10 min and then 
with forskolin 1 µM for 10 min, before termination by aspiration of buffer and addition of 0.1 M 
HCl for 20 min. cAMP concentrations were determined using Cyclic AMP EIA kit (Cayman) 
following manufacturer’s instruction. 
• Kinetic studies 
For dissociation studies, HEK293-M1 cell membranes (70 µg of protein/tube) were preincubated 
with [3H]NMS (1 nM) and either binding buffer or atropine (1 µM final) for 60 min to achieve 
equilibrium. Triplicate determinations of total and nonspecific binding of [3H]NMS, as defined 
above, were then measured at 2, 5, 10, 15, 20, and 30 min after the addition of atropine (1 µM final) 
either in the presence or absence of 1 (1 µM final). Buffer composition, reaction termination, and 
radioactivity determination were all as for HEK293-M1 inhibition binding. The amount of specific 
[3H]NMS bound was calculated and analyzed by Prism using the one-phase exponential decay 
equation. 
• Western blot analysis 
The proteins were extracted as previously described in Cell Membrane Preparation. Proteins were 
denatured at 95 °C for 3 min, then loaded and separated by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis. MagicMark™ XP Western Standard (Invitrogen) served as a molecular weight 
standard. Proteins were transferred to Protran™ nitrocellulose membranes, which were blocked 
with 5% non-fat milk in Tris buffered saline (10 mM Tris–HCl, pH 8), containing 150 mM NaCl 
plus 0.1% Tween-20 for 1.5 h at RT (25 °C). The blots were probed overnight at 4 °C with rabbit 
anti-M1 muscarinic acetylcholine receptor affinity purified polyclonal antibody, diluted 1:1000 in 
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Tris buffered saline containing 0.1% Tween-20, 5% non-fat milk. The membranes were incubated 
with peroxidase conjugated secondary antibodies at a dilution of 1:8000. Blots were finally 
developed with SuperSignal West Pico chemiluminescent substrate for 3 min. The substrate was 
prepared by mixing the SuperSignal West Pico Stable Peroxidase Solution and the SuperSignal 
West Pico Luminol/Enhancer Solution at a ratio of 1:1. After drainage of the solutions, 
chemiluminescence was detected using a luminescent image analyzer LAS-3000 (Fujifilm, Tokyo, 
Japan).  
 
B Inhibition of AChE and BuChE activities  
The method of Ellman et al. was followed.513 Five different concentrations of each compound were 
selected in order to obtain inhibition of AChE or BuChE activities comprised between 20 and 80%. 
The assay solution consisted of 0.1 M potassium phosphate buffer pH 8.0, with the addition of 340 
µM 5,5’-dithio-bis(2-nitrobenzoic acid), 0.02 unit/mm of human recombinant AChE or BuChE 
from human serum (Sigma Chemical) and 550 µM of substrate (acetylthiocholine iodide or 
butyrylthiocholine iodide, respectively). Tested compounds were added to the assay solution and 
preincubated at 37 °C with the enzyme for 20 min before the addition of substrate. Enzyme reaction 
was followed at 412 nm for five min by a double beam spectrophotometer (Jasco V-530). Assays 
were carried out with a blank containing all components except AChE or BuChE in order to account 
for non-enzymatic reaction. The reaction rates were compared, and the percent inhibition due to the 
presence of tested compounds was calculated. Each concentration was analyzed in triplicate, and 
IC50 values were determined graphically from inhibition curves (percent inhibition vs log inhibitor 
concentration). 
 
C Substrate specificity for NQO1 
1, 2, and 8 were tested with respect to their ability to accept electrons from NADH via rat NQO1 
(Sigma), by following the absorbance change of NADH. Menadione was used as a reference 
compound. Briefly, each reaction consisted of NADH, NQO1, and the tested compounds in a final 
volume of Tris-HCl buffer containing bovine serum albumin (0.07%). Reactions were started by the 
addition of NADH. The time course of the reaction was followed by monitoring the absorbance 
decrease of NADH at 340 nm, using an extinction coefficient of 6.22 mM-1 cm-1 in a Jasco 7850 
double-beam spectrophotometer. The extent of nonenzymatic quinone reduction by NADH was 
determined in all cases either in the absence of the enzyme or in the presence of 20 µM dicoumarol. 
The results are expressed in terms of variation of optical density per minute at 340 nm (∆abs/min).  
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1 Introduction 
Benign prostatic hyperplasia (BPH) describes a proliferative process of both stromal and epithelial 
elements of the prostate. BPH leads to a progressive enlargement of the prostate gland that affects 
the patient’s quality of life.514 The incidence of BPH increases from approximately 50% at 60 years 
to 90% in men older than 85 years.515 The clinical manifestation of BPH includes lower urinary 
tract symptoms (LUTS) represented by incomplete bladder emptying, urinary tract infection, acute 
and chronic urinary retention, urosepsis, chronic renal insufficiency, and hematuria.  
In the past, age, genetics, and testosterone were regarded as the primary causes of prostate 
enlargement, but the exact cause of BPH is still unknown. Recently, various etiological hypotheses 
for BPH have been formulated and they are summarized below. 
A Metabolic syndrome 
Metabolic syndrome (MetS) represents a group of medical disorders that increase the risk of 
developing cardiovascular diseases like stroke and diabetes. Obesity, high triglyceride level, low 
HDL cholesterol level, and high blood pressure are the main metabolic risk factors. MetS is 
increasing in countries with Western lifestyles, and in particular in the United States. The 
association between MetS and BPH has been investigated in the past decades in several studies. In 
fact, increased insulin level and type 2 diabetes, increased body weight and body mass index, 
hypertension, and lower high-density lipoprotein were confirmed to be important risk factors of 
prostate enlargement, and patients with MetS had a higher annual growth rate of the prostate.516, 517, 
518
 Moreover, Vikram et al.519 reported an overgrowth of prostate volume in hyperinsulinemic rats 
induced by a high-fat diet. The hypothetical link between hyperinsulinemia and BPH was suggested 
as follows: an increased insulin level, a compensatory phenomenon by insulin resistance, causes an 
increased density of growth hormone receptors in the liver and then results in an increased hepatic 
production of insulin-like growth factor 1, a mitogen for prostate epithelial cells which promotes the 
proliferation of prostate cells.520, 521 
B Lifestyle, food, and exercise 
According to a study carried out by the Prostate Cancer Prevention Trial, high consumption of red 
meat and a high-fat diet were suggested to increase the risk of BPH, whereas high consumption of 
vegetables was associated with a reduced risk of BPH.522 Physical activities were also shown to 
reduce the possibility of prostate enlargement, LUTS, and LUTS-related surgery.523 
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C Inflammation 
It was also suggested a correlation between inflammation and BPH. In fact, the severity of LUTS 
and the intensity of inflammation are related.524 Moreover, inflammation in the prostate increased 
significantly with the increase in prostate volume.525 A large number of inflammatory cells and 
cytokines may be involved in the proliferation of the prostate. It was found that T-lymphocytes, B-
lymphocytes, and macrophages are chronically activated in BPH. They produce IL 2, interferon 
gamma (IFN γ), and transforming growth factor-β (TGF-β), which result in fibromuscular growth of 
the prostate.526  
 
In the past, the choice of treatment for BPH was the transurethral resection of the prostate (TURP) 
or open prostatectomy. Although surgery remains the most effective treatment for complicated or 
severe BPH, its invasive nature and its potential side effects have led to the search for nonsurgical 
and less invasive treatments. Nowadays, the pharmacotherapy of BPH is based on two classes of 
compounds: α1-adrenoreceptor (α1-AR) antagonists and 5α-reductase (5α-R) inhibitors. α1-AR 
antagonists are used to treat the dynamic component of BPH through the inhibition of sympathetic 
tone of the prostate. Conversely, 5α-R inhibitors are administered to reduce the prostatic mass 
through suppression of androgen stimulation of prostatic growth. 
 
1.1 α1-Adrenoreceptor antagonists 
Initially developed as antihypertensive agents, α1-AR antagonists exert their effect by blocking 
sympathetic adrenergic receptors-mediated contraction of the prostatic smooth muscle cells and 
bladder neck. α-ARs are a class of metabotropic GCPRs that are targeted by catecholamines, i. e. 
norepinephrine (noradrenalin) and epinephrine (adrenaline). α-ARs are divided in two subtypes: α1 
and
 
α2. α1 couples to Gq, which results in increased intracellular Ca2+ and in smooth muscle 
contraction. In smooth muscle of blood vessels the principal effect of α1 activation is represented by 
vasoconstriction with the subsequent increase of blood pressure. α1 activation causes also 
contraction of smooth muscle of the urinary system, like prostate, bladder, ureter etc. α2, on the 
other hand, couples to Gi, which causes a decrease of cAMP activity. They are mostly localized in 
pre-synaptic nerve terminals where they decrease the release of neurotransmitters.  
To date, α1-AR has been characterized as α1A, α1B, α1D and α1L but the role of the α1L subtype has 
not to be established yet.527, 528 α1A-AR subtypes are predominant in human prostate and urethra,529, 
530, 531, 532
 while α1B-ARs seem to play a role in the regulation of blood pressure.533 α1D-ARs seem to 
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be predominant in the destrusor muscle. Therefore, their relevant role in the control of the 
symptoms associated with BPH is also postulated.534, 535 
During the last decade a large number of α1 selective antagonists were synthesized for the treatment 
of BPH, but none of those used in clinical practice displays selectivity for the α1A subtype.  
Presumably, some of the adverse side effects associated with non-selective α1A blockade are 
mediated by the activation of α1B–ARs. In the present section, the main classes of α1 selective 
antagonists potentially useful for BPH are reviewed.  
 
1.1.1 Quinazolines 
Quinazoline derivatives are exemplified by prazosin, doxazosin, terazosin and alfuzosin. They are 
the oldest α1 selective antagonists used in clinical practice. The structure of these compounds differs 
for the fragment attached to the quinazoline 2-side chain (Fig. 1). 
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Figure 1: Chemical structures of quinazoline derivatives used in clinical practice.  
 
Prazosin is the prototype α1-AR antagonist. It does not distinguish between α1-AR subtypes [pKi 9.7 
(α1A), 9.6 (α1B) and 9.5 (α1D)]. Because of its relatively short half-life, this compound has to be 
administered twice a day, which is not ideal for BPH, where long-term sustained effects are 
required. Moreover, being non-selective for α1-AR subtypes, prazosin may also induce orthostatic 
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hypotension by antagonizing vascular α1B-ARs. However, the influence of prazosin on α1B-ARs 
may prove beneficial in patients suffering from both hypertension and BPH.536 Like prazosin, 
doxazosin [pKi 8.5 (α1A), 9.0 (α1B) and 8.4 (α1D)] and terazosin [pKi 8.2 (α1A), 8.7 (α1B) and 8.6 
(α1D)] are non-selective α1A-D-AR antagonists, so they may cause orthostatic hypotension. In 
contrast to prazosin, doxazosin and terazosin are longer-acting, with elimination half-lives of 12–20 
h. Alfuzosin is the fourth α1 selective blocker approved by FDA for the treatment of symptomatic 
BPH. Like the previous compounds, it is a non-selective α1A-D-AR antagonist [pKi 8.0 (α1A), 8.0 
(α1B) and 8.5 (α1D)]. However, its excellent tolerance has been attributed to its slow release 
formulation.  
In the past, efforts have been made to synthesized prazosin-related compounds that can distinguish 
between the α1-AR subtypes. For example, Melchiorre and co-workers537, 538 found that the 
replacement of both piperidine and furan rings of prazosin may afford antagonists that are able to 
differentiate among α1-AR subtypes.  
For example, the replacement of the furan ring of prazosin by various substituted phenyl groups has 
yielded several active compounds (Fig. 2).537 The nature of the substituent affected the affinity and 
subsequently the selectivity for the α1-AR subtypes. Any substituent (CHO, Me, OMe and CF3) at 
position 2 caused a decrease in potency compared to prazosin and to the unsubstituted phenyl ring. 
However, they were more selective for α1A- and α1D-subtypes than prazosin. Interestingly, the 2-
trifluoromethyl substituted derivative was markedly selective for α1D-ARs. The insertion of the 
same substituents at position 3 does not cause a significant modification of the selectivity profile. 
The only exception is represented by the 3-OMe derivatives that turned out to be slightly more 
potent at both α1A- and α1B-ARs. All these compounds are less potent than prazosin at α1-AR 
subtypes. The only exception is represented by 3-Me derivative that displayed a potency value at 
α1D comparable to that of prazosin.  
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Figure 2: Replacement of the furan ring of prazosin with a substituted phenyl ring.  
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It was also found that the piperidine ring of prazosin is not essential for the activity and can be 
replaced by an α,ω-alkanediamine.539, 540 Based on these investigations, several hybrid structures 
which combine both prazosin and benextramine were synthesized in an attempt to improve the 
selectivity (Fig. 3).537, 538 Benextramine is the prototype of tetramine disulfides, which inhibits α1-
ARs by an irreversible mechanism of action. 541 
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Figure 3: Hybrids prazosin-benextramine.  
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As shown in Table 1 functional studies revealed that all quinazolines lacking the disulfide bridge 
(X= CH2, VII-XII) behaved like prazosin as competitive antagonists. In contrast, all polyamine 
disulfides (X= S, I-VI) displayed a nonhomogeneous mechanism of inhibition at the three receptor 
subtypes. They seem to be irreversible antagonists at the α1A and α1B subtypes like benextramine, 
and competitive antagonists at the α1D subtype like prazosin. This means that in the active site of α1A 
and α1B there is a thiol function that would make an interchange reaction with the disulfide moiety 
of the antagonist leading to an irreversible blockade. On the other hand, this thiol function might be 
absent in the α1D subtype.  
 
no. position X pKb (pIC50) 
   α1A α1B α1D 
prazosin   8.99±0.01 8.74±0.01 9.71±0.17 
benextramine   (4.79±0.01) (4.17±0.03) (5.30±0.01) 
I 2 S (5.30±0.01) (5.29±0.03) 7.57±0.06 
II 3 S (5.41±0.02) (4.26±0.05) 7.09±0.02 
III 4 S (5.70±0.11) (4.38±0.06) 7.61±0.14 
IV 2 S (5.73±0.01) (5.73±0.05) 8.05±0.15 
V 3 S (5.70±0.11) (4.38±0.06) 7.61±0.14 
VI 4 S (5.33±0.03) (5.67±0.01) 8.50±0.14 
VII 2 CH2 7.74±0.18 6.80±0.12 7.94±0.22 
VIII 3 CH2 7.29±0.03 6.50±0.12 7.43±0.14 
IX 4 CH2 6.97±0.04 7.26±0.21 7.47±0.13 
X 2 CH2 8.17±0.08 7.22±0.10 8.47±0.13 
XI 3 CH2 8.48±0.13 7.41±0.15 9.30±0.21 
XII 4 CH2 8.53±0.20 7.56±0.19 7.90±0.14 
Table 1: Selectivity of I-XII (see Fig. 3) for α1-ARs.537 
 
All disulfide-bearing compounds were more potent than benextramine at the α1A subtype. At the α1B 
subtype I and IV-VI are more potent, while II and III are as potent as benextramine. Interestingly 
V, in which the piperidine ring is replaced by an open amine chain, was 355-fold more potent than 
benextramine at the α1A subtype and it also possessed selectivity for α1A and α1D. As discussed 
above, the carbon analogues VII-XII displayed a competitive interaction at all α1-ARs like prazosin 
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1. They are less potent than prazosin, but in contrast to prazosin, they showed different selectivity 
among the α1-AR subtypes. In particular, compound XI was 7- and 78-fold more potent at α1D 
adrenoreceptors than at α1A and α1B, respectively. 
In order to obtain compounds endowed with both α1-AR antagonist and antioxidant properties the 
furo moiety of prazosin was replaced with lipoyl fragments of lipoic acid, its lower homologues or 
naphthoquinone.542 The choice of lipoic acid and its homologues was dictated by the observation 
that lipoic acid is known as a universal antioxidant. Among the synthesized compounds, the 
derivative in which the 1,2-dithiolane ring was directly connected to its carbonyl group is the most 
interesting (A, Fig. 4). It showed high potency among all the α1-AR subtypes but it was 20-fold 
more selective for α1D-ARs than for α1A-ARs. A comparable biological activity and selectivity 
profile was displayed by naphthoquinone derivative (B, Fig. 4) and additionally, it showed the 
highest antiproliferative and antioxidant effects.  
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Figure 4: Prazosin-derivatives with antioxidant properties. 
  
As discussed above, changing the amine chain attached to the quinazoline ring and the carbonyl 
group is possible to modify the affinity and the selectivity for the three α1-AR subtypes. On the 
other hand, the quinazoline seems to be essential for the interaction. Thus, Campbell et al.543 
suggested that an essential role for the interactions of the 2,4-diamino-6,7-dimethoxyquinazoline 
derivatives is the protonated N1 of the quinazoline system. The role of the N1 in receptor binding 
was also confirmed through the synthesis of a series of isoquinoline derivatives in which the lack of 
this nitrogen atom resulted in no significant affinity for α1-ARs.544 Moreover, Ishiguro et al.545 
suggested a possible binding site for prazosin through molecular modeling (Fig. 5). They found that 
the 4-amino group and 1-nitrogen atom on quinazoline ring possibly interact with the carboxyl 
group of Asp106(α1A), 125(α1B), 176(α1D) in TM3 and the hydroxyl group of Ser188(α1A), 207(α1B), 
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258(α1D) in TM5 by hydrogen bonds. Two methoxy groups of quinazoline ring may also interact 
with hydroxyl group of Thr111(α1A), 130(α1B), 181(α1D) in TM3 and the hydroxyl group of Ser192(α1A), 
211(α1B), 262(α1D) in TM5 and the carbonyl group between the piperidine and furan ring is thought to 
form a hydrogen bond with Ser296 (α1A), 318(α1B), 372(α1D) in TM6. These results showed that the 
aminoacids involved in the interaction of prazosin are the same in all receptor subtypes. This may 
account for the nonselectivity of prazosin to all α1-ARs.  
 
 
Figure 5: Complex of prazosin at the ligand binding site at α1A-, α1B-, α1D-ARs.545  
 
Several evidences suggest that the quinazoline-based α1-adrenoceptor antagonists, doxazosin and 
terazosin, exhibit a potent apoptotic effect against prostate tumor epithelial cells.546, 547, 548, 549 This 
activity seems to be dependent from the quinazoline ring since tamsulosin, a sulphonamide-based 
α1-adrenoceptor antagonist, does not have this effect.547 To identify the precise molecular 
mechanism underlying this apoptosis induction, in vitro experiments were performed in three types 
of cellular lines; DU-145 (that lack α1-adrenoceptors), PC3 (androgen-independent prostate cancer 
cells) and LnCaP (androgen-sensitive prostate cancer cells). It was observed that the apoptotic 
effect against prostate cancer cells was independent from the ability of the two α1-adrenoceptor 
antagonists to antagonize the α1-adrenoceptors. Thus, the irreversible α1-adrenoceptor inhibitor 
phenoxybenzamine does not inhibit the apoptotic effect of doxazosin or terazosin against prostate 
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cancer cells and smooth muscle cells. Doxazosin and terazosin also reduced the viability of PC-3 
prostate cancer cells by inducing apoptosis in a dose-dependent manner after 2 days of treatment. 
This effect is more significant for doxazosin. In contrast, tamsulosin had no effect on PC-3 prostate 
cancer cell viability (Fig. 6).547 
 
Figure 6: Effect of α1-adrenoceptor antagonists on cell viability PC-3 prostate cancer cells. Cells 
were exposed to increasing concentrations of doxazosin, terazosin, and tamsulosin (0, 0.1, 0.5, 1, 5, 
10, 25, 50, and 100 mM). ♦: doxazosin, ■: terazosin, tamsulosin.547  
 
Furthermore, in vivo trials showed that doxazosin administration (at tolerated pharmacologically 
relevant doses) in mice bearing PC-3 prostate cancer xenografts resulted in a significant inhibition 
of tumor growth. Mice were treated with increased oral doses of doxazosin (0, 3, 10 or 100 mg/kg). 
3 mg/kg of doxazosin resulted in a significant decrease in tumor volume of prostate cancer 
xenografts compared with untreated controls. Higher doses of doxazosin did not cause further tumor 
suppression.547  
Interestingly, the two quinazoline based α1-adrenoceptor antagonists also induce apoptosis in the 
androgen-sensitive prostate cancer cells LNCaP. In Table 2, the effect of doxazosin, terazosin, and 
tamsulosin (25 µM) on apoptosis in LNCaP prostate cancer cells are reported. Doxazosin and 
terazosin caused an increase in the number of apoptotic cells (14 and 13%, respectively), while 
tamsulosin treatment had no apoptotic effect against LNCaP cells (1.2%) compared with the control 
(1.1%).548 
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Table 2: Percentage of apoptosis in normal (PrEC) and malignant prostate epithelial cells (LNCaP) 
in response to α1-adrenoceptor antagonists.548  
 
To determine whether androgens have the ability to modify the apoptotic response of prostate 
cancer cells to the quinazoline-based α1-antagonists, the effect of 5α-dihydrotestosterone on 
doxazosin-induced cell death in LNCaP cells was examined. The decrease of cell viability with 
increasing concentration of doxazosin in the absence of DHT was comparable to that obtained in 
the presence of DHT. Therefore, DHT had no protective effect on doxazosin-mediated apoptosis. 
Moreover, cells were treated with doxazosin alone (25 µM), doxazosin in the presence of DHT, or 
DHT alone (1 nM). As shown in Figure 7, the percentage of apoptotic cells induced by doxazosin 
was similar to that obtained in the presence of DHT, whereas DHT alone caused a basal apoptosis 
level, comparable with the values observed for untreated cultures (control). The results suggest that 
the apoptotic activity of doxazosin and terazosin against prostate cancer cells is independent from 
the hormone sensitivity status of the cells.  
 
Figure 7: Effect of androgens on sensitivity of LNCaP cells to doxazosin-induced apoptosis.548  
 
Finally, it was shown that these α1-AR antagonists do not have any effect on cell cycle progression 
in LNCaP prostate cancer cells. In fact, after two days of treatment with drugs at 25 µM, the 
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percentage of relative distribution of the prostate cancer cells in each phase of the cell cycle 
remained very similar to the untreated cells. There was not a significant increase in the number 
of cells in the G2-M phase, suggesting that the prostate antigrowth effect of the quinazolines results 
from targeting the apoptotic pathway without an antiproliferative activity.  
The potential signaling pathways that may underlie the apoptotic effect mediated by the 
quinazoline-based α1-AR antagonists in prostate tumor cells seems to be mediated by the TGF-β 
signal transduction pathway. TGF-β is a multifunctional cytokine which regulates cell proliferation, 
extracellular matrix production and degradation, differentiation and modulation of apoptosis.550 
TGF-β is a physiological regulator of prostatic growth.551, 552 Thus, it inhibits prostate epithelial cell 
proliferation and activates apoptosis in the presence of physiological levels of androgens. Several 
evidence 553, 554 suggested that there was a significant increase in TGF-β expression in the prostates 
of patients treated with terazosin and doxazosin. The apoptotic process initiated by TGF-β, is 
mediated by complex downstream signaling events that lead finally to nuclear gene expression and 
activation of apoptotic events. Moreover, it seems that quinazoline-based compounds are able to 
reduce tumor growth by targeting their invasion and migration potential. Anoikis is a form of 
programmed cell death which is induced by anchorage-dependent cells detaching from the 
surrounding extracellular matrix (ECM). Cells stay close to the tissue to which they belong since 
the communication between proximal cells as well as between cells and ECM provides essential 
signals for growth or survival. When cells are detached from the ECM, they may undergo anoikis. 
However, metastatic tumor cells may escape from anoikis and invade other organs. It was shown 
that some quinazoline-based compounds are able to induce anoikis phenomenon in prostate cancer 
cells. This effect is mediated by reduction in integrin β1 surface expression that mediates cell 
adhesion through collagen and fibronectin.555  
All these results suggest that quinazoline derivatives may have important therapeutic significance in 
the treatment of not only androgen-dependent prostate cancer, but also for androgen-independent 
human prostate cancer. 
 
In the continuing search for quinazoline-based α1-AR antagonists, Melchiorre and co-workers556 
developed cyclazosin (Fig. 8), a compound known to possess high antagonist affinity and 
selectivity for α1D- and α1B-ARs relative to the α1A subtype. To further study the effects of 
doxazosin-related compounds on prostate cancer cells, derivatives of cyclazosin were synthesized, 
through replacement of 2-furoyl ring of cyclazosin with the 2,3-dihydro-1,4-benzodioxine-2-
carbonyl moiety.557 The novel cyclazosin analogues are XIII (cis, cyclodoxazosin), XIV (trans, 
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cyclodoxazosin) and XV (cis, 4aS,8aR) a couple of the four stereoisomers of XIII (Fig. 8). An open 
analog of doxazosin XVI, was also tested. In functional assays XVI (Table 3) was more potent than 
XIII and XIV at all α1-AR subtypes with the exception of XIII at the α1B-subtype. The replacement 
of piperidine with a cis- and trans-decahydroquinoxaline nucleus to give XIII and XIV, 
respectively, is detrimental for the affinity at α1-adrenoceptors. However, the cis isomer XIII was 
more potent than the trans XIV at all the subtypes. Interestingly, in binding assays, the affinity of 
XIII-XVI and cyclazosin at α1-AR subtypes did not reflect the affinity observed in functional 
experiments as already found for a number of other prazosin-related compounds.542  
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Figure 8: Molecular structure of cyclazosin, XIII-XVI.  
 
 
Table 3: Binding (pKi) and functional affinity (pA2 or pKB) constants and in vitro antiproliferative 
activity (IC50) of XIII-XVI, cyclazosin, and doxazosin at cloned human α1-AR.556 
 
The cytotoxic activity of XIII-XVI and doxazosin were evaluated in vitro in PC-3, DU- 145, and 
LNCaP human prostate cancer cells as well as in normal human dermal fibroblasts. As shown in 
Table 3, compounds XIII and XVI were significantly more potent than doxazosin in all tested 
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cells. In particular, XIII exhibited the highest effect, whereas XVI was about 10-fold less potent 
than 1. The trans isomer XIV was 17-fold less potent than XIII at LNCaP cells, and no effect was 
observed in the other cells up to the maximal tested concentration (10 µM). This suggests that the 
stereochemistry may not have a relevant role in the antiproliferative activity in LNCaP cells.  
 
1.1.2 Phenylethylamines 
Phenylethylamines can be identified, from a structural point of view, as the most closely related 
compounds to the endogenous agonist noradrenalin. Tamsulosin and silodosin are the most 
important phenylethylamines used in clinical practice (Fig. 9).  
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Figure 9: Chemical structures of tamsulosin and silodosin. 
 
Tamsulosin shows selectivity for α1A-ARs and α1D- ARs over α1B ARs [pKi 9.70 (α1A), 8.90 (α1B) 
and 9.80(α1D)]. However, clinical advantages attributed to pharmacological selectivity require 
receptor selectivity more than 10-fold, as observed with tamsulosin. Therefore, the slight receptor 
selectivity of tamsulosin is not sufficient to ensure a clinically advantage. Tamsulosin is a chiral 
compound and it was found that stereochemistry at the methyl-bearing carbon atom is critical on its 
pharmacological profile. (S)(+)-tamsulosin displays a greater subtype selectivity, albeit with at least 
10-fold reduction in potency compared with its (R)(-)-tamsulosin.536  
Silodosin (KMD-3213) is a recent α1-AR antagonist approved in 2008 by FDA. Silodosin is 162 
times more selective for α1A than for α1B, and is 55 times more selective for α1A than for α1D.558 The 
unique receptor selectivity profile overcomes the common side effect associated with α1-AR 
antagonists. Silodosin possesses cardiac and blood pressure-related safety profile, and data have 
demonstrated that it does not promote QT-interval prolongation.559  
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In the attempt to search for new α1A-AR antagonists among phenylethylamines, several compounds 
have been synthesized. Related compounds are shown in Figure 10, where the linker between the 
aromatic ring and the basic amine is truncated (JTH-601)560 or extended (WB-4101).561 They 
maintain excellent levels of binding selectivity. 
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Figure 10: Chemical structures of JHT-601 and WB-4101. 
 
WB-4101 is the prototype of α1-AR antagonists bearing a benzodioxan moiety. It became a lead 
molecule and the subject of intensive investigations aimed at improving its affinity and selectivity. 
As a result, a variety of analogues have been studied and characterized for their affinity for cloned 
human α1-AR subtypes. Data showed that the two oxygen atoms at positions 1 and 4 might have a 
different role in receptor binding.562, 563 The oxygen atom at position 4 of WB-4101 is not essential 
for the interaction in fact it could be replaced by a sulfur atom or a methylene unit without affecting 
potency. Differently, the oxygen atom at position 1 seems to contribute to receptor binding. 
Moreover, the insertion of a phenyl ring or a p-tolyl moiety at the 3-position having a trans 
relationship with the 2-side chain afforded phendioxan A and B, respectively (Fig. 11), that 
displayed the highest affinity for native α1A-ARs relative to both α1B and α1D subtypes. 
Starting from this observation, Melchiorre and co-workes564 expanded the study of another aspect of 
SAR leading to several compounds in which the oxygen atom at position 4 of benzodioxan was 
replaced by a phenylmethine group, and the resulting compound was the subject of further 
modifications, such as the exchange of the oxygen atom at position 1 with a sulfur atom, a carbonyl 
group or a methylene unit. In functional assays, compound C was the most potent at α1D-ARs, while 
the prototypes WB-4101 and A are more potent at α1A-ARs. Compound D, bearing a carbonyl 
moiety at position 1, was the most potent at α1A-ARs like the prototypes. Replacing the oxygen with 
a sulfur atom retained the activity. However, the stereochemistry of the substituent in 4- and 2- 
position is essential for the activity. In fact, a trans relationship between the 2-side chain and the 4-
phenyl group is detrimental for binding at α1-ARs as revealed by a comparison between the trans 
and the cis isomers E and F. Cis isomer F was significantly more potent than the trans isomer E at 
α1A-ARs, while it was, however, only slightly more potent at both α1B- and α1D-ARs. 
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Figure 11: Further modification on the lead compound WB-4101. 
 
1.1.3 Piperidines 
Indoramin (Fig. 12) is the first compound of piperidine-based α1-selective antagonists used in 
BPH.565 A significant drawback with indoramin, however, is its poor selectivity. Thus, indoramin 
interacts with other receptors, such as 5-HT and histamine, leading to sedation and to several side 
effects. The major challenge within this class of compounds has been to increase α1 subtype 
selectivity while reducing its polypharmacology. The replacement of the terminal indole group of 
indoramin by a phenyl ketone yielded the second-generation compound SNAP-1069 (Fig. 12). 
SNAP-1069 displayed a 10-fold increase in selectivity for α1A-ARs over α1B-ARs and α1D-ARs but 
it still suffers, however, from a broad spectrum of activities.566 
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Figure 12: Chemical structures of indoramin and SNAP-1069. 
 
Further work was inspired by the discovery of dihydropyridine (DHP) calcium channel blocker 
used for the treatment of hypertension. The first compound was (S)(+)-niguldipine (Fig. 13).  
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Figure 13: Chemical structure of (S)-niguldipine. 
 
Niguldipine is a potent α1-AR antagonist for. In fact, it displays a 100-fold selectivity increase for 
α1A-AR versus the other α1-ARs subtypes [pKi 9.8(α1A), 7.26 (α1B) and 7.00 (α1D)]. Structural 
modifications of the DHP skeleton led to SNAP 5089567 and SNAP 5540568 (Fig. 14), which 
maintained potency and selectivity for the α1A subtype, but they had attenuated or no calcium 
channel activity. Some of the compounds that belong to this class, however, had poor oral 
bioavailability in rats which may be due to the oxidative metabolic conversion of the 
dihydropyridine moiety into a pyridine.  
 
 
 
 
 
 
 
Figure 14: Molecular structure of SNAP 5098 and SNAP 5540. 
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In a further modification, the DHP core was replaced by a dihydropyrimidinone scaffold, as in 
SNAP 6201 (Fig. 15), in order to avoid pharmacokinetic problems. The difluoro analog SNAP 6201 
showed good binding affinity for the α1A receptor, no cardiovascular effects and a good 
pharmacokinetic profile.569 However, in vitro and in vivo evaluation of SNAP 6201 showed that its 
major metabolite, 4-methoxycarbonyl-4-phenylpiperidine, is a potent µ-opioid agonist. 
 
 
 
 
 
 
 
Figure 15: Molecular structure of SNAP 6201. 
 
Modification of the linker in SNAP 6201 gave several compounds with good α1A binding affinity 
and selectivity. One of the most promising molecules is the compound shown in Figure 16, where 
the 4-methyl-4-phenylpiperidine core was essentially inactive at the µ-opioid receptor. Moreover, it 
did not display affinity for other GPCRs.  
 
 
 
 
 
 
 
Figure 16: Further modifications of SNAP 6201. 
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1.2  5α-reductase inhibitors 
BPH is often correlated to an abnormal production of 5α-dihydrotestosterone (5α-DHT). 5α-DHT is 
synthesized from testosterone by the enzyme 5α-R in the prostate (Fig. 17). Two 5α-R isoforms 
have been cloned: 5α1-R and 5α2-R. The type 2 isozyme have been found mainly in the prostate, 
genital skin, seminal vesicles and in the dermal papilla, while the type 1 isozyme have been found 
in non-genital skin and hair follicles. Therefore, inhibitors of 5α2-R are useful drugs to lower the 
DHT level in the prostate. This might be a promising strategy for the treatment of prostate diseases. 
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Figure 17: Conversion of testosterone to DHT. 
 
The mechanism of testosterone reduction is shown in Figure 18. It involves the formation of a 
ternary complex between the enzyme, NADPH and the substrate testosterone. When testosterone 
enters into the active site of the enzyme, a complex is formed through the activation of the enone 
system by a strong interaction with an electrophilic residue present in the active site. The 
delocalized carbocation is then reduced selectively at C-5 by a direct hydride transfer from 
NADPH, leading to the formation of the enolate of DHT. This intermediate is presumably 
coordinated with NADP+ giving the ternary complex E–NADP+–DHT. Then, the departure of DHT 
gives the binary NADP+–enzyme complex, and finally the release of NADP+ leaves the enzyme free 
for further catalytic cycles. 
5α-R 
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Figure 18: Reduction mechanism of testosterone to DHT.570 
 
5α-R inhibitors have been studied for over 25 years as potential drugs for the treatment of diseases 
where DHT is implicated.571 These compounds can be classified into two groups: steroidal and non-
steroidal inhibitors. The steroidal inhibitors are the most important class of compounds since they 
are used in clinical practice. The structure of steroidal inhibitors was based on the testosterone 
skeleton, which has been modified: 
• by the introduction of a nitrogen atom in the A ring (4-azasteroids), in the B ring (6-
azasteroids), and at position 10 (10-azasteroids).  
• by the introduction of a double bond into the above described structures. 
 
In the 4-azasteroid series, the first potent inhibitor of human 5α-R used in clinical practice is 
finasteride (Fig. 19).  
 
 
 
 
 
Figure 19: Molecular structure of finasteride.  
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Finasteride and other close structural analogs are slow-offset, essentially irreversible inhibitors. The 
conversion of the carbonyl in the A-ring of finasteride to an enolate and the subsequent alkylation 
by NADP+ leads to the formation of a very stable and potent enzyme-NADP-dihydrofinasteride 
adduct (Fig. 20). 
 
 
Figure 20: Formation of the enzyme-NADP-dihydrofinasteride adduct.570 
 
Finasteride is a potent inhibitor of 5α-R of type 2 with only weak in vitro activity versus the 5α-R 
type 1 isozyme.572 Finasteride (5 mg per die) is able to reduce about 70% of the serum DHT 
concentration, to reduce the total gland size of 15–25% and to ameliorate the severe symptoms 
associated to BPH. Later studies indicated the presence of a small amount of 5α1-R in the prostate 
gland, and therefore, the use of dual inhibitors was developed as a new hypothesis for improving the 
reduction of DHT levels. This led to the discovery and market introduction of a new, very potent 
dual inhibitor, dutasteride, which was approved by FDA in 2002 for the treatment of BPH.573 
Dutasteride (Fig. 21) , like finasteride, is a 4-azasteroidal derivative with the more lipophilic 2,5-
difluorophenyl substituent in the amide. This drug reduces the serum DHT concentration by about 
90% and the total gland size by 25%.574  
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Figure 21: Molecular structure of dutasteride. 
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2 Aim of the project 
BPH, the nonmalignant enlargement of the prostate caused by increased cellular growth, commonly 
affects elderly men. The incidence of BPH is increasing along with increasing average life 
expectancy.575 BPH causes severe LUTS such as nocturia, incomplete bladder emptying, urgency, 
incontinence, bladder pain, urinary hesitancy, weak stream and straining to void. These 
symptomatic urinary dysfunctions have a significant impact on the lifestyle of older men.576 
Therapeutic approaches for treating BPH aim to decrease symptoms as well as improve the urinary 
flow rate. TURP is the most effective surgical therapy for this disease but it is not without any 
negative aspects. In fact, TURP can cause retrograde ejaculation, impotence, postoperative urinary 
tract infections and urinary incontinence. For these reasons, an increasing number of patients prefer 
conservative and less invasive therapies.  
5α-R inhibitors and α1-AR antagonists are the two main categories of drugs currently available for 
BPH.577 5α-R inhibitors inhibit 5α-R, the enzyme that converts testosterone to its active metabolite 
5α-DHT, reducing prostatic cellular growth.578 Initially developed as antihypertensive agents, α1-
AR antagonists exert their effect by blocking ARs that mediate contraction of the prostatic smooth 
muscle cells and bladder neck, producing lower urinary tract symptoms.579 α-ARs are a class of 
GPCRs belonging to the sympathetic nervous system. α-ARs are divided into two subtypes: α1 and 
α2. The α1 subtype is predominant in the prostate capsule and mediates smooth muscle tone.580 
Blockade of α1-ARs is the predominant form of medical therapy for the treatment of urinary tract 
obstruction due to BPH, as it targets the neural elements which contribute to the symptoms of the 
disease. Several studies indicate that α1-ARs can be classified into at least three subtypes, i.e. α1A/1a, 
α1B/1b and α1D/1d.581 It has been shown that the α1A-AR subtype is the predominant receptor involved 
in human prostate physiology, while α1B-AR seems to play a role in the regulation of blood 
pressure. A potential therapeutic use for the α1D-AR subtype has not been firmly established but 
α1D-ARs are predominant in the destrusor muscle and they seem to be upregulated in the destrusor 
of obstructed rats.534 This suggests a relevant role for this subtype also in the control of the 
symptoms associated with BPH. 
A great deal of interest now lies in the development of α-blockers which target only one receptor 
subtype while not affecting the others. Furthermore, the different localization of these receptor 
subtypes suggests the possibility of designing drugs that interact with a particular subtype in an 
effort to limit the adverse effect profile and improve efficacy. However, the design of an ideal 
selective ligand, which recognizes only one among many receptor subtypes, remains a critical 
challenge in medicinal chemistry.  
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Our research group has long being involved in designing new α1-AR antagonists structurally related 
to prazosin (Fig. 1) 537, 538, 539, 540, 541, 542, 582, 583, 584 Prazosin is one of the oldest α1-AR antagonists 
and the prototype of quinazoline-bearing compounds widely used in the management of 
hypertension. Its congeners, terazosin, doxazosin (Fig. 1) and tamsulosin offer a similar 
pharmacology with a longer duration of action. Furthermore, prazosin and its congeners represent 
the most used approach in treating LUTS associated with BPH.536  
The aim of the project was to synthesized new quinazoline derivatives in an attempt to improve 
affinity and selectivity for the α1-subtypes. We wanted also to exploit the antiproliferative activity 
of these compounds against prostate cancer, since it has been reported that some quinazoline-
derived α1-AR antagonists exert apoptotic activity via an action independent from activation of α1-
ARs and through a mechanism independent from androgens.547, 548 The design strategy of prazosin-
related compounds was based on the observation that the piperidine ring of prazosin is not essential 
for the activity.585, 586 Furthermore, modifying the piperidine and/or the furan unit may afford 
antagonists that are able to differentiate among α1-AR subtypes.537, 538, 587, 588 On the other hand, the 
quinazoline unit of prazosin in essential for the high affinity toward α1-ARs. In fact, Campbell et 
al.543 suggested that an essential role for the interactions of the 2,4-diamino-6,7-
dimethoxyquinazoline derivatives is the protonated N1 of the quinazoline system. The role of the 
N1 in receptor binding was also confirmed through the synthesis of a series of isoquinoline 
derivatives in which the lack of this nitrogen atom resulted in no significant affinity for α1-AR.544 
More recently, the importance of 2,4-diamino-6,7-dimethoxyquinazoline moiety for the interaction 
with α1-AR was also confirmed by Ishiguro and co-workers by molecular modeling.545  
Furthermore, the quinazoline ring seems to be essential for the apoptotic activity of some prazosin-
related compounds because tamsulosin, that lacks the quinazoline moiety, is devoid from this 
important effect.547 
In the light of these considerations, compounds 1 and 2 (Fig. 22) were designed maintaining the 
quinazoline moiety and replacing the piperidine ring with a 3-aminopiperidine unit. The free amine 
function can be protonated at physiological pH giving rise to a possible additional interaction with a 
complementary receptor group, which would increase the possibility to achieve receptor subtype 
selectivity. To investigate the effect of the stereochemistry in biological activity, both enantiomers 
at the 3-position of the aminopiperidine were synthesized. It is well-known that stereochemistry in 
drug discovery is very important. In fact several drugs introduced to the market are single 
enantiomers. The enantiomers of a chiral drug present unique chemical and pharmacological 
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behaviors in a chiral environment, such as the human body, in which the stereochemistry of chiral 
drugs determines their pharmacokinetic, pharmacodynamic, and toxicological actions.  
Compounds 3 and 4 (Fig. 22) were obtained inserting into compound 1 and 2, respectively, the 
furan-2-carbonyl group as in prazosin. Compounds 5 and 6 (Fig. 22) were obtained coupling the 
amine group of 1 and 2, respectively, with a quinone ring to have in the same molecule multiple 
biological activities. Thus, replacing the furoyl moiety of 3 and 4 with a 1,4-naphthoquinone might 
lead to derivatives endowed with both α1-AR antagonism and antioxidant properties observed in 
previous studies with a prazosin-related compound bearing the naphthoquinone moiety.542 
Compounds 7-10 (Fig. 23) were designed combining compounds 1 and 2 and the 1,4-
benzodioxane-2-carbonyl group of doxazosin. The introduction of a second chiral center in the 
molecule results in additional structural elements that might affect activity and affinity for α-ARs 
and display also antiproliferative properties. Since these molecules contain two chiral center, all the 
four diasteroisomers were synthesized.  
Although bearing a chiral center, doxazosin is used in clinical practise as a racemic mixture. In the 
literature there is a debate about the stereochemical specificity of doxazosin for α1-ARs.589, 590, 591 
Thus, the two enantiomers of doxazosin (11-12, Fig. 24) were also synthesized to compare the 
activity of the new molecules with a commercially available drug. 
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Figure 22: Design strategy for compounds 1-6. 
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Figure 23: Design strategy for compounds 7-10. 
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Figure 24: Molecular structures of S- and R-doxazosin. 
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3 Chemistry 
The synthesis of the new quinazoline derivatives are described in Scheme 1-10. Intermediates 13 
(Scheme 1) and 14 (Scheme 2) were obtained through aromatic nucleophilic substitution of (S)-3-
(boc-amino)piperidine and (R)-3-(boc-amino)piperidine, respectively, on 4-amino-2-chloro-6,7-
dimethoxyquinazoline. The syntheses were performed by following an adapted procedure described 
by Althuis et al.592 The reaction required high temperature and long time. To short the reaction time, 
reactions were performed under microwave irradiation. It was found that they were complete after 
50 min at 130 °C. Boc-deprotection with 4M HCl in dioxane led to the primary amines 1 (Scheme 
1) and 2 (Scheme 2). Then, amidation of 1 and 2 with 2-furoyl chloride afforded 3 (Scheme 3) and 
4 (Scheme 4), respectively, in good yields. Moreover, addition reaction between 1 and 2 with 1,4-
naphthoquinone led to the quinazoline-quinones 5 (Scheme 5) and 6 (Scheme 6). In Schemes 9 and 
10 it is shown the coupling between amines 1 and 2 and 2,3-dihydro-benzo[1,4]dioxine-2-carbonyl 
chloride 15 and 16, synthesized from their respective carboxylic acids with thionyl dichloride 
(Scheme 7 and 8). Finally, R- and S-doxazosin were also synthesized as described in Scheme 11. 
The intermediate 17 was obtained through aromatic nucleophilic substitution of piperazine on 4-
amino-2-chloro-6,7-dimethoxyquinazoline under microwave irradiation. Piperazine was used in 
excess (6 equiv.) to avoid the formation of N,N-disubstituted bisquinazolin-piperazines. Then, 
amidation of 17 with the acyl chlorides 15 and 16 afforded S- and R-doxazosin, respectively. 
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4 Results and Discussion 
A Radioligand binding assays 
The affinity profile of 1-12 was evaluated in radioreceptor binding assays on membranes of Chinese 
hamster ovary (CHO) cells expressing human α1-AR subtypes. Binding assays were performed by 
Recordati S.p.A. Binding affinities were expressed as pKi values derived using the Cheng-Prusoff 
equation. The results are reported in Table 4. S- and R- doxazosin (11 and 12) and prazosin were 
also included as reference compounds. An analysis of the results reveals that these compounds did 
not display a noteworthy affinity enhancement toward all α1-AR subtypes compared to doxazosin 
and prazosin. However, the stereochemistry at the 3-C position of the piperidine ring plays an 
important role for the binding at α1-ARs. Thus, we can observe that 3 possessed an affinity for all 
α1-AR subtypes that is more than 100-fold higher compared to its enantiomer 4. The same 
observation applies to 5 vs its enantiomer 6 even though the differences in binding affinity were not 
so marked as between 3 and 4. Moreover, compound 5 seemed to be 13–fold and 4–fold more 
selective for the α1B-AR than for α1A- and α1D-ARs, respectively. The incorporation of an additional 
basic center (1 and 2) was detrimental for the activity. The present finding was in good agreement 
with a study conducted by Cambpell et al.593 on quinazoline-related compounds. They found that 
the prazosin derivative lacking the furoyl moiety displayed a low affinity for α1-ARs. It derives that 
the substituent on the amine group is important for the interaction with α1-ARs. However, 
compound 1 displayed a higher affinity for all three α1-AR subtypes than its enantiomer 2. 
Derivative 1 is slightly more selective for the α1D- relative to the α1B-AR. This finding is interesting 
because also α1D-ARs are thought to have a relevant role in the control of the symptoms associated 
with BPH, while α1B subtype is responsible for the regulation of blood pressure.534, 535, 533 In 
conclusion, the S configuration at the 3-C position of the piperidine ring is an important feature that 
drives the interaction with α1-ARs.  
Doxazosin possesses a chiral center but it is used in clinical practice as a racemic mixture. In the 
literature there is a debate about the stereochemical specificity of doxazosin for the three α1-AR 
subtypes.589, 590, 591 From our results we can observe that 11 and 12 did not display a noteworthy 
difference in affinity toward all α1-AR subtypes. Therefore, it derives that the stereochemistry at the 
benzodioxole ring does not influence α1-AR subtype selectivity as also observed for doxazosin 
derivatives 7-10. A marked difference in affinity was observed between 7 and the two stereoisomers 
9 and 10. Changing the S into the R configuration at the 3-C position of the piperidine ring of 7, as 
in 9 and 10, was detrimental for the affinity. This effect was more evident for the α1A- and α1D-AR 
subtypes. On the other hand, changing the stereochemistry at the benzodioxole ring did not 
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markedly affect the affinity for the α1-AR subtypes. Thus, 7 displayed the same biological profile of 
8, whose affinity for α1B-ARs was, however, 8–fold higher than that of 7. Similarly, 9 and 10 
possessed the same biological profile. They were both more selective for the α1B-AR, but 10 
displayed a 6–fold increase in affinity for α1B-ARs compared to 9.  
 
B Antiproliferative activities 
It is well known that some quinazoline-based α1-AR antagonists possess apoptotic effect against 
prostate tumor cells.547, 548 Therefore, antiproliferative activities of compounds 1-12 were also 
evaluated in vitro by National Cancer Institute (NCI), Bethesda, USA. Compounds were tested at a 
concentration of 10 µM on sixty different human tumor cell lines, representing leukemia, melanoma 
and cancers of the lung, colon, brain, ovary, breast, prostate, and kidney. The aim is to prioritize for 
further evaluation of compounds showing selective growth inhibition or cell killing of particular 
tumor cell lines. If the results obtained meet selection criteria, then the compounds are studied again 
in all sixty cell lines in a 5-dose testing to obtain the IC50 value. Among all the compounds, 5 and 6 
were found to be the most promising in the 1-dose assays. 5-dose assays for 5 and 6 are in progress 
to better investigate their antiproliferative profile. The results regarding the single dose screen of 
derivatives 5 and 6 are reported in Table 5. The numbers reported for the one-dose assay is growth 
relative to the no-drug control, and relative to the time zero number of cells. This allows detection 
of both growth inhibition (values between 0 and 100) and lethality (values less than 0). For 
example, a value of 100 means no growth inhibition. A value of 40 would mean 60% growth 
inhibition. A value of 0 means no net growth over the course of the experiment. A value of -40 
would mean 40% lethality. A value of -100 means all cells are dead.  
An analysis of the results shown in Table 5 revealed that 5 and 6 possessed an antiproliferative 
activity that is more marked for particular cell lines. They were very potent antitumor agent against 
CNS cancer where they caused a lethality that is almost 100%. The only exception in represented 
by SF-268 cell line where 5 and 6 caused a lethality of 47.42% and 52.29%, respectively. There was 
not a noteworthy change in activity between the two enantiomers. This finding is in contrast with 
radioligand binding assays where it was found that the stereochemistry at the 3-C position of the 
piperidine ring was critical for the interaction with α1-ARs. In lung cancer, 5 and 6 seemed to be 
inactive on NCI-H226 cells. In HOP-62, HOP-92 and NCI-H522 cell lines they inhibited cellular 
growth, even though less than 40%. Interestingly, in NCI-H322M and NCI-H460 they were able to 
induce a marked level of lethality. Therefore, these derivates could be promising drugs for the 
treatment of a particular type of lung cancer. Regarding colon cancer, 5 and 6 were quite potent 
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anticancer agents. In fact, it was found that the percent lethality was more than 60% in all cell lines. 
The only exception is represented by HCC-2998 cells, where they were completely inactive, and by 
KM12 cells, where the lethality was 35.24% and 39.21% for 5 and 6, respectively. There was not a 
noteworthy difference in antiproliferative activity between the two enantiomers. Interestingly, in 
melanoma the stereochemistry was an important feature. Compound 6 was completely inactive in 
all cells lines except in LOX IMVI. On the other hand, its enantiomer 5 was found to be a potent 
antiproliferative drug with a lethality value more than 80%. However, in M14, SK-MEL-2 and 
UACC-257 cell lines it was inactive. Regarding ovarian cancer, in OVCAR-4 and NCI/ADR-RES 
cells the stereochemistry seemed to be important. Derivates 6 caused 88% of lethality in the first 
cell line and inhibited 71% of growth in the latter. In contrast, compound 5 was inactive. In renal 
tumor compound 6, compared to 5, was found to be the most promising. It caused cell death in a 
range between 57% and 100%, while in A498 cells was completely inactive. In breast cancer 
derivates 5 and 6 were quite good antiproliferative agents with 6 slightly more potent. Regarding 
leukemia, these derivates caused lethality in all cell lines but, however, they were not as potent as 
for CNS tumor cells. They caused a lethality lower than 50%. The only exception was represented 
by HL-60(TB) cells where the value was about 60%. In this case, the stereochemistry did not seem 
to be critical. Finally, in DU-145 (that lack α1-AR) prostate cancer cells they caused 54% of cell 
death. In PC-3 (androgen-independent) cells 5 and 6 inhibited cellular growth by 77.05% and 
45.51%, respectively. Therefore, compound 5 seemed to be most promising for the treatment of 
BPH. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Affinity constants expressed as pKi (CHO cells) values at human recombinant α1-AR 
subtypes. a Equilibrium dissociation constants (Ki) were derived from IC50 values using the Cheng-
Prusoff equation.594 Ki values were from two to three experiments, which agreed within ±20%. c 
Data from ref.538 
Compound pKia 
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Compound 5  
(Growth Percent)a 
Compound 6  
(Growth Percent)a 
Cell lines 
  
Leukemia   
CCRF-CEM -20.94 -23.52 
HL-60(TB) -60.35 -64.56 
K-562 -47.09 -48.45 
MOLT-4 -37.07 -41.30 
RPMI-8226 -44.06 -50.10 
SR-11 -11.33 -20.07 
Non-Small Cell Lung Cancer 
  
A549/ATCC -74.61 -80.59 
HOP-62 94.54 64.04 
HOP-92 84.75 75.81 
NCI-H226 113.31 107.33 
NCI-H23 87.23 ntb 
NCI-H322M -65.33 -72.21 
NCI-H460 -72.92 -65.70 
NCI-H522 94.29 74.42 
Colon Cancer 
 
  
COLO 205 -71.76 -79.56 
HCC-2998 106.36 92.94 
HCT-116 -83.60 -85.26 
HCT-15 -67.17 -63.47 
HT29 -59.81 -69.15 
KM12 -35.24 -39.21 
SW-620 
 
-60.62 -45.07 
CNS Cancer 
  
SF-268 -47.42 -52.29 
SF-295 -88.95 -96.84 
SF-539 -99.88 -100.00 
SNB-19 -49.73 -74.71 
SNB-75 -92.32 -83.53 
U251 -89.35 -90.22 
Melanoma   
LOX IMVI -65.26 -82.93 
MALME-3M 94.75 -81.28 
M14 96.32 96.18 
MDA-MB-435 64.65 -96.09 
SK-MEL-2 109.29 110.80 
SK-MEL-28 109.41 -85.25 
SK-MEL-5 93.98 ntb 
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Table 5: Antiproliferative activity in one-dose (10 µM) assays of compounds 5 and 6. a Growth 
percent: cell growth relative to the no-drug control. Growth inhibition (values between 0 and 100) 
and lethality (values less than 0). b nt: not tested. 
 
 
 
 
 
 
 
 
UACC-257 95.26 97.68 
UACC-62 87.80 -87.86 
Ovarian Cancer   
IGROV1 -82.33 -81.57 
OVCAR-3 -69.49 57.72 
OVCAR-4 81.54 -88.02 
OVCAR-5 109.78 125.27 
OVCAR-8 -41.17 -57.22 
NCI/ADR-RES 98.99 29.40 
SK-OV-3 112.2 115.99 
Renal Cancer   
786-0  94.75 -92.66 
A498  107.38 93.00 
ACHN  72.00 -100.00 
CAKI-1  64.86 -56.61 
RXF 393  -76.33 -76.65 
SN12C  95.91 65.40 
TK-10  -49.30 -72.60 
UO-31  46.03 -76.10 
Prostate Cancer   
PC-3  22.97 54.49 
DU-145  -53.84 -54.06 
Breast Cancer   
MCF7  -63.30 -77.35 
MDA-MB-231/ATCC  -71.23 -86.77 
BT-549  118.22 105.35 
T-47D  -40.89 -56.23 
MDA-MB-468 -51.31 -55.85 
HS 578T 
 
ntb -49.14 
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5 Conclusions and Future Works 
BPH is a common disease that affects elderly. It is well-know that among α1-ARs, the α1A- and the 
α1B-AR subtypes seem to be involved in the symptoms of BPH. Nowadays, there are no selective 
antagonists for these α1-AR subtypes. In the present thesis, we studied the effect of stereochemistry 
on α1-ARs inhibition by quinazoline-bearing compounds related to prazosin and doxazosin. We 
found that the S configuration at the 3-C position of the piperidine ring increases the affinity of the 
compounds at all three α1-AR subtypes. We also demonstrated that the stereochemistry at the 
benzodioxole ring of doxazosin did not markedly influence the affinity and the selectivity for α1-
ARs. In conclusion, the present investigation has shown that the pharmacophore represented by 
compound 1 can be considered as an useful starting point for the synthesis of enantioselective drugs 
for α1-AR subtypes.  
The antiproliferative activity of 1-12 was also evaluated on sixty different cancer cell lines by NCI 
at the preliminary concentration of 10 µM. Among all the compounds, 5 and 6 were the most 
interesting. Moreover, their activity is more marked for particular cell lines. They were potent 
agents against CNS and colon cancers. It turned out that the stereochemistry is an important feature 
for their antiproliferative activity on some cell lines. Thus, derivates 6, compared to 5, was more 
potent against melanoma, renal and breast cancers. However, derivative 5 seemed to be more 
promising for prostate cancer.  
The antiproliferative studies conducted by NCI were performed at 10 µM. However, in literature, it 
is reported that the apoptotic activity of doxazosin and related compounds was observed at higher 
concentrations.548 For this reason, further studies are in progress to evaluate the activity of 1-12 
against PC-3, DU-145 and LnCap (androgen-sensitive) cells and to clarify the mechanisms 
underlying their apoptotic effect.  
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6 Experimental section 
6.1 Chemistry 
All reactions were carried out at atmospheric pressure with stirring unless otherwise indicated. All 
solvents and chemicals were purchased from suppliers and used without further purification. For 
microwave-assisted organic synthesis a CEM Discover BenchMate reactor was used. Reaction 
progress was monitored by TLC plates pre-coated with silica gel 60 F254 (Sigma Aldrich) visualized 
by UV (254 nm) or chemical stain (KMnO4, bromocresol green and Ce-Mo). Flash and gravity 
column chromatography were performed on silica gel (particle size 40-63 µM, Merck). Melting 
points were determined using Büchi SMP-20 apparatus. Compounds were named relying on the 
naming algorithm developed by CambridgeSoft Corporation and used in Chem-BioDraw Ultra 
11.0. Optical activity was determined using a Perkin Elmer instrument. 1H-NMR and 13C-NMR 
spectra were recorded at 200-400 and 50-100 MHz, respectively, on Varian instruments. Chemical 
shifts were measured in ppm and are quoted as δ, relative to TMS. Multiplicities are quoted as s 
(singolet), d (doublet), t (triplet), q (quartet), quintet and m (multiplet), br (broad) with coupling 
constants defined as J given in Hz. Mass spectra were recorded on a V.G. 7070 E spectrometer or 
on a Waters ZQ 4000 apparatus operating in electrospray (ES) mode. 
 
(S)-2-(3-Amino-piperidin-1-yl)-6,7-dimethoxy-quinazolin-4-ylamine (1) 
 
 
 
 
A solution of HCl in dioxane (25 ml) was added dropwise at 0 °C to a solution of 13 (1.2 g, 3 
mmol) in MeOH (3 ml). The mixture was stirred at RT overnight. The solvent was then evaporated 
under reduce pressure and the residue was basified with 4N NaOH. The aqueous layer was saturated 
with NaCl and extracted with EtOAc (10 x 30 ml). The combined organic phases were dried over 
Na2SO4 and evaporated to dryness affording 1 as a white solid (910 mg, 3 mmol, 100%). 1 was then 
converted into its dihydrochloride salt; mp (salt)= 240 °C; [α]D20 = +49.03; δH (free base, 400 MHz, 
CD3OD) 1.29-1.38 (1H, m, CHH), 1.46-1.57 (1H, m, CHH), 1.69-1.76 (1H, m, CHH), 1.94-1.98 
(1H, m, CHH), 2.72-2.81 (2H, m, CHH-N, CH-NH2), 2.97 (1H, ddd, J 12.9, 11.0, 3.1, CHH-N), 
3.84 (3H, s, OCH3), 3.88 (3H, s, OCH3), 4.39 (1H, dd, J 9.4, 3.9, CHH-N), 4.49-4.56 (1H, m, CHH-
N), 6.83 (1H, s, Ar), 7.27 (1H, s, Ar); δC (free base, 100 MHz, CD3OD) 23.53, 32.98, 44.04, 47.31, 
51.49, 54.78, 55.24, 102.84, 102.93, 104.20, 145.56, 148.84, 154.86, 159.03, 161.73.  
 
N
N
NH2
H3CO
H3CO N
NH2
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(R)-2-(3-Amino-piperidin-1-yl)-6,7-dimethoxy-quinazolin-4-ylamine (2) 
 
 
 
 
A solution of HCl in dioxane (25 ml) was added dropwise at 0°C to a solution of 14 (1.3 g, 3.30 
mmol) in MeOH (3 ml). The mixture was stirred at RT overnight. The solvent was then evaporated 
under reduce pressure and the residue was basified with 4N NaOH. The aqueous layer was saturated 
with NaCl and extracted with EtOAc (10 x 30 ml). The combined organic phases were dried over 
Na2SO4 and evaporated to dryness affording 2 as a white solid (1 g, 3.3 mmol, 100%). 2 was then 
converted into its dihydrochloride salt; mp (salt)= 240°C; ES [M+H+]: 304; [α]D20 = -49.99; δH (free 
base, 400 MHz, CD3OD) 1.23-1.33 (1H, m, CHH), 1.43-1.54 (1H, m, CHH), 1.69 (1H, dt, J 13.3, 
3.9, CHH), 1.90-1.94 (1H, m, CHH), 2.67-2.75 (2H, m, CHH-N, CH-NH2), 2.92 (1H, ddd, J 12.9, 
11.3, 3.1, CHH-N), 3.81 (3H, s, OCH3), 3.86 (3H, s, OCH3), 4.38-4.32 (1H, m, CHH-N), 4.54 (1H, 
dd, J 17.6, 9.0, CHH-N), 6.82 (1H, s, Ar), 7.24 (1H, s, Ar); δC (free base, 100 MHz, CD3OD) 23.65, 
33.26, 44.04, 47.37, 51.74, 54.80, 55.24, 102.86, 102.90, 104.29, 145.50, 148.96, 154.81, 159.07, 
161.70; Anal. Calcd for C15H29Cl2N5O5: C 41.87, H 6.79, N 16.27, found C 42.12, H 6.65, N 15.94. 
 
(S)-Furan-2-carboxylic acid [1-(4-amino-6,7-dimethoxy-quinazolin-2-yl)-piperidin-3-yl]-amide 
(3) 
 
 
 
 
 
A solution of 2-furoyl chloride (77 mg, 0.59 mmol) in DCM (2 ml) was added dropwise at 0 °C to a 
solution of 1 (178 mg, 0.59 mmol) and NEt3 (69 mg, 0.59 mmol) in DCM (4 ml). The mixture was 
stirred at RT for 2 h. The solvent was evaporated under reduced pressure and the crude was purified 
by flash chromatography (CHCl3-MeOH, 9:1) affording 3 as a white solid (200 mg, 0.50 mmol, 
85%). 3 was then converted into its hydrochloride salt; mp (salt)= 226°C; [α]D20 = +96.54; δH (free 
base, 400 MHz, CDCl3) 1.60-1.66 (1H, m, piperidine ring), 1.72-1.82 (1H, m, piperidine ring), 
1.85-1.95 (2H, m, piperidine ring), 3.69-3.75 (1H, m, piperidine ring), 3.90-3.96 (3H, m, piperidine 
ring), 3.90 (3H, s, OCH3), 3.93 (3H, s, OCH3), 4.16-4.23 (1H, m, piperidine ring), 5.82 (2H, br s, 
NH2), 6.41 (1H, dd, J 3.6, 1.7, Ar), 6.94 (1H, s, Ar), 7.02 (1H, d, J 3.6, Ar), 7.07 (1H, s, Ar), 7.14 
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(1H, d, J 7.1, NH-C=O), 7.28-7.29 (1H, m, Ar); δC (100 MHz, CD3OD) 23.49, 29.49, 45.03, 45.76, 
48.59, 55.79, 55.85, 98.24, 101.13, 103.70, 111.70, 114.38, 135.55, 145.31, 147.12, 147.19, 150.86, 
155.57, 158.95, 161.36.  
 
(R)-Furan-2-carboxylic acid [1-(4-amino-6,7-dimethoxy-quinazolin-2-yl)-piperidin-3-yl]-
amide (4) 
 
 
 
 
 
A solution of 2-furoyl chloride (70 mg, 0.54 mmol) in DCM (2 ml) was added dropwise at 0 °C to a 
solution of 2 (163 mg, 0.54 mmol) and NEt3 (55 mg, 0.54 mmol) in DCM (4 ml). The mixture was 
stirred at RT for 2 h. The solvent was evaporated under reduced pressure and the crude was purified 
by flash chromatography (CHCl3-MeOH, 9:1) affording 4 as a white solid (200 mg, 0.50 mmol, 
85%). 4 was then converted into its hydrochloride salt; mp (salt)= 226°C; ES [M+H+]: 398; [α]D20 = 
-96.87; δH (free base, 400 MHz, CDCl3) 1.58-1.66 (1H, m, piperidine ring), 1.73-1.83 (1H, m, 
piperidine ring), 1.86-1.95 (2H, m, piperidine ring), 3.68-3.75 (1H, m, piperidine ring), 3.91-3.99 
(3H, m, piperidine ring), 3.91 (3H, s, OCH3), 3.94 (3H, s, OCH3), 4.17-4.24 (1H, m, piperidine 
ring), 5.76 (2H, br s, NH2), 6.42 (1H, dd, J 3.5, 2.0, Ar), 6.94 (1H, s, Ar), 7.02 (1H, d, J 3.5, Ar), 
7.06 (1H, s, Ar), 7.14 (1H, d, J 7.0, NH-C=O), 7.29-7.30 (1H, m, Ar); δC (free base, 100 MHz, 
CD3OD) 23.39, 29.41, 44.95, 45.72, 48.58, 55.62, 55.68, 98.22, 101.27, 103.75, 111.61, 114.26, 
135.69, 145.13, 147.28, 151.06, 155.78, 158.97, 161.57. 
 
(S)-2-[1-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperidin-3-ylamino]-[1,4]naphthoquinone 
(5) 
 
 
 
 
 
 
A solution of 1,4-naphthoquinone (88 mg, 0.56 mmol) in EtOH (3 ml) was added dropwise to a 
solution of 1 (171 mg, 0.56 mmol) in EtOH (1 ml). The mixture was stirred at RT for 8 h. The 
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solvent was evaporated under reduced pressure and the crude was purified by flash chromatography 
(CHCl3-MeOH, 9.5:0.5) affording 5 as a red solid (220 mg, 0.48 mmol, 86%). 5 was then converted 
into its hydrochloride salt; mp (salt)> 250° C; ES [M+H+]: 460; [α]D20 = +93.51; δH (free base, 400 
MHz, CDCl3) 1.59-1.70 (1H, m, CHH), 1.74-1.85 (2H, m, CH2), 2.02-2.06 (1H, m, CHH), 3.15 
(1H, dd, J 12.9, 8.2, CHH-N), 3.37-3.47 (2H, m, CHH-N, CH), 3.90 (3H, s, OCH3), 4.00 (3H, s, 
OCH3), 4.32-4.35 (1H, m, CHH-N), 4.61 (1H, d, J 12.9, CHH-N), 5.69 (2H, br s, NH2), 6.14 (1H, d, 
J 7.0, NH-Ar), 6.59 (1H, s, Ar), 6.88 (1H, s, Ar), 7.03 (1H, s, Ar), 7.58 (1H, td, J 7.6, 1.2, Ar), 7.69 
(1H, td, J 7.6, 1.2, Ar), 8.00 (1H, dd, J 7.6, 0.8, Ar), 8.07 (1H, dd, J 7.6, 0.8, Ar); δC (free base, 100 
MHz, CDCl3) 23.48, 29.99, 45.45, 48.30, 48.90, 56.09, 56.16, 101.27, 102.49, 102.91, 105. 93, 
125.91, 126.21, 130.68, 131.89, 133.54, 134.57, 145.88, 147.23, 155.07, 160.93, 181.91, 182.45; 
Anal. Calcd for C25H28ClN5O5: C 58.42, H 5.49, N 13.63, found C 58.46, H 5.29, N 13.21. 
 
(R)-2-[1-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperidin-3-ylamino]-[1,4]naphthoquinone 
(6) 
 
 
 
 
 
 
A solution of naphthoquinone (85 mg, 0.54 mmol) in EtOH (3 ml) was added dropwise to a solution 
of 2 (163 mg, 0.54 mmol) in EtOH (1 ml). The mixture was stirred at RT for 8 h. The solvent was 
evaporated under reduced pressure and the crude was purified by flash chromatography (CHCl3-
MeOH, 9.5:0.5) affording 6 as a red solid (210 mg, 0.46 mmol, 85%). 6 was then converted into its 
hydrochloride salt; mp (salt)> 250°C; [α]D20 = -94.46; δH (free base 400 MHz, CDCl3) 1.59-1.69 
(1H, m, CHH), 1.75-1.84 (2H, m, CH2), 2.02-2.06 (1H, m, CHH), 3.13 (1H, dd, J 12.9, 8.6, CHH-
N), 3.35-3.48 (2H, m, CH, CHH-N), 3.89 (3H, s, OCH3), 4.00 (3H, s, OCH3), 4.32-4.36 (1H, m, 
CHH-N), 4.61 (1H, d, J 12.9, CHH-N), 5.73 (2H, s, NH2), 6.14 (1H, d, J 7.0, NH-Ar), 6.58 (1H, s, 
Ar), 6.88 (1H, s, Ar), 7.04 (1H, s, Ar), 7.58 (1H, td, J 7.7, 1.2, Ar), 7.69 (1H, td 7.7, 1.2, Ar), 8.00 
(1H, dd, J 7.7, 1.0, Ar), 8.07 (1H, dd, J 7.7, 1.0, Ar); δC (free base, 100 MHz, CDCl3) 23.49, 30.00, 
45.50, 48.33, 48.91, 56.10, 56.17, 101.34, 102.49, 102.92, 105.87, 125.93, 126.23, 130.69, 131.90, 
133.55, 134.59, 145.93, 147.24, 155,10, 160.97, 181.89, 183.48.  
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(R, S)-2,3-Dihydro-benzo[1,4]dioxine-2-carboxylic acid [1-(4-amino-6,7-dimethoxy-
quinazolin-2-yl)-piperidin-3-yl]-amide (7) 
 
 
 
 
 
 
A solution of 16 (41 mg, 0.21 mmol) in DCM (2 ml) was added dropwise at 0 °C to a solution of 1 
(63 mg, 0.21 mmol) and NEt3 (21 mg, 0.21 mmol) in DCM (2 ml). The mixture was stirred at RT 
for 2 h. The solvent was evaporated under reduced pressure and the crude was purified by flash 
chromatography (CHCl3-MeOH, 9.5:0.5) affording 7 as a white solid (98 mg, 0.21 mmol, 100%). 7 
was then converted into its hydrochloride salt; mp (salt)= 223°C; [α]D20 = +89.71; δH (free base, 400 
MHz, CDCl3) 1.59-1.65 (1H, m, piperidine ring), 1.71-1.81 (1H, m, piperidine ring), 1.83-1.91 (2H, 
m, piperidine ring), 3.63-3.70 (1H, m, piperidine ring), 3.81 (3H, s, OCH3), 3.89 (3H, s, OCH3), 
3.91-3.99 (3H, m, piperidine ring), 4.04-4.09 (1H, m, piperidine ring), 4.09 (1H, dd, J 11.3, 7.8, 
CHH-O), 4.52 (1H, dd, J 11.3, 2.7, CHH-O), 4.58 (1H, dd, J 7.8, 2.7, CH-C=O), 5.66 (2H, br s, 
NH2), 6.52 (1H, d, J 8.2, Ar), 6.67 (1H, td, J 8.2, 1.6, Ar), 6.76 (1H, td, J 8.2, 1.6, Ar), 6.81 (1H, dd, 
J 8.2, 1.6, Ar), 6.84 (1H, s, Ar), 6.97 (1H, s, Ar), 7.17 (1H, d, J 7.0, NH-C=O); δC (free base, 100 
MHz, CDCl3) 22.26, 29.71, 44.66, 46,14, 48.30, 55.88, 56.11, 65.58, 73.09, 101.69, 102.87, 105.61, 
117.10, 117.28, 121.63, 122.21, 141.41, 142.96, 145.81, 154.98, 160.87, 166.76. 
 
(S, S)-2,3-Dihydro-benzo[1,4]dioxine-2-carboxylic acid [1-(4-amino-6,7-dimethoxy-quinazolin-
2-yl)-piperidin-3-yl]-amide (8) 
 
 
 
 
 
 
A solution of 15 (40 mg, 0.20 mmol) in DCM (2 ml) was added dropwise at 0 °C to a solution of 1 
(61 mg, 0.20 mmol) and NEt3 (20 mg, 0.20 mmol) in DCM (2 ml). The mixture was stirred at RT 
for 2 h. The solvent was evaporated under reduced pressure and the crude was purified by flash 
chromatography (CHCl3-MeOH, 9.5:0.5) affording 8 as a white solid (51 mg, 0.11 mmol, 55%). 8 
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was then converted into its hydrochloride salt; mp (salt)= 221°C; [α]D20 = +20.46; δH (free base, 400 
MHz, CDCl3) 1.46-1.53 (2H, m, piperidine ring), 1.77-1.81 (2H, m, piperidine ring), 3.55-3.61 (1H, 
m, piperidine ring), 3.78 (1H, dd, J 12.9, 2.7, piperidine ring), 3.93 (3H, s, OCH3), 3.97 (3H, s, 
OCH3), 3.97-4.07 (3H, m, piperidine ring), 4.23 (1H, dd, J 11.3, 6.7, CHH-O), 4.42 (1H, dd, J 11.3, 
2.7, CHH-O), 4.64 (1H, dd J 6.7, 2.7, CH-C=O), 5.57 (2H, br s, NH2), 6.44 (1H, d, J 8.2, 1.2, Ar), 
6.63 (1H, ddd, J 8.2, 7.0, 2.0), 6.79 (1H, td, J 7.0, 1.2, Ar), 6.84 (1H, dd, J 8.2, 2.0), 6.94 (1H, s, 
Ar), 6.96 (1H, s, Ar), 7.0 (1H, d, J 7.0, NH-C=O); δC (free base, 100 MHz, CDCl3) 21.90, 29.72, 
44.63, 46.13, 48.12, 56.07, 56.18, 65.22, 73.19, 101.60, 102.88, 105.62, 116.90, 117.38, 121.67, 
122.18, 141.39, 143.17, 145.87, 155.13, 160.78, 166.89. 
 
(S, R)-2,3-Dihydro-benzo[1,4]dioxine-2-carboxylic acid [1-(4-amino-6,7-dimethoxy-
quinazolin-2-yl)-piperidin-3-yl]-amide (9) 
 
 
 
 
 
 
A solution of 15 (40 mg, 0.20 mmol) in DCM (2 ml) was added dropwise at 0 °C to a solution of 2 
(61 mg, 0.20 mmol) and NEt3 (20 mg, 0.20 mmol) in DCM (2 ml). The mixture was stirred at RT 
for 2 h. The solvent was evaporated under reduced pressure and the crude was purified by flash 
chromatography (CHCl3-MeOH, 9.5:0.5) affording 9 as a white solid (87 mg, 0.19 mmol, 95%). 9 
was then converted into its hydrochloride salt; mp (salt)= 223 °C; ES [M+H+]: 466; [α]D20 = -89.68; 
δH (free base, 400 MHz, CDCl3) 1.60-1.65 (1H, m, piperidine ring), 1.73-1.81 (1H, m, piperidine 
ring), 1.87-1.92 (2H, m, piperidine ring), 3.62-3.68 (1H, m, piperidine ring), 3.77 (1H, d, J 12.9, 
piperidine ring), 3.83 (3H, s, OCH3), 3.91 (3H, s, OCH3), 3.95 (1H, dd, J 12.9, 4.7, piperidine ring), 
4.01-4.06 (1H, m, piperidine ring), 4.07-4.10 (1H, m, piperidine ring), 4.10 (1H, dd, J 11.3, 7.8, 
CHH-O), 4.54 (1H, dd, J 2.7, 11.3, CHH-O), 4.59 (1H, dd, J 7.8, 2.7, CH-C=O), 5.53 (2H, br s, 
NH2), 6.51 (1H, d, J 7.8, Ar), 6.68 (1H, td, J 7.8, 1.6, Ar), 6.77 (1H, t, J 7.8, Ar), 6.83 (1H, dd, J 7.8, 
1.6, Ar), 6.85 (1H, br s, Ar), 6.93 (1H, s, Ar), 7.18 (1H, d, J 7.0, NH-C=O); δC (free base, 100 MHz, 
CDCl3) 22.20, 29.68, 44.72, 46.12, 48.28, 55.91, 56.13, 65.61, 73.08, 101.56, 102.81, 105.62, 
117.11, 117.28, 121.62, 122.20, 141.42, 142.98, 145.85, 155.04, 160.78, 166.71. 
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(R,R)-2,3-Dihydro-benzo[1,4]dioxine-2-carboxylic acid [1-(4-amino-6,7-dimethoxy-
quinazolin-2-yl)-piperidin-3-yl]-amide (10) 
 
 
 
 
 
 
A solution of 16 (46 mg, 0.23 mmol) in DCM (2 ml) was added dropwise at 0 °C to a solution of 2 
(70 mg, 0.23 mmol) and NEt3 (23 mg, 0.23 mmol) in DCM (2 ml). The mixture was stirred at RT 
for 2 h. The solvent was evaporated under reduced pressure and the crude was purified by flash 
chromatography (CHCl3-MeOH, 9.5:0.5) affording 10 as a white solid (89 mg, 0.19 mmol, 83%). 
10 was then converted into its hydrochloride salt; mp (salt)= 221 °C; [α]D20 = -20.66; δH (free base, 
400 MHz, CDCl3) 1.43-1.49 (2H, m, piperidine ring), 1.75-1.79 (2H, m, piperidine ring), 3.54-3.60 
(1H, m, piperidine ring), 3.80 (1H, dd, J 12.9, 2.7, piperidine ring), 3.91 (3H, s, OCH3), 3.91-3.95 
(1H, m, piperidine ring) 3.95 (3H, s, OCH3), 4.01 (1H, dd, J 13.3, 5.9, piperidine ring), 4.05-4.10 
(1H, m, piperidine ring), 4.22 (1H, dd, J 11.3, 6.4, CHH-O), 4.42 (1H, dd, J 11.3, 2.7, CHH-O),), 
4.63 (1H, dd, J 6.4, 2.7, CH-C=O), 5.60 (2H, br s, NH2), 6.44 (1H, dd, J 8.2, 1.2, Ar), 6.63 (1H, td J 
8.2, 2.0, Ar), 6.79 (1H, td, J 7.0, 1.2, Ar), 6.83 (1H, dd, J 8.2, 2.0, Ar), 6.96 (2H, s, Ar), 7.03 (1H, d, 
J 7.0, NH-C=O); δC (free base, 100 MHz, CDCl3) 21.90, 29.72, 44.62, 46.14, 48.12, 56.07, 56.17, 
65.21, 73.19, 101.65, 102.90, 105.59, 116.90, 117.38, 121.68, 122.18, 141.38, 143.16, 145.86, 
155.13, 160. 
 
(S)-[4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperazin-1-yl]-(2,3-dihydro-
benzo[1,4]dioxin-2-yl)-methanone (11) 
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A solution of 15 (58 mg, 0.29 mmol) in DCM (2 ml) was added dropwise at 0 °C to a solution of 17 
(84 mg, 0.29 mmol) and NEt3 (29 mg, 0.29 mmol) in DCM (2 ml). The mixture was stirred at RT 
for 2 h. The solvent was evaporated under reduced pressure and the crude was purified by flash 
chromatography (CHCl3-MeOH, 9.5:0.5) affording 11 as a white solid (131 mg, 0.29 mmol, 100%). 
11 was then converted into its hydrochloride salt; mp (salt)= 228°C; ES [M+H+]: 452; [α]D20 = 
+90.91; δH (free base, 400 MHz, CDCl3) 3.55-3.65 (2H, m, piperazine ring), 3.72-3.77 (1H, m, 
piperazine ring), 3.86-3.89 (3H, m, piperazine ring), 3.92 (3H, s, OCH3), 3.97 (3H, s, OCH3), 4.02-
4.09 (2H, m, piperazine ring), 4.36 (1H, dd, J 11.7, 8, CHH-O), 4.52 (1H, dd, J 11.7, 1.8, CHH-O), 
4.88 (1H, dd, J 8, 1.8, CH-C=O), 5.33 (2H, br s, NH2), 6.86-6.95 (6H, m, Ar); δC (free base, 100 
MHz, CDCl3) 42.23, 43.79, 44.40, 45.84, 56.08, 56.14, 65.19, 70.67, 101.31, 102.92, 105.65, 
117.29, 117.37, 121.53, 122.24, 142.50, 143.27, 146.07, 155.22, 160.63, 165.08. 
 
(R)-[4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperazin-1-yl]-(2,3-dihydro-
benzo[1,4]dioxin-2-yl)-methanone (12) 
 
 
 
 
 
 
 
 
A solution of 16 (66 mg, 0.33 mmol) in DCM (2 ml) was added dropwise at 0 °C to a solution of 17 
(95 mg, 0.33 mmol) and NEt3 (33 mg, 0.33 mmol) in DCM (2 ml). The mixture was stirred at RT 
for 2 h. The solvent was evaporated under reduced pressure and the crude was purified by flash 
chromatography (CHCl3-MeOH, 9.5:0.5) affording 12 as a white solid (149 mg, 0.33 mmol, 100%). 
12 was then converted into its hydrochloride salt; mp (salt)= 228°C; [α]D20 = -90.30; δH (free base, 
400 MHz, CDCl3) 3.56-3.65 (2H, m, piperazine ring), 3.71-3.79 (1H, m, piperazine ring), 3.86-3.91 
(3H, m, piperazine ring), 3.93 (3H, s, OCH3), 3.97 (3H, s, OCH3), 4.03-4.10 (2H, m, piperazine 
ring), 4.36 (1H, dd, J 11.7, 8, CHH-O), 4.52 (1H, dd, J 11.7, 2.3, CHH-O), 4.89 (1H, dd, J 8, 2.3, 
CH-C=O), 5.38 (2H, br s, NH2), 6.84-6.94 (6H, m, Ar); δC (free base, 100 MHz, CDCl3) 42.25, 
43.79, 44.43, 45.84, 56.11, 56.15, 65.17, 70.67, 101.41, 102.93, 105.61, 117.29, 117.37, 121.55, 
122.24, 142.48, 143.26, 146.06, 155. 20, 160.67, 165.10. 
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(S)-[1-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperidin-3-yl]-carbamic acid tert-butyl ester 
(13) 
 
 
 
 
 
4-Amino-2-chloro-6,7-dimethoxyquinazoline (600 mg, 2.5 mmol) and (S)-3-(Boc-amino)piperidine 
(1 g, 5 mmol) were dissolved in isoamylic alcohol (20 ml). The mixture was stirred under 
microwave irradiation at 130 °C for 50 min. After evaporating the solvent under reduced pressure, 
the crude was purified by flash chromatography (petrol-EtOAc-CHCl3-MeOH, 3:2:4:1) affording 
13 as a white solid (1 g, 2.5 mmol, 100%); δH (400 MHz, CDCl3) 1.26 (9H, s, OtBu), 1.36-1.38 
(2H, m, piperidine ring), 1.52-1.58 (1H, m, piperidine ring), 1.67-1.72 (1H, m, piperidine ring), 
3.23-3.32 (2H, m, piperidine ring), 3.54-3.57 (1H, br m, piperidine ring), 3.61 (3H, s, OCH3), 3.69 
(3H, s, OCH3), 3.80-3.84 (1H, m, piperidine ring), 4.00-4.03 (1H, br m, piperidine ring), 5.09 (1H, 
br s, NH-C=O), 6.15 (2H, s, NH2), 6.76 (1H, s, Ar), 7.00 (1H, s, Ar); δC (100 MHz, CDCl3) 22.74, 
28.20, 30.47, 44.15, 46.62, 49.08, 55.54, 55.70, 78.90, 102.34, 102.90, 105.03, 145.27, 148.93, 
154.50, 155.33, 158.69, 160.99.  
 
(R)-[1-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperidin-3-yl]-carbamic acid tert-butyl ester 
(14) 
 
 
 
 
 
4-Amino-2-chloro-6,7-dimethoxyquinazoline (600 mg, 2.5 mmol) and (R)-3-(Boc-amino)piperidine 
(1 g, 5 mmol) were dissolved in isoamylic alcohol (20 ml). The mixture was stirred under 
microwave irradiation at 130 °C for 50 min. After evaporating the solvent under reduced pressure, 
the crude was purified by flash chromatography (petrol-EtOAc-CHCl3-MeOH, 3:2:4:1) affording 
14 as a white solid (1 g, 2.5 mmol, 100%); δH (400 MHz, CDCl3) 1.41 (9H, s, OtBu), 1.56-1.63 
(2H, m, piperidine ring), 1.70-1.77 (1H, m, piperidine ring), 1.84-1.89 (1H, m, piperidine ring), 
3.53 (1H, dd, J 12.7, 6.8, piperidine ring), 3.63-3.73 (2H, m, piperidine ring), 3.83 (1H, dd, J 7.0, 
2.7, piperidine ring), 3.87 (3H, s, OCH3), 3.92 (3H, s, OCH3), 4.02 (1H dd, J 12.8, 2.7, piperidine 
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ring), 4.91 (1H, d, J 6.7, NH-C=O), 5.69 (2H, s, NH2), 6.91 (1H, s, Ar), 6.95 (1H, s, Ar); δC (100 
MHz, CDCl3) 22.67, 28.41, 30.61, 44.40, 46.70, 49.21, 55.96, 56.10, 79.21, 101.83, 102.91, 105.47, 
145.66, 154.93, 155.38, 158.88, 160.80 
 
(S)-2,3-Dihydro-benzo[1,4]dioxine-2-carbonyl chloride (15) 
O
O
O
Cl
 
Thionyl dichloride (256 mg, 2.15 mmol) was added dropwise at 0 °C to a solution of (S)-2,3-
dihydro-benzo[1,4]dioxine-2-carboxylic acid (97 mg, 0.54 mmol) in toluene (2 ml). The mixture 
was stirred at reflux for 4 h. The solvent was then evaporated to dryness affording 15 as a yellow oil 
(107 mg, 0.54 mmol, 100%); δH (400 MHz, CDCl3) 4.35 (1H, dd, J 11.8, 2.7, CHH-O), 4.75 (1H, 
dd, J 11.8, 2.7, CHH-O), 5.10 (1H, t, J 2.7, CH-C=O), 6.91-6.98 (3H, m, Ar), 7.02-7.04 (1H, m, 
Ar); δC (100 MHz, CDCl3) 63.77, 78.58, 117.27, 117.58, 122.47, 122.74, 141.39, 142.82, 170.26.  
 
(R)-2,3-Dihydro-benzo[1,4]dioxine-2-carbonyl chloride (16) 
 
 
 
Thionyl dichloride (400 mg, 3.36 mmol) was added dropwise at 0 °C to a solution of (R)-2,3-
dihydro-benzo[1,4]dioxine-2-carboxylic acid (202 mg, 1.12 mmol) in toluene (4 ml). The mixture 
was stirred at reflux for 4 h. The solvent was then evaporated to dryness affording 16 as a yellow oil 
(222 mg, 1.12 mmol, 100%); δH (200 MHz, CDCl3) 4.34 (1H, dd, J 12.0, 2.8, CHH-O), 4.76 (1H, 
dd, J 12.0, 2.8, CHH-O), 5.10 (1H, t, 2.8, CH-C=O), 6.93-7.09 (4H, m, Ar); δC (50 MHz, CDCl3) 
63.87, 78.70, 117.40, 117.72, 122.61, 122.89, 142.54, 142.99, 170.44.  
 
6,7-Dimethoxy-2-piperazin-1-yl-quinazolin-4-ylamine (17) 
 
 
 
 
 
4-Amino-2-chloro-6,7-dimethoxyquinazoline (300 mg, 1.25 mmol) and piperazine (646 mg, 7.5 
mmol) were dissolved in isoamylic alcohol (10 ml). The mixture was stirred under microwave 
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irradiation at 130 °C for 50 min. After evaporating the solvent under reduced pressure, the crude 
was purified by flash chromatography (DCM-MeOH-aqueous 33% ammonia, 8:2:0.1) affording 17 
as a pale yellow solid (320 g, 1.1 mmol, 88%); δH (400 MHz, CDCl3) 2.95 (4H, t, J 4.9, piperazine 
ring), 3.92 (4H, t, J 4.9, piperazine ring), 3.93 (3H, s, OCH3), 3.97 (3H, s, OCH3), 5.12 (2H, br s, 
NH2), 6.79 (1H, s, Ar), 6.92 (1H, s, Ar). 
 
6.2 Biology 
A Radioligand Binding Assays 
Binding to cloned human α1-AR subtypes was performed in membranes from CHO cells 
transfected by electroporation with DNA expressing the gene encoding each α1-AR subtype. 
Cloning and stable expression of the human α1-AR gene was performed as previously described.595 
CHO cell membranes (30 µg proteins) were incubated in 50 mM Tris-HCl (pH 7.4) with 0.2 nM 
[3H]prazosin, in a final volume of 1.02 ml for 30 min at 25 °C, in absence or presence of competing 
drugs (1 pM to10 µM). Non-specific binding was determined in the presence of 10 µM 
phentolamine. The incubation was stopped by addition of ice-cold Tris-HCl buffer and rapid 
filtration through 0.2% polyethylenimine pretreated Whatman GF/B or Schleicher & Schuell GF52 
filters. Binding data were analyzed using the non-linear curve-fitting program Allfit.596 Equilibrium 
inhibition constants (Ki) were derived from the Cheng–Prusoff equation,594 Ki = IC50/(1 + L/Kd), 
where L and Kd are the concentration and the equilibrium dissociation constant of the radioligand. 
pKi values are the mean ± SE of 2-3 separate experiments performed in triplicate. 
 
B Antiproliferative activity  
The human tumor cell lines of the cancer screening panel are grown in RPMI 1640 medium 
containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical screening experiment, cells 
are inoculated into 96 well microtiter plates in 100 µl at plating densities ranging from 5000 to 
40000 cells/well depending on the doubling time of individual cell lines. After cell inoculation, the 
microtiter plates are incubated at 37° C, 5% CO2, 95% air and 100% relative humidity for 24 h 
prior to addition of experimental drugs. After 24 h, two plates of each cell line are fixed in situ with 
TCA, to represent a measurement of the cell population for each cell line at the time of drug 
addition (Tz). Experimental drugs are solubilized in dimethyl sulfoxide at 400-fold the desired final 
maximum test concentration and stored frozen prior to use. At the time of drug addition, an aliquot 
of frozen concentrate is thawed and diluted to twice the desired final maximum test concentration 
with complete medium containing 50 µg/ml gentamicin. Additional four, 10-fold or ½ log serial 
dilutions are made to provide a total of five drug concentrations plus control. Aliquots of 100 µl of 
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these different drug dilutions are added to the appropriate microtiter wells already containing 100 µl 
of medium, resulting in the required final drug concentrations.  
Following drug addition, the plates are incubated for an additional 48 h at 37°C, 5% CO2, 95% air, 
and 100% relative humidity. For adherent cells, the assay is terminated by the addition of cold 
TCA. Cells are fixed in situ by the gentle addition of 50 µl of cold 50% (w/v) TCA (final 
concentration, 10% TCA) and incubated for 60 min at 4°C. The supernatant is discarded, and the 
plates are washed five times with tap water and air dried. Sulforhodamine B (SRB) solution (100 
µl) at 0.4% (w/v) in 1% acetic acid is added to each well, and plates are incubated for 10 min at RT. 
After staining, unbound dye is removed by washing five times with 1% acetic acid and the plates 
are air dried. Bound stain is subsequently solubilized with 10 mM trizma base, and the absorbance 
is read on an automated plate reader at a wavelength of 515 nm. For suspension cells, the 
methodology is the same except that the assay is terminated by fixing settled cells at the bottom of 
the wells by gently adding 50 µl of 80% TCA (final concentration, 16% TCA). Using the seven 
absorbance measurements [time zero, (Tz), control growth, (C), and test growth in the presence of 
drug at the five concentration levels (Ti)], the percentage growth is calculated at each of the drug 
concentrations levels. Percentage growth inhibition is calculated as:  
 
[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti>/=Tz  
[(Ti-Tz)/Tz] x 100 for concentrations for which Ti<Tz.  
 
Three dose response parameters are calculated for each experimental agent. Growth inhibition of 
50% (GI50) is calculated from [(Ti-Tz)/(C-Tz)] x 100= 50, which is the drug concentration 
resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control 
cells during the drug incubation. The drug concentration resulting in total growth inhibition (TGI) is 
calculated from Ti= Tz. The LC50 (concentration of drug resulting in a 50% reduction in the 
measured protein at the end of the drug treatment as compared to that at the beginning) indicating a 
net loss of cells following treatment is calculated from [(Ti-Tz)/Tz] x 100= -50. Values are 
calculated for each of these three parameters if the level of activity is reached; however, if the effect 
is not reached or is exceeded, the value for that parameter is expressed as greater or less than the 
maximum or minimum concentration tested.  
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DEVELOPMENT OF NEW ISOCYANIDE-BASED 
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1 Introduction 
Multicomponent reactions (MCRs) are defined as reaction in which three or more components 
condense to give a single product.597 They are highly atom efficient methods in which relatively 
complex molecules can be obtained in a one-pot reaction from simple starting materials. Thus, they 
exemplify many of the desired features of an “ideal synthesis”. They are a very useful tool for the 
generation of compound libraries for drug discovery. 
 
1.1 History of MCRs 
Despite having received much attention over the last few decades, isocyanide-based multi-
component reactions (IMCRs) have a long history which dates back to the publication of the 
Passerini three-component reaction (P-3CR) in 1921.598, 599 
The P-3CR involves the condensation of an aldehyde, an isocyanide and a carboxylic acid to give 
highly functionalized α-carboxyamide (Scheme 1). 
 
 
 
 
Scheme 1 
 
This reaction exploits the ambiphilic nature of the isocyanide moiety, which is able to act as both a 
nucleophile and an electrophile sequentially at the same carbon atom.  
The isocyanide inserts into the acid-activated aldehyde a to give nitrilium ion b. which is in turn 
attacked by the resultant carboxylate. An O-O’ acyl transfer then takes place leading the final 
product c (Scheme 2). 
 
 
 
 
Scheme 2 
 
Sample et al.600 recently put this reaction to excellent use in the total synthesis of eurystatin A 
(Scheme 3). A P-3CR reaction led to the intermediate a in good yield (75%), which was then 
elaborated in just six steps to give the natural product. 
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Scheme 3 
 
The Strecker synthesis of α-aminoacids via α-amino-cyanide was first published in 1850 and it is 
generally considered to be the first MCR.601 Strecker reaction involves the reaction between an 
aldehyde, ammonia and potassium cyanide to give an α-amino-cyanide a which is subsequently 
hydrolyzed to give the amino-acid b (Scheme 4). 
 
 
 
Scheme 4 
 
Robinson’s synthesis of the alkaloid Tropinone (Scheme 5) from succinic dialdehyde a, 
methylamine b and acetonedicarboxylic acid c, carried out in 1917, is the first important application 
of MCRs in natural product synthesis.602  
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Scheme 5 
 
The mechanism603 starts with the formation of an imine a between methylamine and succinaldehyde 
(Scheme 6). Then intramolecular addition of the imine to the second aldehyde unit and ring closure 
leads to the intermediate b. Intermolecular Mannich reaction between b and the enolate of 
acetonedicarboxylic acid gives c, which, following loss of water, affords d. Second Mannich 
reaction between the imine function and the enolate of acetonedicarboxylic acid of d, followed by 
ring closure, gives e, which is converted into Tropinone by warming. 
 
 
 
 
 
 
 
 
 
 
Scheme 6 
 
Many important heterocycle syntheses are MCRs. 1,4-Dihydropyridines such as Nifedipin (an 
antihypertensive) were first synthesized in a four-component reaction by Hantzsch (H-4CR),604 
from ammonia, aldehyde a, and two molecules of acetoacetic ester b (Scheme 7) in 1882. 
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Scheme 7 
 
The mechanism of the H-4CR is shown in Scheme 8. The reaction starts with a Knoevenagel 
condensation between the aldehyde and the first molecule of acetoacetic ester leading to a. A 
second key intermediate is the ester enamine b, which is produced by condensation of the second 
equivalent of the β-ketoester with ammonia. Further condensation between these two molecules 
gives the dihydropyridine derivative c. 
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Scheme 8 
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Later in 1890, Hantzsch discovered the synthesis of substituted pyrroles d from β-ketoesters a, α-
haloketones b and primary amines c (Scheme 9). 
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Scheme 9 
 
A further important MCR is the Bucherer-Bergs reaction (BB-4CR)605 discovered in 1941. It can be 
understood as an extension of the Strecker reaction by one component (CO2). The BB-4CR allows 
the synthesis of hydantoins from a ketone, potassium cyanide and ammonium carbonate (Scheme 
10). Whereas the Strecker three-component reaction is an equilibrium reaction and often delivers 
the products in unsatisfactory yields, the BB-4CR is practically irreversible upon addition of CO2. It 
still is an important method for the synthesis of unnatural α-amino acids. 
R R1
O
+ (NH4)2CO3 + KCN HN
H
NO
O
R
R1
 
Scheme 10 
 
Since its discovery in the late 1950s,606, 607 the Ugi four-component reaction (U-4CR) has become 
one of the most important and widely used of all MCRs.608, 609 
As with the P-3CR, the U-4CR also employs the unique reactivity of isocyanides in their 
condensation with an aldehyde, a primary amine and a carboxylic acid (Scheme 11). 
 
 
Scheme 11 
 
Imine a, formed upon condensation of the primary amine and aldehyde, is protonated by the 
carboxylic acid and attacked by the isocyanide to give nitrilium ion b. Attack by the carboxylate 
followed by Mumm rearrangement610 (O-N acyl transfer) then gives the α-amidoamide product c 
(Scheme 12). 
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Scheme 12 
 
Since its discovery, the reaction has been studied extensively and has seen a great number of 
extensions and developments. Several modifications of U-4CR have been described. These 
modifications involve the variation of one of the components or the introduction of a linkage 
between two of them, which leads to interesting potentially drug-like derivatives of the original α- 
acylamino amide product.611, 612, 613 
Giovenzana recently reported a modified U-4CR,614 which involves the use of bis-secondary 
diamines as mimics for the primary amine. The bis-diamine splits the N-alkylation and N-acylation 
steps between two different nitrogen atoms, giving even more highly functionalized products in 
excellent yield (Scheme 13). 
 
 
 
 
 
 
 
 
 
 
Scheme 13 
 
The synthetic utility of this reaction was elegantly demonstrated in the one step synthesis of 
vasodilator b from piperazine a (Scheme 14 ). This route is both higher yielding than the previous 
synthesis,615 as well as being far more atom efficient, clearly proving this to be a powerful synthetic 
transformation.  
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Scheme 14 
 
In the same year, Motherwell616 reported the IMCRs of oxazolidines with carboxylic acids to give 
ethanolamine derivative (Scheme 15). 
 
 
 
 
 
Reaction conditions: a) TsOH (10%), MeCN, 18-24 h reflux. 
Scheme 15 
 
The acid-catalyzed ring opening of the oxazolidine a (readily formed from an aminoalcohol and a 
carbonyl compound) gives the iminium species b, which is attacked by isocyanide to give nitrilium 
ion c (Scheme 16). Two plausible mechanisms can be envisaged from this intermediate. The 
carboxylic acid could form the α-adduct and undergo the acyl migration to the desired product e 
(path a). Alternatively, the hydroxyl group could trap the nitrilium ion and form the six-membered 
intermediate d, which could be attacked by the carboxylic acid at the β-carbon and form the same 
multicomponent product e (path b). 18O-labelled acetic acid later confirmed that the reaction does 
indeed proceed via path a.617 The intermediate d could be trapped with various nucleophiles as 
shown in Scheme 17. Indeed SN2 reactions at the β-carbon were found to work with 5-phenyl-1H-
tetrazole, thiobenzoic acid and thiophenol, forming new C-S and C-N bonds while increasing the 
complexity of the final product. 
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Scheme 17 
 
Moreover combining the aldehyde and carboxylic acid components in bifunctional substrates a and 
b allowed the synthesis of eight, nine and ten-membered lactones (Scheme 18).618 Sheppard and co-
workers optimized reaction conditions in microwave, reducing reaction times and increasing the 
yield. 
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Scheme 18 
 
In 2007, the use of aminoboranes as an “iminium ion” generators was reported for Ugi-type 
reactions for secondary amines, aldehydes and isocyanides without a carboxylic acid component.619 
One of the possible mechanisms is shown in Scheme 19. The aminoborane b is generated from the 
free amine and a. The intermediate b then reacts with the aldehyde through nucleophilic attack of 
its amino group to the carbonyl group and the subsequent B-O formation giving the intermediate c. 
The cleavage of the C-O bond in c leads to the formation of the iminium ion d which reacts with the 
isocyanide, giving the Ugi-product f through e. More recently, the same properties were described 
for the cheap and readily available trimethoxyborane.620 
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Scheme 19 
 
An interesting application of MCRs is in the one-pot three-component regioselective synthesis of 
linear naphtho[2,3-b]-furan-4,9-diones.621 Among the class of heterocyclic quinones, 
naphthofuroquinones have attracted a big interest because of their presence in natural products, and 
for their pharmacological activities. A great number of naphthofuroquinones are natural products 
exhibiting a broad spectrum of biological activity. For example, some naphthofuroquinone 
derivatives as avicequinones622 and maturinones623 have shown a diversity of biological activities of 
medical importance, such as anticancer, antibacterial, and anti-inflammatory activities.624 
The one-pot three-component condensation reactions (Scheme 20) of 2-hydroxy-1,4-
naphthoquinone a with various aldehydes b in the presence of alkyl isocyanides c proceeded rapidly 
in refluxing toluene and were complete after 4 h to afford 2-(alkylamino)-3-alkyl or 
arylnaphtho[2,3-b]furan-4,9-diones d in good yields. 
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Although the mechanism of this reaction have not been established, the authors suggested that  
the synthesis of naphtho[2,3-b]-furan-4,9-dione derivatives d, can be rationalized by initial 
formation of a conjugated electron-deficient enone a’ (Scheme 21) by a Knoevenagel condensation 
of the cyclic 2-hydroxy-1,4-naphthoquinone a and the aldehyde b. The next step of this mechanism 
could involve a [4+1] cycloaddition reaction of the electron-deficient heterodyne moiety of adduct 
a’ with the isocyanide to afford an iminolactone intermediate b’. The subsequent isomerization of 
iminolactone b’ leads to formation of product d. 
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Scheme 21 
 
Moreover, Nair et al.625 reported a novel synthesis of iminolactones based on the reaction between 
cyclohexyl isocyanide and dimethyl acetylenedicarboxylate with o- and p-quinones (Scheme 22). 
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Scheme 22 
 
In Scheme 22 the reaction with 2,5-dimethyl p-benzoquinone is shown but, similar reactivity was 
also observed with 1,2-benzoquinones and with a large number of other quinones. The formation of 
the product can be rationalized as shown in Scheme 23 . 
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1.2 Isocyanides 
Isocyanides, formerly known as isonitriles, are compounds with an extraordinary functional group. 
The chemistry of isocyanides is characterized by three properties: α-acidity, α-addition and the easy 
formation of radicals. 
A Formation of radicals 
Isocyanides and in particular phenyl isocyanide are substrates for radical-induced cyclization. A 
famous example is the synthesis of the ABCD ring moiety of the topoisomerase II inhibitor 
campothecin by Curran et al. (Scheme 24).626  
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Scheme 24 
 
B α-Acidity 
The α-acidity is increased by electron-withdrawing substituents in the α-position like carboxylic 
esters, nitriles, phosphonic esters or sulfonyl groups. This property is displayed by R-substituted 
tosylmethyl isocyanides (TOSMIC) used in the van Leusen multicomponent reaction (vL-3CR).627 
TOSMIC (Fig. 1) represents a densely functionalized building block with three important groups 
contributing to a multitude of reactions: the isocyano function undergoes typical α-addition 
reactions, the acidic α-carbon atom, and the sulphonyl group in the α-position that has two 
functions, acting both as a sulphinyl leaving group and further enhancing the acidity of the α-
carbon. 
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Figure 1: TOSMIC structure. 
 
The vL-3CR constitutes an important application of isocyanides in MCR to obtain 1,4,5-
trisubstituted imidazoles which are otherwise not easily accessible. It is a reaction between an 
aldehyde, a primary amine and TOSMIC. The mechanism shown in Scheme 25 involves the 
nucleophilic attack of the α-acidic carbon of TOSMIC to a Schiff base followed by cyclization with 
loss of tosylsulphinic acid.  
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Scheme 25 
 
C α-Addition 
The synthetically most important property of isocyanides is the reaction with nucleophile and 
electrophile at the isocyanide carbon. In fact, they have two resonance structures a and b (Scheme 
26), and their characteristic IR absorption at ca. 2000 cm-1 indicates that b resonance structure gives 
more contribution. 
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In the isocyanide group both N and C atoms assume sp hybrid states as shown in Figure 2. 
 
Figure 2: Hybrid states of isocyanide. 
 
One of the hybrid orbitals of nitrogen is used to form a sigma bond with the hydrocarbon part while 
the other hybrid orbital is used to form an sp-sp σ bond with the C atom. One of the unhybridised p 
orbitals of the N atom forms a ppi-ppi bond with a similar orbital on the C atom. The other 
unhybridised p orbital of the nitrogen atom, containing a lone pair of electrons, overlaps with an 
empty p-orbital on the carbon atom to form another pi-bond as shown in Figure 3. 
 
 
Figure 3: Orbital structure of R-NC. 
 
Isocyanides undergo hydrolysis in acid medium to form formic acid and primary amines (Scheme 
27). 
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The present work was carried out using tert-butyl-isocyanide (tBu N=C) because it is a readily 
available and highly nucleophilic isocyanide as shown in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Comparison of the nucleophilicities of isocyanides and other C nucleophiles.628 
 
Hundreds of isocyano group containing natural products were isolated, mainly from marine species. 
Moreover, many natural isocyanides show a strong antibiotic, fungicidal, or antineoplastic effect.629 
Examples of bioactive natural products that contain an isocyano group are shown in Figure 5. 
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Figure 5: Examples of naturally occurring isocyanides: a) the antibiotic xanthocillin, b) leptocillin 
from Penicillium chrysogenum, c) the antimalarial kalihinol A from Pseudomonas sp., d) 
isocyanopupukean from Pyrenochaeta spaeropsidales, d) acenthellin-1 from Chromobacterium 
spec. 
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1.3 MCRs in Drug Discovery 
By far, most applications of IMCRs described until today arise from the area of drug discovery. 
Potentially, the ease of performance, the time-saving aspect, the versatility and diversity of 
scaffolds, and the very large chemical space will attract chemists in pharmaceutical companies to 
use MCRs for their projects. Another interesting aspect of MCRs in the context of drug discovery is 
the effective assembly of scaffolds out of smaller fragments. The following overview describes 
examples of MCRs used in drug discovery, taken from recent patent and journal literature. 
 
1.3.1 Tubulin Inhibitors 
Potent, orally available tubulin inhibitors have potential applications in cancer therapy. The 
imidazole MCR of van Leussen was used for this purpose.630 Herein, R-substituted TOSMIC a 
reacts with primary amines b and aldehydes c to form 1,4,5-trisubstituted imidazoles d and e 
(Scheme 28). Thus, d and e show IC50 values of 170 and 32 nM in the cancer cell line NCI-H460 
and oral bioavailabilities of 82 and 36%, respectively. Moreover, mice xenograft models revealed 
that both have remarkable oral efficacy against the solid murine M5076 reticulum sarcoma cell line. 
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Scheme 28 
 
1.3.2 Phosphatase Inhibitors 
Morphochem workers used the Groebcke MCR to prepare a new class of specific PTP1B inhibitors. 
Groebcke reaction is a three-component reaction to obtain fused 3-aminoimidazoles d from 
aromatic heterocyclic 2-aminoazines a, aldehydes b, and isocyanides c in the presence of a variety 
of Lewis acids or Brønsted acids (Scheme 29). The relevance of this powerful 3-component 
202 
transformation is significant because imidazo[1,2-a]heterocycles of this nature have received a great 
deal of attention in drug discovery. Imidazopyridines, imdazopyrazines, and imidazopyrimidines, in 
particular, have been the focus of pharmaceutical investigations across a broad range of therapeutic 
areas. 
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Scheme 29 
 
PTP1B also known as protein-tyrosine phosphatase 1B is an enzyme that is the founding member of 
the protein tyrosine phosphatase (PTP) family. PTP1B is a negative regulator of the insulin 
signaling pathway and is considered a promising potential therapeutic target, in particular for 
treatment of type 2 diabetes. Several inhibitors exhibited low micromolar activity and remarkable 
selectivity versus similar phosphatase. An example of a novel PTP1B inhibitor, synthesized by one-
pot Groebcke MCR, is shown in Scheme 30.  
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1.3.3 GPCR Ligands 
G-protein coupled receptors are by far the most important drug discovery target of the past, present, 
and foreseeable future. Because of the rareness of biostructural information in the GPCR field, 
however, the most common way to initiate chemistry programs is via high-throughput screening 
(HTS). GSK scientists discovered compounds which bind to the 7-transmembrane receptor EP1 
(whose natural ligand is prostaglandin PGE2) with high affinities. The EP1 receptor is associated 
with smooth muscle contraction, pain, inflammation, allergic activities, renal regulation, and gastric 
or enteric mucus secretion. A series of EP1 receptor antagonists have been synthesized by the vL3-
CR of TOSMIC, 2-O-benzyl anilines and m-formylbenzoic acid esters after subsequent 
saponification. 631 An example is shown in Scheme 31. 
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Scheme 31 
 
An U-4CR was used to prepare nitrogen-containing heterocyclic derivatives as chemokine receptor 
CCR5 antagonists 632 Chemokines are a family of small cytokines, or proteins secreted by cells. 
These proteins exert their biological effects by interacting with G protein-linked transmembrane 
receptors called chemokine receptors, which are selectively found on the surfaces of their target 
cells. Some chemokines are considered pro-inflammatory and can be induced during an immune 
response to recruit cells of the immune system to a site of infection. An example of these new 
CCR5 antagonists synthesized by a U-4CR is shown in Scheme 32.  
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Scheme 32 
 
1.3.4 Aspartyl Protease Inhibitors 
Several aspartyl proteases are important human disease targets. These involve α-secretase 
(Alzheimer and other neurodegenerative diseases), HIV protease (AIDS), cathepsin D (malaria), 
and renin (cardiovascular diseases). Banfi et al.633 and Sample et al.634 reported the P-3CR with 
isocyanides, carboxylic acids, and N-Boc-protected aldehydes yielding after Boc-deprotection and 
rearrangement, a multitude of complex peptide-like substances a possessing a central α-hydroxy-β-
aminoacid unit (Scheme 33). This type of monomer has been widely used in the synthesis of 
enzyme inhibitors.635 Moreover, a simple oxidation will produce oligopeptides b containing an α-
oxo-β-aminoacid unit, which is an even more attractive structure, thanks to its similarity with 
protease transition state.636 
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Scheme 33 
 
Aspartyl proteases inhibitors are also useful for treating the HIV infection that causes AIDS. HIV is 
a virus that contains an aspartyl protease (HIV-PR) that is essential for the life-cycle of HIV. HIV-
PR cleaves newly synthesized polyproteins at the appropriate places to create the mature protein 
components of an infectious HIV virion. Without effective HIV-PR, HIV virions remain 
uninfectious. The cost of HIV protease inhibitors is highly dependent on the complexity of the 
synthesis. Unfortunately, all currently available HIV protease inhibitors are made by very long and 
costly sequential syntheses. Recently, a novel sequence of P-3CR of R-ketocarboxylic acid esters a, 
isocyanides b, and substituted acetic acids c and a subsequent Dieckmann ring closing reaction 
were used to construct five-membered acid amides d (Scheme 34).637 The particular chemistry can 
be performed in a one-pot manner in 96-well plates. A big library of new compounds was 
synthesized and revealed several low micromolar to nanomolar inhibitors. They represent a starting 
point for novel HIV protease inhibitors synthesized by a much shorter route. This example nicely 
presents the advantages of MCR chemistry. All currently available HIV protease inhibitors are 
synthesized via linear syntheses of 15 steps or more. In contrast, these inhibitors are synthesized by 
a sequence of only two steps. 
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Scheme 34 
 
1.3.5 Protein-Protein Interaction Inhibitors 
The p53 gene has been the subject of intense study, since it was discovered that more than 50% of 
human cancers are caused by mutations in p53 gene. The hdm2 oncogene product suppresses the 
transcriptional activity of p53 by direct binding to the N-terminal transactivation domain of p53. It 
has been recently revealed by an X-ray structure that the protein-protein interaction between hdm2 
and p53 is mediated by a small piece of an R-helix. From the crystal structure and mutational 
studies, it is evident that three hydrophobic pockets occupied by Phe19, Trp23, and Leu26 of p53 gene 
are crucial for this interaction. The discovery and optimization of a series of 1,4-benzodiazepine-
2,5-diones (BDPs) that act as potent antagonists of the HDM2-p53 interaction has been reported.638 
The library was synthesized utilizing the highly efficient and versatile U-4CR: an anthranilic acid c, 
an amine b, an aldehyde a, and isocyanocyclohexene d were combined, followed by acid catalyzed 
cyclization of the intermediate e, producing the desired BDPs f in good yield and purity (Scheme 
35).  
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Twenty-two thousand BDPs were produced in this way. Compound a’ (Fig. 6) showed a potent Ki 
of 67 nM. This is surprising, taking into account the relatively small size of these molecules as 
compared to the p53 binding. In Fig. 6 the interaction between a’ and p53-hdm2 is shown.639 In 
yellow are the side chains of F19, W23, L26 of the R-helical amphiphatic p53 peptide. In blue is the 
superimposed benzodiazepine. The green surface represents the acceptor protein mdm2. A nice 
spatial overlap of the p-chlorophenyl and the second p-chlorophenyl substituents with Phe and Ile, 
respectively, and of the p-iodophenyl with the indole side chain is observed. 
 
Figure 6: X-ray structure of compound a’ and p53-hdm2.639 
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2 Research project 
2.1 Hydroxy-carbonyl compounds in multicomponent reactions 
In an attempt to expand upon the methodologies being developed in the Sheppard group, the aim of 
this project was to extend MCRs to a wide range of molecules for example the aldol products 1 and 
2 and 5-hydroxy-2-pentanone shown in Figure 7.  
 
 
 
 
Figure 7: Chemical structures of 1, 2 and 5-hydroxy-2-pentanone. 
 
The aldol reaction is amongst the most widely used carbon carbon bond forming reactions and 
therefore the starting β-hydroxy ketones or β-hydroxy aldehydes are readily available. By analogy 
to the above reactions, it is hypotized that an isocyanide and an amine could react with an aldol  
product to form the nitrilium ion a (Scheme 36), which could again react with carboxylic acids and 
undergo an acyl migration to one of the hydroxyl group to give c, or alternatively, be trapped by the 
nearby hydroxyl group to form the cyclic intermediate b. It can be envisaged that the formation of 
an amide bond would drive nucleophiles to open in an SN2 reaction to give the product d. 
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2.2 Aminoalcohols in multicomponent reactions 
We were interested in exploring new MCRs using aminoalcohols that have a three-carbon chain 
containing a substituent, such as a methyl group (6, 7 and 8) or an allyl group (9), to see how the 
substituent can modify the reactivity and whether it provides any stereoseletivity in the reaction. We 
would also explore how the aminoalcohol carbon chain inserted in a bulky cycle like a benzene (10) 
can change the chemical reactivity. Examples of aminoalcohols used are shown in Figure 8. 
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Figure 8: Examples of aminoalcohols used in MCRs. 
 
By analogy to the above reactions, it was hypothesized that the reaction between the aminoalcohol 
and the carbonyl compound makes the intermediate a (Scheme 37), which is attacked by the 
isocyanide to give the seven-membered intermediate b. Then, b can be opened by a nucleophile in 
an SN2 reaction to give the final product c. Alternatively, the intermediate b, which is in equilibrium 
with the nitrilium ion d, can react with a carboxylic acid to give the intermediate e, and after acyl 
transfer the final product f. 
 
  
 
 
 
 
 
 
 
 
 
 
Scheme 37 
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2.3 Carbonyl-carboxylic substrates in multicomponent reactions 
Moreover, to increase molecular diversity and to give access to novel drug-like structures, we were 
interested in trying MCRs between aminoalcohols and molecules that contain both the carbonyl 
group and the carboxylic moiety. Examples are shown in Figure 9. 
 
 
 
 
 
Figure 9: Molecules that contain both the carbonyl group and the carboxylic moiety. 
 
These molecules allow the synthesis of medium-ring heterocycles. The proposed mechanism is 
shown in Scheme 38. The iminium ion a, formed upon condensation of the secondary amine and 
aldehyde, is attacked by the isocyanide to give nitrilium ion b. Attack by the carboxylate gave the 
intermediate c, which leads to the medium-ring d after rearrangement. The synthesis of medium 
rings is often difficult due to the unfavorable thermodynamics of the ring closing process.640 
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3 Results and Discussion 
The following section will be divided into two parts. MCRs of aldol products will be presented first, 
followed by reactions of aminoalcohols. 
 
3.1 Hydroxy-carbonyl products 
To test if simple aldol products can participate in an IMCR as shown above in Scheme 36, a β-
hydroxy ketone 1 (Scheme 39) and a β-hydroxy aldehyde 2 (Scheme 40 ) were synthesized using a 
protocol developed by List641 and Mase642 respectively. 
 
 
 
Scheme 39 
 
 
 
 
Scheme 40 
 
1 was then reacted with tert-butyl isocyanide, diethylamine and trimethoxyborane (Scheme 41).  
 
 
 
 
Reaction conditions: β-hydroxy ketone 1 (1 equiv.), amine (1.5 equiv.), isocyanide (1.5 equiv.), 
B(OMe)3 (3 equiv.), DCE, RT, 2 days or 83°C, 4h. 
Scheme 41 
 
We envisaged that, in the presence of trimethoxyborane, the reaction between β-hydroxy ketone, 
secondary amine and isocyanide will form the nitrilium ion a and, after cyclization, the imino 
lactone b (Scheme 36). Different reaction conditions were tried out (RT for 2 days and reflux 4h,) 
but the enone a’ (Scheme 41) was observed. 
Since the reaction with a β-hydroxy ketone did not work, we decided to use 5-hydroxy-2-
pentanone, a more stable hydroxy ketone. We tried out both three-component and four-component 
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reactions. All the reactions were performed in the microwave for 15 minutes. The three-component 
reactions (Scheme 42) involved the reaction between 5-hydroxy-2-pentanone, a secondary 
(diethylamine) or a primary (benzylamine) amine and tert-butyl isocyanide. Each reaction was 
performed with and without the catalyst trimethoxyborane. The reaction with the boron derivative 
was performed in 1,2-dichloroethane, (reaction conditions a). Instead methanol was used for 
reactions without catalyst (reaction conditions b). No reaction gave the desired product. From crude 
1H-NMR we could see only starting materials. 
Four-component reactions were also performed in the same way as the three-component reactions, 
but with the addition of a nucleophile i.e. thiophenol (Scheme 43, reaction condition a and b). In 
this case, we wanted to see if the imino lactone intermediate, formed from the reaction between 
ketone, amine and isocyanide, can be opened by a nucleophile to give the multicomponent products 
(Scheme 36). Also in this case, no reaction worked.  
Finally, we performed three-component (Scheme 42, reaction conditions c) and four-component  
reactions (Scheme 43, reaction conditions c) using tris(2,2,2,-trifluoroethyl) borate (B(OCH2CF3)3) 
as catalyst. B(OCH2CF3)3 is more electrophile than B(OMe)3 so the formation of the iminium ion 
could be more favorable. All the reactions were performed in MeCN but, again, no reaction worked. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Reaction conditions: a) hydroxy ketone (1 equiv.), amine (1.5 equiv.), isocyanide (1.5 equiv.), 
B(OMe)3 (3 equiv.), DCE, microwave 83 °C, 15 min., b) hydroxy ketone (1 equiv.), amine (1.5 
equiv.), isocyanide (1.5 equiv.), MeOH, microwave 65°C, 15 min., c) hydroxy ketone (1 equiv.), 
amine (1 equiv.), isocyanide (1 equiv.), B(OCH2CF3)3 (2 equiv.), CH3CN, microwave 82 °C, 15 
min. 
Scheme 42 
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Reaction conditions: a) hydroxy ketone (1 equiv.), amine (1.5 equiv.), isocyanide (1.5 equiv.), 
thiophenol (1.5 equiv.), B(OMe)3 (3 equiv.), DCE, microwave 83 °C, 15 min., b) hydroxy ketone (1 
equiv.), amine (1.5 equiv.), isocyanide (1.5 equiv.), thiophenol (1.5 equiv.), MeOH, microwave 
65°C, 15 min., c) hydroxy ketone (1 equiv.), amine (1 equiv.), isocyanide (1 equiv.), thiophenol (1 
equiv.), B(OCH2CF3)3 (2 equiv.), CH3CN, microwave 82 °C, 15 min. 
Scheme 43 
 
Since the reactions with hydroxy ketones did not work, we tried MCRs using the β-hydroxy 
aldehyde 2. As for 5-hydroxy-2-pentanone, we performed three-component and four-component 
reactions. All the reactions were performed in the microwave for 15 minutes. The three-component 
reactions (Scheme 44) involved the reaction between the β-hydroxy aldehyde 2, a secondary 
(diethylamine) or a primary (benzylamine) amine and tert-butyl isocyanide. Each reaction was 
performed with and without the catalyst trimethoxyborane. The reaction with the boron derivative 
was performed in 1,2-dichloroethane. Instead methanol was used for reactions without catalyst. No 
reaction gave the desired product. From crude 1H-NMR we could see only starting materials. 
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Reaction conditions: β-hydroxy aldehyde (1 equiv.), amine (1.5 equiv.), isocyanide (1.5 equiv.), a) 
B(OMe)3 (3 equiv.), DCE, microwave 83 °C, 15 min., b) MeOH, microwave 65°C, 15 min. 
Scheme 44 
 
Four-component reactions were performed in the same way as three-component reactions but with 
the addition of the nucleophile thiophenol (Scheme 45). The reaction between the β-hydroxy 
aldehyde 2, benzylamine, tert-butyl isocyanide and thiophenol, with and without the catalyst 
B(OMe)3 did not work. Replacing benzylamine with diethylamine gave an unsuspected result; the 
reaction with B(OMe)3, did not work, but the reaction without catalyst gave the products 3, 4 and 5 
as shown in Scheme 45.  
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Reaction conditions: β-hydroxy aldehyde (1 equiv.), amine (1.5 equiv.), isocyanide (1.5 equiv.), 
thiophenol (1.5 equiv.), a) B(OMe)3 (3 equiv.), DCE, microwave 83°C, 15 min., b) MeOH, 
microwave 65°C, 15 min. 
Scheme 45 
 
To explain the formation of 3, 4 and 5 we have envisaged that the cyclic intermediate a is formed 
from the reaction between the β-hydroxy aldehyde and tert-butyl isocyanide (Scheme 46). Then 
water acts as a nucleophile opening a and leading to the formation of 4. Finally, compound 3 is 
formed by oxidation of 4. Alternatively the imino group of the intermediate a can be hydrolyzed by 
water giving the lactone 5 (Scheme 47). 
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Scheme 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 47 
 
To confirm this hypothesis , we repeated the reaction, in different conditions, between the aldehyde 
2, tert-butyl isocyanide and the nucleophile thiophenol. We hoped that, once the imino lactone a is 
formed, thiophenol instead of water, can open a in an SN2 process giving three-component product 
as shown in Scheme 48.  
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Scheme 48 
 
The following conditions were tried out to lead to the formation of the desired products. We 
performed the reaction in different solvents and we found out that the reaction in DMSO, 
acetonitrile, and isopropanol did not work. We tried also to use dry MeOH and the drying agent 
trimethyl orthoformate to reduce water in the reaction mixture but, in both cases, we noticed from 
1H-NMR the formations of 3, 4 and 5. Also the addition of B(OMe)3 led to the formation of the 
same products (Scheme 49). 
 
 
 
 
Reaction conditions: β-hydroxy aldehyde (1 equiv.), isocyanide (1 equiv.), thiophenol (1 equiv.), a) 
B(OMe)3 (2 equiv.), DCE, microwave 83°C, 15 min., b) MeOH, microwave 65°C, 15 min., c) dry 
MeOH, microwave 65°C, 15 min., d) trimethyl orthoformate (1 equiv.), dry MeOH, microwave 
65°C, 15 min. 
Scheme 49 
 
Finally we performed the reaction between only the aldehyde 2 and tert-butyl isocyanide to see if 
the desired imino lactone a is formed (Scheme 50). Then, if the reaction works, we hypothesized 
that a can be opened by thiophenol, giving the multicomponent product as shown in Scheme 48. 
Also this last attempt was unsuccessful. 
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Reaction conditions: a) aldehyde (1 equiv.), isocyanide (2 equiv.), MeOH, microwave 65°C, 15 
min. b) aldehyde (2 equiv.), isocyanide (1 equiv.), MeOH, microwave 65°C, 15 min.  
Scheme 50 
 
3.2 Aminoalcohols 
The amino alcohols used for MCRs are shown in Figure 10.  
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Figure 10: Aminoalcohols used for MCRs. 
 
3.2.1 Synthesis of aminoalcohols 
Compound 6 was synthesized from methyl-vinyl ketone and benzylamine. Michael addition of the 
amine to the double bond643 gave the intermediate 11, and after reduction of the carbonyl group 
with NaBH4, the aminoalcohol 6 is formed (Scheme 51).  
 
 
 
Scheme 51 
 
Compound 7 was synthesized from methyl methacrylate and benzylamine. Michael addition of the 
amine to the double bond,643 gave the intermediate 12. Reduction of the carbonyl group with 
LiAlH4 afforded the aminoalcohol 7 (Scheme 52).  
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Scheme 52 
 
The synthesis of aminoalcohol 8 is shown in Scheme 53. After reaction between methyl crotonate 
and benzylamine,643 the carbonyl group of intermediate 13 was reduced to alcohol giving the 
compound 8. 
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Scheme 53 
 
The synthesis of aminoalcohol 9 is shown in Scheme 54. Michael addition between benzylamine 
and methyl acrylate643 gave the intermediate 14. Reduction of the carbonyl group with LiAlH4 
afforded the aminoalcohol 15 which was treated with di-t-Butyl dicarbonate leading to the N-
protected aminoalcohol 16. The hydroxyl group was subsequently oxidized to aldehyde affording 
17. Reaction with vinyl magnesium bromide (18) and deprotection with trifluoroacetic acid gave the 
final aminoalcohol 9. 
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For the synthesis of 10 several ways were tried out. The first attempt is shown in Scheme 55. 
Phthalimide was reduced with tin in glacial acetic acid and HCl affording 2,3-dihydro-isoindol-1-
one 19.644 Methylation of 19 (Method A) gave a mixture of two compounds. The major compound 
was 20 while the desired 21 was the minor. If the methylation would have given 21 in good yield, 
we could have tried the reduction with LiEt3BH. 
 
NH
O
O
Tin
NH
O
MeI,  NaH
CH3COOH,  HCl,
19  (28%)
118 °C
dry THF, RT
  
Scheme 55 
 
The second way is shown in Scheme 56. We performed the reaction between phthaldialdehyde, 
benzylamine or propylamine. We hoped that, if an imine is formed, reduction of the imine gives the 
aminoalcohols a’ and b’ shown below. We tried the reaction at reflux in toluene with Dean- Stark 
apparatus, or at RT in methanol but all attempts did not give a successful result. The crude 1H-NMR 
revealed the imine was not formed. 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction conditions: Phthaldialdehyde (3 equiv.), amine (1 equiv.), a) toluene, reflux with Dean- 
Stark apparatus, 4 h, b) dry MeOH, RT overnight.  
Scheme 56 
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The last attempt is shown in Scheme 57. Methylation of phthalimide gave the intermediate 22 
which was reduced to 21 with zinc in acetic acid (Method B).645 Reduction of 21 with an excess (5 
equiv.) of LiEt3BH646 produced many side products and none of them could be isolated. On the 
other hand, reduction with 2 equivalents of LiEt3BH did not work. From crude 1H-NMR we could 
observe only starting materials.  
 
 
 
 
 
Scheme 57 
 
3.2.2 Multicomponent reactions with aminoalcohol 8 
As described in the introduction, the four-component reaction between N-alkylamino alcohols, 
aldehydes, isocyanides and carboxylic acids leads to N-acyloxy amides e (Scheme 16). Replacing 
carboxylic acids with general nucleophiles leads to multicomponent products (Scheme 17). 
The first attempt was to try a four-component reaction between the aminoalcohol 8, pentanal, tert-
butyl isocyanide and the nucleophile thiophenol (Scheme 58). Surprisingly the reaction did not give 
the desired product a. New products were observed and the main product could be identified as 23. 
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We therefore decided to synthesize at first the N-O cyclic acetal a shown above in Scheme 37. We 
hypothesized the isocyanide and thiophenol could react easier with this intermediate leading to the 
formation of the desired product. The synthesis of the intermediate is shown in Scheme 59. The 
reaction between 8 and para-chlorobenzaldehyde gave the intermediate 24 which was used without 
further purification in the next step.  
 
 
 
 
 
Scheme 59 
 
It was found that, from the reaction between 24, tert-butyl isocyanide and thiophenol, the main 
product was 25 (Scheme 60). From crude 1H-NMR and 13C-NMR we could see that also the desired 
26 is formed, but the conversion is too low and it could not be fully isolated. 
 
 
 
 
 
 
 
 
Scheme 60 
 
To explain why 25 is formed, it is thought that the acidity of thiophenol causes the hydrolysis of the 
N-O acetal 24 and the release of the aminoalcohol 8 which can react with tert-butyl isocyanide 
giving the cyclic intermediate a (Scheme 61). Then, thiophenol opens the cycle in a SN2 with 
liberation of the tert-butylamino group, giving the product 25.  
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Scheme 61 
 
To confirm this hypothesis, the reaction between 8, tert-butyl isocyanide and thiophenol was 
performed leading to 25 in 31% yield (Scheme 62).  
N
H
OHPh
8
N
SH
+ +
a
 
Reaction conditions: 8 (1 equiv.), tert-butyl isocyanide (1 equiv.), thiophenol (1 equiv.), a)MeOH, 
microwave 65 °C, 15 min.  
Scheme 62 
 
Since the reaction with thiophenol did not give the desired product in good yield, we decided to 
attempt the reaction using another nucleophile like benzoic acid. From the mechanism discussed 
above (Scheme 37), the reaction should give the product shown in Scheme 63. From crude 1H-
NMR we could see new products but none of them could be fully isolated and identified. 
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Reaction conditions: 23 (1 equiv.), tert-butyl isocyanide (1 equiv.), benzoic acid (1 equiv.) para-
toluenesulphonic acid (10%), a) isopropanol, microwave 82 °C, 15 min. 
Scheme 63 
 
We were moreover interested in reactions between an aminoalcohol and a bifunctional substrate 
that contains the aldehyde group and the carboxylic acid to allow the synthesis of medium ring 
heterocycles. The first attempt was to try a MCR between 2-carboxy-benzaldehyde, aminoalcohol 8 
and tert-butyl isocyanide. The reaction did not give the desired nine-membered ring shown in 
Scheme 64. 
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Reaction conditions: 8 (1 equiv.), tert-butyl isocyanide (1 equiv.), 2-carboxy-benzaldheyde (1 
equiv.), a) MeOH, microwave 65 °C, 15 min. 
Scheme 64 
 
We therefore turned our attention to another bifunctional substrate, 4-oxo-butyric acid. The reaction 
between 8, 4-oxo-butyric acid and tert-butyl isocyanide gave the products shown in Scheme 65. It 
was possible to separate the two diasteroisomers and from the comparison of J-couplings and from 
NOESY experiments we could state that the major compound (53% yield) is the cis isomer while 
the minor compound (23% yield) is the trans (Fig. 11). 
  
 
 
 
 
 
Scheme 65 
 
 
 
 
 
 
 
 
 
 
                                       27-cis                                                                        27-trans 
Figure 11: Nine membered-ring heterocycles 27. 
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3.2.3 Multicomponent reactions with aminoalcohol 7 
Then we decided to investigate MCRs with another aminoalcohol (7). As we did for the 
aminoalcohol 8, at first, the reaction between 7 and para-chlorobenzaldehyde was performed to 
obtain the intermediate 28 (Scheme 66). 
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Scheme 66 
 
The intermediate 28 was then used in the three-component reaction with tert-butyl isocyanide and 
thiophenol (Scheme 67). The reaction gave 29 in 2.6% yield. To increase the yield of this product, 
different conditions were tried out. We repeated the reaction at RT and 40 °C and with more 
equivalents of nucleophile and isocyanide but none led to a more successful result. 
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Scheme 67 
 
The reaction between 7 and the bifunctional substrate 2-carboxy benzaldehyde should give the 
product shown in Scheme 68 but the reaction did not work.  
 
  
 
 
 
 
Reaction conditions: 7 (1 equiv.), tert-butyl isocyanide (1 equiv.), 2-carboxy-benzaldheyde (1 
equiv.), a) MeOH, microwave 65 °C, 15 min. 
Scheme 68 
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On the other hand the reaction between 7 and 4-oxo-butyric acid gave the nine-membered ring 30 
(Scheme 69). The 1H-NMR and 13C-NMR revealed a mixture of cis and trans products, but it was 
not possible to separate the two diasteroisomers by flash chromatography. The two diasteroisomers 
are in a ratio of 1:1.1. 
 
 
 
 
 
Scheme 69 
 
3.2.4 Multicomponent reactions with aminoalcohol 6 
We decided to turn our attention to the aminoalcohol 6. At first, we tried the four-component 
reaction between 6, pentanal, tert-butyl isocyanide and thiophenol. The reaction gave the desired 
compound 31 (Scheme 70) but the yield was very low (2%). Only one of the two possible 
diasteroisomers was isolated.  
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Scheme 70 
 
In order to increase the yield, we decided firstly to synthesize the cyclic intermediate 32 (Scheme 
71), as we did for the aminoalcohols 7 and 8. 32 was formed from the reaction between 6 and para-
chlorobenzaldehyde. 
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The intermediate 32 was then used in the three-component reaction with tert-butyl isocyanide and 
thiophenol. The reaction should give the product shown in Scheme 72. From crude 1H-NMR we 
could still observe starting materials and, unfortunately, the desired product could not be isolated 
and characterized. It is possible that the intermediate 32 is very stable, and it cannot be easily 
opened by a nucleophile as thiophenol to give the desired multicomponent product. 
 
 
  
 
 
 
 
Reaction conditions: 32 (1 equiv.), tert-butyl isocyanide (1 equiv.), thiophenol (1 equiv.), a) MeOH, 
microwave 65 °C, 15 min.  
Scheme 72 
 
The reaction between the aminoalcohol 6 and the bifunctional substrate 4-oxo-butyric gave the 
nine-membered heterocycle 33 (Scheme 73). Only one of the two diasteroisomers could be isolated 
and from NOESY experiment and from comparison of J-couplings it was possible to identify the 
diasteroisomer as trans (Fig. 12). From crude 1H-NMR it was not possible to observe the cis 
diasteroisomer because the crude 1H-NMR was very complex.  
 
OH
H
O
O
N
H
OH NPh + +
6
MeOH
MW, 65°C
  
 
Scheme 73 
 
 
 
 
 
 
N
HN
O
Ph
S
Cl
x 
O
O
N
PhO
HN
33
228 
 
 
 
 
 
 
 
 
Figure 12: Nine membered- ring heterocycles 33 (trans). 
 
3.2.5 Multicomponent reactions with aminoalcohol 9 
We then decided to turn our attention to the aminoalcohol 9. Two plausible mechanisms can be 
envisaged for this aminoalcohol (Scheme 74). First of all the reaction between 9 and an aldehyde 
could give the intermediate a, which reacts with an isocyanide to form the seven-membered ring 
intermediate b. As we observed with the other aminoalcohols, the nucleophile could open the cycle 
with a SN2 reaction affording the product c. Alternatively, the nucleophile could attack the double 
bond giving the final product d.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 74 
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To study this mechanism, the reaction between 9 and para-chloro benzaldehyde was performed at 
first, affording the intermediate 34 (Scheme 75).  
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Scheme 75 
 
The intermediate 34 was then allowed to react with tert-butyl isocyanide and the nucleophile 
thiophenol as shown in Scheme 76. Analysis by TLC and 1H-NMR revealed a complex mixture of 
products. None was fully isolated and characterized but none of the desired products was present.  
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Reaction conditions: 34 (1 equiv.), tert-butyl isocyanide (1 equiv.), 2-carboxy-benzaldheyde (1 
equiv.), a) MeOH, microwave 65 °C, 15 min., b) MeOH, RT, 8 h. 
Scheme 76 
 
3.2.6 Multicomponent reactions with carbonyl-carboxylic compounds 35 and 35’ 
Finally, we decided to investigate MCRs using others bifunctional substrates like the pyridine 
derivatives shown in Figure 13. 
 
 
 
 
 
Figure 13: Pyridine derivatives used in MCRs. 
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Compounds 35 (3-Formyl-isonicotinic acid) and 35’ (4-Formyl-nicotinic acid) were synthesized 
from reduction of 3,4-pyridinedicarboxylic anhydride with Li(OtBu)3AlH (Scheme 77).647 From 
1H-NMR and 13C-NMR it was possible to observe that 35 and 35’ are in equilibrium with the 
hydroxyphthalide form 35a and 35’b, respectively. It was not possible to purify and separate 35 and 
35’ because these pyridine derivatives are not very soluble in most organic solvents. 
N
O
O
O
Li(OtBu)3AlH
N
OH
O
O
H
+
N
H
O
O
OH
N
O
O
HO
N
O
OH
O
35 35'
35a 35'b
dry THF, RT
 
Scheme 77 
 
The mixture of 35 and 35’ was used in a three-component reaction with the aminoalcohol 7 and 
tert-butyl isocyanide (Scheme 78). By analogy to the mechanism envisaged in Scheme 38, the 
reaction should give the products shown in Scheme 78. From crude 1H-NMR we could observe 
only starting materials  
 
 
 
 
 
 
 
 
 
 
 
 
 
231 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction conditions: 35-35’ (1 equiv.), 7 (1 equiv.), tert-butyl isocyanide (1 equiv.), a) MeOH 
microwave 65 °C, 15 min.  
Scheme 78 
 
Finally, the mixture of 35 and 35’ was reacted with a simpler aminoalcohol, 2-methylamino-ethanol 
(Scheme 79). 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction conditions: 35-35’ (1 equiv.), 2-methylamino-ethanol (1 equiv.), tert-butyl isocyanide (1 
equiv.), a) MeOH microwave 65 °C, 15 min.  
Scheme 79 
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Also in this case, from crude 1H-NMR we could observe only starting materials. We can envisage 
that hydroxyphthalide form 35a and 35’b are more stable than the form with free carboxylic and 
aldehyde group. So these functional groups are not able to interact with the aminoalcohol and 
isocyanide and lead to the synthesis of medium ring heterocycles. 
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4 Conclusions and Future Works 
We explored MCRs of aldol products like 1 and 2 and a hydroxy ketone like 5-hydroxy-2-
pentanone. We tried out three-component reactions (Scheme 41, 42 and 44) between these 
bifunctional molecules, tert-butyl isocyanide and a primary or secondary amine. None of the 
reactions gave the desired imino lactone. We also tried four-component reactions, adding the 
nucleophile thiophenol, (Scheme 43 and 45) but all attempts to synthesize the desired Ugi-type 
products were unsuccessful. It was only possible to identify the side products 3, 4 and 5. 
 
We also investigated new isocyanide-based MCRs using three-carbon chain aminoalcohols that 
contain a methyl substituent. We demonstrated that the reaction between an aminoalcohol, an 
aldehyde, tert-butyl isocyanide and thiophenol gave amide products in low yield. We can envisage 
that, the cyclic N,O-acetal obtained from the reaction between the aminoalcohol and the aldehyde 
(Scheme 37), is very stable and cannot easily be opened by a nucleophile. All attempts to increase 
the yield were unsuccessful. Moreover, increasing the temperature or increasing the reaction time 
did not improve the yield but sometimes increased the amount of side products. 
 
Reactions between the new aminoalcohols 6, 7 and 8 and the bifunctional substrate 2-carboxy 
benzaldehyde did not work but surprisingly with 4-oxo-butyric acid the nine-membered ring 
heterocycles were obtained in moderate yields. The synthesis of medium rings is often difficult due 
to the unfavorable thermodynamics of the ring closing process, so these reactions are valuable as 
they offer a one-pot route to synthesize functionalized medium ring systems from readily available 
starting materials. 
 
In the future it would be interesting focus on the optimization of the reaction conditions to improve 
the yields of these nine-membered ring heterocycles. Moreover if the work was carried on, we 
would investigate the synthesis of a more diverse range of aminoalcohols and other bifunctional 
substrates for the synthesis of nine, ten, eleven-membered ring products. 
 
Finally different reaction conditions for 5-benzylamino-pent-1-en-3-ol (aminoalcohol 9) would be 
explored because it would be interesting study the chemistry of an aminoalcohol which has a 
reactive group like a double bond.  
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5 Experimental section 
All reactions were carried out at atmospheric pressure with stirring unless otherwise indicated. All 
solvents and chemicals were purchased from suppliers and used without further purification. 
Reactions were monitored by TLC and 1H-NMR. TLC plates pre-coated with silica gel 60 F254 on 
aluminium (Merk KGaA) were used, being visualized by UV ( 254 or 365 nm) or chemical stain 
(KMnO4, and phosphomolybdic acid). Normal phase silica gel (DBH, 40-63 µm) was used for flash 
column chromatography.  
Melting points were determined using Reichert hot-stage apparatus and are uncorrected. Infrared 
(IR) spectra were recorded on a Perkin-Elmere spectrum 100 FT-IR spectrometer as thin film . 
1H-NMR spectra were recorded at 300 MHz, 500 MHz, and 400 MHz on a Bruker Avance 
spectrometers or at 600 MHz on a AMX600 spectrometer. Chemical shifts were measured in ppm 
and are quoted as δ, relative to TMS. Multiplicities are quoted as s (singolet), d (doublet), t (triplet), 
q (quartet), quintet and m (multiplet), br (broad) with coupling constants defined as J given in Hz.  
13C-NMR was recorded at 75 MHz, 100 MHz and 125 MHz, on a 300 MHz,, 400 MHz, and 500 
MHz Bruker Avance spectrometers respectively, and at 150 MHz on a AMX600 spectrometer. 
High and low resolution mass spectra were recorded by Dr. Lisa Haigh using a VG70 SE 
instrument operating in modes CI, EI, ES, and FAB. 
 
4-Hydroxy-5-methyl-hexan-2-one (1)641 
 
 
 
L-Proline (144 mg, 1.25 mmol) was stirred in a mixture of acetone (8 ml) and DMSO (33 ml) at RT 
for 15 min. Isobutyraldehyde was added (300 mg, 4.16 mmol) and the mixture was stirred at RT for 
3 days. After evaporating the solvent, ammonium chloride (10 ml) was added and then extracted 
with ethyl acetate (2 x 10 ml). The combined organic layers were washed with brine (10 ml), dried 
over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (ethyl 
acetate-petrol, 8:2) to give the hydroxy ketone as a yellow oil (243 mg, 1.87 mmol, 45% ); vmax 
(film/cm-1) 3434, 2961, 2877, 1705; δH (500 MHz, CDCl3) 0.90 (3H, d, J 6.8, CH3) 0.93 (3H, d, J 
6.8, CH3), 1.63-1.73 (1H, m, CH-(CH3)2), 2.20 (3H, s, CH3-C=O), 2.53 (1H, dd, J 9.6, 17.5, CHH-
C=O), 2.62 (1H, dd, J 17.5, 2.5, CHH-C=O), 3.79-3.83 (1H, ddd, J 9.6, 5.8, 2.5, CH-OH); δC (125 
MHz, CDCl3) 17.8, 18.4, 30.9, 33.1, 47.0, 72.3, 210.4. 
 
 
O OH
235 
3-Hydroxy-2,2-dimethyl-3-(4-nitro-phenyl)-propionaldehyde (2)642  
 
 
 
p-Nitrobenzaldehyde (1 g, 6.6 mmol) was dissolved in anhydrous DMSO (7 ml) and 
isobutyraldehyde (571 mg, 7.92 mmol) was added. To the mixture, acetic acid (1.65 mmol) and 
pyrrolidine (0.33 mmol) were added. After stirring for 2 h at RT, the reaction mixture was directly 
purified by flash chromatography (petrol-ethyl acetate, 8:2) affording the aldol product as a white 
solid (563 mg, 2.5 mmol, 38%); ES [M+H+]:
 
224, C11H14NO4; δH (500 MHz, CDCl3) 0.98 (3H, s, 
CH3), 1.06 (3H, s, CH3), 5.04 (1H, s, CH-OH), 7.50 (2H, d, J 8.4, Ar), 8.21 (2H, d, J 8.4, Ar), 9.61 
(1H, s, HC=O); δC (125 MHz, CDCl3) 15.68, 19.96, 50.86, 76.23, 123.19, 128.49, 146.94, 147.67. 
205.91. 
 
N-tert-Butyl-2-hydroxy-3,3-dimethyl-4-(4-nitro-phenyl)-4-oxo-butyramide (3) 
N-tert-Butyl-2,4-dihydroxy-3,3-dimethyl-4-(4-nitro-phenyl)-butyramide (4) 
3-Hydroxy-4,4-dimethyl-5-(4-nitro-phenyl)-dihydro-furan-2-one (5) 
 
 
 
 
 
Aldehyde 2 (75 mg, 0.34 mmol), diethylamine (37 mg, 0.50 mmol), tert-butyl isocyanide (42 mg, 
0.50 mmol) and thiophenol (56 mg, 0.50 mmol) were dissolved in MeOH (0.85 ml). The mixture 
was stirred under microwave irradiation at 65°C for 15 min. The solvent was evaporated under 
reduced pressure and the crude was purified by flash chromatography (petrol-ethyl acetate, 7:3) 
affording a mixture of 3 and 4 as a transparent oil in a ratio of 1:1.5, respectively (18.3 mg). 
3 and 4: vmax (film/cm-1) 3360, 2972, 1642, 1605, 1518, 1350, 851, 733.  
3: δH (600 MHz, CDCl3) 1.17 (3H, s, CH3), 1.19 (3H, s, CH3), 1.39 (9H, s, tBu), 3.79 (1H, d, J 5.8, 
OH), 4.22 (1H, d, J 5.8, CH-OH), 6.43 (1H, br s, NH), 7.38 (2H, d, J 8.8, Ar), 8.29 (2H, d, J 8.8, 
Ar); δC (150 MHz, CDCl3) 22.39, 23.06, 28.92, 44.90, 51.44, 78.84, 123.53, 129.07, 139.80, 
147.83, 164,42, 170.68.  
4: δH (600 MHz, CDCl3) 0.85 (3H, s, CH3), 0.89 (3H, s, CH3), 1.41 (9H, s, tBu), 3.06 (1H, d, J 4.5, 
OH), 4.22 (1H, d, J 4.5, CH-OH), 4.63 (1H, d, J 3.9, OH), 4.69 (1H, d, J 3.9, CH-OH), 6.50 (1H, br 
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s, NH), 7.53 (2H, d, J 8.8, Ar), 8.18 (2H, d, J 8.8, Ar); δC (150 MHz, CDCl3) 18.93, 19.77, 28.86, 
43.20, 51.69, 75.60, 76.85, 122.89, 129.07, 147.30, 148.66, 172.12.  
5 (not isolated): δH (500 MHz, CDCl3) 0.62 (3H, s, CH3), 1.35 (3H, s, CH3), 4.37 (1H, s, CH-OH), 
5.20 (1H, s, CH-COO), 7.49 (2H, d, J 8.7, Ar), 8.28 (2H, d, J 8.7, Ar); δC (125 MHz, CDCl3) 14.75, 
22.56, 46.49, 76.90, 84.59, 123.76, 126.85, 141.23, 142.76, 175.73. 
 
4-Benzylamino-butan-2-ol (6) 
 
 
 
11 (676 mg, 3.81 mmol) was dissolved in MeOH (5 ml) and NaBH4 (288 mg, 7.62 mmol) was 
added carefully at 0°C. The mixture was stirred at RT for 15 min. After evaporating the solvent, 
NaBH4 in excess was quenched at 0°C with 2M HCl. The aqueous phase was washed with DCM (2 
x 20 ml), basified with 1M NaOH, and then extracted with DCM (3 x 20 ml). The combined 
organic layers were dried over MgSO4 and concentrated in vacuo affording 6 as an orange oil (668 
mg, 3.73 mmol, 98%); vmax (film/cm-1) 3295, 3062, 3027, 2963, 2924, 2832, 1494, 1453, 733; δH 
(500 MHz, CDCl3) 1.17 (3H, d, J 6.2, CH3), 1.60-1.64 (1H, m, CHH), 1.48-1,55 (1H, m, CHH), 
2.78 (1H, td, J 10.9, 3.4, CHH-N), 3.01 (1H, ddd, J 12.0, 4.8, 3.4, CHH-N) 3.74 (1H, d, J 13.1, 
CHH-Ph), 3.82 (1H, d, J 13.1, CHH-Ph), 3.99 (1H, m, CH-CH3), 7.27-7.34 (5H, m, Ar); δC (125 
MHz, CDCl3) 23.71, 37.11, 48.09, 53.84, 69.13, 127.17, 128.21, 128.51, 139.65.  
 
3-Benzylamino-2-methyl-propan-1-ol (7) 
 
 
A solution of 12 (500 mg, 2.40 mmol) in anhydrous THF (5 ml) was added carefully at 0 °C and 
under an argon atmosphere, to a suspension of LiAlH4 (137 mg, 3.60 mmol) in anhydrous THF. 
The mixture was warmed at RT and then stirred for 2 h. The reaction was quenched at 0 °C by 
dropwise addition of water (0.1 ml), followed by 1N NaOH (0.4 ml) and water (0.3 ml). Then, the 
mixture was filtered, dried over MgSO4 and concentrated in vacuo affording 7 as a yellow oil (421 
mg, 2.35 mmol, 98%); vmax (film/cm-1) 3303, 2954, 2832, 1495, 1453, 1041, 740; δH (300 MHz, 
CDCl3) 0.76 (3H, d, J 6.9, CH3), 1.82-1.91 (1H, m, CH-CH3), 2.53 (1H, dd J 11.7, 2.0, CHH-N), 
2.72-2.77 (1H, m, CHH-N), 3.46 (1H, dd J 10.7, 1.9, CHH-OH), 3.57-3.62 (1H, m, CHH-OH), 3.65 
(1H, d, J 13.2, CHH-Ph), 3.74 (1H, d, J 13.2, CHH-Ph), 7.18-7.30 (5H, m, Ar); δC (125 MHz, 
CDCl3) 15.04, 34.48, 54.16, 56.62, 70.48, 127.26, 128.23, 128.58, 139.31. 
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3-Benzylamino-butan-1-ol (8) 
 
 
 
A solution of 13 (504 mg, 2.87 mmol) in anhydrous THF (5 ml) was added carefully at 0 °C and 
under an argon atmosphere to a suspension of LiAlH4 (163 mg, 4.30 mmol) in anhydrous THF. The 
mixture was warmed at RT and then stirred for 2 h. The reaction was quenched at 0 °C by dropwise 
addition of water (0.2 ml), followed by 1N NaOH  (0.5 ml) and water (0.6 ml). Then, the mixture 
was filtered, dried over MgSO4 and concentrated in vacuo affording 8 as a yellow oil (430 mg, 3.40 
mmol, 84%); vmax (film/cm-1) 3294, 1453, 1085, 906, 698; δH (500 MHz, CDCl3) 1.21 (3H, d, J 6.6, 
CH3), 1.57 (1H, dtd, J 14.5, 8.5, 3.5, CHH), 1.74 (1H, dtd J 14.5, 6.2, 3.1, CHH), 2.98-3.04 (1H, m, 
CH-CH3), 3.78, (1H, ddd, J 10.7, 8.5, 3.1, CHH-OH), 3.79 (1H, d, J 12.8, CHH-Ph), 3.84-3.88 (1H, 
m, CHH-OH), 3.89 (1H, d, J 12.8, CHH-Ph), 7.24-7.27 (3H, m, Ar), 7.30-7.33 (2H, m, Ar); δC (125 
MHz, CDCl3) 20.32, 37.30, 51.20, 53.51, 62.09, 127.19, 128.28, 128.57, 139.85. 
 
5-Benzylamino-pent-1-en-3-ol (9) 
 
 
 
Trifluoroacetic acid (103 mg, 0.90 mmol) was added dropwise at 0° C to a solution of 18 (44 mg, 
0.15 mmol) in DCM (1 ml). The mixture was stirred at RT for 2 h after which it was quenched with 
water. The aqueous layer was washed with DCM (3 x 10 ml), basified with 1N NaOH  and then 
extracted with DCM (3 x 10 ml). The combined organic phases were dried over MgSO4 and 
evaporated to dryness affording 9 as a yellow-orange oil (22 mg, 0.11 mmol, 80%); vmax (film/cm-1) 
3457, 3021, 2970, 2947, 1437; δH (400 MHz, CDCl3), 1.58-1.67 (1H, m, CHH), 1.79 (1H, dddd, J 
14.6, 9.4, 6.4, 3.1, CHH), 2.85 (1H, ddd J 12.0, 9.4, 3.4, CHH-N), 3.03 (1H, ddd, J 12.0, 6.4, 3.5 
CHH-N), 3.77 (1H, d, J 13.0, CHH-Ph), 3.83 (1H, d, J 13.0, CHH-Ph), 4.36-4.40 (1H, m, CH-OH), 
5.12 (1H, dd, J 10.5, 1.7, HCH=CH), 5.30 (1H, ddd, J 17.3, 1.7, HCH=CH), 5.88 (1H, ddd, J 17.3, 
10.5, 5.1, CH2=CH), 7.26-7.37 (5H, m, Ar); δC (100 MHz, CDCl3) 34.78, 47.56, 53.78, 74.01, 
113.80, 127.28, 128.23, 128.54, 139.20, 140.97. 
 
4-Benzylamino-butan-2-one (11)643 
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Methyl vinyl ketone (1 g, 14.30 mmol), dissolved in anhydrous Et2O (3.6 ml), was added at 0 °C 
over a period of 3 h to a solution of benzylamine (3 g, 28.60 mmol) dissolved in anhydrous Et2O (7 
ml). The solvent was evaporated under reduced pressure and the crude was purified by flash 
chromatography (petrol-DCM-ethanol, 1:8.5:0.5) affording 11 as a yellow oil (676 mg, 3.81 mmol, 
27%); vmax (film/cm-1) 3320, 3062, 3028, 2923, 2824, 1715, 1603, 1494, 735, 699; δH (500 MHz, 
CDCl3) 1.97 (3H, s, CH3), 2.47 (2H, t, J 6.4, CH2-C=O), 2.71 (2H, t, J 6.4, CH2-N), 3.65 (2H, s, 
CH2-Ph), 7.10-7.16 (2H, m, Ar), 7.19-7.21 (3H, m, Ar); δC (125 MHz, CDCl3) 30.03, 43.71, 43.88, 
53.98, 126.91, 128.09, 128.38, 140.36, 208.20.  
 
3-Benzylamino-2-methyl-propionic acid methyl ester (12)643 
 
 
 
A mixture of methyl methacrylate (10 g, 0.10 mol) and benzylamine (11 g, 0.10 mol) in MeOH (50 
ml) was stirred at reflux for 20 h. After evaporating the solvent, the crude was purified by flash 
chromatography (petrol-ethyl acetate, 8:2) affording 12 as a yellow oil (9 g, 0.04 mol, 43%); vmax 
(film/cm-1) 3328, 2921, 2841, 1730, 1453, 1436, 1169, 735, 697; δH (300 MHz, CDCl3) 1.12 (3H, d, 
J 6.9, CH3), 2.57-2.68 (2H, m, CH2), 2.78-2.87 (1H, m, CH-CH3), 3.61 (3H, s, OCH3), 3.73 (2H, s, 
CH2-Ph), 7.15-7.27 (5H, m, Ar); δC (125 MHz, CDCl3) 15.28, 40.04, 51.54, 52.12, 53.73, 126.91, 
128.04, 128.36, 140.35. 
 
3-Benzylamino-butyric acid methyl ester (13)643 
 
 
 
A mixture of methyl crotonate (10 g, 0.10 mol) and benzylamine (11 g, 0.10 mol) in MeOH (50 ml) 
was stirred at reflux for 20 h. After evaporating the solvent, the crude was purified by flash 
chromatography (petrol-ethyl acetate, 8:2) affording 13 as a yellow oil (13 g, 0.07 mol, 68%); vmax 
(film/cm-1) 3318, 2955, 2870, 1731, 1453, 1436, 1174, 732; δH (500 MHz, CDCl3) 1.07 (3H, d, J 
6.3, CH3), 2.29 (1H, dd, J 15.0, 5.7, CHH-COO), 2.40 (1H, dd, J 15.0, 6.8, CHH-COO), 3.05-3.11 
(1H, m, CH-CH3), 3.56 (3H, s, OCH3), 3.65 (1H, d, J 13.4, CHH-Ph), 3.74 (1H, d, J 13.4, CHH-Ph), 
7.13-7.16 (1H, m, Ar), 7.22 (2H, t, J 7.5, Ar), 7.26 (2H, t, J 7.5, Ar); δC (150 MHz, CDCl3) 20.16, 
41.10, 49.54, 51.02, 51.38, 126.95, 128.13, 128.39, 140.11, 172.67. 
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3-Benzylamino-propionic acid methyl ester (14)643 
 
 
 
A mixture of methyl acrylate (10 g, 0.12 mol) and benzylamine (13 g, 0.12 mol) in MeOH (50 ml) 
was stirred at reflux for 20 h. After evaporating the solvent, the crude was purified by flash 
chromatography (petrol-ethyl acetate, 8:2) affording 14 as a yellow oil (15 g, 0.08 mol, 65%); vmax 
(film/cm-1) 3328, 2951, 2841, 1730, 1453, 1436, 1169, 734, 697; δH (300 MHz, CDCl3) 2.42 (2H, t, 
J 6.5 CH2-COO), 2.78 (2H, t, J 6.5 CH2-N), 3.55 (3H, s, OCH3), 3.69 (2H, s, CH2-Ph), 7.23-7.11 
(5H, m, Ar); δH (75 MHz, CDCl3) 34.38, 44.47, 51.36, 53.65, 126.86, 128.02, 128.32, 140.34, 
172.98. 
 
3-Benzylamino-propan-1-ol (15) 
 
 
A solution of 14 (5 g, 28.30 mmol) in anhydrous THF (10 ml) was added carefully at 0°C and under 
an argon atmosphere, to a suspension of LiAlH4 (1 g, 28.30 mmol) in anhydrous THF. The mixture 
was warmed at RT and then stirred for 2 h. The reaction was quenched at 0 °C by dropwise addition 
of water (1 ml), followed by 1N NaOH (2.5 ml) and water (3 ml). Then, the mixture was filtered, 
dried over MgSO4, and concentrated in vacuo affording 15 as a yellow oil (3 g, 18 mmol, 64%); 
vmax (film/cm-1) 3291, 2930, 2840, 1494, 1453, 1068, 732, 697; δH (500 MHz, CDCl3) 1.64-1.69 
(2H, m, CH2), 2.88 (2H, t, J 5.8 CH2-N), 3.77 (2H, s, CH2-Ph), 3.79 (2H, t, J 5.4, CH2-OH), 7.24-
7.34 (5H, m, Ar); δC (125 MHz, CDCl3) 30.91, 49.26, 54.04, 64.16, 127.24, 128.23, 128.58, 139.60. 
 
Benzyl-(3-hydroxy-propyl)-carbamic acid tert-butyl ester (16) 
 
 
 
Boc2O (201 mg, 0.92 mmol) was added at 0 °C to a solution of 15 (160 mg, 0.97 mmol) in DCM (1 
ml). The mixture was stirred at RT for 1 h. The solvent was evaporated under reduced pressure and 
the crude was purified by flash chromatography (petrol-ethyl acetate, 7:3) affording 16 as a yellow 
oil (169 mg, 0.64 mmol, 64%); vmax (film/cm-1) 3451, 2970, 2943, 1740, 1666, 1415, 1160, 733, 
698; δH (400 MHz, CDCl3, 58°C) 1.50 (9H, s, OtBu), 1.66-1.72 (2H, m, CH2), 3.39 (2H, t, J 6.1, 
Ph N
H
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CH2-N), 3.60 (2H, br m, CH2-OH), 4.43 (2H, s, CH2-Ph), 7.24-7.36 (5H, m, Ar); δC (125 MHz, 
CDCl3) 28.44, 30.25, 42.26, 50.54, 58.47, 80.62, 127.29, 127.38, 128.61, 138.19, 157.17  
 
Benzyl-(3-oxo-propyl)-carbamic acid tert-butyl ester (17) 
 
 
 
Oxalyl chloride (53 mg, 0.42 mmol) was added dropwise to a solution of DMSO (65 mg, 0.83 
mmol) in dry CH2Cl2 (4 ml) cooled to -78 °C. The solution was stirred at this temperature for 15 
min., after which 16 (85 mg, 0.32 mmol) was added. The resulting mixture was stirred for 1 h at -
78°C, then NEt3 (162 mg, 1.6 mmol) was added and the mixture was stirred at RT for 4 h. The 
reaction was quenched with water and the phases were separated. The organic layer was washed 
with brine, dried over MgSO4, filtered and evaporated to dryness. The crude was purified by flash 
chromatography (petrol-ethyl acetate, 9:1) affording 17 as an orange oil (80 mg, 0.64 mmol, 95%); 
vmax (film/cm-1) 2971, 1728, 1737, 1688, 1453, 1414, 1162, 734, 699, δH (400 MHz, CDCl3) 1.44 
(9H, s, OtBu), 2.55 (2H, td, J 6.7, 1.4, CH2-C=O), 3.48 (2H, t, J 6.7, CH2-N), 4.41 (2H, s, CH2-Ph), 
7.19-7.29 (5H, m, Ar), 9.67 (1H, t, J 1.4, HC=O); δH (100 MHz, CDCl3) 28.30, 40.80, 43.11, 50.99, 
80.03, 127.22, 127.42, 128.47, 138.25, 155.41, 200.14. 
 
Benzyl-(3-hydroxy-pent-4-enyl)-carbamic acid tert-butyl ester (18) 
 
 
 
A solution of vinyl magnesium bromide (383 mg, 2.92 mmol) in anhydrous THF was added slowly 
at -78°C to a solution of 17 (192 mg, 0.73 mmol ) in anhydrous THF (2 ml). The mixture was 
stirred at -78°C for 3 h. The reaction was quenched with a solution of NH4Cl (40 ml). The aqueous 
phase was extracted with Et2O (3 x 10 ml). The combined organic layers were dried over MgSO4, 
filtered and evaporated to dryness affording 18 as a orange oil (119 mg, 0.41 mmol, 56%); vmax 
(film/cm-1) 3449, 2971, 1739, 1690, 1416, 1163, 699; δH (400 MHz, DMSO, 100°C) 1.43 (9H, s, 
OtBu), 1.58-1.73 (2H, m, CH2), 3.25 (2H, ddd, J 8.1, 6.6, 3.6, CH2-N), 3.96 (1H, br m, CH-OH), 
4.34 (1H, br s, OH), 4.40 (2H, s, CH2-Ph), 4.99 (1H, dd, J 10.5, 1.7, HCH=CH), 5.15 (1H, dd, J 
17.2, 1.7, HCH=CH), 5.83, (1H, ddd, J 17.2, 10.5, 5.5, CH2=CH), 5.35-5.32 (2H, m, Ar), 7.27-7-23 
(3H, m, Ar); δH (125 MHz, DMSO) 28.03, 35.28 (br), 43.35, 59.75 (br), 68.94, 78.70, 113.17, 
126.94, 127.10, 128.39, 138.78 (br), 142.07, 170.33.  
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2,3-Dihydro-isoindol-1-one (19)645 
 
 
 
Tin powder (13 g, 10.7 mmol) was added to a vigorously stirred suspension of phthalimide (6 g, 41 
mmol) in a mixture of glacial acetic acid (5 ml) and concentrated HCl (2.5 ml). The reaction 
mixture was heated at reflux for 2 h and then filtered hot. The filtrate was concentrated and the 
residue portioned between DMC and water. The organic layer was separated and the aqueous phase 
extracted with DCM (3 x 20 ml). The combined organic extracts were dried over MgSO4, filtered 
and concentrated in vacuo. The crude was purified by flash chromatography (petrol-ethyl acetate, 
1:9) affording 19 as a white solid (1.53 g, 11.00 mmol, 28%); mp= 150 °C; δH (300 MHz, CDCl3) 
4.44, (2H, s, CH2), 7.44-7.48 (2H, m, Ar), 7.51 (1H, d, J 8.0, Ar), 7.83, (1H, t, J 8.0, Ar); δC (100 
MHz, CDCl3), δc (125MHz, CDCl3) 45.91, 123.25, 123.70, 128.03, 131.75, 132.36, 143.42, 172.45,  
 
3-Methoxy-1H-isoindole (20) 
2-Methyl-2,3-dihydro-isoindol-1-one (21) 
 
 
 
 
Method A: 19 (1.8 g, 13.40 mmol) was added under argon to a suspension of NaH (643 mg, 26.80 
mmol) in anhydrous THF (15 ml). After 30 min, MeI (3 g, 20.10 mmol) was added and the mixture 
was stirred at RT for 18 h. The solvent was evaporated, water (15 ml) was added and the aqueous 
layer neutralized with 10% HCl. After extraction with ethyl acetate (3 x 15 ml) and evaporation of 
the solvent, the crude was purified by flash chromatography (petrol-ethyl acetate, 2:8) affording a 
mixture of 20 and 21 as a white solid in a ratio of 2:1, respectively (500 mg). 
Method B645: A solution of N-methyl phthalimide (1.57 g, 13.50 mmol) in acetic acid (32 ml) was 
heated to 60 °C and Zn dust was added at once with mechanical stirring. The reaction mixture was 
heated at reflux with stirring for 4 h and then filtered hot on a sintered Buchner-type funnel. The 
filter cake was washed with acetic acid (3 x 10 ml). The filtrate was evaporated to a small volume 
under reduced pressure. Saturated solution of NaHCO3 was added and the mixture was extracted 
with CHCl3 (3 x 20 ml). The combined extracts were washed once with water and dried over 
MgSO4. Evaporation of the solvent under reduced pressure afforded 21 as a white solid (1.50 g, 
10.20 mmol, 76%). 
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20 (not isolated): δH (500 MHz, CDCl3) 1.61 (2H, s, CH2), 2.95 (3H, s, CH3), 7.37 (2H, m, Ar), 
7.48 (1H, t, J 7.8, Ar), 7.73 (1H, d, J 7.8, Ar); δc (75 MHz, CDCl3, mixture of two rotamers) 23.22, 
23.35, 88.30, 88.67, 119.82, 121.64, 123.12, 123.19, 129.48, 129.66, 130.48, 131.89, 132.27, 
136.20, 143.02, 140.12, 166.65, 167.25. 
21: mp= 114 °C; δH (500 MHz, CDCl3) 3.19 (3H, s, CH3), 4.37 (2H, s, CH2), 7.42-7.46 (2H, m, 
Ar), 7.52 (1H, t, J 7.6, Ar), 7.79 (1H, d, J 7.6, Ar); δc (75MHz, CDCl3) 29.33, 51.91, 122.58, 
123.33, 127.86, 131.07, 132.77, 140.98, 168.51. 
 
2-Methyl-isoindole-1,3-dione (22) 
 
 
 
Phthalimide (2 g, 13.60 mmol) and K2CO3 are dissolved in DMF (20 ml). After 15 min, MeI was 
added and the mixture was stirred at reflux for 3 h after which water (120 ml) was added and the 
aqueous phase was extracted with EtOAc (3 x 20 ml). The combined organic phases were washed 
with a solution of LiCl, dried over MgSO4, filtered and evaporated to dryness affording 22 as a 
yellow solid (1.57 g, 13.50 mmol, 99%); mp= 135 °C; δH (500 MHz, CDCl3) 3.14 (3H, s, CH3), 
7.67 (2H, dd, J 5.4, 3.0, Ar), 7.79 (2H, dd, J 5.4, 3.0, Ar); δc (125 MHz, CDCl3) 23.97, 123.19, 
132.27, 133.91, 168.49.  
 
2-Phenylsulfanyl-octanoic acid tert-butylamide (23) 
 
 
 
8 (158 mg, 0.88 mmol), pentanal (101 mg, 0.88 mmol), tert-butyl isocyanide (73 mg, 0.88 mmol) 
and thiophenol (97 mg, 0.88 mmol) were dissolved in MeOH (1 ml). The mixture was stirred under 
microwave irradiation at 65°C for 15 min. Evaporation of the solvent under reduced pressure 
afforded 23 (100 mg, not isolated); δH (600 MHz, CDCl3) 0.67-0.69 (1H, br m, CHH), 0.85 (3H, t, 
CH3), 0.99-1.04 (2H, br m, CHH, CHH), 1.12-1.17 (2H, m, CH2), 1.19-1.28 (4H, CH2, CHH, 
CHH), 1.40 (9H, s, tBu), 1.44-1.50 (1H, br m, CHH), 2.86 (1H, d, J 9.2, CH-C=O), 7.40 (2H, d, J 
6.0 Ar), 7.57.7.59 (3H, m, Ar); δH (150 MHz, CDCl3) 14.24, 22.78, 26.41, 29.31, 29.34, 32.08, 
37.52, 55.85, 56.30, 129.29, 129.38, 131.07, 136.72, 160.77.  
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3-Benzyl-2-(4-chloro-phenyl)-4-methyl-[1,3]oxazinane (24) 
 
 
 
Para-chlorobenzaldehyde (235 mg, 1.67 mmol) and 8 (200 mg, 1.11 mmol) were dissolved in 
MeOH (1 ml). The mixture was stirred under microwave irradiation at 65°C for 15 min. 
Evaporation of the solvent under reduced pressure affording 24 as a mixture of two diasteroisomers 
in a ratio of 1:1.4 (220 mg, not isolated).  
Diasteroisomer A (major): δH (500 MHz, CDCl3) 1.34 (3H, d, J 7.3, CH3), 1.32-1.40 (2H, m, CH2), 
3.16-3.22 (1H, m, CH-CH3). 3.77 (1H, d, J 14.6, CHH-Ph), 3.83, (1H, d, J 14.6, CHH-Ph), 4.06 
(2H, dd, J 7.1, 4.2, CH2O), 5.61 (1H, s, CH), 7.22 (2H, d, J 8.6, Ar), 7.30-7.37 (5H, m, Ar), 7.34 
(2H, d, J 8.6, Ar).  
Diasteroisomer B (minor): δH (500 MHz, CDCl3) 1.06 (3H, J 6.7, CH3), 1.99 (1H, ddd, J 25.4, 12.2, 
5.0, CHH), 2.04-2.10 (1H, m, CHH), 3.29-3.36 (1H, m, CH-CH3), 3.63 (1H, d, J 16.1, CHH-Ph), 
3.68 (1H, d, J 16.1, CHH-Ph), 3.85 (1H, td J 12.0, 2.7, CHH-O), 4.26 (1H, ddd, J 12.0, 5.0, 1.0, 
CHH-O), 5.27 (1H, s, CH-Ph), 7.11-7.14 (1H, m, Ar), 7.19-7.25 (4H, m, Ar), 7.47 (2H, d, J 8.3, 
Ar), 7.50 (2H, d, J 8.3, Ar);  
δC (150 MHz, CDCl3, mixture of two diasteroisomers) 18.41, 21.71, 25.07, 29.17, 47.32, 47.80, 
49.44, 57.31, 63.24, 68.19, 86.33, 94.17, 126.10, 126.89, 127.43, 127.93, 128.20, 128.23, 128.40, 
128.45, 128.58, 128.74, 133.27, 133.62, 138.53, 138.65, 140.50, 142.41. 
 
N-(1-Methyl-3-phenylsulfanyl-propyl)-formamide (25) 
2-[Benzyl-(1-methyl-3-phenylsulfanyl-propyl)-amino]-N-tert-butyl-2-(4-chloro-phenyl)-
acetamide (26) 
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24 (310 mg, 1.03 mmol), tert-butyl isocyanide (86 mg, 1.03 mmol) and thiophenol (113 mg, 1.03 
mmol) were dissolved in MeOH (1 ml). The mixture was stirred under microwave irradiation at 
65°C for 15 min. After evaporating the solvent, the crude was purified by flash chromatography 
(DCM-ether, 9.5:0.5) affording 25 as colorless oil (15 mg, 0.05 mmol, 5%); vmax (film/cm-1) 3460, 
3058, 3027, 2970, 2933, 1740,1665,1437, 1419, 738, 688; ES [M+H+]: 300.1418, C18H21NOS; δH 
(500 MHz, CDCl3 mixture of two rotamers) 1.09 (3H, d, J 6.7, CH3), 1.16 (3H, d, J 6.7, CH3), 1.65-
1.75 (2H, m, CH2), 1.81-1.87 (1H, m, CHH), 1.94-2.01 (1H, m, CHH), 2.64 (1H, dt, J 7.4, 12.9, 
CHH-S), 2.72-2.82 (3H, m, CHH-S, CH2-S), 3.78-3.84 8 (1H, m, CH-CH3), 2.25-2.29 (1H, m, CH-
CH3), 4.45 (1H, d, J 15.2, CHH-Ph), 4.49 (1H, d, J 15.2, CHH-Ph), 4.30 (1H, d, J 15.2, CHH-Ph), 
4.33 (1H, d, J 15.2, CHH-Ph), 7.18-7.34 (20H, m, Ar), 8.30 (2H, s, HC=O); δc (150MHz, CDCl3, 
mixture of two rotamers) 18.53, 20.78, 30.53, 30.88, 33.52, 34.29, 44.16, 49.31, 49.75, 53.06, 
126.59, 127.55, 128.07, 128.71, 129.71, 129.88, 135.48, 138.07; 163.16, 163.75. 
26 (not isolated, two diasteroisomers in a ratio of 1:1.5):  
Diasteroisomer A (major): δH (600 MHz, CDCl3) 1.10 (3H, d, J 6.5, CH3), 1.21-1.29 (1H, m, CHH), 
1.39-1,46 (1H, m; CHH), 1.57 (9H, s, tBu), 2.96-3.02 (1H, m, CH-CH3), 3.24 (1H, br m, CHH-S), 
3.42 (1H, br m, CHH-S), 3.70 (1H, d, J 14.7, CHH-Ph), 3.91 (1H, d, J 14.7, CHH-Ph), 4.49 (1H, s, 
CH-C=O), 6.89 (2H, d, J 6.7, Ar), 6.94 (2H, d, J 8.2, Ar), 7.04 (2H, d, J 7.5, Ar), 7.15 (2H, d, J 7.5, 
Ar), 7.12-7.19 (5H, m, Ar), 7.28 (1H, t, J 7.6, Ar); δc (150 MHz, CDCl3) 17.51, 29.37, 36.98, 51.38, 
52.67, 57.46, 61.31, 64.98, 126.65, 128.09, 128.17, 128.70, 129.06, 129.18, 130.86, 131.59, 133.30, 
136.17, 137.86, 141.44, 155.38. 
Diasteroisomer B (minor): δH (600 MHz, CDCl3) 0.41 (3H, d, J 6.1, CH3), 1.39-1,46 (1H, m, CHH), 
1.58 (9H, s, tBu), 1.68-1.75 (1H, m, CHH), 3.24 (1H, br m, CH-CH3), 3.34 (1H, d, J 13.9 CHH-Ph), 
3.58-3.62 (1H, m, CHH-S), 3.73 (1H, br m, CHH-S), 4.01 (1H, d, J 13.9, CHH-Ph), 4.55 (1H, s 
CH-C=O), 6.74 (2H, d, J 7.5, Ar), 6.89 (2H, d, J 6.7, Ar), 6.94 (2H, d, J 8.2, Ar), 7.04 (2H, d, J 7.5 
Ar), 7.12-7.19 (6H, m, Ar); δc (150 MHz, CDCl3) 17.51, 29.37, 36.98, 51.38, 53.57, 57.46, 61.60, 
65.51, 126.65, 128.09, 128.17, 128.70, 129.06, 129.18, 130.86, 131.59, 133.30, 136.17, 137.86, 
141.44, 155.38. 
 
5-Benzyl-4-methyl-9-oxo-[1,5]oxazonane-6-carboxylic acid tert-butylamide (27) 
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8 (114 mg, 0.64 mmol), 4-oxo-butyric acid (65 mg, 0.64 mmol) and tert-butyl isocyanide (53 mg, 
0.64 mmol) were dissolved in MeOH (1 ml). The mixture was stirred under microwave irradiation 
at 65°C for 15 min. After evaporating the solvent, the crude was purified by flash chromatography 
(petrol-ethyl acetate, 8:2) affording 27-cis as a white solid (119 mg, 0.34 mmol, 53%) and 27-trans 
as a colorless oil (52 mg, 0.15 mmol, 23%); vmax (film/cm-1) 3364, 2965, 2930, 1735, 1669, 1515, 
1453, 1238, 755, 703. 
27-cis: mp= 107 °C; EI [M]+: 346.22521, C20H30N2O3; δH (400 MHz, DMSO, 110°C) 1.23 (9H, s, 
tBu), 1.26-1.28 (1H, m, CHH-CH2O), 1.34 (3H, d, J 7.5, CH3), 1.99-2.09 (1H, m, CHH-CH2O), 
2.12-2.23 (1H, m, CHH-CH2COO), 2.38-2.51 (3H, m, CH2-COO, CHH-CH2COO), 3.17-3.25 (1H, 
m, CH-CH3), 3.48 (1H, dd, J 8.8, 1.7, CH-C=O), 3.69 (1H, d, J 14.7, CHH-Ph), 3.77 (1H, d, J 14.7, 
CHH-Ph), 3.91 (1H, td J 10.8, 5.8, CHH-O), 4.67 (1H, ddd, J 10.8, 6.6, 2.8, CHH-O), 6.41 (1H, br 
s, NH), (1H, tt J 7.4, 1.6, Ar), 7.30 (2H, t, J 7.4, Ar), 7.34 (2H, d, J 7.4); δc (100MHz, DMSO, 
110°C) 22.53, 23.18, 28.46, 30.97, 33.60, 47.58, 50.68, 60.55, 62.82, 70.20, 127.00, 128.35, 129.61, 
140.08, 172.20, 173.72; Anal. Calcd for C20H30N2O3: C 69.33, H 8.73, N 8.09, found C 69.04, H 
8.82, N 7.90. 
27-trans: ES [M+H+]: 347.23405, C20H31N2O3; δH (400 MHz, DMSO, 110°C) 1.04 (3H, d, J 6.5, 
CH3), 1.31 (9H, s, tBu), 1.37-1.44 (1H, m, CHH-CH2O), 1.45-1.52 (1H, m, CHH-CH2O), 1.86-1.96 
(1H, m, CHH-CH2COO), 2.03-2.12 (1H, m, CHH-CH2COO), 2.29-2.37 (2H, m, CH2-COO), 3.27 
(1H, dd, J 10.6, 2, CH-C=O), 3.32-3.37 (1H, m, CH-CH3), 3.70 (1H, d, J 14.1, CHH-Ph), 3.98 (1H, 
d, J 14.1, CHH-Ph), 4.07 (1H, td, J 10.2, 4.8 CHH-O), 4.27-4.32 (1H, m, CHH-O), 6.52 (1H, br s, 
NH), 7.22 (1H, t, J 7.3 Ar), 7.29 (2H, t, J 7.3, Ar), 7.39 (2H, d, J 7,3); δc (100MHz, CDCl3) 18.07, 
25.41, 28.94, 30.73, 33.21, 47.13, 50.27, 51.34, 61.28, 61.35, 127.58, 128.95, 130.07, 138.91, 
171.27, 73.83. 
 
3-Benzyl-2-(4-chloro-phenyl)-5-methyl-[1,3]oxazinane (28) 
 
 
 
Para-chlorobenzaldehyde (350 mg, 2.49 mmol) and 7 (298 mg, 1.66 mmol) were dissolved in 
MeOH (1.5 ml). The mixture was stirred under microwave irradiation at 65°C for 15 min. 
N
O
Cl
Ph
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Evaporation of the solvent under reduced pressure afforded 28 as a mixture of two diasteroisomers 
in a ratio of 1:4.5 (301 mg, not isolated).  
Diasteroisomer A (major): δH (500 MHz, CDCl3) 0.74 (3H, d, J 6.4, CH3), 2.25-2.31 (1H, m, CH-
CH3), 2.35 (1H, t, J 11.8 , CHH-N), 3.06-3.09 (1H, m, CHH-N), 3.29 (1H, d, J 14.0, CHH-Ph), 3.38 
(1H, t, J 11.0, CHH-O), 3.66 (1H, d, J 14.0, CHH-Ph), 4.21 (1H, ddd, J 11.0, 4.4, 2.1, CHH-O), 
5.05 (1H, s, CH-Ph), 7.29-7.35 (5H, m, Ar), 7.39 (2H, J 8.5, Ar), 7.59 (2H, J 8.5, Ar).  
Diasteroisomer B (minor): δH (500MHz, CDCl3) 0.88 (3H, d, J 6.7 CH3), 2.11-2.17 (1H, m, CH-
CH3), 2.63 (1H, dd J 13.1, 3.6, CHH-N), 2.77 (1H, dd, J 13.1, 8.3, CHH-N), 3.54 (1H, dd, J 11.2, 
7.6, CHH-O), 3.70 (1H, d, J 13.6, CHH-Ph), 3.82 (1H, ddd, J 11.2, 3.9, 1.0, CHH-O), 4.08 (1H, d, J 
13.6, CHH-Ph), 5.11 (1H, s, CH-Ph), 7.25.7.28 (2H, m, Ar), 7.36-7.41 (3H, m, Ar), 7.43 (2H, J 8.3, 
Ar), 7.62 (2H, J 8.3, Ar). 
δC (125 MHz, CDCl3, mixture of two diasteroisomers) 14.46, 15.56, 25.89, 52.38, 53.03, 57.01, 
57.17, 69.46, 74.80, 90.61, 93.81, 126.97, 127.15, 128.36, 128.45, 128.50, 128.57, 128.64, 128.76, 
128.80, 129.42, 133.74, 134.04, 138.23, 138.30, 139.12, 139.29. 
 
2-[Benzyl-(2-methyl-3-phenylsulfanyl-propyl)-amino]-N-tert-butyl-2-(4-chloro-phenyl)-
acetamide (29) 
S
N
Ph
Cl
NH
O
 
28 (605 mg, 2.00 mmol), tert-butyl isocyanide (166 mg, 2.00 mmol) and thiophenol (220 mg, 2.00 
mmol) were dissolved in MeOH (2 ml). The mixture was stirred under microwave irradiation at 
65°C for 15 min. After evaporating the solvent, the crude was purified by flash chromatography 
(DCM-ether, 9:1) affording 29 as a yellow solid and as a mixture of two diasteroisomers in a ratio 
of 0.7:1 (25 mg, 0.51 mmol, 3%); vmax (film/cm-1) 3155, 2926, 2854, 1640, 1468, 1384, 911, 740, 
651; ES [M+H+]: 495.2215, C29H36N2OSCl; Anal. Calcd for C29H37ClN2O2S: C 67.88, H 7.27, N 
5.26, found C 67.33, H 6.94, N 5.19. 
Diasteroisomer A (major): δH (600 MHz, CDCl3) 0.56 (3H, d, J 6.7, CH3), 1.58 (9H, s, tBu), 1.76 
(1H, m, CH-CH3), 2.07 (1H, dd, J 12.4, 2.3, CHH-N), 2.54 (1H, t, J 12.4, CHH-N), 2.91 (1H, d, J 
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13.4, CHH-Ph), 3.30 (1H, t, J 9.7, CHH-S), 3.54 (1H, d, J 9.7, CHH-S), 4.14 (1H, d, J 13.4, CHH-
Ph), 4.53 (1H, s, CH-Ph), 4.94 (1H, br s, NH), 6.73 (2H, d, J 8.2, Ar), 6.76 (2H, d, J 7.6, Ar), 6.99 
(2H, t, J 7.6, Ar), 7.16-7.19 (1H, m, Ar), 7.20 (2H, d J 8.2, Ar), 7.30-7.35 (5H, m, Ar); δc (150 
MHz, CDCl3) 15.23, 29.53, 32.13, 56.21, 57.31, 57.59, 66.12, 69.09, 127.27, 128.07, 128.59, 
128.63, 128.85, 129.18, 130.69, 131.52, 133.47, 133.93, 135.56, 139.29, 155.02.  
Diasteroisomer B (minor): δH (600 MHz, CDCl3) 0.84 (3H, d, J 6.7, CH3), 1.58 (9H, s, tBu), 1.86 
(1H, br m, CH-CH3), 2.54 (1H, t, J 12.4, CHH-N), 2.68 (1H, t, J 9.8, CHH-S), 3.04-3.07 (1H, m, 
CHH-N), 3.26 (1H, br m, CHH-S), 3.82 (1H, d, J 13.0, CHH-Ph), 4.03 (1H, d, J 13.0, CHH-Ph), 
4.40 (1H, s, CH-Ph), 4.94 (1H, br s, NH), 6.57 (2H, d, J 7.5 Ar), 6.83-6.86 (4H, m, Ar), 7.08 (1H, t, 
J 7.5, Ar), 7.23 (2H, d, J 7.2, Ar), 7.30-7.35 (5H, m, Ar); δc (150 MHz, CDCl3) 15.11, 29.67, 31.73, 
55.94, 57.31, 57.71, 65.99, 69.90, 127.27, 128.30, 128.59, 128.63, 128.85, 129.48, 130.69, 131.45, 
133.47, 133.93, 135.86, 139.29, 155.02. 
 
5-Benzyl-3-methyl-9-oxo-[1,5]oxazonane-6-carboxylic acid tert-butylamide (30) 
O
O
N
PhO
HN
 
7 (108 mg, 0.61 mmol), 4-oxo-butyric acid (62 mg, 0.61 mmol) and tert-butyl isocyanide (51 mg, 
0.61 mmol) were dissolved in MeOH (1 ml). The mixture was stirred under microwave irradiation 
at 65°C for 15 min. After evaporating the solvent, the crude was purified by flash chromatography 
(petrol-ethyl acetate, 8:2) affording 30 as a colorless oil and as a mixture of two diasteroisomers in a 
ratio of 1:1.1 (175 mg 0.22 mmol, 34%); vmax (film/cm-1) 3365, 3058, 2965, 1730, 1669, 1507, 
1454, 1265, 732, 700; ES [M+H+]: 347.23301, C20H31O3N2. 
Diasteroisomer A (major): δH (600 MHz, CDCl3) 0.88 (3H, d, J 7.2, CH3), 1.40 (9H, s, tBu), 2.05-
2.14 (1H, m, CHH-CH2COO), 2.18-2.29 (2H, m, CHH-CH2COO, CH-CH3), 2.20 (1H, dd, J 14.0, 
1.2, CHH-N), 2.36 (1H, ddd, J 12.7, 10.1, 6.3, CHH-COO), 2.42-2.45 (1H, m, CHH-COO), 3.29 
(1H, dd, J 14.0, 9.8, CHH-N), 3.35-3.46 (2H, m, CH-C=O, CHH-O), 3.42 (1H, d, J 13.3, CHH-Ph), 
3.91 (1H, d, J 13.3, CHH-Ph), 4.92 (1H, dd J 10.8, 7.4, CHH-O), 7.24-7.28 (1H, m, Ar), 7.23-7.35 
(4H, m, Ar). 
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Diasteroisomer B (minor): δH (600 MHz, CDCl3) 0.57 (3H, d, J 7.0, CH3), 1.34 (9H, s, tBu), 1.46-
1.51 (1H, m, CHH-CH2COO), 1.75-1.83 (1H, m, CH-CH3), 1.97 (1H, ddd, J 15.0, 13.3, 3, CHH-
COO), 2.46-2.48 (1H, m, CHH-COO), 2.51-2.62 (1H, m, CHH-CH2COO), 2.70 (1H, dd, J 14.5, 
8.8, CHH-O), 2.84-2.88 (1H, m, CHH-O), 2.87 (1H, dd, J 12.2, 4.1, CH-C=O), 3.35-3.46 (1H, m, 
CHH-N), 3.49 (1H, d, J 13.6, CHH-Ph), 3.90 (1H, d, J 13.6, CHH-Ph), 4.54 (1H, dd, J 10.9, 6.5, 
CHH-N), 7.24-7.32 (5H, Ar). 
δc (150 MHz, CDCl3, mixture of two diasteroisomers) 15.78, 17.05, 24.45, 25.99, 28.35, 28.89, 
29.72, 33.05, 33.36, 51.22, 51.34, 53.26, 56.00, 57.83, 62.60, 67.82, 68.87, 127.28, 127.42, 128.22, 
128.63, 129.57, 129.61, 138.42, 138.50, 170.18, 171.37, 173.09, 173.66.  
 
2-[Benzyl-(3-phenylsulfanyl-butyl)-amino]-octanoic acid tert-butylamide (31) 
 
 
 
 
 
6 (187 mg, 1.04 mmol), pentanal (119 mg, 1.04 mmol) and tert-butyl isocyanide (87 mg, 1.04 
mmol) were dissolved in MeOH (1 ml). The mixture was stirred under microwave irradiation at 
65°C for 15 min. After evaporating the solvent, the crude was purified by flash chromatography 
(DCM-ether, 9.5:0.5) affording 31 as a colorless oil (10 mg, 0.02 mmol, 2%); vmax (film/cm-1) 3461, 
2970, 2927, 2855, 1738, 1455; ES [M+H]+: 469.3247, C29H45N2OS; δH (600 MHz, CDCl3) 0.82-
0.86 (2H, m, CH2), 0.87 (3H, t, J 6.7, CH3), 1.05 (3H, d, J 6.1, CH3), 1.15-1.19 (2H, m, CH2), 1.22-
1.28 (5H, m, 2CH2, CHH), 1.38-1.45 (2H, m, CH2), 1.47 (9H, s, tBu), 1.78 (1H, m, CHH), 2.54 
(1H, dt, J 13.3, 4.2, CHH-N), 3.03 (1H, ddd, J 13.3, 10.8, 3.5, CHH-N), 3.27 (1H, J 9.2, 4.4, CH-
C=O), 3.40 (1H, d, J 13.3, CHH-Ph), 3.70 (1H, m, CH-CH3), 3.78 (1H, d, J 13.3, CHH-Ph), 7.14 
(2H, d, J 7.2, Ar), 7.16-7.23 (6H, m, Ar), 7.24 (2H, d, J 7.2, Ar); δc (150 MHz, CDCl3) 14.22, 22.69, 
23.47, 25.88, 26.35, 29.41, 29.74, 31.76, 35.04, 47.97, 54.83, 56.95, 62.84, 69.04, 127.16, 127.99, 
128.42, 129.06, 129.77, 132.50, 134.49, 139.27, 153.92. 
 
 
 
N
HN
O
Ph
S
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3-Benzyl-6-methyl-2-phenyl-[1,3]oxazinane (32) 
N
O
Ph
Cl
 
Para-chlorobenzaldehyde (140 mg, 0.42 mmol) and 6 (63 mg, 0.35 mmol) were dissolved in MeOH 
(0.5 ml). The mixture was stirred under microwave irradiation at 65°C for 15 min. Evaporation of 
the solvent under reduced pressure afforded 32 as a mixture of two diasteroisomers in a ratio of 
1:6.7 (100 mg, not isolated). 
Diasteroisomer A (major): δH (600 MHz, CDCl3) 1.30 (3H, d, J 6.2, CH3), 1.37 (1H, m, CHH), 
1.74-1.81 (1H, m, CHH), 2.69 (1H, td, J 12.8, 3.0, CHH-N), 3.03 (1H, ddd, J 12.8, 4.3, 2.0, CHH-
N), 3.18 (1H, J 13.9, CHH-Ph), 3.56 (1H, J 13.9, CHH-Ph), 3.80 (1H, m, CH-CH3), 5.07 (1H, s, 
CH-Ph), 7.20-7.28 (5H, m, Ar), 7.34 (2H, d, J 8.6, Ar), 7.50 (2H, d, J 8.6, Ar); δc (150 MHz, 
CDCl3) 22.13, 29.43, 49.29, 51.93, 74.35, 93.85, 126.96, 128.36, 128.59, 128.64, 128.85, 133.94, 
138.65, 139.29. 
Diasteroisomer B (minor): peaks too broad. Not distinctly observed.  
 
5-Benzyl-2-methyl-9-oxo-[1,5]oxazonane-6-carboxylic acid tert-butylamide (33) 
O
O
N
PhO
HN
 
6 (65 mg, 0.36 mmol), 4-oxo-butyric acid (102 mg, 0.36 mmol) and tert-butyl isocyanide (30 mg, 
0.36 mmol) were dissolved in MeOH (0.5 ml). The mixture was stirred under microwave irradiation 
at 65°C for 15 min. After evaporating the solvent, the crude was purified by flash chromatography 
(petrol-ethyl acetate, 8:2) affording 33 as a pale yellow solid (13 mg, 0.04 mmol, 12%); mp= 142 
°C; vmax (film/cm-1) 3359, 3026, 2971, 2929, 1730, 1667, 1498, 1456, 1116, 731. 700.4; ES 
[M+Na+]: 369.2145, C20H30N2O3Na; δH (600 MHz, CDCl3) 1.29 (3H, d, J 6.6, CH3), 1.32-1.35 (1H, 
m, CHH-CH2N), 1.33 (9H, s, tBu), 1.42-1.46 (1H, m, CHH-CH2COO), 1.95 (1H, ddd, J 15.4, 13.3, 
3.0, CHH-COO), 2.14-2.19 (1H, m, CHH-CH2N), 2.27 (1H, dd, J 4.8, 1.7, CHH-N), 2.46 (1H, dt, J 
15.4, 3.8, CHH-COO), 2.53-2.60 (1H, m, CHH-CH2COO), 2.79 (1H, dd, J 12.3, 4, CH-C=O), 3.39 
250 
(1H, d, J 13.5, CHH-Ph), 3.43 (1H, dd, J 11.5, 1.7, CHH-N), 3.93 (1H, d, J 13.5, CHH-Ph), 4.96 
(1H, br s, NH), 5.18 (1H, dqd, J 7.6, 6.6, 2.5, CH-CH3), 7.28 (1H, t, J 7.3, Ar), 7.37 (2H, t, J 7.3, 
Ar), 7.42 (2H, d, J7.3, Ar); δc (150 MHz, CDCl3) 21.30, 25.80, 29.08, 29.78, 33.78, 43.54, 51.56, 
57.48, 62.48, 67.31, 127.63, 128.95, 129.65, 138.55, 170.19, 173.66.  
 
3-Benzyl-2-(4-chloro-phenyl)-6-vinyl-[1,3]oxazinane (34) 
N
O
Ph
Cl
 
9 (22 mg, 0.11 mmol) and para-chloro benzaldehyde (31 mg, 0.22 mmol) were dissolved in MeOH 
(0.5 ml). The mixture was stirred under microwave irradiation at 65°C for 15 min. Evaporation of 
the solvent under reduced pressure afforded 34 as a mixture of two diasteroisomers in a ratio of 1:9 
(31 mg, not isolated).  
Diasteroisomer A (major): δH (500 MHz, CDCl3) 1.40-1.44 (1H, m, CHH), 1.84-1.93 (1H, m, 
CHH), 2.78 (1H, td, J 12.8, 2.9, CHH-N), 3.06 (1H, ddd J 13.2, 4.3, 2.0, CHH-N), 3.21 (1H, d, J 
13.9, CHH-Ph), 3.55 (1H, d, J 13.9, CHH-Ph), 4.16-4.21 (1H, m, CH-CH=CH2), 5.15 (1H, dd, J 
10.6, 1.3, CHC=CHH), 5.18 (1H, s, CH-Ph), 5.31 (1H, dd, J 17.4, 1.3, CHC=CHH), 5.94 (1H, ddd, 
J 17.4, 10.6, 5.3, CH=CH2), 7.19 (2H, d, J 7.1, Ar), 7.24 (2H, t, J 7.1, Ar), 7.29-7.32 (1H, m, Ar), 
7.31 (2H, d, J 8.3, Ar), 7.52 (2H, d, J 8.3, Ar); δc (150 MHz, CDCl3) 27.09, 28.48, 48.78, 51.28, 
78.48, 93.41, 115.04, 126.92, 128.30, 128.48, 128.51, 128.71, 133.88, 138.62, 139.16.  
Diasteroisomer B (minor): peaks too broad. Not distinctly observed.  
 
3-Formyl-isonicotinic acid (35)647 
4-Formyl-nicotinic acid (35’)647 
 
 
 
A solution of tert-butyl alcohol (556 mg, 7.50 mmol) was added carefully at 0 °C and under an 
argon atmosphere to a suspension of LiAlH4 (95 mg, 2.50 mmol) in anhydrous THF. The mixture 
was stirred at 0 °C for 30 min. A white suspension of Li(OtBu)3AlH was formed. The solution of 
N
OH
O
O
H
N
H
O
O
OH
35 35'
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Li(OtBu)3AlH (341 mg, 1.34 mmol) previously prepared, was added slowly at 0 °C and under an 
argon atmosphere, to a solution of 3,4-pyridinedicarboxylic anhydride (200 mg, 1.34 mmol) 
dissolved in anhydrous THF (1 ml). The mixture was stirred for 2 h at RT, after which it was 
quenched with water (10 ml). The aqueous phase was extracted with EtOAc (3 x 3 ml). Evaporation 
of the aqueous phase afforded a mixture of 35 and 35’ as a white solid (44 mg, 0.29 mmol, 22%, not 
isolated); δH (600 MHz, CDCl3) 5.85 (1H, s, CH-OH, hydroxyphthalide form), 5.90 (1H, s, CH-OH, 
hydroxyphthalide form), 7.50 (1H, d, J 4.9, Ar) 7.57 (1H, d, J 5.10, Ar), 7.62 (1H, d, J 4.7), 7.74 
(1H, d, J 4.9), 8.52 (1H, d, J 4.7, Ar), 8.54 (1H, d, J 5.10, Ar), 8.60 (1H, d, J 4.9, Ar), 8.67 (1H, s, 
Ar), 8.74 (1H, d, J 4.9), 8.83 (1H, s, Ar), 8.88 (1H, s, Ar), 8.89 (1H, s, Ar), 10.60 (1H, s, HC=O), 
10.73 (1H, s, HC=O); δc (150 MHz, CDCl3) 97.54, 97.75, 122.64, 123.12, 124.35, 124.60, 131.05, 
133.39, 135.53, 146.94, 148.67, 149.59, 150.16, 150.54, 151.01, 151.48, 152.74, 154.30, 172.88, 
175.49, 193.72, 193.80.  
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